<!DOCTYPE html>
<html lang="en-US"><head>
    
    
    <title>UCSF指南 | 跨性别在线·文档库</title>
    
    
    
    
    <link rel="preload" href="/assets/css/0.styles.de912082.css" as="style"><link rel="preload" href="/assets/js/app.00bfe73e.js" as="script"><link rel="preload" href="/assets/js/2.85a7ba3d.js" as="script"><link rel="preload" href="/assets/js/15.1830f165.js" as="script"><link rel="prefetch" href="/assets/js/10.fab577b8.js"><link rel="prefetch" href="/assets/js/11.b6e6aca1.js"><link rel="prefetch" href="/assets/js/12.427002fe.js"><link rel="prefetch" href="/assets/js/13.e71a3749.js"><link rel="prefetch" href="/assets/js/14.2a6fda3c.js"><link rel="prefetch" href="/assets/js/3.ab90edae.js"><link rel="prefetch" href="/assets/js/4.16d72554.js"><link rel="prefetch" href="/assets/js/5.abd6b395.js"><link rel="prefetch" href="/assets/js/6.4ca8dcfb.js"><link rel="prefetch" href="/assets/js/7.f914f806.js"><link rel="prefetch" href="/assets/js/8.c0c311f8.js"><link rel="prefetch" href="/assets/js/9.98342100.js">
    <link rel="stylesheet" href="/assets/css/0.styles.de912082.css">
  <script charset="utf-8" src="/assets/js/15.1830f165.js"></script><meta name="description" content=""></head>
  <body>
    <div id="app"><div class="theme-container"><header class="navbar"><div class="sidebar-button"><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" role="img" viewBox="0 0 448 512" class="icon"><path fill="currentColor" d="M436 124H12c-6.627 0-12-5.373-12-12V80c0-6.627 5.373-12 12-12h424c6.627 0 12 5.373 12 12v32c0 6.627-5.373 12-12 12zm0 160H12c-6.627 0-12-5.373-12-12v-32c0-6.627 5.373-12 12-12h424c6.627 0 12 5.373 12 12v32c0 6.627-5.373 12-12 12zm0 160H12c-6.627 0-12-5.373-12-12v-32c0-6.627 5.373-12 12-12h424c6.627 0 12 5.373 12 12v32c0 6.627-5.373 12-12 12z"></path></svg></div> <a href="/" class="home-link router-link-active"><!----> <span class="site-name">跨性别在线·文档库</span></a> <div class="links" style="max-width: 1725px;"><!----> <nav class="nav-links can-hide"><div class="nav-item"><a href="/" class="nav-link">
  文档库首页
</a></div><div class="nav-item"><a href="http://transonline.org.cn" target="_blank" rel="noopener noreferrer" class="nav-link external">
  主站首页
  <span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a></div><div class="nav-item"><a href="http://www.beian.gov.cn/portal/registerSystemInfo?recordcode=22010302000315" target="_blank" rel="noopener noreferrer" class="nav-link external">
  吉公网安备 22010302000315号
  <span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a></div><div class="nav-item"><a href="http://beian.miit.gov.cn" target="_blank" rel="noopener noreferrer" class="nav-link external">
  吉ICP备2020007559号-1
  <span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a></div> <!----></nav></div></header> <div class="sidebar-mask"></div> <aside class="sidebar"><nav class="nav-links"><div class="nav-item"><a href="/" class="nav-link">
  文档库首页
</a></div><div class="nav-item"><a href="http://transonline.org.cn" target="_blank" rel="noopener noreferrer" class="nav-link external">
  主站首页
  <span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a></div><div class="nav-item"><a href="http://www.beian.gov.cn/portal/registerSystemInfo?recordcode=22010302000315" target="_blank" rel="noopener noreferrer" class="nav-link external">
  吉公网安备 22010302000315号
  <span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a></div><div class="nav-item"><a href="http://beian.miit.gov.cn" target="_blank" rel="noopener noreferrer" class="nav-link external">
  吉ICP备2020007559号-1
  <span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a></div> <!----></nav>  <ul class="sidebar-links"><li><section class="sidebar-group depth-0"><p class="sidebar-heading open"><span>UCSF指南</span> <!----></p> <ul class="sidebar-links sidebar-group-items"><li><a href="/ucsf/#指南简介" class="sidebar-link">指南简介</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#参考文献" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#贡献者" class="sidebar-link">贡献者</a><ul class="sidebar-sub-headers"></ul></li><li><a href="/ucsf/#翻译贡献者" class="sidebar-link">翻译贡献者</a><ul class="sidebar-sub-headers"></ul></li><li><a href="/ucsf/#译者声明" class="sidebar-link">译者声明</a><ul class="sidebar-sub-headers"></ul></li><li><a href="/ucsf/#证据分级" class="sidebar-link">证据分级</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-2" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#术语和定义" class="sidebar-link">术语和定义</a><ul class="sidebar-sub-headers"></ul></li><li><a href="/ucsf/#创造安全和热情的诊所环境" class="sidebar-link">创造安全和热情的诊所环境</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#性别认同-两步" class="sidebar-link">性别认同（两步）：</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-3" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#跨性别患者与体检" class="sidebar-link">跨性别患者与体检</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-2" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#跨性别女性阴道检查的特殊考虑" class="sidebar-link">跨性别女性阴道检查的特殊考虑</a></li><li class="sidebar-sub-header"><a href="/ucsf/#跨性别男性盆腔检查的特殊考虑" class="sidebar-link">跨性别男性盆腔检查的特殊考虑</a></li><li class="sidebar-sub-header"><a href="/ucsf/#其它特殊考虑" class="sidebar-link">其它特殊考虑</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-4" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#性别肯定治疗及程序概述" class="sidebar-link">性别肯定治疗及程序概述</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#提供性别肯定治疗及程序的支持性证据" class="sidebar-link">提供性别肯定治疗及程序的支持性证据</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-5" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#开始激素治疗" class="sidebar-link">开始激素治疗</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#评估准备状态和适当性" class="sidebar-link">评估准备状态和适当性</a></li><li class="sidebar-sub-header"><a href="/ucsf/#处方提供者的资格" class="sidebar-link">处方提供者的资格</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-6" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#女性化激素治疗概述" class="sidebar-link">女性化激素治疗概述</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-3" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#雌激素" class="sidebar-link">雌激素</a></li><li class="sidebar-sub-header"><a href="/ucsf/#抗雄激素-一般方法" class="sidebar-link">抗雄激素——一般方法</a></li><li class="sidebar-sub-header"><a href="/ucsf/#抗雄激素-其它方法" class="sidebar-link">抗雄激素——其它方法</a></li><li class="sidebar-sub-header"><a href="/ucsf/#药量滴定和监测概述" class="sidebar-link">药量滴定和监测概述</a></li><li class="sidebar-sub-header"><a href="/ucsf/#监测雌二醇水平" class="sidebar-link">监测雌二醇水平</a></li><li class="sidebar-sub-header"><a href="/ucsf/#监测睾酮水平" class="sidebar-link">监测睾酮水平</a></li><li class="sidebar-sub-header"><a href="/ucsf/#监测促性腺激素水平" class="sidebar-link">监测促性腺激素水平</a></li><li class="sidebar-sub-header"><a href="/ucsf/#在使用注射雌激素的患者中监测激素水平" class="sidebar-link">在使用注射雌激素的患者中监测激素水平</a></li><li class="sidebar-sub-header"><a href="/ucsf/#解释性别相关的非激素实验室结果" class="sidebar-link">解释性别相关的非激素实验室结果</a></li><li class="sidebar-sub-header"><a href="/ucsf/#基于患者中心目标的个体化药量" class="sidebar-link">基于患者中心目标的个体化药量</a></li><li class="sidebar-sub-header"><a href="/ucsf/#特殊考虑与状况" class="sidebar-link">特殊考虑与状况</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-7" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#男性化激素治疗概述" class="sidebar-link">男性化激素治疗概述</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-4" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#对激素水平的解读的总体意见" class="sidebar-link">对激素水平的解读的总体意见</a></li><li class="sidebar-sub-header"><a href="/ucsf/#监测睾酮水平-2" class="sidebar-link">监测睾酮水平</a></li><li class="sidebar-sub-header"><a href="/ucsf/#监测使用注射睾酮的患者的激素水平" class="sidebar-link">监测使用注射睾酮的患者的激素水平</a></li><li class="sidebar-sub-header"><a href="/ucsf/#监测雌二醇水平-2" class="sidebar-link">监测雌二醇水平</a></li><li class="sidebar-sub-header"><a href="/ucsf/#解释性别相关的非激素实验室结果-2" class="sidebar-link">解释性别相关的非激素实验室结果</a></li><li class="sidebar-sub-header"><a href="/ucsf/#基于患者中心目标的个体化药量-2" class="sidebar-link">基于患者中心目标的个体化药量</a></li><li class="sidebar-sub-header"><a href="/ucsf/#特殊考虑与状况-2" class="sidebar-link">特殊考虑与状况</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-8" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#跨性别男性的骨盆疼痛与持续月经" class="sidebar-link">跨性别男性的骨盆疼痛与持续月经</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-骨盆疼痛" class="sidebar-link">概论：骨盆疼痛</a></li><li class="sidebar-sub-header"><a href="/ucsf/#概论-持续性月经和意外阴道流血" class="sidebar-link">概论：持续性月经和意外阴道流血</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-9" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#性别酷儿、性别非常规和性别非二元人群" class="sidebar-link">性别酷儿、性别非常规和性别非二元人群</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-5" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#术语" class="sidebar-link">术语</a></li><li class="sidebar-sub-header"><a href="/ucsf/#过渡" class="sidebar-link">过渡</a></li><li class="sidebar-sub-header"><a href="/ucsf/#性别非二元人群中性别肯定的特殊方法" class="sidebar-link">性别非二元人群中性别肯定的特殊方法</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-10" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#心血管疾病" class="sidebar-link">心血管疾病</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-6" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#计算风险" class="sidebar-link">计算风险</a></li><li class="sidebar-sub-header"><a href="/ucsf/#降低风险" class="sidebar-link">降低风险</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-11" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#糖尿病" class="sidebar-link">糖尿病</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-12" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#骨骼健康和骨质疏松" class="sidebar-link">骨骼健康和骨质疏松</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-7" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#跨性别女性骨质疏松症的风险" class="sidebar-link">跨性别女性骨质疏松症的风险</a></li><li class="sidebar-sub-header"><a href="/ucsf/#跨性别男性骨质疏松症的风险" class="sidebar-link">跨性别男性骨质疏松症的风险</a></li><li class="sidebar-sub-header"><a href="/ucsf/#目前非跨性别人群的筛查指南" class="sidebar-link">目前非跨性别人群的筛查指南</a></li><li class="sidebar-sub-header"><a href="/ucsf/#跨性别女性和男性的筛查建议" class="sidebar-link">跨性别女性和男性的筛查建议</a></li><li class="sidebar-sub-header"><a href="/ucsf/#筛查方式" class="sidebar-link">筛查方式</a></li><li class="sidebar-sub-header"><a href="/ucsf/#特殊考虑因素" class="sidebar-link">特殊考虑因素</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-13" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#跨性别健康和hiv" class="sidebar-link">跨性别健康和HIV</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-8" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#预防" class="sidebar-link">预防</a></li><li class="sidebar-sub-header"><a href="/ucsf/#治疗hiv的同时进行激素治疗" class="sidebar-link">治疗HIV的同时进行激素治疗</a></li><li class="sidebar-sub-header"><a href="/ucsf/#激素治疗和艾滋病相关机会性感染和预防的管理" class="sidebar-link">激素治疗和艾滋病相关机会性感染和预防的管理</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-14" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#跨性别健康和丙型肝炎" class="sidebar-link">跨性别健康和丙型肝炎</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-9" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#慢性hcv和激素治疗" class="sidebar-link">慢性HCV和激素治疗</a></li><li class="sidebar-sub-header"><a href="/ucsf/#慢性hcv治疗和激素治疗" class="sidebar-link">慢性HCV治疗和激素治疗</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-15" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#跨性别者与性传播疾病-sti" class="sidebar-link">跨性别者与性传播疾病（STI）</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-10" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#性行为史与风险评估" class="sidebar-link">性行为史与风险评估</a></li><li class="sidebar-sub-header"><a href="/ucsf/#体检与性传播疾病筛查" class="sidebar-link">体检与性传播疾病筛查</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-16" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#睾丸和阴囊疼痛及相关问题" class="sidebar-link">睾丸和阴囊疼痛及相关问题</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-11" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#治疗方法" class="sidebar-link">治疗方法</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-17" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#无定形硅胶和其他填充物使用" class="sidebar-link">无定形硅胶和其他填充物使用</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-12" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#寻求软组织注入的动机" class="sidebar-link">寻求软组织注入的动机</a></li><li class="sidebar-sub-header"><a href="/ucsf/#并发症及不良反应" class="sidebar-link">并发症及不良反应</a></li><li class="sidebar-sub-header"><a href="/ucsf/#诊断" class="sidebar-link">诊断</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-18" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#跨性别人群的生育选项" class="sidebar-link">跨性别人群的生育选项</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-13" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#跨性别女性的生殖选项" class="sidebar-link">跨性别女性的生殖选项</a></li><li class="sidebar-sub-header"><a href="/ucsf/#跨性别男性的生殖选项" class="sidebar-link">跨性别男性的生殖选项</a></li><li class="sidebar-sub-header"><a href="/ucsf/#儿童和青少年的生育能力保存" class="sidebar-link">儿童和青少年的生育能力保存</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-19" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#跨性别人群中癌症筛查的一般方法" class="sidebar-link">跨性别人群中癌症筛查的一般方法</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-20" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#跨性别女性中的乳腺癌筛查" class="sidebar-link">跨性别女性中的乳腺癌筛查</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-14" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#跨性别女性中的乳腺癌风险" class="sidebar-link">跨性别女性中的乳腺癌风险</a></li><li class="sidebar-sub-header"><a href="/ucsf/#考虑开始筛查的年龄" class="sidebar-link">考虑开始筛查的年龄</a></li><li class="sidebar-sub-header"><a href="/ucsf/#使用女性化激素的时长" class="sidebar-link">使用女性化激素的时长</a></li><li class="sidebar-sub-header"><a href="/ucsf/#筛查频率" class="sidebar-link">筛查频率</a></li><li class="sidebar-sub-header"><a href="/ucsf/#筛查方式-2" class="sidebar-link">筛查方式</a></li><li class="sidebar-sub-header"><a href="/ucsf/#特殊考虑因素-2" class="sidebar-link">特殊考虑因素</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-21" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#跨性别女性中的前列腺和睾丸癌考虑因素" class="sidebar-link">跨性别女性中的前列腺和睾丸癌考虑因素</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#前列腺癌" class="sidebar-link">前列腺癌</a></li><li class="sidebar-sub-header"><a href="/ucsf/#睾丸癌" class="sidebar-link">睾丸癌</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-22" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#跨性别男性的乳腺癌筛查" class="sidebar-link">跨性别男性的乳腺癌筛查</a><ul class="sidebar-sub-headers"></ul></li><li><a href="/ucsf/#跨性别男性的宫颈癌筛查" class="sidebar-link">跨性别男性的宫颈癌筛查</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-15" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#筛查建议" class="sidebar-link">筛查建议</a></li><li class="sidebar-sub-header"><a href="/ucsf/#改善患者体验" class="sidebar-link">改善患者体验</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-23" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#跨性别男性卵巢癌和子宫内膜癌的考虑因素" class="sidebar-link">跨性别男性卵巢癌和子宫内膜癌的考虑因素</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#子宫内膜癌" class="sidebar-link">子宫内膜癌</a></li><li class="sidebar-sub-header"><a href="/ucsf/#卵巢癌" class="sidebar-link">卵巢癌</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-24" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#跨性别及性别非常规人群的心理健康" class="sidebar-link">跨性别及性别非常规人群的心理健康</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#初级护理下的心理健康" class="sidebar-link">初级护理下的心理健康</a></li><li class="sidebar-sub-header"><a href="/ucsf/#跨性别人群对心理健康的主要需求" class="sidebar-link">跨性别人群对心理健康的主要需求</a></li><li class="sidebar-sub-header"><a href="/ucsf/#环境与社会的考虑" class="sidebar-link">环境与社会的考虑</a></li><li class="sidebar-sub-header"><a href="/ucsf/#对性别焦虑的诊断" class="sidebar-link">对性别焦虑的诊断</a></li><li class="sidebar-sub-header"><a href="/ucsf/#性别认同的特殊考虑" class="sidebar-link">性别认同的特殊考虑</a></li><li class="sidebar-sub-header"><a href="/ucsf/#降低危害" class="sidebar-link">降低危害</a></li><li class="sidebar-sub-header"><a href="/ucsf/#寻找心理健康提供者" class="sidebar-link">寻找心理健康提供者</a></li><li class="sidebar-sub-header"><a href="/ucsf/#合作护理" class="sidebar-link">合作护理</a></li><li class="sidebar-sub-header"><a href="/ucsf/#总结" class="sidebar-link">总结</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-25" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#男性化胸部手术的术后护理与常见问题" class="sidebar-link">男性化胸部手术的术后护理与常见问题</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-16" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#初级和紧急护理条件下的术后护理" class="sidebar-link">初级和紧急护理条件下的术后护理</a></li><li class="sidebar-sub-header"><a href="/ucsf/#皮瓣和切口并发症及疤痕" class="sidebar-link">皮瓣和切口并发症及疤痕</a></li><li class="sidebar-sub-header"><a href="/ucsf/#血肿-血清肿" class="sidebar-link">血肿/血清肿</a></li><li class="sidebar-sub-header"><a href="/ucsf/#感染" class="sidebar-link">感染</a></li><li class="sidebar-sub-header"><a href="/ucsf/#乳头-乳晕复合体和乳头移植并发症" class="sidebar-link">乳头-乳晕复合体和乳头移植并发症</a></li><li class="sidebar-sub-header"><a href="/ucsf/#轮廓不规则" class="sidebar-link">轮廓不规则</a></li><li class="sidebar-sub-header"><a href="/ucsf/#乳腺癌风险" class="sidebar-link">乳腺癌风险</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-26" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#女性化隆胸成形术的术前和术后护理" class="sidebar-link">女性化隆胸成形术的术前和术后护理</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-17" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#初级和紧急护理中的术后并发症" class="sidebar-link">初级和紧急护理中的术后并发症</a></li><li class="sidebar-sub-header"><a href="/ucsf/#性别肯定女性化乳房成形手术的麻醉并发症" class="sidebar-link">性别肯定女性化乳房成形手术的麻醉并发症</a></li><li class="sidebar-sub-header"><a href="/ucsf/#血肿" class="sidebar-link">血肿</a></li><li class="sidebar-sub-header"><a href="/ucsf/#血清肿" class="sidebar-link">血清肿</a></li><li class="sidebar-sub-header"><a href="/ucsf/#感染-2" class="sidebar-link">感染</a></li><li class="sidebar-sub-header"><a href="/ucsf/#切口并发症" class="sidebar-link">切口并发症</a></li><li class="sidebar-sub-header"><a href="/ucsf/#植体破裂" class="sidebar-link">植体破裂</a></li><li class="sidebar-sub-header"><a href="/ucsf/#植体错位和包膜挛缩" class="sidebar-link">植体错位和包膜挛缩</a></li><li class="sidebar-sub-header"><a href="/ucsf/#尺寸不足及美观畸形" class="sidebar-link">尺寸不足及美观畸形</a></li><li class="sidebar-sub-header"><a href="/ucsf/#乳房肿块" class="sidebar-link">乳房肿块</a></li><li class="sidebar-sub-header"><a href="/ucsf/#乳房软组织注入" class="sidebar-link">乳房软组织注入</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-27" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#阴道成形术-术后并发症及护理" class="sidebar-link">阴道成形术，术后并发症及护理</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-18" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#术后即时考虑" class="sidebar-link">术后即时考虑</a></li><li class="sidebar-sub-header"><a href="/ucsf/#术后延期-后期维护及考虑" class="sidebar-link">术后延期/后期维护及考虑</a></li><li class="sidebar-sub-header"><a href="/ucsf/#瘘管" class="sidebar-link">瘘管</a></li><li class="sidebar-sub-header"><a href="/ucsf/#肉芽组织" class="sidebar-link">肉芽组织</a></li><li class="sidebar-sub-header"><a href="/ucsf/#尿路感染-uti" class="sidebar-link">尿路感染（UTI）</a></li><li class="sidebar-sub-header"><a href="/ucsf/#阴道敏感度与性高潮" class="sidebar-link">阴道敏感度与性高潮</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-28" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#阴茎成形术和阴蒂释放术-概述和术后考虑" class="sidebar-link">阴茎成形术和阴蒂释放术——概述和术后考虑</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-19" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#与阴茎成形术相关的风险" class="sidebar-link">与阴茎成形术相关的风险</a></li><li class="sidebar-sub-header"><a href="/ucsf/#游离或带蒂皮瓣阴茎成形术后直接或早期-一个月内的-并发症" class="sidebar-link">游离或带蒂皮瓣阴茎成形术后直接或早期（一个月内的）并发症</a></li><li class="sidebar-sub-header"><a href="/ucsf/#游离或带蒂皮瓣阴茎成形术后长期并发症" class="sidebar-link">游离或带蒂皮瓣阴茎成形术后长期并发症</a></li><li class="sidebar-sub-header"><a href="/ucsf/#勃起植入物" class="sidebar-link">勃起植入物</a></li><li class="sidebar-sub-header"><a href="/ucsf/#排尿困难" class="sidebar-link">排尿困难</a></li><li class="sidebar-sub-header"><a href="/ucsf/#阴蒂释放术" class="sidebar-link">阴蒂释放术</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-29" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#子宫切除术" class="sidebar-link">子宫切除术</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-20" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#手术方法" class="sidebar-link">手术方法</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-30" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#束胸、包装和翻折隐藏" class="sidebar-link">束胸、包装和翻折隐藏</a><ul class="sidebar-sub-headers"></ul></li><li><a href="/ucsf/#脱毛" class="sidebar-link">脱毛</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-21" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#方法与利弊" class="sidebar-link">方法与利弊</a></li><li class="sidebar-sub-header"><a href="/ucsf/#脱毛过程中的疼痛管理" class="sidebar-link">脱毛过程中的疼痛管理</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-31" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#跨性别者语音与交流-嗓音健康和考虑因素" class="sidebar-link">跨性别者语音与交流——嗓音健康和考虑因素</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-22" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#语音症状" class="sidebar-link">语音症状</a></li><li class="sidebar-sub-header"><a href="/ucsf/#声音女性化" class="sidebar-link">声音女性化</a></li><li class="sidebar-sub-header"><a href="/ucsf/#声音男性化" class="sidebar-link">声音男性化</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-32" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#美国跨性别人群的医保覆盖问题" class="sidebar-link">美国跨性别人群的医保覆盖问题</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-23" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#保险和健康福利计划的复杂性" class="sidebar-link">保险和健康福利计划的复杂性</a></li><li class="sidebar-sub-header"><a href="/ucsf/#获得覆盖-改变范式" class="sidebar-link">获得覆盖：改变范式</a></li><li class="sidebar-sub-header"><a href="/ucsf/#私有和公共保险改革" class="sidebar-link">私有和公共保险改革</a></li><li class="sidebar-sub-header"><a href="/ucsf/#性别特异性过程中的拒绝赔付" class="sidebar-link">性别特异性过程中的拒绝赔付</a></li><li class="sidebar-sub-header"><a href="/ucsf/#推翻性别不匹配-code-45" class="sidebar-link">推翻性别不匹配：Code 45</a></li><li class="sidebar-sub-header"><a href="/ucsf/#歧视申诉" class="sidebar-link">歧视申诉</a></li><li class="sidebar-sub-header"><a href="/ucsf/#拒绝赔付与歧视" class="sidebar-link">拒绝赔付与歧视</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-33" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#法定与身份证件" class="sidebar-link">法定与身份证件</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-34" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#性别隔离体系" class="sidebar-link">性别隔离体系</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-35" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#无家可归的跨性别者个体" class="sidebar-link">无家可归的跨性别者个体</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-24" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#无家可归状态与性别肯定治疗" class="sidebar-link">无家可归状态与性别肯定治疗</a></li><li class="sidebar-sub-header"><a href="/ucsf/#预防-2" class="sidebar-link">预防</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-36" class="sidebar-link">参考文献</a></li></ul></li><li><a href="/ucsf/#跨性别和性别非常规儿童和青少年的健康考虑因素" class="sidebar-link">跨性别和性别非常规儿童和青少年的健康考虑因素</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header"><a href="/ucsf/#概论-25" class="sidebar-link">概论</a></li><li class="sidebar-sub-header"><a href="/ucsf/#为青少年创造积极的空间" class="sidebar-link">为青少年创造积极的空间</a></li><li class="sidebar-sub-header"><a href="/ucsf/#精神健康支持" class="sidebar-link">精神健康支持</a></li><li class="sidebar-sub-header"><a href="/ucsf/#青春期前性别非常规儿童" class="sidebar-link">青春期前性别非常规儿童</a></li><li class="sidebar-sub-header"><a href="/ucsf/#跨性别青少年的医疗保健" class="sidebar-link">跨性别青少年的医疗保健</a></li><li class="sidebar-sub-header"><a href="/ucsf/#早期青春期中的内源性青春期抑制" class="sidebar-link">早期青春期中的内源性青春期抑制</a></li><li class="sidebar-sub-header"><a href="/ucsf/#获得治疗的同意" class="sidebar-link">获得治疗的同意</a></li><li class="sidebar-sub-header"><a href="/ucsf/#gnrh类似物的剂量" class="sidebar-link">GnRH类似物的剂量</a></li><li class="sidebar-sub-header"><a href="/ucsf/#监测使用gnrh类似物的青少年" class="sidebar-link">监测使用GnRH类似物的青少年</a></li><li class="sidebar-sub-header"><a href="/ucsf/#激素替代治疗" class="sidebar-link">激素替代治疗</a></li><li class="sidebar-sub-header"><a href="/ucsf/#青春期后青少年的诱导闭经" class="sidebar-link">青春期后青少年的诱导闭经</a></li><li class="sidebar-sub-header"><a href="/ucsf/#在跨性别青少年中使用激素替代治疗的准备" class="sidebar-link">在跨性别青少年中使用激素替代治疗的准备</a></li><li class="sidebar-sub-header"><a href="/ucsf/#使用gnrh类似物抑制青春期的青少年的激素替代治疗" class="sidebar-link">使用GnRH类似物抑制青春期的青少年的激素替代治疗</a></li><li class="sidebar-sub-header"><a href="/ucsf/#跨性别男性青少年-使用gnrh类似物时的激素治疗" class="sidebar-link">跨性别男性青少年——使用GnRH类似物时的激素治疗</a></li><li class="sidebar-sub-header"><a href="/ucsf/#跨性别女性青少年-使用gnrh类似物时的激素治疗" class="sidebar-link">跨性别女性青少年——使用GnRH类似物时的激素治疗</a></li><li class="sidebar-sub-header"><a href="/ucsf/#终止gnrh类似物使用的时机" class="sidebar-link">终止GnRH类似物使用的时机</a></li><li class="sidebar-sub-header"><a href="/ucsf/#不使用gnrh类似物抑制青春期的青少年的激素替代治疗" class="sidebar-link">不使用GnRH类似物抑制青春期的青少年的激素替代治疗</a></li><li class="sidebar-sub-header"><a href="/ucsf/#跨性别男性青少年-未使用gnrh类似物时的激素治疗" class="sidebar-link">跨性别男性青少年——未使用GnRH类似物时的激素治疗</a></li><li class="sidebar-sub-header"><a href="/ucsf/#跨性别女性青少年-未使用gnrh类似物时的激素治疗" class="sidebar-link">跨性别女性青少年——未使用GnRH类似物时的激素治疗</a></li><li class="sidebar-sub-header"><a href="/ucsf/#跨性别青少年的手术干预" class="sidebar-link">跨性别青少年的手术干预</a></li><li class="sidebar-sub-header"><a href="/ucsf/#参考文献-37" class="sidebar-link">参考文献</a></li></ul></li></ul></section></li></ul> </aside> <main class="page"> <div class="theme-default-content content__default"><h1 id="ucsf指南"><a href="#ucsf指南" class="header-anchor">#</a> UCSF指南</h1> <p><strong>UCSF-Transgender-PGACG-6-17-16-译文</strong></p> <p><em><strong>关于跨性别者和性别非二元人群的初级和性别肯定护理指南</strong></em></p> <p><strong>跨性别者健康促进中心</strong></p> <p>家庭和社区医疗部 加州大学旧金山分校</p> <p>第二版——2016年6月17日发布</p> <p>编辑 - Madeline B. Deutsch, MD, MPH</p> <p><img src="data:image/jpeg;base64,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" alt="UCSF logo"></p> <p><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAakAAACWCAYAAABkd3eXAAAABmJLR0QA/wD/AP+gvaeTAAAACXBIWXMAAA7EAAAOxAGVKw4bAAAgAElEQVR4nO2de3QU153nv70YBEJIxcsyGKwixhAZGxpw7MUZi9KsTUi8GMmeJHN0sGnt5kQ7SWaRJmTOnFgZSWfk2WyisaSZPEYTz6gJDCcTJ5Yw8YRgn6jAZ3D8ABpszIBNKPEwljG4JbB4Odv7x63qrrp1q7qqulvP3+ccHaiq+6rq7vut372/+7sAQRAEQRAEQRAEQRAEQRAEQRAEQeSW0HA3YCSRSCTCACTutHFO0//MaKFQiD9HEARBZIlxJ1KJREIBIOt/q8EEKJyFolX93z1gYhYLhUKxLJRLEAQxbhnTIpVIJGQACoBl+r/ZECO/qABiYOKlhkKh+DC0gSAIYlQy5kRKH7LbiOETpXTEAOwA0E2WFkEQhDtjQqR0YdoEoAL2OaWRjAagG8AWEiyCIAg7o1akEomEBCACJk7ysDYmO8QAtINZWDQkSBAEgVEoUiarKTLMTckVcTDrqok8BwmCGO+MGpHSvfIawOaaxgtRAO00FEgQxHhlxIvUOBUnnm4AdWRZEQQx3hixIqW7j7eCOUMQjCiYWNGcFUEQ44IRJ1K6Q0QtmPU0JMSv34DadwGHLvajaNJEKMUzEZ5RNFTV+yUONgTYONwNIQiCyDUjSqQSiUQFmPUkD1Wd0ROnUff6W4hfv2E5r9wyC533hyEX5A9VU/wSA7Oq1OFuCEEQRK4YESKlW0+dGOKhvbajv0fd6285XpcmTcTJRx+ENGmi5fzFa5exQ3sDJwb6MGXCJNxeWIz18j2YctOkXDdZRBuYJyANARIEMeYYdpHSHSO6MMSLcLXLg1jw3Etp00Vun4/Ozy5PHl+8dhlPH34BVz65bkk3d+p0fO3ONTahig9+jJh2AgCg3Lk0Cy0XEgNQTV6ABEGMNW4azsoTiUQr2PxT1olfuYytr7yA+JXLkKYU4JFlZSiZOSd5vfv0+57KiZ44bRGp3acP2wQKAN77+CO8fv4EyuaUsvoHP0b1j/8O3W/sS6aR8gsQWf0QWp+oCXpbToQBHEwkEnWhUKgt24UTBEEMF8MiUvrwXhdy5Fbee+EcPvPURsSvXE6e+5tf/TNe/IsfYtm8O1iay4Oey4td7E86UpwdvOiY7q2Lp1E2pxTxwY+x4M83Ij542XI9PngZbb/uQqz3BHq+8z0/t+SV1kQisQzkAUgQxBjhvwx1hXrEiJPI4bqnbz7bbhEogFlWf/KPfxWoPPOc1JQJzvNOxlBf3U//0SZQZtS3DyO658VAbfFABECP7sJPEAQxqhlSkUokEhEAPcjx/NPzh/YKz/deOJf8f4lHrz1p0kSLh9/Colsc0941Yz4AeBKgLXtzJlJAavhvJEaBJwiC8MyQiZQuUJ3IokDFTpyDevgktD7/I1uR2+fbvPZE1JZ+ynL8wC2fxtyp023p7poxH5+ZfTu0832e6o9pv/fW0OBIYBZVJNcVEQRB5IohmZPKtoNE/PJVVDZth3roZPJc5+ZHEVnDHBweWVYmtKZWL1qR/L80aSJaP3MXqv/joGM94RlF2MSJ1JSbJuFrd67B6+dP4MQAEyRDoABAmlrg6R7k2cWW4+43juPQqT4U5eehYuViyLOzsphYAtCZSCQQCoWi2SiQIAhiKMm5C3oikehEliOWV7c8h+huu7gc/PHXEL59DuJXLuOhp7+OQ2feSV6TphRYHCcM1L4LqP6Pg9A4R4ra0k+hYdliT9YWz4L/vTGtRRVZ/RA6/9c32f107ER07+FUW/Mno7NmHSruWeS7bheqSagIghht5FSkciFQAFD+rX+xWFEGjY//MRoeLwfAHCWej+1F78VzkKYU4PFVD0Oa4mzlxC72I37jEwBAeHphIHEy6H7jFVT+XZPjdSm/AAe/+0PIs4sR3XsY1R07BWkm42T71yHlTw7cDgEkVARBjCpyNtyXK4EC2HCfiKKCVIcuTSnAE6u+4LnMbMbqq7hnFWo/X4m2X3fZrkn5BWh9oiY53Ldj/zFhGfHBq4j19kEpLclau0BDfwRBjDJyIlL6ZH0kSN6+nXvxzlPPYODw8eS5eRsexh1PfgVTSthi3Ir7SxE7cc6STyqYjIr7S4M2Oeu0PlGD9feswpa9LyaH/sIlt2PT5yts81FDDAkVQRCjhqwP95m8+Hzz9l+2QfvBz4TXJhZNw32/+REKl7I5paatPWjr2of45auQiyV0NVYhfPscYd6RjNtw30c/+WYuq15OYZQIghjpZFWk9HU5zu5yLlx8+QB+97mvuaaZUjIH5UftQ2ijHa+OE4dPH8XzB19Cyaxb8Uj4QRTlF2ZSbRxAOQkVQRAjmayJlB7h4CACroM6/NW/wZltL6RN90e/25q0psYS6tFe7Dl6ytEF/Vs/ewr/8FI0eSzlF+LVhudRMvPWTKqNgQkVhVAiCGJEkpU5KVMsvsALda+cOpc+EYBP+i8FrWJEo5SWODpJHD591CJQABAfHEDz83+Pn1T/30yqDYMNzVZmUghBEESuyFbEiVawDi8wNxVNy1JTxh7xwQHh+d4Pz2aj+IpEItGYjYIIgiCyTcYipe+mG8m0nOJ1ZWnTTCyahmlLs7rAlWA0UJw/giBGIhmJlD4PFciTj2fehocxs2yFa5rS79diYpG3sENjibLF92HZfLt7ff0jf57Narr0YVuCIIgRQ0aOE4lEogdZ3HLjRv9lvPPUMzY39Cklc3Dn9+o8WVtjlf7BAfzDS1uw99irkPKn4RsPRlC2+L5sV9MWCoXqsl0oQRBEUAKLVCKRqAWbi/LNq+f78Nr5PsSvXwMALC6ajtW3zEXxFLYlxo3+y7hkWsw74wF3C2u8E/vgAtoPvAltgO1hpcyfg00r7oaU57z3lQvloVBIzWb7CIIgghJIpDJxN3/+1Ekcuvih7fzkCRPwxMJPJ4WK8Eb0yHFU71Jt5+XCaej58n+HXOjbIUUDW+hLbukEQQw7QeekWhFAoPquDAoFCgCu/uEP+M3ZUwGbMz7RBi4JBSp1bU+QYmVkcVsVgiCITPAtUolEQgFQEaSyY/3uL+e9ly8lhwCJ9Gw5ctz1unr6PWgDgdaVNdD28wRBjASCWFKB5qG80n/9ei6LH3do/ZeDZs2K1yZBEEQm+BIpPXhs4PU0eRMmpE1TUkCLerNJQOcJAFB0q5kgCGLY8BsWqSGTyhYXSdj7/llc/cMfhNeXzZiVSfHjjtXz5gLY73hdLpyG8M0zM6miAYCaSQGETlVzGGyYfLV+pg7b6+3BfauaZVM6CcAWbK+PDk0jCWLk4VmkdCtKzqQyaVIe1tx6G3afPWUTquIp+Vhz622ZFD/uUObPQWTJIkQd5qY61yoZV5FIJBRySQ9AVbOElNhUwO5opJnSmtPJXDrnLZ4JYhzgx5IKZEXF4myb97C0AACzlkoKpuG18314/8ogJk+4CYuLJLKiAtK5VoFcNA3Rt44nnSSU+XPRsGollPlZ2V+LrKlg1ML5NxPH9nrmRVTVrIAFZ3ZCy2qrCGKU4WmdVJCNDKPab1EX+2fEb3wMAJCn3ozWZf8TFbdmPUoCkXtogW8mMCHqMZ1Rsb2+XJBOAvCR5dz2+qxvTEoQowmvjhOb/BTaffZVVL/+90mBAgDt4w9Que//JC0rYlTh6/MnbCjcsdNGk7xTkpr1lhDEKCOtSOkeXr48+trfsW+H7uUaMWKpoHVTGcFvFNbrkI7/nWnZbwpBjC68zElt9Fuoev4tx2vaxx/4LW7UUt68DerRVH/UU7/BcWPDUUAEQOMwt2G0InPHTpYU71zhJGYEMW5wtaT0rRsifguVp94ctD1jilhvn+V4FAsUEOBlhUiicMdOIrWaO3ZKRxDjhnTDfZEghUbkP3a8ttHl2lhCO9+P+ODV5LE8u2gYW5MVZH2DS8IPzBnCiuHZZ0fmjrUst4YgRh3pRCrQ2/OmO9ZBmX2X7XxE/mNXARtL8FaUPGtM7Ce4frgbMArx4wwhW45Ei30JYpzhOCelT5QHCoEkTZyKHqUZ3WdfxaF+5s23evZdQuFyQjvfj+79x7DnaC/iH1+DPLsIq0tLUHHPIkj5k9Pm3fLyYahv90KamodwyS3Y+MBSV2vGqK9/kAW4bXj0AcfrRfl5qF17r2sb9hy1TidIU/Ms81PhkmLH+zDaH+t9X097C9avXIRwSbFjffHBq+h+4zh6P+y3tN8oC0DaZ+CBCgDVgXKySAoNYENfMthQVgxAE7bXay75ImDehTJYlIaoQzoFbJlEXC+z26VMCWwd03qkvuMxMAFpT9MeyXQfYTBrJ6bnUwU5vDlDsPab8SZQLN8mvT0S2D3sAdDmaLGlFg8bbWu3PC9W5kakRLPJ4d5EZcuwfs7Q27QDQNTFijTXa+T19h0hxjSOazAy2dQwE+KDV9H0y5fRtus14XUpfzI6a9ah4p5FvvN21qxDpGxp8tgQni17D9ssn8S/Ppn8f9NzL6Pxl3st11sff8gmVN1vHMeO/cfQ/cZxy1CfiJNt3xAKRt3WF323f8/RXnS/kYo6IeVPxkc/+Sa63ziO6o6dybZI+ZNx8G+/kqlQVYZCIWcBEFHV3Ai3ha1AuUOIoE5Yh5zjABbYOjomZPw6vkqhULEOuhPOW83EAVQ75I3AfZsae532e2/C9vpGh3aZF/V2Y3t9pUM9hli2wnlIPgb2XI1FwxVgoiyKflGeFKGq5lbYt2qJYXv9cse2pNrUCPdF/5pelybIK6rXIA5gOQnV+MRtuM/X0I56+hzqel5B+c9/hepdqmOoHjfig1dR3rwt2UlX3LMIjY+VWTrV+OBVoQCY80r5k9H4WBm66r5oSVPdsRPaeWZpqEd7saD2B6jb+qKjg4NRJi9QAJIWF19+dO/htAIF2Oeo4oNXsfzbzyTbX7v2XnTVfdFibTm13yxQALPSYr19FoEy6szC3Ji/IT8mNEbH1QRgOqyhfiSIOja7QBlpI1y6MMQLzTVBmREwITAsjkr9z5xWg2hILiWEEoBuAAv0vGZEL3W8M4S9bAZvcR1ySGcIVA/YszBENaS3y1xexHTcpR+L5shUvdxOiIUi/YiK9XOOAiiH3epWHQTKXK/xHWkzpRB/R4hxgXC4T/fqU7wWUtfzCtoOvGk5Fz1yHO0H3kTPl9Z5jsRd+fQvkoJhtho2PrAUC2p/4GpFmfO2Pv5QMq9SWmIZZtM+jEOeXYRwSTF66jcAALbsPYzo3sPJNMawWnXHzmReKX9yWvHp+os/Sf6/vHmb5ZpRl1EWj1ksze1v31VsaX/3/mOoXXuva/vl2UWobH3W1t7OmnWu7feI9yG/quZapDpKNWlBVDWrsHY61k6QvZFHwKwBDdb9yzbB6MBSnTWQ6qArIAremhoOBFjHXmmyMuJ6OVFsr7ffG583ZeFoqGo2p5Rteb07Qyzjjt2G+1qRemZR0xDoIVif1XoYz8qIXGGPfhHTz5tfClRYf//uQ4+pz4vlNT/DquZlYAJULRyqtebtNn1HdsAqmLJrG4gxi5MlpXgtIHrkuE2gDGIfXHDcOZan6bmXLYJgHtaSZxeh8bEy9NRvEAqUW16ePUdPJdMppSVQSktsnfmykuKkhWIMkbmVaWCUx2OuSyktsc0tRTmREd2jgWHBubW/+43jSYvLoPGxMtc5LR9IiUTCy5u1DKsQbXFJLZvyVej5NIjfxmXdqgFYZyuBddSVung0YXt9G+yYra1uy5AhsySqhQIlyusP2XLkPGQlc8fidOz5RExn3J6rCPscWeplgg2r2YPaus0jyXD/nNvBhviiAfIShKPjBD9E4UjTPuetIgCg+10NsQ8uuG4ZER+8irZfp+ZhRJ0078jgJa96tBfah6nfl1JagvUr7WXzHfqh3r7kkGNP/QaES4pRxw0Jri51jtge/9g6FJjO4aFu64uW9huWVtD2G6JVu/ZeSFMnQ327V/j84oNXob59CodOsXtbdlux7dnHevtsInhQe3+jbsVoLp1uA6xDS6xzZ2/y5o5JhbVTVMGGi9pNlk4U1o55I6qajYn/GIC65BXxfE8EVhHYYUvj7JDRKMzLOljz8J4GvnO3O0OowjoYVvFw9uyz1mmkY+Jl9saN2trD4If7jLktgAl1TL9nM3sc2gLYh+GsIs6+H5pDXuswrTGfx56b+T5VOEWDZ59DxLF1KcvMGCo2tkCJA9hh+dzdy9Joy5ThwUmkFK8FeNmePHbeXaT4eZz1Kxd7rR7tu1635dXO96Nu2+7kXI08uwidNescF9Pyc1KGVdNZsy4pMGaxANxdyo1O38BNpPh7X61bRnVbX0y2Q55dhIZHyxytOb79RtuN9CKB4p0qDOTZReiq+2KyzXVbX7QMN+rU6n9NEEWhsP/YRUNKGtiwHN+psTkWK+1ceYr+r3XYzhlrR+rm+WeHX4ahcg4ChjehyHrjvySasAb2vLykq4BVMLv1OblWpJ6JCndvPP4F1Mhn9ojkfyhO7ZFh/VxUD5+FOa9iOqOahN8YstTAhFN1KUmG+3xVo/6MumC3VitQ1bwJKQcT97KqmmXhSxCRU2wipc9HpR/O8UH8mt3JwEw7582m3Ol9X6noXuv88o79x5Kdb7rOHbBbIQCzMCruWWTzpDPj5oBguI4bSFOdXea3mIb5AOa63vTLlxEfvAopfzIaHnvA1d1d1H6ltCTtPVe2PguAWW4bH2DTIe27XoN6tBflzdtwsv3rlrmz1scfsohtefO2cji/IVdwxxKAk0i9wTq7kotgb/cq7C9P1Wk9vlgHJZvOqJ7rtYuCBuCgfi4OJp7Ort7235FTmCOZO9Yc0vGCWYHUvI0Gkeinrwtg3nuNAdrDf85uFhcPH7RYAnu2Egyr1J/lIvaaZLQi5dJuWIsKUnN7rbC+GKWi1KeWKzTAxwgTkT1ElpQvgZLyJiF+7bprGmXeXMdr2vl+S0cr5U9Ouw7KINbbZ+uko3sPJ737Nq39TPo1VR/a+xfDQcOAtyTShTfih/uchga18/02K8iYB8uk/Q2PiYdGDdpN3pNmD8iKexYl4w1G9x52FEcpfzIS//qkFgqFNIcqeA9AGYbF4d6puzYbVpHSPFpEfEfq7gRghe+UZP3fKLyt3eGdIVSHdAp37NTZ8+lk+Bd9WXCOt1yt9ThbMvzn7OfZKtxxGJl9R1Zzw5RRbK/XTBZbHGaX/O31KqqaK8FeniKwPgPJNFQrwf45EkOISKQUPwXUrrwbjS7zUsr8ua5DfXwn7WdyXzAMhdq196LhsQc8C53hSGGm9fGHLPn9WFGidjkNDYraHylbioZHyzy7ivPtl2cXpRVR45lvEoiQcifzhuRd7M3zZkppCXrqN4Th/IatcMfdYG+wQcTJgO8AmQNF+s6Z72Dspqcz/AtbDGx4UfOYX+aOne4//fAaswj5L5K/Dt0+R8bKMM9/2cM4uZXNPx8/ny+fNwomtkG/Iwr44UP2HGX9OGYrm4mYU9t6uHOGgBJDjMi7z9dbQ8OqlYgsEXujyYXT0LnW3ULm52/c4MWilztWSktsAmMgcgBgZXJzTbOLbENlRhSHVBr2OxYt2hUNvxmCE+vts4gyX65SWoLOmnVCgRJZjaL2V3iYz5Om5jm2Nf6x2M0+UrYUjY+VofGxMmxkz0dscdvnVwCzE4Q1rSSYpHdCtHutPWyXvZN1njy0563lzvD3uMVRoKqaWwV1250hqpplfeGqGZk71vRn02kq034f2+sbHZ5rWHAv4jKs65HsbU7NJ0ZMXpVu5dlh91xhOhZ9d5pcviNeggpEwbxBjT9DeDX937Dt8xF/VwFjIXRKlOLYXj/dc9QNIquIRMr7j1qnc62CzrUKKhbKUObPhTJ/LlrLV+HgE49BLpyWhWayTnr5t5/B8m8/Yzlnxsn60M73o7x5m23tknHNjMi6UN+2WjyrS2+DerQXla3PovLpX1jL44bfDMsw1tuH8uZtWP7tZ5LtdhIEnvjgVVS2Povl337G1l7+eLWHSOuGYwq/kNkY5mPlWIcoN5YtRcOjD6Dh0QcMEXd6mZEF55yGgboANKTthNh1keWmWDoaJngnuU7Qa0faCaBV/9cpr/g+UotRO03nZC5VTO8kuwDUch0+L2YqUtEkDLFR0tyBUa9RR6tAVHhx6BYIg12kUs4Zrcn7cu7gndrTZWqPSHA1h7w9YM9LJLpmerG9XjX9GcN6GphVxcoyvhvMqjRefKJcWXG9jMZkXm9CSeSAjIf7DCJLFjlaVJlidPDxwavYWOY832JYOGaMDj4+eBXhEnv7vGynwQtP/ONrqO5gmzfy8z8i4VSP9qLy6V8gPngVkbKlFuFKhxH1Qjvfj4p7FtmEmB8y9DJcGilbivZdryWF31hrZbQnUrbUy7YictqK3GAduwIjNpv1Wi2MOG+sY6uFMafAhEAxpW4AUG1ybec73fTtTHkdajC7s3vBusbIfB98vRpSE/XdyWFK1hFLlnSpMmOwWzpubTE6dRls8j/KpeBfLERzX/wH349UlA6zo4rsoz3We/YCy9uJ1DID73nt1IHdQxjAQW6ILwb3z7wazKGjFlXNO8iaGnoslpTu2Tes8B234W1mdPBunm68V53RCcd6+xAuKbZFXBCFWBJ18ry1UrdtN+KDV9H4WJmtM+eHIA0rzmi/uQ3pBMUQZ6f2uw0tpqOnfkMy5JR6tNdSB99GpbRENITq5GAjmlNIpWVDPwdhDekTN11XwDrzLl08DOvE6CDbubIrYI17x0eb4K2f1PgzG0oywgXFkd6d3XwfUtL6SrXPXJfC5VWQEkLzJD3/HCW9TP7Z2K048/AVe24HkerURXH/ZO5YZBny7TGC+0YtIiPurBVTe8Jce9yjlJitX2al9YA5vaT7XDSwlwNRe4y2xsAWKdfp6VSk5kmXm8o2ytpiyqvpbW8CRb0YFnhLyqnjEdJ7+RL2vH8WfVcGUVJQiPtmF6OkwN/wXlF+nuU4PngVTc+9jNWlt1nC/fAdPJCa5DdQ3z6V3MepfddrybzmEEJmgjptaOf7oZSWCNcf8WWarRO+/SUCqyjW2wcpfzK2vHwYbb9+TbcAWft5oXAaWvSClD85OXznRuvjDzleSyQSUigU4iejY2BhhswvPA16h7oe1nVSlYJJe0OUFFP+aNKTb3t9N6qaNaQ6DGM4yUgX5ZrJd26KaegmgpRbvCjIbTf4kExVzTHTfRh5xQFprRhp0wmh8dzSiS3Aht92wPpcYzB7sVnhf99amjYb7XGyNvjPeZNupZS4tod51vFlNaCqeQvs9+K+zIBda0x7F6z+NrhZpk5lsc823edL5Agv28cL6bsyiJ+++5/J42P9H+FY/0f46uIlKJ6S77mcipWLLZ5jAGwBXWvX3ivsLNevXGRJGx+8igW1P7CkEYmDAS8oXj0CwyXFljh9ljKm5tnOiSKmA+J7N8+5AcwtvLNmnaMziKVuj+3PImGI32C7YV98q5iOVYg76zDEb/t8B9kOezBXp450B+xu6Ob5DRXOHSGfV4Y97h1vQRnw9+YkhCIxsce5Y55oKqzPMQLrc27D9nrx0JVoDkl8z/w5N9HjP2cJ1sWwbXByiGDDd+a8FbA+a8PScRN0YhzAO04oXjO+el48n+J03gl5dpFjrDrd1dnxbT5cYg/jYy63q+6LrkFVeTdrJ0vE7O1Xcc8ioVVjYHZckGcX4eDffsVxiFKeXeR6ravui7ZI6Gb4ocUsxebLBnUQd74aWMcj7vTYEJJ5Xsepg4xy5Ucd0hnhjkQiopraooluwiWvBtb5LncJX2Ruo3Ef9rTsnKofGUIWdSjTyQVa1fO5za3I3LHmkM4cPy8KZ4Ey2iMSYyOfm0u5KC+QcvP3EkmEGAdY9pNKJBKN8BgS/6fv/id6L9tDIpUUTMMTCz/tqxHxwauofPoXyQ0KS2axtT5e5lfY0N7rlnOiGHQieLd0eZYkrNPYp8rYdDEd1R07PW/QOBTtzyHVoVAoKrzC3txl05m4S4cuzus2SZ0KydOdtlw231EB1gHGIVoz45xXgnWYzM99KADcFsOa2yfDS1gh+3opt/iJwWBzfJqn+2RpUxa1H8cC+3ck+/dCjHoCi9Sr5/uw+6x9IeyaW2/DfbNHzBs9kVuaQqFQ43A3giCyRipChayfiY4Z4WQvTYp+pGbNU5G9yFUgR8+Mn5NKv8hGZ9mMWTh08UP0XRlMniueko9lM2Zlq20EQRC5h1mnxrb1vHOJs6PFSCcluOv1f60WeGZlG6MT6yFaf5dFeJGSvWacPGECvrp4CQ5d/BD916+jaNIkEiiCIEYXVc09cJ6Lj4/aeTH75pY8WgZlN8JtxM3rcLhHAnv3GZAwEQQxiqlDysJYD6vnZ1Y72yGGOeuk4AUrk3uLIuXso8AqWFl/ZhmL1GhCPX0Oe868l3E5G5cssoV7anrFffNHM0V5kxCePQvK/DkZt6XtwJvY8a416kTn2tW+w1GJns3622XX4MAAgJYOGfaN4lRsrlHTVtrSYQwXyNwVDSwaQjc21wR7k23pkJDa5E5Gakgi5TwBbMHmmvQ/KvE9+mNzTaOgXAX2t/goNtdoAdojfub+2h4DEEtbv7hNjb7zmPH+fNzQwJ6D5jmHdZ0eX9foFSlmAaoARLESM7MQzRtZDsEzy0ik4pevor3rFUR3H4DWF4dcLCGyZgUaHi9Pn3kY2HPmPdeI7V5ZPW+uTQSClCvlTULtyrvRsGpl4LY07dtv2yqlff9baC1f5asc0bPpfldDz5fWQcqb5JZVhtj0Vx1ztHSEkQp540QEQCtaOtieTV7FiolTrUObYKpTAVCLlg4NQHUaUZVdyvNKo+CcIih3NaxvwH7ao/pI60xLRwxAOzbXRH3kGqrnk56WDhVAnacXECt8NGyn/b9GGxJ37Pxc7N6s6TwueT+GrD8zUYBZz5R/61/QuPW30PpY/6H1xdG49bco/9a/ZKVxY534teto3Lcf5T//Vdo9uUREjxwX5oseOQlKkTsAABmbSURBVJaN5iH2wQU0ZUHULTCBMuK5pcNYHHpQz+el7IPw17HJAHrQ0jFSAogqGVslmcNeIlo6vD33kYcC9p2J+Mwnc8ej15KyonDHbvdVC/b7NP4iacqWuWPVe7O8EVikorsPInbinPCaeugkorsPBm7UeEM9/V4gMdhy5LjwfPzadUQdrvml7cCb6H5Xy0pZOp3wH2lfhmhbDjMp8ZODNArMqhopHXLDCGkLe6Yjoy1B6PTZdpk7Hisi5cfa4YMQp3sGCneseWiPL3iR8rz985YX3UVox76jQdozbmk78CZiH1zwnF4buAT1tPP82o4sCkv1LjWQpWeDzUE5dRoqnH8QcbhtOMeG+IxI3UFpCjA8lEu69PsabiSMbqHyZiHb51a0UevZZ0fmjt2+53xazTGl91BbGZEzxwmveyUNJRuXLMJqh63sy3++03IcvnkmWpX7hWnTOhPo9HzJHpIpfu0a2g+8JRSYLUeOI3yzt7mk9v1vuV7vfleDNnApK/t5xa9dR/UuFV3r12RalKijYzHajDmnlMNDA1KiU51mTqoBYgsqDhbnL+WMwBwJFC6PKpy4dycGv9t6+EMG62Ddo4cHQ9R2Cdbgrvy1VqSfK0tXRzaIwhq6ySAM63fGQEFLh+zBmYLPly79aELhjt1EyvobdXcnl7lj1WuD/BBYpORi95e88KduCVp0zpALp3nutKW8vIy975zyVyyUUbljt20YLXbeuyXlZd5py5HjGTllmOl+V0PbgTdRu+Ju82nVZzGibZrbLQLE/t+Glo4oDCHZXOO8OJCJTq3gCouDx1tHrLOKoqWjG6zjVSDe1iIdcU8ejJkRQUvHDtf7D4ZT27t1RxWRU4uClo6ID2eKXD2fXodyVd1hogd2wZGRXnT4+7WPKrG9zQxv0XYPke+NfMaL13rT2R0w9kxLn1+BddFsXM8fN53ThDEf7btFO3v22TfJ1DgLk3eiUGBFA0/QZ2aCFyl7JQ5sqlzlOu+06VGxFUIwNq24O/Bcj8hhovH+lWjb/6blfPSt7IkUwDwJlXlzPVuSHknFfTPDxMrLm/gmh/OVrsN3rPxq/S17JA/rdKKlI5hbeBA218TQ0lEO4CTsnf0mZLb5YG5hbe+G3RpUkP6Fip+L0ZL/Yx11J6yWQxheIiuw2IaieVgFbGsT5wDHqR2RFcHVCu5Yhfiz4cXX+ptg97ZRL08k7ub1VXWwRuDgA4Wm5rpY27tgfWYKqpqn+x1G5eekNK8Zw7fPQefmRyEVWAOoSgWT0bn50bSW1ngnk45e5DCxcckiVCyULee0gUtZdXqIX7uO6t+ollM+ixA1phUtHa26RRQERXAu6vktfqg6/+BIMG9LPxQ4vyCER8g8mRtBXaBl7lgDYFgCIoccSbD+yArLa8yVdoMNl0a5OsWeqKxsczSMGJjFz5dh4ORP4C5S1r3R0sHn5ctWAbg9M1GetPCWlK9OJ7JmOZRlC9C97yj6L19FUcFkRB5abhMuwo6b04MbIoeJioUy5MJp2Lhksc2rb8uR4zbx8opcOA3agDXSfeyDC6jreQWt5asQCoVi+oJLr+yBeM6jFsy7Lgb2Rd/hY6hI9KXnd+/NBbJHV3FvC5vN6UW7+rZ01GJzTZs9eY7YXBPV3fL5zkts+drx+nw0n+ux0rFecE71kI+fi1FNVhDAREvm0ritN7Lm3V5fqZ8H7Hut8XllWIctY7BumaLqG4uah7md2sJ79ln392Hbu9Tp9fIhoirTDM/ZBZCJq/Mz8/9iaxWpUCgUSyQSvgqQiyXUVvpbODre0QYuoa7nFdv58Oz01pXIYWK9LkLK/Dk2YcnEgSJy1yLEPrhgs8baDryJhz91W5AhMmMeyOmtLaz/GYtst8BtIa+TQIqG+Vhat1hmRt5Q2jQMGd7XY6ke0wHMi1GCvQNoRUuHOsQeiDGIBNOrSHl7PiqyNYTY0lEL8UuL5prP7qWmcZ1tFNvrq1HV7K1ztO4wDbi/NPF1A9bhQTa3Kt4g1NpmMWJrx1ta5984u0fz7zgOwxOUIX5mAeL6iRwnNARYa3Kj/zLObn0Bfb9iVueU2+Zg3uMPY8YDK/wWNWYQhUpST59ztKLWe7B4eIcJKW8SIktSe09F7lpkixyRiQNF51oF6k+22+bAHvrFC/A99LO5Jo6Wjmqktnt3Qwbr5DahpaPShzUylJ14rqgEW5TMP99Ofb5oqNCGsC6vrBZYaCWwbq9hxst8Hp8vjpRQGJ2twqVRXcrjvQyZNcLE0DyHqoFfWmHdTgMQOVcwgbC2x7nzl7ljTZjKLjrp9gYTDSOmhjbZM/NWdxqyIlJ9O/fi8Ff/Bjf6rUNDZ7a9gHkbHsbSf/pOkLaNevyESlLmz03rTShymIgsWWw53rjELlKZOFBIeZPQtf5zNhd9pOZK/A2tba7pRkvHcjhPCIvq6UFLR7lHoZJ9tWcksrlGQ0tHHexzUWGwDnDHkLdp5KDAXzw/L843fHky2PcuZsovc2k0YUkpTz6DGLbXa3rk8E16uXGw302bwELirU/R74tvr9uLmWw5cl7H5NUyc0qvmPIZyyZkLk26MoWIRGoPfHwJBg6/IxQogzPbXsBN0jTc+b1a4XWCOVF4WYMkWqAbv3bNZrHxQ36GA0XQuSll/hzUrrgbbQfe5C/xHkbeYENW5foQnJNnEU8ngAUeSh/pE/veYHNC62F/xkP5Q5IF50ayJyRPnccXG37exhCSapOIyFwaJwcN/rscR1XzSVP+KIA6oYdbav8nA6e4efy8myiNaIGyKkzHkLljcZkpnH5nlaZ74+v3HCzCjJMl5Zl3nnrGUaCSBf7gZ1jw9S9jSknmUb/HGpEli9Bafn+6IK6Onnpewx9l4kABAK3lq6CeeU8UFSOYUAHQOxAVzBU8jJRgyYLUMlo6wpY5mc01Klo67ClbOioEa4s02KNWbHSoywsqNtfkeuitGuyNVebO516o2FCuIrjidTh1KJ6PE0xgvK8vkwXn2rkhNH6Nn+pQFi8giv5vN5g4aS7t4H9L9med2gXXzCGH8nghcatb5o7TCYpozWMT98x48Xer3xGRSPka0+/b6U0cz2x7AXc8+RU/RY95KhbK6FyreErrFKfPK9mIQNH5OQXLt/4yo3Y4wsSHDa+wwKBOnmX89zMG+9DDJvBrWNi8RKPlXEuHschwZJKaw0vv8JF9xEKY+wXM2cDPHCYgWpS6vb6ROyfb0ngrSwXrvL20h+/4ReIjGnVwKpv/Xbi55/N1p7OYZe5Yg30XY1Ea39gCzIZCoRhGl0k/Ykl886vJP9HWGd3vap7XMUXfyjxgbKZCF755pu8tQGy0dEho6eh0dbpgLslRwRVZcE40P6MEiIA9MmGdrXPcwlzArFqRZ150SNshpgmba0LJP3HH531dmT0iA6vDjmw5YvNMsu5qbi6LL89ZoKqa+RcBWZSMQ/S5aKhqrhCs2+IXKKvJeu33zR/H9LSSoJ2itjYJhjAVyxFz65cEkS1ccYqCrvophEhP7Yq7hQt463peSRu81bCCMiUbQle74m4o88XxDz1ihP8/6HONFSC28qMOaTs9CNXomL9icQWHxmuRuXE7WW6imHnDjSi2odc1WoDI7ZoPL2Tv/I3PogtAl0moRO7v4hf+quZOAK26Q4VTW1QuTy3EQmY4MfGfG59W08tohT3wrv0emZD16O1MCZV9rgvgRy6cPfu6AHT6ESqn2H174HGuYWbZClzYeyBtuuJ1oiHM8YVouEwbuISmfftdLRSRBdRavgrh2bNc66tT91nmkDJ1oDD44X/7bPWS6LNu653EsMWhxo9BBvPaU8E6P1X3apPBREz09qbZzrA8bQ7pO9HSsRHMQ8oYIQjrf5uQ2VCfn45QvPOsP5zc0oMgansRnOcDAbZeTc2wDjfS70gsgs1LRmFfJN6Alo5uD+vK3IWBIXPHmi4yYQBqmgWvmu0MyxsB+z5GXfKm6mVC2YDUeiRz+Ya7PG8B8vcmg4lT3JJWHDlDRiqGY4xrp3240W5Fydyx8cwUMI/HKDziJFKq1wLuePIruLD3a65pZpatQOHSO7wWOWYJ3zxT6CXXduBNrF8oC13QRQ4TcuE0PtCrkI1LFiH2gXXRcKYOFABw58zp3WBfdC/rnRhsmw6RkCgwhgVEThApNJcOp0kvQ/RjS5WfXWT421yxMaPanN3SgyDDX9tj8D/k6LcOFcHXZdVBPFfjJXI7P7kvmgcSuVsbHoDm4MQiq4kJGWAMB7YiJVDOcfsYy0z5DCHiX8hk/V/VMo8m2kYj9XvlHThEDhZGxIsY7IuJnSxLMwp3LCF1374COguH+/R5Kc1LATMeWOG6Dqpw6SKs+Lfv+WnTmKbh/pVC54XqXaowvciK8ioy/BoqICtDh2ooFIrrnlP8RKkbhmNEUJzXuxjBYjOfS41mmD+3sLk6rx5r2YJ1UiM5CK9zrEFFH750g+9wNQ81Gp26tfMWL6jdhKpmRR8uOwirQImcgMxE9OHAk0iJnWjIVYO945cd2t0msGIUQV5Jr08U7YKf6+pHeoznXOl3zym3nXlVr4XM2/Aw/utvfoR5Gx5OupnPLFuBO79Xhz/63U8xsajAT5vGNFLeJOHQnjZwSRihQjSPtGnlXZ7rEglahg4UZkeFJngVHjaUUw5/wmbQltadmFlZCxBsPpW93W2uEc1vjDSyIcZeacLmmuUjWqAMmICrgisNaYIX89c0QRrR/Vc7iFKUO66AMa/D6jIsE1Fe/pyEVPSKGFgHz6eJw7o2ya3NUT1WH48mONeG7fUigQK87SPl9MxEaV1xEylfq9oNi6r8aBe+MPg73LfrR5C/8WXEzpyF+s670C5e9Nu2MUvFQlkoHo379lvmkERWjzJ/ri838o2mkEkGGTpQpMQiZcF4Y3NNHJtr6sDEJIr0na0GJh7eNs9j5ZfrbdI85NDAhHZBDvZsyg3smQfZ/8orGtiLxIIszKMNNaLvojFU5oTMHWuCNObvRhzAcpc5lSaIv9fGPJCTQBl5RURhtWhipn/F5bFzqqXs7fVOv1VzOkP03H5zomF1nihSz8GwHKMe8tlwDaaZSCQ+QsCJ2tiZs6j8yTPQLqTEqbZ8NRq+8HlIU6YEKTKnqKfPWY6lvEm+ttPg8wPOmx4CbNsL0XbxclFBUoS0gUvQ+i87Xs9m2zzWFQuFQstthTGXZetkrtdJcObhpwiueJn0Tld2WC+7BKkfVgxsvYj3YK3MXd7LD9MZkdMBe8OXubMxT5aL12fur+3e6ha3RwmUz61u8fNx/27ZnwtD9PzZXI/12Ti7i1fobUm/UaE9/h4TDO8bHBrhk2IAtthEiKWR03b6zCGiQm+zliatMafX7fH+UmTjmbmQTqQMLxRfxK9cwYK/bkL8yhXbtdry1Wh97FG/RRIjg7pQKBRkuI4gCCIQbsN9QMB1EdHfvSYUKABo69njeI0Y8YyOITGCIMYMriIVCoVUBHAL7U8jQrEzZ/0WSQw/3aFQSBvuRhAEMb5IZ0kBAXY5LUoz5xSed6vfIonhZyRGGyAIYozjRaSi8OnyWrHsbkfnCOWOhSPScYJwRQuFQjTURxDEkJNWpEKhUBw+5yLkGTPQ+ieP2sQoPO9WdH2VIqGPQnxb0wRBENnA1bvPIJFIyGCrnn0Rv3IF3YffRO+Fi1g271ZULE2F8ol9cAHxa9d9u3oTQ04cwAL9ZYUgCGJI8SRSQHB3dB719DlU71Iti1TlwmnoXKuk3T6dcKb994ew4332HhEumoW/XvQZSBPzslF0UygUasxGQQRBEH7xI1IyAlhTZtTT51D+852O13u+tI6EKgAr9vwbDg18aDknTczD/rIvQ84PvskhyIoiCGKY8eI4AQDQ3Y+jmVTmFETV63XCTvvvD9kECgDiN67hL468nHHxJFAEQQwnnkVKJ/AOobEPLqSNvq0NXBKGCiKcMYb4/F7zQBzBgsESBEFkDV8ipVtTgYQq3e6zftMROaeOrCiCIIYbv5YUwN6ufXdeUt6krKYjGG5zThnMR8VCoVA0aGaCIIhs4Vuk9Ldr3/vuhG+emTZ6t1w4jdzRffLXi+519OJ7eskDQYv1tjUGQRBEjgliSUGPPqD6zde5VsnoOmFHzp+G395fgdUzb7Wce+4zX8D6WxYEKbJNj9lIEAQx7Hh2QefRXdIPwud+U7EPLqByx27bOqmu9WvIikpD7MQ5xE68D/kWCcrSQAKUDg3AcpqLIghipBBYpAAgkUjUgm2L7Btjkz1+Y70jlz5Bw9HLeOXiDQDAqhkT0VRagCXTbsqkqaOeysbt6N53NHkcvn0Oer7/PyAVTM5mNeVkRREEMZLISKQAIJFIdIHt/pgxA58kcN+eCxi4kbCcL5wYwqurZ6LwpoybOypp63oFdT/+d9v5yJrl6NyctQ0k20KhEM1FEQQxogg0J8VRjQDefiJ29V2zCRQADNxIYFfftWxUMSrZYbKgzGh9WRuVi5FAEQQxEslYpPT5i/IstAVnrvy/QNeIjIgDqBzuRhAEQYjIykRPKBSKJRKJOgScnzKYN8VZM/lrOw++hEOnmYVRMutWPBJ+EEX5hZlUP2xc6T2HM9teSB4Xr1uNwqV3JI83PrQc6iF79IgsOU9U0467BEGMVLI6yZONSOlr9n2EIwOfWM4tKbwJu++fDgDoHxzAmu9vSAqUQcmsW/Hs13+MpfNLM6l+yHnnqWfwzlPP2M7P2/Awlv7Td5LHdT/+d7R1vZI8rq1chdY/+0Km1VOEc4IgRjRZ90RIJBIHAYSD5h/4JCH07jOcJu5resQmUAZSfiGOfbdn1FhUfTv3Yv+X/9Lx+h1PfgV3PJnaJDJ++Spivz8HuXg65GJfnv8ioqFQyPeibIIgiKEkFyIlAehBBkLlxM6DL+GLP/wz1zQtf/okvvFgJNtV54Se0kpc6T3neH1i0TQ8dO7FXFSthkKhrMwjEgRB5JJsePdZMDlSaNku28mCMvP8wZeyXW3OcBMoALjRfwkXXz6Q7WpjIEcJgiBGCVkXKSApVJXIkmv6aKbvyiD2vv8eDl38EFf/8Ifk+Rv9l4ejOTGwBbvj/nMhCGJ0kLMwDrrHXznY0F/GEygAc45IxyPLH7SdU4/2AgDCJcWQ8jOL0BC/fgNNh44h9tEAAECaeBPW3zYHkdvn29I+f+okDl1MbUg4ecIpPLHw0yieko+JRQWYWDQNN/rd99iatnRRRu01QQJFEMSoI+chHBKJRBhZFKrFf6Wg98OzwmtSfiFebXgeJXqwVe18P8qf2grtfL9+fTJ66jcgXFJsy3vlk+t4b/AjTM+bihl5BcLyYxf7Ub57H+LXb9iuKbfMQpfyGUiTJgIADl38EM+fsruNS5Py8Od3LgXg7NlnwHv4ZQAJFEEQo5KcDPeZCYVCMQALwDrKjHn26z+GJPDek/ILsftb25ICBQB123YnBQoA4oNXUdn6rC3vDu0N1L/+b/jRkd146kAXfnRkN658Yt18MX79hqNAAYD6/oeoe/2t5PGxfrEexK9fQ9+VQQDMe2/ehoeF6QqXLkLp97MSBIIEiiCIUcuQRG0NhUJx09BfRl5/S+eX4th3e7B133PYe+xVxAcv4ZHlD2Ld8ocsAgUAsd4+W36zaAHA7jOHsfec1SHjxEAffnZiH6oXK8lz0ROnHQXKnKZh2WLIBfmu6fImTEjdzz99BzPKVqBv5158og/93brhYUfx8kkUtMMuQRCjmCELLa53lMuzseC3KL8Q33gwktbVXJ4l2USJn5N6/YMTwrxvXTyNK59cx5Sb2E7BO06/76ltsY8GIBfkY3GRhGP9H9muS5PyIE2yblI4L3uiZIYCxhIEMerJ+XAfj76AdEg6z01r77Wdq/289dzFa85edu8N2kUmHdplNpS3bMYsLJsxy3Jt8oQJ+NKChb7L9EkcLNQRCRRBEKOeYdmkKRQKtSUSiRiALmTJoUJExT2L0FO/AXuOnoJ2Po71Kxej4h6rt9zcqdPx3sd2MZpy0yTcXphysJCnTvFUZ3hGUfL/j9y2APfNLsax/jiKJk3C4qLpmGwa6ssBGoBKfR6QIAhi1DOsGzTp0Sm6ACjD1YYTA3340ZHdtvOfm78Ma+YtTR6rfRdQ/pv/cC1LLsjHyUftLvBDRDeYBUXzTwRBjBmGfLjPTCgUiuvheYZtaOr2wmJ8bcka3DWDrXOaO3U6/nTh/RaBAgCleKZwLZSZzs8uz1k7XYiDWU+VJFAEQYw1RsxWt/p6qlYMo1XlhaZDx9B29PcWTz+5IB+dn10OpXjmUDenG8x7TxvqigmCIIaCESNSBolEohZAA3I4V5Up8es3LBEnzPNQQ4QGJk7dQ10xQRDEUDLiRApIzlW1IkNX9TFKE5h7OQ3tEQQx5hmRImUwWoYAh4go2CaF2jC3gyAIYsgYVseJdIRCoZjuWFEOQB3m5gwXUQALQqEQbfNOEAQxkkkkEkoikehKjA86E4mEPNzPnCAIYjgZ0cN9Tuid9yawOasR62ARAA3AFtCcE0EQBIBRKlJmEolEBMB6ABXD3JRMiALYQd56BEEQVka9SBkkmEdgBUaHYMXB5th2AOgmq4kgCELMmBEpM7pgKQBW6/9mtD1IloiBCdMespgIgiC8MSZFisckWmEw4ZL1v1wRA5tfOgQmTDGylgiCIPwzLkTKiUQioej/Nf4tgT/x0gD06v9XAcQpAjlBEARBEARBEARBEARBEARBEARBEARBEARBEASRMf8fX2v8xiDpn/sAAAAASUVORK5CYII=" alt="logo"></p> <h2 id="指南简介"><a href="#指南简介" class="header-anchor">#</a> 指南简介</h2> <p>加州大学旧金山分校跨性别者健康促进中心自豪地发布这一关于跨性别者和性别非二元人群的初级和性别肯定护理指南。跨性别者拥有和出生时被指定的生理性别不同的性别认同。据估计0.5%的美国人口是跨性别者[1]。众多需求估计显示跨性别者在获取初级卫生保健上遇到了一系列的困难。2006年对加利福尼亚州600多名跨性别人群的调查发现，由于先前的不尊重或歧视，30％的人推迟寻求医疗保健服务，其中10％的人推迟接受初级卫生保健[2]。2011年覆盖了所有50个州超过6000名跨性别者的跨性别歧视调查发现了几处值得注意的不平等之处，包括28％由于过去的歧视而延误了医疗服务，以及19％直接拒绝了医疗服务。最令人担忧的是，50%的受访者报告称需要向他们的医疗提供者教授其医疗相关知识。[3]</p> <p>该指南旨在通过为初级卫生保健提供者和卫生系统提供工具和知识来满足其跨性别者和性别非常规患者的保健需求来解决这些差距。指南扩展了原有的UCSF跨性别者初级卫生保健方案；其自2011年推出以来，已经为美国和世界各地的数千家医疗提供者和政策制定者服务；2015年11月，仅激素管理的网页就吸引了超过5000名访问者。这些指导原则补充了现有的世界跨性别健康专业协会照护准则和内分泌学会指南，因为这些指导原则专门设计用于以实证为基础的日常初级保健，包括在资源有限的环境下。[4,5]</p> <p>指南的总体结构和涵盖的主题列表是与促进中心的医学咨询委员会（MAB）协商制定的，该委员会由来自各类学术领域和社区卫生服务领域的专业临床医生组成。对总体设计和结构做出贡献的还有对促进中心自2011年启动原议定书以来收到的一系列咨询请求的回顾。这一指南随后使用“写作——同行评审”方法编写。来自MAB内外的主要作者被邀请参加个别主题讨论，之后采用同行评议和修改后的共识流程来达成本文提出的最终指导方针。多样化的作者团体使得我们能够制定一份广泛适用的文件，而不是仅反映单一医疗中心（如UCSF）的实践。</p> <p>如果没有我们的医疗咨询委员会和其他作者和审稿人的贡献，以及CoE同事JoAnne Keatley， MSW和E. Michael Reyes, MD, MPH，以及Lissa Moran在文献调研、参考书目管理、版本控制、审稿、格式化和汇编同行评议方面的重要帮助，这些指南不可能完成。Ben Zovod也协助了文献调研、参考书目管理和汇编同行评议的工作。他们的奉献精神和辛勤工作使得我们完成了有价值的、广泛适用的、循证的和科学上合理的最终作品。希望您认为本指南富有实用性，并欢迎任何反馈或问题。这将有助于制定未来的修订版本。感谢您关注跨性别和性别非常规人士的健康。</p> <p>Madeline B. Deutsch, MD, MPH</p> <p>Editor</p> <p><em>Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People</em></p> <p>Director of Clinical Services</p> <p>Center of Excellence for Transgender Health</p> <p>Associate Professor of Clinical Family and Community Medicine Department of Family and Community Medicine</p> <p>University of California, San Francisco Madeline.Deutsch@ucsf.edu</p> <h3 id="参考文献"><a href="#参考文献" class="header-anchor">#</a> 参考文献</h3> <ol><li>Conron KJ, Scott G, Stowell GS, Landers SJ. Transgender Health in Massachusetts: Results From a Household Probability Sample of Adults. Am J Public Health. 2012 Jan;102(1):118–22.</li> <li><a href="http://transgenderlawcenter.org/pubs/the-state-of-transgender-california" target="_blank" rel="noopener noreferrer">The State of Transgender California<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. Transgender Law Center. [cited 2013 Apr 1]. Available from:  http://transgenderlawcenter.org/pubs/the-state-of-transgender-california</li> <li>Grant JM, Mottet LA, Tanis J, Harrison J, Herman J, Keisling M.  <a href="http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf" target="_blank" rel="noopener noreferrer">Injustice at every turn: a report of the National Transgender Discrimination Survey<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. National Center for Transgender Equality and National Gay and Lesbian Task Force; 2011 [cited 2016 Mar 17]. Available from: http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf</li> <li>Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, DeCuypere G, Feldman J, et al. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7. Int J Transgenderism. 2012;13(4):165–232.</li> <li>Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ 3rd, Spack NP, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009 Sep;94(9):3132–54.</li></ol> <h2 id="贡献者"><a href="#贡献者" class="header-anchor">#</a> 贡献者</h2> <p><strong>Madeline B. Deutsch, MD, MPH</strong></p> <p>University of California, San Francisco, Department of Family and Community Medicine Center of Excellence for Transgender Health</p> <p><strong>Paula Amato, MD</strong></p> <p>Oregon Health and Science University</p> <p><strong>Mark Courey, MD</strong></p> <p>University of California San Francisco, Voice and Swallowing Center</p> <p><strong>Curtis Crane, MD</strong></p> <p>Brownstein &amp; Crane Surgical Services</p> <p><strong>lore m. dickey, PhD</strong></p> <p>Northern Arizona University</p> <p><strong>Jamison Green, PhD</strong></p> <p>Jamison Green &amp; Associates, Transgender Policy Consultants and Educators</p> <p><strong>Jennifer Hastings, MD</strong></p> <p>University of California San Francisco, Department of Family &amp; Community Medicine Planned Parenthood Mar Monte, Transgender Healthcare Program</p> <p><strong>Katherine T. Hsiao, MD, FACOG</strong></p> <p>Sutter Health, California Pacific Medical Center, Department of Obstetrics and Gynecology</p> <p><strong>Dan H. Karasic, MD</strong></p> <p>University of California San Francisco School of Medicine, Department of Psychiatry</p> <p><strong>Esther A. Kim, MD</strong></p> <p>University of California San Francisco, Department of Surgery, Division of Plastic and Reconstructive Surgery</p> <p>University of California San Francisco, Department of Surgery at San Francisco General Hospital</p> <p><strong>Toby R. Meltzer, MD</strong></p> <p>Toby R. Meltzer MD, PC Plastic and Reconstructive Surgery</p> <p><strong>Juno Obedin-Maliver, MD, MPH</strong></p> <p>University of California San Francisco Medical Center</p> <p>Stanford University School of Medicine - Lesbian, Gay, Bisexual, and Transgender Medical Education Research Group</p> <p><strong>Johanna Olson-Kennedy, MD</strong></p> <p>Children's Hospital Los Angeles, Department of Adolescent and Young Adult Medicine</p> <p><strong>Tonia Poteat, PhD, MPH, PA-C</strong></p> <p>Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, Center for Public Health and Human Rights, Center for AIDS Research</p> <p><strong>Asa Radix, MD, MPH</strong></p> <p>Callen Lorde Community Health Center, Research and Education</p> <p><strong>Cecily Reeves, PhD, FNP-C/PA-C</strong></p> <p>Samuel Merritt University, School of Nursing</p> <p><strong>Stephen M. Rosenthal, MD</strong></p> <p>University of California San Francisco, Pediatric Endrocrinology Clinics, Child and Adolescent Gender Center</p> <p><strong>Sarah Schneider, MS, SLP-CC</strong></p> <p>University of California San Francisco, Department of Otolaryngology Head and Neck Surgery University of California San Francisco, Voice and Swallowing Center</p> <p><strong>Nathaniel G. Sharon, MD</strong></p> <p>University of New Mexico, Division of Child and Adolescent Psychiatry</p> <p><strong>Eric D. Wang, MD</strong></p> <p>University of California San Francisco, Department of Surgery, Division of Plastic and Reconstructive Surgery</p> <p><strong>Linda Wesp, MSN, NP-C</strong></p> <p>University of Wisconsin-Milwaukee, College of Nursing</p> <p><strong>Andre A. Wilson, MS</strong></p> <p>Jamison Green &amp; Associates, Transgender Policy Consultants and Educators</p> <p><strong>Jeannine Wilson Stark, LE, CPE</strong></p> <p>Transgender SF Electrolysis</p> <p><strong>Barry Zevin, MD</strong></p> <p>San Francisco Department of Public Health, Tom Waddell Health Center</p> <h2 id="翻译贡献者"><a href="#翻译贡献者" class="header-anchor">#</a> 翻译贡献者</h2> <p><strong>Fluorescence</strong></p> <p>第1-7, 10, 19-22, 30, 32-37, 39章；校对第8-9, 11-18, 23-29, 38章；审阅</p> <p><strong>L.Ryland</strong></p> <p>第8-9, 23-25章</p> <p><strong>舞清歌</strong></p> <p>第11-15章</p> <p><strong>Aria</strong></p> <p>第16-18, 26-29章；校对第1-7, 10, 19-22, 30-31, 36-37, 39章；审阅</p> <p><strong>薛定猫养的鳄鱼</strong></p> <p>第30章</p> <p><strong>夏末微凉</strong></p> <p>第31章；校对第32-35章</p> <p><strong>TeH Ghost</strong></p> <p>第38章</p> <p><strong>yaoyao</strong></p> <p>GitBook制作；审阅</p> <p><strong>八意音羽</strong></p> <p>审阅</p> <p><strong>北歌经年</strong></p> <p>审阅</p> <p><strong>Fubuki</strong></p> <p>审阅</p> <p><strong>依蓝</strong></p> <p>审阅</p> <p><strong>Kristall</strong></p> <p>宣传推广</p> <h2 id="译者声明"><a href="#译者声明" class="header-anchor">#</a> 译者声明</h2> <p>本指南是<a href="http://transhealth.ucsf.edu/trans?page=guidelines-home" target="_blank" rel="noopener noreferrer"><em>Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People</em><span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>的中文译文，经UCSF跨性别者健康促进中心授权翻译。</p> <p>如发现翻译错误或有其它问题，请联系 fluortester+pgacg@gmail.com 或知乎私信<a href="https://www.zhihu.com/people/floria_serene" target="_blank" rel="noopener noreferrer">@Fluorescence<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>。</p> <p>本指南内容仅代表原作者观点，可能不尽完备。指南翻译目的在于增进相关人士对有关知识及原作者当地实践状况的了解，不作为任何医疗指导。文中涉及的医疗信息和数据等仅供参考，可能不适用于中国跨性别人群的生理状况和社会条件。如果读者有相关医疗需要，请务必联系相应科室专业医生，并在必要时接受专业的精神科医师诊断，强烈不建议读者根据本指南自行开展任何相关医疗活动。</p> <h2 id="证据分级"><a href="#证据分级" class="header-anchor">#</a> 证据分级</h2> <p>这些指南中的部分建议已按等级分级制度（GRADE）的某些组成部分加以调整[1]，并包含两个额外项目，以说明建议所依据的研究细节，以及进行此类研究的人群。每项分级的建议将包括进行研究的人群（跨性别者（T）、非跨性别者（NT）或两者（T/NT））；在建议的所有来源中最强形式的基本证据（荟萃分析、随机实验、观察性研究、专家意见）的指示。最后，根据上述标准以及专家意见解释现有数据所确定的建议的强度，对建议的强度作了全面分级（强、中、弱）。</p> <p>重要建议以<strong>粗体</strong>列出。一些建议不分等级，由于它们是基于其它专业组织的已有建议给出。</p> <p>表 1-1. 证据分级</p> <p><strong>存在数据以给出特定建议的人群</strong></p> <table><thead><tr><th><strong>描述</strong></th> <th><strong>编码</strong></th></tr></thead> <tbody><tr><td>跨性别人群中的至少一些数据</td> <td><strong>T</strong></td></tr> <tr><td>没有跨性别人群中的数据，但有其他人群中的数据</td> <td><strong>NT</strong></td></tr> <tr><td>没有数据（仅专家建议）</td> <td><strong>X</strong></td></tr></tbody></table> <p><strong>给出特定建议的最强有效数据</strong></p> <table><thead><tr><th><strong>描述</strong></th> <th><strong>编码</strong></th></tr></thead> <tbody><tr><td>元分析</td> <td><strong>M</strong></td></tr> <tr><td>随机受控研究</td> <td><strong>R</strong></td></tr> <tr><td>观察性研究</td> <td><strong>O</strong></td></tr> <tr><td>专家共识</td> <td><strong>C</strong></td></tr></tbody></table> <p><strong>建议的总体强度，考虑了上述因素与专家对有效数据在上下文中的解释</strong></p> <table><thead><tr><th><strong>描述</strong></th> <th><strong>编码</strong></th></tr></thead> <tbody><tr><td>强</td> <td><strong>S</strong></td></tr> <tr><td>中</td> <td><strong>M</strong></td></tr> <tr><td>弱</td> <td><strong>W</strong></td></tr></tbody></table> <h3 id="参考文献-2"><a href="#参考文献-2" class="header-anchor">#</a> 参考文献</h3> <ol><li>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008 Apr 26;336(7650):924–6.</li></ol> <h2 id="术语和定义"><a href="#术语和定义" class="header-anchor">#</a> 术语和定义</h2> <p>由于不同文化和语言中跨性别和性别非常规的用语多样，因此对术语进行详细讨论超出了本指南的范围。下面是一些常见的术语的定义，将在本指南中使用，如下所示。</p> <p><strong>（社会）性别/性别认同</strong> <em>Gender/Gender Identity</em>:性别方面一个人的内在自我意识以及他们如何融入世界。</p> <p><strong>（生理）性别</strong> <em>Sex</em>: 历史上指在出生时分配的性别，基于对外生殖器、染色体和性腺的评估。在日常生活语言经常与性别（Gender）交替使用，然而两个词语存在差别，尤其在涉及跨性别的上下文中。</p> <p><strong>性别表达</strong> <em>Gender expression</em>: 个人表达或显示其性别的外在方式。这可能包括衣服和发型的选择, 或言语举止。性别认同和性别表达可能不同；例如，女性（跨性别或非跨性别）的外观可能同时具有男性和女性特征，或男性（跨性别或非跨性别）可能有一种女性化的自我表达形式。</p> <p><strong>跨性别者</strong> <em>Transgender</em>: 性别认同与出生时所分配的性别不同的人，可缩写为“trans”。跨性别男性是具有男性性别认同和女性出生分配性别的人；跨性别女性是具有女性性别认同和男性出生分配性别的人。非跨性别者可被称为<strong>顺性别者</strong>（Cisgender，cis在拉丁语中意为同一侧）。</p> <p><strong>性别非常规</strong> <em>Gender non-conforming</em>: 一个人的性别认同与出生时所分配的不同, 但可能更为复杂、流动、多方面，或者比跨性别者定义更加模糊。<strong>性别酷儿</strong> <em>Genderqueer</em>是另一种被拥有这类认同的个体使用的术语。</p> <p><strong>性别非二元</strong> <em>Non-binary</em>: 跨性别者或性别非常规者，自我认同既非男性又非女性。</p> <p><strong>跨男性/跨女性</strong> <em>Trans-masculine/trans-feminine</em>: 根据性别认同的方向性描述性别非常规或非二元人的用语。一个跨男性的人有男性光谱的性别认同，尽管原始出生证明上列明性别为女性。一个跨女性的人有女性光谱的性别认同，尽管原始出生证明上列明性别为男性。在本指南的某些部分中, 为了简明起见，跨性别男性/女性的概念涵盖了在对应光谱范围内的性别非常规或非二元人群。</p> <p><strong>ta们</strong> <em>They/Them/Their</em>: 对具有非二元或非常规性别认同人群的性别中立称呼。</p> <p><strong>变性人</strong> <em>Transsexual</em>: 一个更具临床意义的术语，历史上被用来描述为性别肯定寻求医疗干预 (激素替代治疗，手术) 性别肯定的跨性别者。这一术语如今较少使用，尽管有些个体和社群对这一术语仍有强烈和肯定性的联结。</p> <p><strong>易装者/变装皇后/变装国王</strong> <em>Cross dresser / drag queen / drag king</em>: 这些术语通常指的是那些为娱乐、自我表达或性快感而穿不同于他们出生时分配的性别的服饰的人。一些易装者可能与跨性别者部分重叠。<strong>易装癖</strong>（Transvestite）一词不再用于英语，并被认为是贬义的。</p> <p><strong>性取向</strong> <em>Sexual orientation</em>: 仅描述性吸引力，与性别认同没有直接关系。跨性别者的性取向应由个体来界定，通常基于生活中的性别描述；一个被其他女性吸引的跨性别女性是女同性恋, 而被其他男性吸引的跨性别男性是男同性恋。</p> <p>简明起见，在本指南中，词语<strong>跨性别者</strong>将作为一个集合被用来指代跨性别者、性别非常规和性别酷儿，除非另有说明；而不属于跨性别的人群以非跨性别者指代。</p> <h2 id="创造安全和热情的诊所环境"><a href="#创造安全和热情的诊所环境" class="header-anchor">#</a> 创造安全和热情的诊所环境</h2> <p>主要作者： Madeline B. Deutsch, MD, MPH</p> <h3 id="概论"><a href="#概论" class="header-anchor">#</a> 概论</h3> <p>跨性别者可能因为先前的歧视或在诊所环境中的不尊重而避免寻求护理。[1,2]提供安全、热情和文化上适当的诊所环境不仅对确保跨性别者寻求护理，而且对为后续护理再度回到诊所至关重要。为跨性别护理创建适当的环境有以下几个关键部分。</p> <p><strong>文化谦逊</strong>：这一概念指的是个人认识到他们自己的经历或身份可能不会投射到他人的经历或身份上。每个患者都应该被视为一个单独个体不带偏见地接触。临床上常常会遇到对术语的个体偏好，复杂或新颖的性别认同以及性别肯定治疗的不同愿望。在“其所处的状况下”不带评判地（在某些情况下，甚至包括外观的正面评价）会见患者将增强患者 – 医疗提供者关系并避免患者有受到侮辱或病态化的感受。虽然一些患者可能能够成为医疗服务提供者的信息来源，[3]其他患者可能会因此而不适。不应该经常期望患者明确地“教导”他们的医疗提供者，并且医疗提供者应该将病史方面的询问限制在与当前就诊或问题相关的提问范围内。</p> <p><strong>员工培训</strong>：除医疗服务提供者外，前台员工，护理人员，实验室和X射线工作人员等通常也都在患者护理的第一线。应向所有诊所工作人员和医疗服务提供者提供有关跨性别健康问题的培训，并应将其纳入所有员工的标准招聘和入职流程。</p> <p><strong>等候区</strong>：应包括跨性别主题的海报，艺术品，小册子，杂志等，以表明服务跨性别社群的努力。</p> <p><strong>盥洗室</strong>：政策应将所有盥洗室定义为性别中立，或明确指出患者可根据自己的喜好选择女性或男性的房间。在后一种情况下，至少建立一个性别中立的盥洗室将能够为非二元性别和过渡期人士，以及在任何区分性别的空间中都会感到不适者提供一个安全的空间。</p> <p><strong>流利的术语</strong>：提供者应该了解跨性别社区使用的基本术语。除了指南中描述的术语（基于北美英语使用），其他本地或个人术语可能存在，也可能随时间而变化。其他国家或地区的术语可能有所不同。提供者应该熟悉当地的术语，并在与个体接触时基于文化谦逊的原则确定使用哪些特定术语。</p> <p><strong>性别身份数据</strong>：包括所选姓名，所选代词，当前性别认同和原始出生证明上列出的性别。未能收集和使用性别身份数据会产生若干重要影响，包括造成性少数群体对政策制定者和研究人员不可见，[4]难以追踪跨性别者的器官清单&lt;1&gt;和预防性卫生需求，[5]以及因未能使用所选名称和代词而降低患者满意度。[6]根据国家协调员的要求，性别认同数据已被添加到美国卫生和人类服务部的卫生信息技术有效使用阶段3指南。[7]</p> <p>加州大学旧金山分校跨性别健康促进中心，波士顿芬威健康中心，加州大学戴维斯分校，梅奥诊所，美国疾病控制和预防中心（CDC）以及许多其他组织和专家倡导使用两步收集性别认同数据的方法。该方法同时询问性别身份以及原始出生证明上列出的性别；跨性别者可以被确定为性别身份与出生性别不同的人。已经发现这种方法优于提出单个问题，通过选择“男性”，“女性”和“跨性别者”来询问社会性别/生理性别，因为一些跨性别者可能选择“男性”或“女性”，从而导致他们跨性别身份实质上的不可见。[8]</p> <p>不幸的是，许多电子病历（EMR）系统供应商在开发性别认同数据功能方面落后，从而造成实践中和这些数据在记录中存储位置的混杂不清。[9]除性别认同和出生性别外，跨性别者也可能选择与其法定名称不同的名称，并且可能使用与其身份证件上列出的法律性别不同的代词。因此，还建议EMR包含用于记录所选名称和代词的功能。这样，理想的EMR将允许为所有角度的所有用户显示所选名称和代名词。此外，一旦法律文件发生变化以反映性别认同和所选名称，EMR应包括从普通用户的角度删除跨性别状态指标的功能，允许跨性别者保留隐私。关于一个人的跨性别状态和过渡史的具体细节，包括器官清单和激素使用信息，可以存储在病历的医学和外科病史部分。[6]</p> <p>以下列出了收集性别认同数据的推荐术语。[10]诊所可以通过添加简要描述或免责声明将这些问题整合到他们的患者登记表格或处理流程中，以避免使不适用此类问题的患者感到困惑。</p> <h3 id="性别认同-两步"><a href="#性别认同-两步" class="header-anchor">#</a> 性别认同（两步）：</h3> <p><strong>1. 你的性别认同是什么?</strong></p> <ul><li>男性</li> <li>女性</li> <li>跨性别男性</li> <li>跨性别女性</li> <li>性别酷儿 / 性别非常规</li> <li>其它认同 （请填写）</li> <li>拒绝回答</li></ul> <p><strong>2. 你出生时被指派的性别是什么？</strong></p> <ul><li>男性</li> <li>女性</li> <li>拒绝回答</li></ul> <h3 id="参考文献-3"><a href="#参考文献-3" class="header-anchor">#</a> 参考文献</h3> <ol><li>Melendez RM, Pinto RM. HIV prevention and primary care for transgender women in a community-based clinic. J Assoc Nurses AIDS Care JANAC. 2009 Oct;20(5):387–97.</li> <li>Grant JM, Mottet LA, Tanis J, Harrison J, Herman J, Keisling M. <a href="http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf" target="_blank" rel="noopener noreferrer">Injustice at every turn: a report<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf" target="_blank" rel="noopener noreferrer">of the National Transgender Discrimination Survey<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. National Center for Transgender Equality and National Gay and Lesbian Task Force; 2011 [cited 2016 Mar 17]. Available from: http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf</li> <li>Deutsch MB. Evaluation of patient-oriented, internet-based information on gender-affirming hormone treatments. LGBT Health. 2016 Feb 1;</li> <li>Bauer GR, Hammond R, Travers R, Kaay M, Hohenadel KM, Boyce M. “I don’t think this is theoretical; this is our lives”: how erasure impacts health care for transgender people. J Assoc Nurses AIDS Care JANAC. 2009 Oct;20(5):348–61.</li> <li>Deutsch MB, Green J, Keatley J, Mayer G, Hastings J, Hall AM, et al. Electronic medical records and the transgender patient: recommendations from the World Professional Association for Transgender Health EMR Working Group. J Am Med Inform Assoc JAMIA. 2013 Aug;20(4):700–3.</li> <li>Deutsch MB, Buchholz D. Electronic health records and transgender patients--practical recommendations for the collection of gender identity data. J Gen Intern Med. 2015 Jun;30(6):843–7.</li> <li>Cahill SR, Baker K, Deutsch MB, Keatley J, Makadon HJ. <a href="http://online.liebertpub.com/doi/full/10.1089/lgbt.2015.0136" target="_blank" rel="noopener noreferrer">Inclusion of sexual orientation and<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://online.liebertpub.com/doi/full/10.1089/lgbt.2015.0136" target="_blank" rel="noopener noreferrer">gender identity in Stage 3 Meaningful Use Guidelines<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>: a huge step forward for LGBT health. LGBT Health [Internet]. 2015 Dec 24 [cited 2015 Dec 31]; Available from: http://online.liebertpub.com/doi/full/10.1089/lgbt.2015.0136</li> <li>Tate CC, Ledbetter JN, Youssef CP. A two-question method for assessing gender categories in the social and medical sciences. J Sex Res. 2012 Sep 18;1–10.</li> <li>Deutsch MB, Keatley J, Sevelius J, Shade SB. Collection of gender identity data using electronic medical records: survey of current end-user practices. J Assoc Nurses AIDS Care JANAC. 2014 Apr 12;</li> <li>Cahill S, Makadon H. <a href="http://online.liebertpub.com/doi/abs/10.1089/lgbt.2013.0001" target="_blank" rel="noopener noreferrer">Sexual orientation and gender identity data collection in clinical settings<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://online.liebertpub.com/doi/abs/10.1089/lgbt.2013.0001" target="_blank" rel="noopener noreferrer">and in electronic health records: a key to ending LGBT health disparities<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>. LGBT Health [Internet]. 2013 [cited 2013 Aug 25]; Available from: http://online.liebertpub.com/doi/abs/10.1089/lgbt.2013.0001</li></ol> <blockquote><p>&lt;1&gt; . 译者注：指病人现有的器官列表。在跨性别病人中这可能随接受手术干预的阶段而不同。</p></blockquote> <h2 id="跨性别患者与体检"><a href="#跨性别患者与体检" class="header-anchor">#</a> 跨性别患者与体检</h2> <p>主要作者: Linda Wesp, MSN, NP-C</p> <h3 id="概论-2"><a href="#概论-2" class="header-anchor">#</a> 概论</h3> <p>无论性别表现如何，体检都应与存在的解剖结构相关，并且不对解剖结构或身份做出假设。需使用敏感病史以了解接受激素治疗和手术干预情况下多样和个体化的变化和特征。在整个就诊过程中应考虑到医疗保健环境中潜在的先前负面经历，包括歧视以及身体或情感虐待。[1]</p> <p>在进行体检时，提供者应使用性别肯定的方法。性别肯定（Gender Affirmation）是指个人通过社会互动确认其性别认同的过程。[2]这包括在整个就诊期间用正确的名称和代词指代。这还包括使用身体部位的一般术语，或询问患者是否有供使用的首选术语。[3]只应对那些与特定就诊原因有关的身体部位进行检查。例如，在因急性上呼吸道感染就诊的情况下，检查生殖器是不合适的。</p> <p>在接受激素治疗的患者中，第二性征可能存在一系列发育，在某种程度上取决于激素使用的持续时间和起始年龄。</p> <p>跨性别男性可能有面部和体毛生长，阴蒂增大，肌肉质量增加，男性化脂肪再分布，雄激素性脱发和痤疮。跨性别女性可能有乳房发育（通常不发达），女性化脂肪再分布，肌肉质量减少，体毛变细或缺乏，面部毛发变细或缺乏，皮肤变软，变薄，睾丸尺寸减小或完全缩回。[4]接受过性别肯定手术的患者可能会根据所执行过的程序，使用的方法和并发症的发生而有不同的体检结果。提供者应维护一个器官清单，以指导筛查和处理某些特定主诉。</p> <h3 id="跨性别女性阴道检查的特殊考虑"><a href="#跨性别女性阴道检查的特殊考虑" class="header-anchor">#</a> 跨性别女性阴道检查的特殊考虑</h3> <p><em>（参见性传播疾病和阴道成形术指南）</em></p> <p>在跨性别女性中创建的新阴道的解剖结构与先天性阴道的不同之处在于它具有盲端，缺少子宫颈或周围的穹窿，并且可能方向更加靠后。因此，使用肛门镜可能是在解剖学上更合适的视觉检查方法。可以插入肛门镜，移除套管针，并且撤回肛门镜时可见阴道壁在肛门镜末端周围塌陷。</p> <h3 id="跨性别男性盆腔检查的特殊考虑"><a href="#跨性别男性盆腔检查的特殊考虑" class="header-anchor">#</a> 跨性别男性盆腔检查的特殊考虑</h3> <p><em>(参见性传播疾病和宫颈癌筛查指南)</em></p> <p>盆腔检查程序可能对跨性别男性和其他跨男性个体的造成创伤和焦虑。跨性别男性更倾向于不及时进行宫颈癌筛查[5]，且细胞学采样取材不当率更高[6]。必须向实验室明确提供的样品确实是宫颈涂片（特别是如果列出的性别标记是“男性”），以避免样品作为肛门涂片错误地处理或丢弃。检查要求上应标明睾酮的使用或闭经的存在。</p> <p>如果患者个人表达对检查的困扰或担忧，可以推迟检查直至信任关系建立。有关盆腔检查和筛查的详细信息的网站可以在checkitoutguys.ca找到。[7]可以使用各种技术（包括双合诊检查和/或窥器检查）减少盆腔检查的不适：</p> <ul><li>事先与患者讨论程序，包括步骤的顺序。在开始检查之前，留出时间让患者表达任何疑虑。</li> <li>在检查期间允许患者在房间内有支持人员，用耳机听音乐，或利用他们可能具有的任何其他对策分散注意力。</li> <li>全程直接解释每一步，例如说：“我现在会用手触摸”，“接下来你会感到一些压力”，“你现在会听到窥器的咔哒声”，并提醒患者可以根据他们的要求随时停止检查。</li> <li>避免使用身体部位的医学术语，除非事先讨论过这些是患者希望您使用的首选术语。一些患者可能更喜欢将阴道称为“前面”或“前孔”。</li> <li>提供镜子使患者可以直接观察检查过程。</li> <li>在检查前20-60分钟给予口服苯二氮䓬类药物可能对患有严重焦虑症的人有帮助。</li> <li>在检查前1-2周使用通常用于绝经期治疗的阴道雌激素可减少睾酮治疗后常见的阴道萎缩。</li> <li>允许自行收集某些检查物可能会避免在某些情况下进行窥器检查的需要，例如用拭子获得阴道涂片来分析异常的阴道分泌物。目前正在调查用于HPV检测标本的自我收集。</li> <li>在拒绝窥器检查的情况下，作为建立舒适和信任的第一步，考虑提供体外和/或双合诊检查。正面经历可能会使患者考虑将来进行进一步检查。</li></ul> <h3 id="其它特殊考虑"><a href="#其它特殊考虑" class="header-anchor">#</a> 其它特殊考虑</h3> <p>束胸以产生男性化的外观可能导致皮肤破裂或其他皮肤并发症。患者可能不愿意去除粘合剂进行体检。[3]</p> <p>对于所有跨性别男性患者，建议进行恰当和谨慎的病史采集和有关安全束胸的教育。[8]</p> <p>睾丸和阴茎的翻折隐藏可能导致疝气或外部腹股沟环的其他并发症，或会阴部的皮肤破裂。所有跨性别女性都建议进行恰当和谨慎的病史采集和教育。[8]</p> <p>在情况适当且有迹象时，应进一步评估暗示间性别（Intersex）情况的结果。[4]</p> <h3 id="参考文献-4"><a href="#参考文献-4" class="header-anchor">#</a> 参考文献</h3> <ol><li>Grant J, Mottet L, Tanis J, Herman J, Harrison J, Keisling M. National Transgender Discrimination Survey; <a href="http://www.thetaskforce.org/static_html/downloads/resources_and_tools/ntds_report_on_health.pdf" target="_blank" rel="noopener noreferrer">Report on Health and Healthcare<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. Washington, DC: National Center for Transgender Equality and National Gay and Lesbian Task Force; 2010 Oct [cited 2016 Mar 10] p. 1–23. Available from: http://www.thetaskforce.org/static_html/ downloads/ resources_and_tools/ntds_report_on_health.pdf</li> <li>Sevelius JM. Gender Affirmation: a framework for conceptualizing risk behavior among transgender women of color. Sex Roles. 2013 Jun 1;68(11-12):675–89.</li> <li>Dutton L, Koenig K, Fennie K. Gynecologic care of the female-to-male transgender man. J Midwifery Womens Health. 2008 Aug;53(4):331–7.</li> <li>Feldman JL, Goldberg JM. Transgender Primary Medical Care. Int J Transgenderism. 2006 Sep 1;9(3-4):3–34.</li> <li>Peitzmeier SM, Khullar K, Reisner SL, Potter J. Pap test use is lower among female-to-male patients than non-transgender women. Am J Prev Med. 2014 Dec;47(6):808–12.</li> <li>Peitzmeier SM, Reisner SL, Harigopal P, Potter J. Female-to-male patients have high prevalence of unsatisfactory Paps compared to non-transgender females: implications for cervical cancer screening. J Gen Intern Med. 2014 May;29(5):778–84.</li> <li>Sherbourne Health Centre. Check It Out Guys [Internet]. 2010 [cited 2016 Mar 10]. Available from: http://www.checkitoutguys.ca/</li> <li>Vancouver Coastal Health. <a href="http://transhealth.vch.ca/social-transition-options/binding-packing-tucking/binding" target="_blank" rel="noopener noreferrer">Binding<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. Transgender Health Information Program. [cited 2016 Mar 10]. Available from: http://transhealth.vch.ca/social-transition-options/binding-packing- tucking/binding</li></ol> <h2 id="性别肯定治疗及程序概述"><a href="#性别肯定治疗及程序概述" class="header-anchor">#</a> 性别肯定治疗及程序概述</h2> <p>主要作者：Madeline B. Deutsch, MD, MPH</p> <h3 id="提供性别肯定治疗及程序的支持性证据"><a href="#提供性别肯定治疗及程序的支持性证据" class="header-anchor">#</a> 提供性别肯定治疗及程序的支持性证据</h3> <p>跨性别者可能寻求一系列性别肯定干预中的任意一些项，包括激素治疗、手术、面部毛发移除、嗓音和交流干预训练，以及行为性适应（如生殖器翻折隐藏或包装）。根据世界跨性别健康专业协会的看法，以上各类性别肯定治疗对跨性别者而言是必要的。[1]低质量研究也表明，在经过HRT或手术等性别肯定治疗后一系列社会心理状况会得到改善[2-5]。Sevelius性别肯定模型描述了无法获取性别肯定治疗与高危行为和HIV感染相关[6]。然而并非所有的跨性别者都会寻求所有的干预措施，而有的甚至不寻求此类干预。与过去的实践，即设立一条精神评估→激素→手术的路径不同，当前的照护标准是允许每位跨性别个体只寻求其所渴望的确认其性别认同的干预措施。[7]</p> <p>**医疗干预：**激素替代治疗是跨性别者寻求的主要医疗干预。这种治疗可以使获得的第二性征更符合个人的性别认同。</p> <p>**手术干预：**跨性别者可以进行各种性别肯定手术。这些包括特定于性别肯定的手术，以及非跨性别人群中也通常进行的手术。</p> <p>针对跨性别人群的手术：</p> <ul><li><ul><li>女性化阴道成形术</li> <li>男性化阴茎成形术/阴囊成形术</li> <li>阴蒂释放术（阴蒂的释放/增大，可能包含尿道延长）</li> <li>男性化胸腔手术（“平胸术”）</li> <li>面部女性化手术</li> <li>甲状软骨减小成形术（气管软骨削除）</li> <li>嗓音手术</li></ul></li></ul> <p>不限定于跨性别人群的手术：</p> <ul><li><ul><li>乳房增大成形术</li> <li>子宫切除术/卵巢切除术</li> <li>睾丸切除术</li> <li>阴道切除术</li></ul></li></ul> <p>**其它干预：**包括面部毛发去除，声音改变，生殖器翻折隐藏和包装，以及束胸。</p> <h3 id="参考文献-5"><a href="#参考文献-5" class="header-anchor">#</a> 参考文献</h3> <ol><li><a href="http://www.wpath.org/site_page.cfm?pk_association_webpage_menu=1352&amp;pk_association_webpage=3947" target="_blank" rel="noopener noreferrer">WPATH Clarification on Medical Necessity of Treatment, Sex Reassignment, and Insurance Coverage for Transgender and Transsexual People Worldwide<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. [cited 2014 Jan 21]. Available from: http://www.wpath.org/site_page.cfm?pk_association_webpage_menu=1352 &amp;pk_association_webpage=3947</li> <li>Gómez-Gil E, Zubiaurre-Elorza L, Esteva I, Guillamon A, Godás T, Cruz Almaraz M, et al. Hormone-treated transsexuals report less social distress, anxiety and depression. Psychoneuroendocrinology. 2012 May;37(5):662–70.</li> <li>Meier SLC, Fitzgerald KM, Pardo ST, Babcock J. The effects of hormonal gender affirmation treatment on mental health in female-to-male transsexuals. J Gay Lesbian Ment Health. 2011;15(3):281–99.</li> <li>Newfield E, Hart S, Dibble S, Kohler L. Female-to-male transgender quality of life. Qual Life Res. 2006 Jun 7;15(9):1447–57.</li> <li>White Hughto JM, Reisner SL. A systematic review of the effects of hormone therapy on psychological functioning and quality of life in transgender individuals. Transgender Health. 2016 Jan 13;1(1):21–31.</li> <li>Sevelius JM. Gender Affirmation: A framework for conceptualizing risk behavior among transgender women of color. Sex Roles. 2013 Jun 1;68(11-12):675–89.</li> <li>Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, DeCuypere G, Feldman J, et al. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7. Int J Transgenderism. 2012;13(4):165–232.</li></ol> <h2 id="开始激素治疗"><a href="#开始激素治疗" class="header-anchor">#</a> 开始激素治疗</h2> <p>主要作者： Madeline B. Deutsch, MD, MPH</p> <h3 id="评估准备状态和适当性"><a href="#评估准备状态和适当性" class="header-anchor">#</a> 评估准备状态和适当性</h3> <p>虽然历史上在激素治疗开始之前需要来自精神卫生专业人员的“推荐信”，但是许多大量且经验丰富的跨性别医疗服务提供者多年来一直使用“知情同意”途径来开始激素治疗。WPATH护理标准第7版将这两种启动激素替代治疗的途径都视作有效。医疗服务提供者如果认为能够评估和诊断性别焦虑，并评估提供知情同意的能力（能够理解风险、益处、替代方案、未知因素、限制、不治疗的风险），则能够在未经精神健康服务提供者事先评估或转介的情况下开始激素替代治疗。[1]对多个环境中12个此类诊所的实践进行的研究发现后悔风险极小，并且没有已知的医疗事故诉讼案例。[2]关于评估各种性别肯定治疗的准备状态和适当性的更多细节可以在关于精神健康的主题中找到。</p> <h3 id="处方提供者的资格"><a href="#处方提供者的资格" class="header-anchor">#</a> 处方提供者的资格</h3> <p>开具激素替代治疗处方属于一系列医疗服务提供者的服务范围，包括初级保健医生、产科医生、妇科医生和内分泌科医生、高级执业护士和医师助理。[1]根据实践背景和法律规定，具有处方权的其他提供者（自然疗法提供者，护士助产士）也可能适合开出处方和管理此类护理。用于治疗的大多数药物是大多数处方者已经熟悉的常用物质，因它们可用于治疗更年期、避孕、多毛症、男性型秃发、前列腺炎或异常子宫出血。</p> <h3 id="参考文献-6"><a href="#参考文献-6" class="header-anchor">#</a> 参考文献</h3> <ol><li>Deutsch MB, Feldman JL. Updated recommendations from the world professional association for transgender health standards of care. Am Fam Physician. 2013 Jan 15;87(2):89–93.</li> <li>Deutsch MB. Use of the informed consent model in the provision of cross-sex hormone therapy: a survey of the practices of selected clinics. Int J Transgenderism. 2012 May;13(3):140–6.</li></ol> <h2 id="女性化激素治疗概述"><a href="#女性化激素治疗概述" class="header-anchor">#</a> 女性化激素治疗概述</h2> <p>主要作者： Madeline B. Deutsch, MD, MPH</p> <h3 id="概论-3"><a href="#概论-3" class="header-anchor">#</a> 概论</h3> <p>女性化激素治疗的目标是发展女性的第二性征，并抑制/减少男性的第二性征。一般影响包括乳房发育（通常到Tanner分期2或3），面部和身体皮下脂肪的重新分布，肌肉质量的减少，体毛的减少（以及较小程度的面部毛发减少），汗液和气味模式的变化，以及脱发的停止和可能的逆转。性和性腺的影响包括勃起功能的降低，性欲的改变，精子数量和射精的减少或缺失，以及睾丸尺寸缩小。女性化激素治疗也会带来情绪和社交功能的变化。治疗的一般方法是将雌激素与雄激素阻断剂结合，并在某些情况下加入孕激素。</p> <h3 id="雌激素"><a href="#雌激素" class="header-anchor">#</a> 雌激素</h3> <p>用于女性化治疗的雌激素的主要类别是17-β雌二醇，这是一种具有“生物同质性”的激素，因为它在化学上同质于人卵巢所分泌的激素。一般方法类似于无性腺（即特纳综合征）或绝经期状态中的雌激素替代，但包括一些剂量修改。17-β雌二醇（或简称雌二醇）最常通过透皮贴剂，口服 &lt;2&gt; 或舌下含服，或注射共轭的酯（戊酸雌二醇或环戊丙酸雌二醇）给药。尚未对注射戊酸雌二醇或环戊丙酸雌二醇进行过疗效研究，可能是因为如今它们在跨性别护理环境之外不常使用；由于这种有限的使用，制造商几乎没有动力生产这种药物，并且已经有短缺报道。雌二醇的其他给药途径如透皮凝胶或喷雾剂被配制用于治疗绝经期血管舒缩症状；这些途径尽管对一些跨性别女性方便有效，但在另一些跨性别女性中，可能无法达到生理女性范围内血液水平。专业药店也提供复合外用乳膏和凝胶；如要使用这些药物，建议处方者与配药师（compounding pharmacist）协商，以了解个别制剂的具体细节和剂量。也存在复方戊酸雌二醇或环戊丙酸雌二醇注射剂，并且对于那些必须为其处方支付现金的人来说，可能是短缺时的或更具成本效益的替代方案。</p> <p>结合马雌激素（倍美力™）如今不被建议使用，原因包括无法精确测量其血液水平和可能的促凝性与心血管风险。[1,2]马雌激素来源于怀孕的、留置尿管的马的尿液，没有证据证明其效果比常用的人类雌激素效果更优。关于马雌激素的生产方法已经有伦理问题提出。（http://www.aspca.org/fight-animal-cruelty/equine-cruelty/premarin.aspx）</p> <p>炔雌醇是避孕制剂中使用的合成雌激素&lt;3&gt; ，与血栓形成风险增加有关[3,4]。在用于避孕方面，炔雌醇具有更持续和可靠的周期调控能力，因此具有更好的耐受性，从而抵消了潜在的增加静脉血栓栓塞的风险。[5]<strong>在用于性别肯定的情况下，不需要考虑周期或出血调控，因此炔雌醇的使用及其固有风险不被认可（分级：T O S）。</strong></p> <p>雌激素的副作用可能包括偏头痛，情绪波动，潮热和体重增加。</p> <h3 id="抗雄激素-一般方法"><a href="#抗雄激素-一般方法" class="header-anchor">#</a> 抗雄激素——一般方法</h3> <p>抑制睾酮产生和阻断其作用有助于抑制/最小化男性第二性征。不幸的是，许多这些特征在青春期后是永久性的并且是不可逆转的。与过去用于影响垂体促性腺激素抑制的超生理雌激素水平（及相关风险）相比，雄激素拮抗剂允许患者使用较低的雌二醇剂量。[6]</p> <p><strong>螺内酯</strong>是美国最常用的雄激素拮抗剂。螺内酯是一种保钾利尿剂，在较高剂量下也具有直接的抗雄激素受体活性以及对睾酮合成的抑制作用。[6]根据用于治疗脱发的非跨性别者中的数据，每日200mg的药量是安全的，而高达每日400mg的剂量也没有造成负面效应。[7]高钾血症是最严重的风险，但其发生十分罕见，除非使用者肾功能不全，或在没有密切监测的情况下用于正在使用ACE或ARB类降压药者。由于其利尿效应，使用者可能有自限性的多尿、多饮和体位性晕厥。</p> <p><strong>5-α还原酶抑制剂</strong>包括非那雄胺和度他雄胺。非那雄胺能阻断2型和3型5-α还原酶介导睾酮转化为强效雄激素二氢睾酮的过程[8]。每天1mg非那雄胺被FDA批准用于治疗男性型秃发，而5mg剂量被批准用于治疗前列腺肥大。[9]度他雄胺0.5mg更有效地阻断1型还原酶，其存在于毛囊皮脂腺单位中，因此可具有更显著的女性化效果。由于这些药物不会阻止睾酮的产生和作用，因此它们的抗雄激素作用小于完全阻断时的抗雄激素作用。对于不能耐受或有使用螺内酯的禁忌症的人，5-α还原酶抑制剂可能是一个良好的选择。5-α还原酶抑制剂也可用作寻求部分女性化的患者的单一药剂，或用于在完全雄激素阻断或睾丸切除术后继续表现出男性化特征或脱发的患者。</p> <h3 id="抗雄激素-其它方法"><a href="#抗雄激素-其它方法" class="header-anchor">#</a> 抗雄激素——其它方法</h3> <p>抗雄激素还可以单独使用，以减少男性化和引起极小乳房发育，或用于那些希望首先尝试单独降低睾酮水平的患者，或有雌激素治疗禁忌症的患者。在没有雌激素替代的情况下，一些患者可能有令人不快的潮热症状和情绪与动力低落。在接受前列腺癌治疗的男性中，长期完全雄激素阻断而没有激素替代导致骨质流失，预计这种效应也会发生在跨性别人群中。[10]<strong>对于此类人群，在调整用药剂量以达到期望的临床效果和目标睾酮水平之外，也同时需要监测促性腺激素（卵泡生成素LH和黄体生成素FSH）水平。足够低的监测结果能说明当前激素水平足以维持骨密度（分级：T O W）。</strong>[11]</p> <p>在许多国家，醋酸环丙孕酮，一种具有强抗雄激素活性的合成孕激素被广泛使用。醋酸环丙孕酮与罕见的急性重症肝炎发作有关。[12]比卡鲁胺是一种用于治疗前列腺癌的直接抗雄激素，也具有较小但未完全量化的肝功能异常风险（包括几例急性重症肝炎）；虽然在考虑比卡鲁胺在前列腺癌治疗中的益处时，这些风险是可接受的，但在性别肯定治疗的背景下，这种风险得到的认可较少。[13]目前尚没有证据可以证明这种分析。</p> <p>在一些患者中，使用标准方案可能难以甚至不可能实现雄激素的完全阻断。在具有良好药物依从性的最大抗雄激素剂量给药中的情况下，如果睾酮仍旧持续升高，应考虑自主内源性产生（即肿瘤）以及存在未披露的外源性睾酮（即为维持勃起功能）。睾丸肿瘤的评估应该进行阴囊检查，以及检测血清人绒毛膜促性腺激素（hCG）、乳酸脱氢酶（LDH）和甲胎蛋白（AFP）水平，并在可能的情况下进行阴囊成像[14]。一旦排除了这些原因，其他选择可包括促性腺激素释放激素类似物（GnRH）或睾丸切除术。GnRH类似物常用于需要青春期延迟的青春期前跨性别青少年的治疗[15]，并且在跨性别成人的护理中也有描述[16]。使用GnRH类似物的缺点主要包括成本和获得保险的困难，以及需要重复注射，或每日多次鼻腔喷雾，或手术植入。睾丸切除术，对于不愿意保留性腺的跨性别女性可能是理想的选择；这个简短、便宜的门诊手术只需要几天的时间进行康复，并且不影响未来可能进行的阴道成形术。</p> <p><strong>孕激素:</strong> 孕激素在女性化激素治疗方案中的作用尚未得到合理设计的研究的证实，但是许多跨性别者和药物提供商报告了其促进乳房及乳晕发育、情绪改善和性欲增长。[17,18]没有证据表明在跨性别护理环境中的孕激素使用是有害的。实践中有的使用者对孕激素的使用反映良好而有的使用者可能发现其对情绪的负面影响。尽管通过对促性腺激素的拮抗，孕激素存在抗雄激素的作用，孕激素同样在理论上有直接促进雄化的风险。该类药物包括微粉化的生物同质性孕酮（黄体酮）&lt;4&gt; 以及许多合成孕激素。在跨性别护理中最常用的合成孕激素是口服醋酸甲羟孕酮（安宫黄体酮）。</p> <p>虽然妇女健康倡议（WHI）对使用甲羟孕酮的心血管疾病和乳腺癌风险存在担忧，但由于多种原因，这些担忧可能不适用于跨性别医疗。首先，跨性别女性患乳腺癌的风险可能比非跨性别女性更低。其次，WHI的这一分支涉及在更年期妇女的样本中使用结合马雌激素与甲羟孕酮的组合，其中一些人在开始使用激素时已绝经长达10年。第三，虽然具有统计学意义，但WHI研究结果的临床意义至多是微乎其微的。该研究旨在评估更年期激素疗法在预防慢性病中的作用。结合马雌激素加甲羟孕酮组的实际发现是每10000人年超过7次心脏病事件，8次中风，8次肺栓塞和8次浸润性乳腺癌的绝对风险，而总体死亡率无变化。[19]因此WHI的这个分支较早停止并且得出结论，联合更年期激素疗法不适用于预防慢性疾病。</p> <p>性别肯定护理与WHI的研究结果存在许多差异：人群往往更年轻；不使用马雌激素；治疗重点不是预防慢性疾病而是性别肯定干预措施，而这些措施对精神健康和生活质量有诸多益处。<strong>考虑人群特征和治疗目标的差别，增加极小的总体风险，没有差别的死亡率，以及更新的同时使用其他形式雌激素的数据得到确认，在跨性别女性中使用孕激素的风险可能极小甚至不存在（分级：NT O M）。</strong></p> <p>注射用醋酸甲羟孕酮（Depo-Provera®）在跨性别女性中较少使用。其他合成孕激素必要时可在处方集限制下使用；一些证据表明，去甲孕烷衍生的孕激素（炔诺酮、甲炔诺孕酮&lt;5&gt; ）可能会增加静脉血栓栓塞的风险。[20]</p> <p>表 7-1. 激素准备和药量(分级: T O M)</p> <table><thead><tr><th><strong>激素种类</strong></th> <th><strong>低初始剂量b</strong></th> <th><strong>初始剂量</strong></th> <th><strong>最大剂量c</strong></th> <th><strong>备注</strong></th></tr></thead> <tbody><tr><td><strong>雌激素</strong></td> <td></td> <td></td> <td></td> <td></td></tr> <tr><td><strong>雌二醇（口服/舌下）</strong></td> <td>1mg/日</td> <td>2-4mg/日</td> <td>8mg/日</td> <td>2mg时建议分为每日两次</td></tr> <tr><td><strong>雌二醇（经皮）</strong></td> <td>50mcg</td> <td>100mcg</td> <td>100-400</td> <td>每片的最大剂量为100mcg，更换频率取决于品牌/产品。同时超过两片可能对使用者较为麻烦。</td></tr> <tr><td><strong>戊酸雌二醇（肌注）a</strong></td> <td>&lt;20mg IM 两周一次</td> <td>20mg IM两周一次</td> <td>40mg IM两周一次</td> <td>若出现周期症状可分为一周一次</td></tr> <tr><td><strong>环戊丙酸雌二醇（肌注）</strong></td> <td>&lt;2mg IM</td> <td>2mg IM</td> <td>5mg IM</td> <td>若出现周期症状可分为一周一次</td></tr> <tr><td><strong>孕激素</strong></td> <td></td> <td></td> <td></td> <td></td></tr> <tr><td><strong>甲羟基孕酮</strong></td> <td>2.5mg 每日睡前</td> <td></td> <td>5-10mg 每日睡前</td> <td></td></tr> <tr><td><strong>微粒化孕酮</strong></td> <td></td> <td></td> <td>100-200mg</td> <td></td></tr> <tr><td><strong>雄激素拮抗剂</strong></td> <td></td> <td></td> <td></td> <td></td></tr> <tr><td><strong>螺内酯</strong></td> <td>25mg 每日一次</td> <td>50mg 分为每日两次</td> <td>200mg分为每日两次</td> <td></td></tr> <tr><td><strong>非那雄胺</strong></td> <td>1mg每日一次</td> <td></td> <td>5mg 每日一次</td> <td></td></tr> <tr><td><strong>度他雄胺</strong></td> <td></td> <td></td> <td>0.5mg每日一次</td> <td></td></tr></tbody></table> <blockquote><p>a. 与复方制剂同样在美国药典中可用</p> <p>b. 低初始剂量适用于期望（或由于既往史需要）较低剂量或缓慢增加剂量的人群。</p> <p>c. 达到最大的效果并不一定需要最大剂量，同时最大剂量并不代表目标的或理想的剂量。剂量的增加需要根据使用者反馈和激素水平监测进行。</p></blockquote> <p>许多使用者渴望开始最大剂量的女性化激素治疗，而不愿将剂量缓慢增加。存在较弱证据显示从较低剂量雌激素开始治疗并随时间增加剂量能增进跨性别女性的乳房发育。 <strong>螺内酯的雌激素受体激动剂作用可能会限制乳房发育，因为其可能导致未成熟的乳房芽融合。正因如此早期仅使用缓慢增加的雌二醇而随后增加螺内酯可能是一种替代性的方法[17]，这也与青春期延迟儿童中的实践相一致。（分级：T O W）</strong> 滴定增加的螺内酯剂量同时也可以减少体位性晕厥或多尿等副作用。建议药物提供者在开始提供激素前与使用者讨论这些考虑因素从而确保使用者在得到足够信息的情况下做出决策。</p> <p>表 7-2. 女性化激素治疗的实验室监测</p> <table><thead><tr><th>**检测项目&lt;6&gt; **</th> <th><strong>备注</strong></th> <th><strong>基线</strong></th> <th><strong>3个月*</strong></th> <th><strong>6个月*</strong></th> <th><strong>12个月*</strong></th> <th><strong>每年</strong></th> <th><strong>按需</strong></th></tr></thead> <tbody><tr><td><strong>血尿素/肌酐/血钾</strong></td> <td>仅在使用螺内酯时</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td></tr> <tr><td><strong>脂质</strong></td> <td>没有证据支持监测的必要性；遵医嘱</td> <td>基于USPSTF 指南</td> <td></td> <td></td> <td></td> <td></td> <td>X</td></tr> <tr><td><strong>A1c或葡萄糖</strong></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td></tr> <tr><td><strong>雌二醇</strong></td> <td></td> <td></td> <td>X</td> <td>X</td> <td></td> <td></td> <td>X</td></tr> <tr><td><strong>总睾酮</strong></td> <td></td> <td></td> <td>X</td> <td>X</td> <td>X</td> <td></td> <td>X</td></tr> <tr><td><strong>性激素结合球蛋白(SHBG)*</strong>*</td> <td></td> <td></td> <td>X</td> <td>X</td> <td>X</td> <td></td> <td>X</td></tr> <tr><td><strong>白蛋白*</strong>*</td> <td></td> <td></td> <td>X</td> <td>X</td> <td>X</td> <td></td> <td>X</td></tr> <tr><td><strong>泌乳素</strong></td> <td>仅在有高泌乳素血症症状时</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>X</td></tr></tbody></table> <ul><li>仅在第一年</li></ul> <p>** 用于计算生物可利用睾酮；监测生物可利用睾酮是可选的，可能对复杂病例有帮助（见文本）（ http://www.issam.ch/freetesto.htm ）</p> <h3 id="药量滴定和监测概述"><a href="#药量滴定和监测概述" class="header-anchor">#</a> 药量滴定和监测概述</h3> <p>对跨性别者激素水平的诠释尚不是循证的，非跨性别人群中的生理激素水平可被用作参考区间。然而，顺性别女性中的雌激素水平未必与特定的第二性征有相关性（即，顺性别女性中较高的雌激素水平未必带来更大的乳房），而且特定的生理表现可能有复杂的原因，尤其是依赖于遗传和HRT开始的年龄。剂量的增加应当在医疗反馈、激素水平监测和安全性监测（在有风险因子的情况下，如螺内酯使用者的吸烟、肾功能和血钾）。一般的剂量调整方法，是同时增加雌激素和抗雄激素剂量直至雌激素水平落入生理女性范围；在这一目标达成时，剂量调整可以专注于增加雄激素拮抗。</p> <p>雄激素的药量滴定可能有几种方法。一种方法是继续增加雌激素直至达到女性生理范围的上限。这种方法的缺点是患者可能开始出现如下所述的雌激素副作用。另一种方法是维持目前的生理雌激素剂量并在抗雄激素和/或添加孕激素时增加药量。</p> <p>一些医疗服务提供者选择不进行激素水平测试，仅监测临床进展或变化。这种方法的风险在于，如果激素水平（特别是睾酮）没有达到目标范围，但根据临床检查判断进展是合适的，女性化的程度可能达不到最优，并且激素水平不符合一般生理情况的状况也会被掩盖。相反，内分泌学会指南建议每3个月监测激素水平。[21]在实践中，这是不现实的，并且一旦达到稳定剂量就不再带来更多价值。一项跨性别女性服用4mg/天分剂量口服雌二醇或100mcg透皮雌二醇加100-200mg/天分剂量螺内酯的前瞻性研究发现，所有女性均达到生理雌二醇水平，但只有2/3的女性达到女性睾酮水平。[22]一些性别非常规/非二元患者可能更喜欢维持中间范围内的雌二醇或睾酮水平。无论选择何种初始剂量方案，剂量可以在3-6个月间向上滴定。应检查第3个月和第6个月时的雌二醇和睾酮水平，并相应地滴定剂量。对于使用螺内酯的患者，在第3个月和第6个月检查肾功能和血钾，然后每6-12个月检查一次。虽然激素水平的实验室监测可能看起来很复杂，但其难度与由初级护理提供者管理的其他类似复杂的实验室监测的病症（例如甲状腺疾病，抗凝或糖尿病）相似。</p> <p>一旦激素水平达到了目标范围，只需要每年监测激素水平即可。与其他涉及维持激素治疗（更年期或避孕）的情况一样，对于稳定的激素治疗方案，每年一次就诊就足够了。其它在维持阶段需要测量激素水平的原因包括显著的代谢改变（如发生糖尿病或甲状腺异常）、显著体重改变、主观或客观的雄化证据，或新的可能由激素不平衡造成或加强的症状（如潮热或偏头痛）。此类情况下激素使用者可能需要更频繁地就医以处理并发状况。就医频率的增加对于具有复杂心理社会情况的患者也可能是有用的，以允许提供辅助或环绕式（Wraparound）服务。</p> <p>目前的内分泌学会建议仅测量总睾酮和雌二醇。与内分泌学会的建议一致的是，患有睾酮缺乏的非跨性别男性的治疗中只需要监测总睾酮，除非睾酮处于临界水平。然而，由于睾酮在确保最大化女性化方面特别值得关注，因此跨性别女性中生物可利用睾酮的计算可能仍然具有价值。具体而言，外源性雌激素（尤其是口服）可能与性激素结合球蛋白（SHBG）水平升高有关；这种升高因人和激素治疗方案而异。因此，在患者关注或总睾酮在女性范围但仍有持久的男性化特征的情况下，计算生物可利用的睾酮可以帮助微调激素方案以获得最佳效果。</p> <p>在跨性别护理的背景下，对实验室结果的解释需要特别注意。许多来源公布了血清雌二醇，总雌激素，游离/总和/生物同质性睾酮和性激素结合球蛋白的目标范围。但是，这些具体范围可能因不同的实验室和技术而异。此外，如果患者的登记性别与其预期的激素性别不同，则实验室结果报告中提供的参考范围的解释可能不适用。例如，仍然登记为男性的跨性别女性将得到为男性报告的实验室参考范围；很明显，这些范围不适用于使用女性化激素治疗的跨性别女性。性别酷儿或性别非常规/非二元患者的激素水平可能故意处于男性和女性规范的中间范围。鼓励医疗提供者咨询当地实验室以获得“男性”和“女性”规范的激素水平参考范围，然后再根据当前激素性别而不是登记的性别来应用正确的范围解释结果。</p> <h3 id="监测雌二醇水平"><a href="#监测雌二醇水平" class="header-anchor">#</a> 监测雌二醇水平</h3> <p>2009年内分泌学会指南建议监测血清雌二醇水平并维持在顺性别女性的周期中点 &lt;7&gt; 水平。[21]这一建议仅基于专家意见且可能过分保守，同时激素水平常常难以准确控制。[23]鼓励医疗服务提供者了解其当地实验室雌二醇进行的检查中的特定雌二醇参考范围，因为参考范围可能不一致。没有证据表明在充分的抗雄效果下较高的雌二醇水平能带来更多的女性化或乳房发育。</p> <p>维持雌激素水平在非跨性别女性经期的生理范围内可以最大限度地降低风险和副作用，并且在临床上有意义。注意，雌二醇测定不能准确测量结合雌激素（倍美力™）或炔雌醇（在大多数复合口服避孕药 &lt;8&gt; 中存在）的水平，并且通常会导致较低的测量结果。</p> <p>在自行使用结合雌激素或炔雌醇的患者中，检查总雌激素水平是合理的，这可以在这些情况下提供更准确的估计。该测定还测量一些次要的雌激素类物质，如雌三醇和雌酮。有证据表明，与注射形式相比，使用口服雌二醇会导致首次肝脏代谢引起的血清雌酮水平升高[24,25]。这可能解释了为什么有些患者在使用相同剂量的不同形式雌激素下“感觉不同”。</p> <h3 id="监测睾酮水平"><a href="#监测睾酮水平" class="header-anchor">#</a> 监测睾酮水平</h3> <p>非跨性别男性中，由于与促性腺激素的脉冲释放相关，睾酮水平会快速波动（在早晨时间内水平较高），因此睾酮水平难以测量。游离睾酮代表未与血清蛋白结合的睾酮部分，并且取决于性激素结合球蛋白（SHBG）的水平。虽然可以测量游离睾酮，但分析并不可靠。[26]关于自由与总睾酮水平的作用缺乏共识；总睾酮水平可靠且容易获得，但它们没有描述实际的生物可利用睾酮水平。生物可利用的睾酮是游离睾酮加上与白蛋白弱结合的睾酮。[27]SHBG在雌激素存在的情况下升高，尤其是存在外源性雌激素补充时，而对于口服雌激素的情况，由于存在肝脏首过效应，效果比注射途径更显著[28]。<strong>对于跨性别护理，内分泌学会建议监测总睾酮水平，目标范围&lt;55ng/dl&gt;&lt;9&gt; 。</strong>[21]生物可利用睾酮的计算可能有助于指导给药，并且可以从总睾酮，白蛋白和SHBG水平计算得到（ http://www.issam.ch/freetesto.htm ）。[29]生物可利用睾酮的一般参考范围是&gt;72ng/dl （2.5nmol/L）。[30-32]</p> <h3 id="监测促性腺激素水平"><a href="#监测促性腺激素水平" class="header-anchor">#</a> 监测促性腺激素水平</h3> <p>必要时，可以使用当地的正常性腺状态下实验室范围作为参考来测量促性腺激素（促黄体生成素LH和卵泡生成素FSH）水平。</p> <h3 id="在使用注射雌激素的患者中监测激素水平"><a href="#在使用注射雌激素的患者中监测激素水平" class="header-anchor">#</a> 在使用注射雌激素的患者中监测激素水平</h3> <p>雌激素注射剂的药代动力学研究十分有限。两项早期研究仅检查了单剂量药代动力学，因此无法应用于稳态给药。[33]在每月合并5mg雌二醇环丙酸酯和25mg醋酸甲羟孕酮的可注射避孕药的情况下，雌二醇水平的研究发现注射后2-4天达到峰值水平，最大雌二醇水平约为250pg/ml，谷浓度约为50pg/ml。[34,35]在前文推荐的剂量下能达到生理雌二醇水平，而更频繁的注射能减少激素波动。对注射剂使用者而言，一般只需要在周期中点测量雌二醇水平。然而如果使用者有周期症状（如偏头痛和情绪波动），在波峰（注射后1-2天）和波谷时测量雌二醇和睾酮水平可能显示给药周期中激素的剧烈波动。在这种情况下，建议改用口服或透皮药物，或减少给药周期（注意同时减少每次的药量，从而维持相同时间内总剂量不变）。一项研究表明，当雌二醇皮下注射而不是肌内注射时，药代动力学结果相似[34]。</p> <h3 id="解释性别相关的非激素实验室结果"><a href="#解释性别相关的非激素实验室结果" class="header-anchor">#</a> 解释性别相关的非激素实验室结果</h3> <p>碱性磷酸酶（ALP）、血红蛋白（HGB）与红细胞比容（HCT）和肌酐（Cr）水平会随检查者的当前激素状况而变化。一系列因素对这些变化有影响：骨量、肌肉量、肌细胞数量、是否有月经，以及睾酮的红细胞生成效应。尽管跨性别女性没有月经，激素水平在女性范围内者将失去男性睾酮的红细胞生成效应，因此使用女性的参考值下限来解释血红蛋白和红细胞比容水平是合理的。同时，由于不存在月经和在尚保留性腺者中可能存在未被检测到的脉冲式雄激素活动，使用男性的参考值上限同样是合理的。对跨性别女性而言，考虑到原本的骨骼和肌肉量/肌细胞数，肌酐和碱性磷酸酶使用男性的参考值上限也是合适的。这在登记为女性的服用螺内酯的跨性别女性中特别重要：她们可能具有显示异常升高的肌酐的实验室结果指标。在此情况下，提供者应参考其实验室的男性正常范围。[19]</p> <p>表 7-3.女性化激素治疗中的跨性别女性解释部分实验室结果时的正常值上下限</p> <table><thead><tr><th><strong>检查结果</strong></th> <th><strong>正常值下限</strong></th> <th><strong>正常值上限</strong></th></tr></thead> <tbody><tr><td><strong>肌酐</strong></td> <td>未定义</td> <td>男性值</td></tr> <tr><td><strong>血红蛋白/红细胞比容</strong></td> <td>女性值</td> <td>男性值</td></tr> <tr><td><strong>碱性磷酸酶</strong></td> <td>未定义</td> <td>男性值</td></tr></tbody></table> <h3 id="基于患者中心目标的个体化药量"><a href="#基于患者中心目标的个体化药量" class="header-anchor">#</a> 基于患者中心目标的个体化药量</h3> <p>一些患者可能需要有限的激素效应或男性和女性性别特征的混合。实例包括保留勃起功能而在其它方面最大化女性化，或除了身体或面部毛发消除或乳房增长之外的最小女性化效果。虽然操纵给药方案和选择药物可以使患者实现这一目标，但与患者就预期和未知因素进行清晰的讨论非常重要。具体而言，不可能预先选择可预测地允许患者达到特定性别特征配置的精确激素方案。</p> <p>此外，个体遗传和生理差异可导致血液水平以及使用相同途径和剂量的不同个体之间对治疗的响应广泛变化。在这些情况下，最好的方法是从低剂量开始，缓慢推进，滴定达到效果。同时，对激素治疗的反应也是个体化的，并且如乳房增长等度量结果在程度和时间进程方面都是可变的。女性化速度和程度的可能预测因素包括遗传因素，治疗开始时的年龄和身体状态。[17]应向患者为变化发生的典型时间范围提供咨询，并建议她们避免与其他人的经历进行比较。轶事来源表明最大限度的女性化可能会在2-5年内发生。[36]</p> <h3 id="特殊考虑与状况"><a href="#特殊考虑与状况" class="header-anchor">#</a> 特殊考虑与状况</h3> <p>**烟草使用：**烟草使用与雌激素治疗相结合会增加静脉血栓栓塞的风险。所有吸烟的跨性别女性应在每次就诊时就烟草风险和戒烟方案接受咨询。许多跨性别女性可能无法或不愿意戒烟；这不应该代表雌激素治疗的绝对禁忌症。经过深入细致的知情同意讨论后，使用降低危害的方法开出雌激素是合理的，且透皮雌激素方式更佳。<strong>阿司匹林81mg/日可被视为吸烟者的另一项预防措施，但尚未明确该措施可能引发的消化道出血和预防静脉血栓栓塞两者间的风险/受益比率（分级：X C W）。优先使用透皮雌激素以最小化风险（分级：T O S）。</strong></p> <p>**失去勃起功能：**考虑到使用这类药物时的典型禁忌症和预防措施，西地那非（万艾可）和他达拉非（希爱力）可用于在任何阶段或任何女性化激素治疗方案中保留勃起功能。个体结果可能有所不同。取决于患者的目标，检查总睾酮和生物可利用的睾酮水平，并考虑减少雄激素阻断以允许睾酮增加是合理的。</p> <p>**低性欲：**对于跨性别女性性欲的研究发现，83％从未或很少经历过自发性欲望，76％从未或很少经历过反应性欲望，22％以某种方式符合上述两项而到达性欲减退症（HSDD）的标准，从而导致个人或人际关系上的痛苦。该研究还发现生殖器手术后性欲降低。[37]另一项研究发现，跨性别女性的HSDD率为34％，非跨性别女性为23％。该研究发现，跨性别女性的性欲和睾酮水平之间没有相关性，尽管在非跨性别女性中激素和欲望之间存在显著相关性。[38]一项未发表的研究发现，性欲和睾酮水平之间存在正相关关系，但用硫酸二氢表雄酮（DHEA-S）治疗无效。[39]因此，目前尚不清楚HSDD是否与雄激素阻断或性腺切除后激素变化有关，或与激素治疗或生殖器手术相关的解剖学、功能和心理变化有关。</p> <p>**性腺切除术后：**由于雌激素给药应基于生理女性水平，因此在性腺切除术后不需要减少雌激素给药。一些患者可以选择使用较低剂量，只要给药足以维持骨密度就是合适的。<strong>可以根据LH和FSH水平来评估在性腺切除术后低雌激素替代者中给药的充分性（分级：T O W）。[11]</strong></p> <p>**年长跨性别女性：**年长的跨性别女性初始治疗可能具有较慢和较小程度的变化。由于老年人的并发状况水平较高，因此可能存在较高的不良反应风险。尽管如此，大量女性已经开始在较高年龄使用激素，并且据报道安全性和满意度可接受。[40]没有证据支持年长的跨性别女性应当继续使用或停止使用激素。</p> <p>由于美国绝经的平均年龄为49岁[41]，因此在接受性腺切除术的跨性别女性中考虑在50岁左右停止激素治疗是合理的。这可能与非跨性别女性经历更年期相似。保留性腺但停止激素治疗的跨性别女性可能会恢复男性化。建议讨论这种方法的利弊，并进行个性化的共同决策&lt;10&gt; （shared decision making）。</p> <p>**垂体腺瘤（催乳素瘤）和溢乳：**催乳素升高和垂体泌乳素瘤的生长是与雌激素治疗相关的理论风险；有几起病例报道。[42]然而，随着生理剂量的雌激素的施用，与非跨性别女性的群体背景率相比，没有明确的证据说明催乳素瘤的风险增加。**此外，内分泌学会关于偶发性泌乳素瘤治疗的指导方针只是在没有暗示性视觉或其他症状（显著溢乳、头痛）下的期待治疗（expectant management）。[43]无症状跨性别女性的血清催乳素水平常规筛查不会对治疗产生影响，如果进行进一步检查，可能会导致额外成本或伤害。因此，建议仅在出现视力障碍、过度溢乳的情况下，或在新发头痛的情况做出考虑，对血清催乳素水平进行检查。**值得注意的是，一些跨性别女性在其激素疗法疗程的早期经历了极少量的溢乳。来自一个以上导管和/或双侧的非血性少量溢乳的存在几乎肯定是生理性的，并且不值得进一步评估。</p> <p>**静脉血栓栓塞：**来自更年期女性研究的数据表明，使用透皮雌二醇不会增加静脉血栓栓塞的风险[44]。当使用结合马雌激素（倍美力™）时，有一些数据提示血栓形成和心血管风险增加[1,2]。与口服17-β雌二醇相关的风险数据是矛盾的，一些数据表明风险没有增加，另一些数据表明风险增加2.5-4倍。[20,44]然而即使在增加2.5倍的情况下，由于一般人群中静脉血栓栓塞的背景率也很低（千分之一至万分之一），因此绝对风险增加很少。[3]有弱证据表明口服雌二醇舌下给药可能由于绕过了肝脏首过效应降低血栓栓塞风险，一项研究显示雌二醇峰值血液水平增加13倍，但24小时曲线下面积相似。[45]一项关于舌下雌二醇治疗产后抑郁症的研究发现治疗的耐受性良好，而且这种途径所增加的脉冲性可能能更接近地模仿自然卵巢雌激素的分泌。[46]舌下给药需要确保雌二醇片剂是微粉化的；虽然大多数常用的雌二醇片剂都是微粉化的，但建议在书面处方中另行说明，或咨询配药师。</p> <p>还有一些有限的证据表明更年期妇女静脉血栓栓塞的风险可能更多地取决于孕激素的选择，并且孕烷衍生的孕激素（如甲羟孕酮）与口服雌二醇联合使用并不会增加风险，而去甲孕烷衍生的孕激素（如炔诺酮）与口服雌二醇一起使用时可使风险增加80％。[20]之前的研究报道，在使用高剂量（100-200mcg/日）炔雌醇的跨性别女性（同时包含吸烟者和非吸烟者）中，静脉血栓栓塞的风险增加20至40倍[47,48]。一项对荷兰跨性别女性的回顾性队列研究发现，一旦标准方案中炔雌醇被具有生物同质性的雌二醇替代，静脉血栓栓塞的风险就不会增加。[49]</p> <p>没有充足证据指导具有危险因素或具有先前静脉血栓栓塞个人史（无论当时是否使用雌激素）的跨性别女性的雌激素治疗。使用透皮雌二醇而不进行抗凝治疗的具有活化蛋白C抗性（与凝血因子V Lieden突变相关的高凝状态的作用机制）的11名跨性别女性的报告显示在平均64个月治疗后没有发现凝血事件。[50]</p> <p>**图1-5描述静脉血栓栓塞病史或危险因素和雌激素使用的各种情景的方法。**在与主要胃肠道或颅内出血相关的风险背景下，应考虑决定开始间歇性（即长途飞行前）或长期抗凝治疗或抗血小板治疗。**不推荐将常规静脉血栓栓塞预防和阿司匹林用于未选择的跨性别人群。**在没有风险因素的情况下，不推荐常规筛查促血栓形成突变。[50]无论情况如何，对于继续吸烟的有静脉血栓栓塞重要危险因素或病史的患者，不应给予雌激素治疗。</p> <p>图 7-1. 有静脉血栓栓塞个人史患者中的雌激素治疗</p> <p><img src="data:image/png;base64,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" alt="img"></p> <p>图 7-2. 有静脉血栓栓塞家族史而无个人史患者中的雌激素治疗</p> <p><img src="data:image/png;base64,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" alt="img"></p> <p>图 7-3. 使用口服或注射雌激素的患者初次诊断为静脉血栓栓塞</p> <p><img src="data:image/png;base64,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" alt="img"></p> <p>图 7-4. 使用透皮雌激素的患者初次诊断为静脉血栓栓塞</p> <p><img src="data:image/png;base64,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" alt="img"></p> <p>图 7-5. 使用透皮雌激素且已知有高凝状态患者出现急性静脉血栓栓塞</p> <p><img src="data:image/gif;base64,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" alt="img"></p> <p>**自身免疫疾病：**性激素和自身免疫疾病之间存在某种确定但不完全明确的联系。睾酮与整体免疫抑制有关，自身免疫状况在非跨性别女性中比男性更常见[51]。睾酮剥夺导致Th1：Th2比率增加。[52]然而，正如怀孕期间多发性硬化症中出现的矛盾改善所证明，这种关系更加复杂。[51]在已经接受睾丸切除术或完全雄激素阻断的跨性别女性中，有证据表明补充二氢表雄酮（DHEA）可能会抵消一些向自身免疫的转变。[53]女性化治疗开始后，应告知患有自身免疫疾病的患者，其病情可能会恶化（或改善）。</p> <p>激素剂量应该从低剂量开始并缓慢推进，监测症状恶化，并与可能在处理自身免疫疾病的任何专家合作。</p> <p>**偏头痛：**偏头痛具有明确的激素因素，可能会被雌激素治疗加剧。有偏头痛病史的患者应考虑从低剂量开始，并在耐受时再向上滴定。考虑到相关的潜在周期性激素变化，口服或透皮雌激素可能优于注射雌激素。[54]虽然有先兆的偏头痛与使用口服避孕药的女性卒中风险增加有关[55]，但尚不清楚这种风险是否在使用生物同质性的雌二醇时同样存在。</p> <p>**精神健康状况：**虽然激素可能导致情绪障碍（例如经前焦虑症或产后抑郁症），但没有明确证据表明雌激素治疗与精神健康问题的发作或恶化直接相关。事实上，有一项研究发现，一旦雌激素治疗开始，跨性别女性就会改善社交功能并减少焦虑和抑郁。[56]与其他任何患者一样，跨性别女性的心理健康状况应通过广泛的鉴别诊断得到。由于潜在的周期性水平变化，建议避免注射雌激素，否则可能导致或加重现有的情绪症状。</p> <p>**癌症史患者中的雌激素治疗：活跃的雌激素敏感性癌症是雌激素治疗的禁忌症。**对于既往有雌激素敏感性癌症（乳腺癌，垂体癌）病史的患者，建议咨询肿瘤科医生。虽然雄激素剥夺是晚期前列腺癌的主要治疗方法，但目前尚不清楚雌激素治疗是否可能会给予独立保护或增加患前列腺癌的风险。[57]由于假阴性测试的高风险，使用抗雄激素或雌激素治疗的患者应认为前列腺特异抗原不可靠。</p> <p>**围手术期女性化激素使用：**没有直接研究生物同质性雌激素使用者围手术期静脉血栓栓塞的风险。两个英国专业组织的指南建议在围手术期停止更年期激素治疗，但两者都承认在正确预防（即肝素或压迫装置）的情况下可能不需要这样做。[58]对激素避孕使用者围手术期使用炔雌醇的研究结果不一，并且存在矛盾和方法学限制。[59]许多外科医生坚持认为跨性别女性在任何性别肯定程序之前和之后都会停用雌激素数周。[60,61]这些建议对外科医生来说可能是善意的；然而，对于跨性别女性，因进行与性腺切除术同时的生活和身体改变的过程，雌激素的突然和持续的完全戒断会产生深远的影响。术后抑郁症是一个非常重要的问题，并且可能与围手术期经历的剧烈激素变化（包括停止雌激素）方面有一些关联。<strong>没有证据表明没有特定危险因素（吸烟，个人或家族史，过量服用或使用合成雌激素）的跨性别女性必须在手术前后停止雌激素治疗，特别是适在当采取预防措施和进行知情同意讨论在此期间停止激素治疗的利弊的情况下。可能的替代方案包括使用较低剂量的雌激素，和/或如果尚未使用则改为透皮途径。[62]</strong></p> <h3 id="参考文献-7"><a href="#参考文献-7" class="header-anchor">#</a> 参考文献</h3> <ol><li>Shifren JL, Rifai N, Desindes S, McIlwain M, Doros G, Mazer NA. A comparison of the short- term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. J Clin Endocrinol Metab. 2008 May;93(5):1702–10.</li> <li>Ho JY-P, Chen M-J, Sheu WH-H, Yi Y-C, Tsai AC-W, Guu H-F, et al. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Hum Reprod Oxf Engl. 2006 Oct;21(10):2715–20.</li> <li>Hugon-Rodin J, Gompel A, Plu-Bureau G. Mechanisms in endocrinology: epidemiology of hormonal contraceptives-related venous thromboembolism. Eur J Endocrinol. 2014 Dec 1;171(6):R221–30.</li> <li>Asscheman H, Giltay EJ, Megens JAJ, de Ronde WP, van Trotsenburg MAA, Gooren LJG. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol Eur Fed Endocr Soc. 2011 Apr;164(4):635–42.</li> <li>Koetsawang S, Mandlekar AV, Krishna UR, Purandare VN, Deshpande CK, Chew SC, et al. A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. Contraception. 1980 May;21(5):445–59.</li> <li>Prior JC, Vigna YM, Watson D. Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism. Arch Sex Behav. 1989 Feb;18(1):49– 57.</li> <li>Sinclair R, Patel M, Dawson TL, Yazdabadi A, Yip L, Perez A, et al. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Br J Dermatol. 2011 Dec;165 Suppl 3:12–8.</li> <li>Rittmaster RS. 5alpha-reductase inhibitors. J Androl. 1997 Dec;18(6):582–7.</li> <li>Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α- reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011 Mar;8(3):872–84.</li> <li>Bienz M, Saad F. Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review. BoneKEy Rep. 2015;4:716.</li> <li>Esteva I, Yahyaoui R, Cano G, Giraldo F, Bergero T, Ruiz de Adana S, et al. Evolution of gonadal axis after sex reassignment surgery in transsexual patients in the Spanish public health system. Int J Transgenderism. 2006 Jun 1;9(2):15–22.</li> <li>Bessone F, Lucena MI, Roma MG, Stephens C, Medina-Cáliz I, Frider B, et al. Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases. Liver Int Off J Int Assoc Study Liver. 2016 Feb;36(2):302–10.</li> <li>Kolvenbag GJCM, Blackledge GRP. Worldwide activity and safety of bicalutamide: a summary review. Urology. 1996 Jan;47(1, Supplement 1):70–9.</li> <li>Wolf-Gould CS, Wolf-Gould CH. A transgender woman with testicular cancer: a new twist on an old problem. LGBT Health. 2015 Dec 24;</li> <li>Rosenthal SM. Approach to the patient: transgender youth: endocrine considerations. J Clin Endocrinol Metab. 2014 Dec;99(12):4379–89.</li> <li>Dittrich R, Binder H, Cupisti S, Hoffmann I, Beckmann MW, Mueller A. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc. 2005 Dec;113(10):586– 92.</li> <li>Wierckx K, Gooren L, T’Sjoen G. Clinical review: Breast development in trans women receiving cross-sex hormones. J Sex Med. 2014 May;11(5):1240–7.</li> <li>Orentreich N, Durr NP. Proceedings: Mammogenesis in transsexuals. J Invest Dermatol. 1974 Jul;63(1):142–6.</li> <li>Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321–33.</li> <li>Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, et al. Hormone therapy and venous thromboembolism among postmenopausal somen: impact of the route of estrogen administration and progestogens: the ESTHER Study. Circulation. 2007 Feb;115(7):840–5.</li> <li>Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ, Spack NP, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009 Jun 9;94(9):3132–54.</li> <li>Deutsch MB, Bhakri V, Kubicek K. Effects of cross-sex hormone treatment on transgender women and men. Obstet Gynecol. 2015 Mar;125(3):605–10.</li> <li>Quest Diagnostics. Estradiol [Internet]. Test Center Info - For Physicians &amp; Hospitals. [cited 2015 Nov 20]. Available from: http://www.questdiagnostics.com/testcenter/TestDetail.action?ntc=4021&amp;fromFlyOut=true</li> <li>Ansbacher R. The pharmacokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol. 2001 Feb;184(3):255–63.</li> <li>O’Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol. 1995 Sep;35(9 Suppl):18S – 24S.</li> <li>Ly LP, Handelsman DJ. Empirical estimation of free testosterone from testosterone and sex hormone-binding globulin immunoassays. Eur J Endocrinol Eur Fed Endocr Soc. 2005 Mar;152(3):471–8.</li> <li>Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007 Feb;92(2):405–13.</li> <li>Serin IS, Ozçelik B, Başbuğ M, Aygen E, Kula M, Erez R. Long-term effects of continuous oral and transdermal estrogen replacement therapy on sex hormone binding globulin and free testosterone levels. Eur J Obstet Gynecol Reprod Biol. 2001 Dec 1;99(2):222–5.</li> <li>Carnegie C. Diagnosis of hypogonadism: clinical assessments and laboratory tests. Rev Urol. 2004;6(Suppl 6):S3–8.</li> <li>Sih R, Morley JE, Kaiser FE, Perry HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997 Jun;82(6):1661–7.</li> <li>Korenman SG, Morley JE, Mooradian AD, Davis SS, Kaiser FE, Silver AJ, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab. 1990 Oct;71(4):963–9.</li> <li>Nelson R, O’Kane D, Heser D, Klee G. A simple and rapid assay for bioavailable-testosterone. Clin Chem. 2001 Jun;47(6):A20–A20.</li> <li>Düsterberg B, Nishino Y. Pharmacokinetic and pharmacological features of oestradiol valerate. Maturitas. 1982 Dec;4(4):315–24.</li> <li>Sierra-Ramírez JA, Lara-Ricalde R, Lujan M, Velázquez-Ramírez N, Godínez-Victoria M, Hernádez-Munguía IA, et al. Comparative pharmacokinetics and pharmacodynamics after subcutaneous and intramuscular administration of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg). Contraception. 2011 Dec;84(6):565–70.</li> <li>Thurman A, Kimble T, Hall P, Schwartz JL, Archer DF. Medroxyprogesterone acetate and estradiol cypionate injectable suspension (Cyclofem) monthly contraceptive injection: steady- state pharmacokinetics. Contraception. 2013 Jun;87(6):738–43.</li> <li>Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, DeCuypere G, Feldman J, et al. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7. Int J Transgenderism. 2012;13(4):165–232.</li> <li>Wierckx K, Elaut E, Van Hoorde B, Heylens G, De Cuypere G, Monstrey S, et al. Sexual desire in trans persons: associations with sex reassignment treatment. J Sex Med. 2014 Jan;11(1):107–18.</li> <li>Elaut E, De Cuypere G, De Sutter P, Gijs L, Van Trotsenburg M, Heylens G, et al. Hypoactive sexual desire in transsexual women: prevalence and association with testosterone levels. Eur J Endocrinol Eur Fed Endocr Soc. 2008 Mar;158(3):393–9.</li> <li>Sivakumaran D, Seal L. A retrospective study on the use of androgen therapy in trans women to treat HSSD. EPATH conference; 2015 Mar 13; Ghent, Belgium.</li> <li>Gooren L, Lips P. Conjectures concerning cross-sex hormone treatment of aging transsexual persons. J Sex Med. 2014 Aug;11(8):2012–9.</li> <li>Tom SE, Cooper R, Patel KV, Guralnik JM. Menopausal Characteristics and Physical Functioning in Older Adulthood in the NHANES III. Menopause N Y N. 2012 Mar;19(3):283–9.</li> <li>Goh HH, Li XF, Ratnam SS. Effects of cross-gender steroid hormone treatment on prolactin concentrations in humans. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 1992 Jun;6(2):113–7.</li> <li>Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011 Apr;96(4):894–904.</li> <li>Canonico M, Plu-Bureau G, Lowe G, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. Bmj. 2008;336(7655):1227.</li> <li>Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW. Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 beta-estradiol. Obstet Gynecol. 1997 Mar;89(3):340–5.</li> <li>Ahokas A, Kaukoranta J, Wahlbeck K, Aito M. Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17beta-estradiol: a preliminary study. J Clin Psychiatry. 2001 May;62(5):332–6.</li> <li>Asscheman H, Gooren LJG, Eklund PLE. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism. 1989;38(9):869–73.</li> <li>van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf). 1997 Sep;47(3):337–42.</li> <li>Asscheman H, Giltay EJ, Megens JAJ, de Ronde W, van Trotsenburg MAA, Gooren LJG. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011 Jan 25;164(4):635–42.</li> <li>Ott J, Kaufmann U, Bentz EK, Huber JC, Tempfer CB. Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. Fertil Steril. 2010;93(4):1267– 72.</li> <li>Gold SM, Voskuhl RR. Estrogen and testosterone therapies in multiple sclerosis. In: Progress in Brain Research [Internet]. Elsevier; 2009 [cited 2015 Nov 21]. p. 239–51. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0079612309175167</li> <li>Trigunaite A, Dimo J, Jørgensen TN. Suppressive effects of androgens on the immune system. Cell Immunol. 2015 Apr;294(2):87–94.</li> <li>Labrie F. DHEA, important source of sex steroids in men and even more in women. Prog Brain Res. 2010;182:97–148.</li> <li>Chai NC, Peterlin BL, Calhoun AH. Migraine and estrogen. Curr Opin Neurol. 2014 Jun;27(3):315–24.</li> <li>Nappi RE, Merki-Feld GS, Terreno E, Pellegrinelli A, Viana M. Hormonal contraception in women with migraine: is progestogen-only contraception a better choice? J Headache Pain. 2013;14:66.</li> <li>Gómez-Gil E, Zubiaurre-Elorza L, Esteva I, Guillamon A, Godás T, Cruz Almaraz M, et al. Hormone-treated transsexuals report less social distress, anxiety and depression. Psychoneuroendocrinology. 2012 May;37(5):662–70.</li> <li>Misawa A, Inoue S. Estrogen-related receptors in breast cancer and prostate cancer. Front Endocrinol. 2015;6:83.</li> <li>Royal College of Obstetricians and Gynaecologists. Venous Thromboembolism and Hormone Replacement Therapy, 3rd edition [Internet]. United Kingdom; 2011 May [cited 2015 Nov 21]. Report No.: 19. Available from: <a href="http://www.rcog.org.uk/globalassets/documents/guidelines/gtg19vtehrt310511.pdf" target="_blank" rel="noopener noreferrer">https://www.rcog.org.uk/globalassets/documents/guidelines/gtg19vtehrt310511.pdf<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a></li> <li>Whitehead EM, Whitehead MI. The pill, HRT and postoperative thromboembolism: cause for concern? Anaesthesia. 1991 Jul 1;46(7):521–2.</li> <li>Johnson RL, Hemington-Gorse SJ, Dhital SK. Do cosmetic surgeons consider estrogen- containing drugs to be of significant risk in the development of thromboembolism? Aesthetic Plast Surg. 2008 Apr 30;32(5):743–7.</li> <li>Asscheman H, T’Sjoen G, Lemaire A, Mas M, Meriggiola MC, Mueller A, et al. Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review. Andrologia. 2014 Sep;46(7):791–5.</li> <li>Brighouse D. Hormone replacement therapy (HRT) and anaesthesia. Br J Anaesth. 2001 May 1;86(5):709–16.</li></ol> <blockquote><p>&lt;2&gt; . 译者注：常见的口服剂有诺坤复™（Estrofem™），此外国内常用的戊酸雌二醇片如补佳乐™（Progynova™）效果与17-β雌二醇口服剂类似。</p> <p>&lt;3&gt; . 译者注：常见的包含炔雌醇的药物包括达英-35™、妈富隆™、优思明™、特居乐™等。</p> <p>&lt;4&gt; . 译者注：常见的包含黄体酮的药物包括琪宁™、益玛欣™等。</p> <p>&lt;5&gt; . 译者注：常见的包含甲炔诺孕酮的药物包括悦可婷™、毓婷™以及Cyclo-Progynova™（“环补”）等。</p> <p>&lt;6&gt; . 译者注：对于醋酸环丙孕酮使用者而言，可能有必要同时监测肝功能水平。</p> <p>&lt;7&gt; . 译者注：2017年内分泌学会指南中的具体建议是维持在普通的非绝经女性水平，不超过100-200pg/mL</p> <p>&lt;8&gt; . 译者注：同时包含雌激素和孕激素的避孕药，不同于仅包含孕激素的单方避孕药</p> <p>&lt;9&gt; . 译者注：1.9nmol/L</p> <p>&lt;10&gt; . 译者注：指在医护人员充分告知患者（及家属等相关人员）各种治疗和护理方案的利弊后，患者与医护人员共同权衡做出决策的过程。</p></blockquote> <h2 id="男性化激素治疗概述"><a href="#男性化激素治疗概述" class="header-anchor">#</a> 男性化激素治疗概述</h2> <p>主要作者： Madeline B. Deutsch, MD, MPH</p> <h3 id="概论-4"><a href="#概论-4" class="header-anchor">#</a> 概论</h3> <p>男性化激素治疗的目的是发育出男性的第二性征，并抑制女性的第二性征，总体来说包括面部毛发的增长，声音男性化，面部和身体皮下脂肪的重新分布，肌肉质量增加，体毛增加，汗液和气味模式的变化，额头发际线的逐步退化，以及可能的男性秃发。对性和性腺的影响包括性欲增加，阴蒂增长，阴道干燥和月经停止。使用激素后往往能（但不是绝对能）继续排卵，且生育功能可能会受到长期影响，尽管一些跨性别男性能在停止使用睾酮后成功怀孕。[1]男性化激素治疗可能带来情绪和社会功能的变化，尽管这些变化因人而异，不能一概而论。这种治疗一般采用不同形式的外源性睾酮。</p> <p>目前在美国使用的所有睾酮制剂都具有“生物同质性”，因为它们在化学上与人睾丸所分泌的睾酮相同。过去常见于健身社群中的口服甲基睾酮和其它合成药品导致了对跨性别男性中睾酮对肝带来的负面效应的缺乏依据的担忧。睾酮可分散于多种注射制剂与局部制剂，这样的设计已经被用于治疗雄激素水平较低的非跨性别男性（见表）。由于这些药物的标签剂量（不包括在表中）是基于治疗睾酮水平低而非无睾酮的男性，因此跨性别男性可能需要比非跨性别男性更高的剂量（见下表）。</p> <p>表 8-1. 激素制剂和剂量（分级：T O M）</p> <table><thead><tr><th><strong>雄激素种类</strong></th> <th><strong>初始-低剂量b</strong></th> <th><strong>初始-典型</strong></th> <th><strong>最大剂量-典型c</strong></th> <th><strong>意见</strong></th></tr></thead> <tbody><tr><td><strong>环戊丙酸睾酮a</strong></td> <td>肌肉注射/皮下注射 20 mg/周</td> <td>肌肉注射/皮下注射 50mg/周</td> <td>肌肉注射/皮下注射 100mg/周</td> <td>对于每2周给药，每种剂量加倍</td></tr> <tr><td><strong>庚酸睾酮a</strong></td> <td>肌肉注射/皮下注射20mg/周</td> <td>肌肉注射/皮下注射 50mg/周</td> <td>肌肉注射/皮下注射 100mg/周</td> <td>同上</td></tr> <tr><td><strong>1%外用睾酮凝胶</strong></td> <td>每天早晨12.5-25mg</td> <td>每天早晨50mg</td> <td>每天早晨100mg</td> <td>可以来自于泵或贴片</td></tr> <tr><td><strong>1.62%外用睾酮凝胶d</strong></td> <td>每天早晨20.25mg</td> <td>每天早晨40.5 – 60.75mg</td> <td>每天早晨103.25mg</td> <td>同上</td></tr> <tr><td><strong>睾酮贴片</strong></td> <td>每天下午1-2mg</td> <td>每天下午 4mg</td> <td>每天下午 8mg</td> <td>贴片分为2mg和4mg两种尺寸，需要更低的剂量可以切割</td></tr> <tr><td><strong>睾酮软膏e</strong></td> <td>10mg</td> <td>50mg</td> <td>100mg</td> <td></td></tr> <tr><td><strong>2%睾酮腋下凝胶</strong></td> <td>每天早晨 30mg</td> <td>每天早晨 60mg</td> <td>每天早晨90-120mg</td> <td>只能用泵给药，一个泵含30mg</td></tr> <tr><td><strong>十一酸睾酮f</strong></td> <td>N/A</td> <td>肌肉注射750mg,</td> <td>N/A</td> <td>需要在厂商监测项目中进行<strong>f</strong></td></tr></tbody></table> <blockquote><p>a. 与复方制剂同样在美国药典中可用</p> <p>b. 对性别酷儿和非二元性别者建议使用的初始 - 低剂量标准。</p> <p>c. 最大剂量并不意味着效果的最大化。此外，这些剂量范围不一定代表目标或理想剂量。剂量增加应基于患者反应和/或监测的激素水平。有些患者可能需要比此更低的剂量，有些患者则可能需要更多。‘</p> <p>d. 使用1.62％凝胶中低于20.25mg的剂量，或2％腋下凝胶中低于30mg的剂量可能很难达到，因为测量泵或包的半数值难度过大。要求剂量低于20.25mg并且保证不超过1％凝胶的患者可能需要事先授权申请。</p> <p>e. 睾酮的浸出制剂由配药房制备。具体的吸收和活性各不相同，建议咨询其配药师具体的推荐剂量。</p> <p>f. 十一酸睾酮已被广泛用于美国以外的跨性别治疗多年。[2,3]它最近在美国也投入使用。十一酸睾酮与罕见的肺部脂栓塞和过敏性反应有关。因此，在美国，该药物只能通过AVEED风险评估和缓解策略（REMS）计划（ <em>https://www.aveedrems.com/AveedUI/rems/preHome.action</em> ） 有限获得。所有注射必须由经过培训和注册的医疗保健提供者在办公室或医院环境中进行，并在之后30分钟监测是否发生不良反应。</p></blockquote> <p><strong>注射途径（肌内注射与皮下注射）：虽然注射用睾酮被标记为肌内途径，但许多医疗提供者使用皮下途径给予睾酮，并且功效和患者满意度都反馈良好，且不伴有并发症。皮下给药的优点在于皮下注射的针头较小，造成疼痛较轻，并且可以避免长期（可能&gt;50年）肌肉注射引起的肌肉瘢痕或纤维化（分级：T O M）。[4,5]</strong></p> <p><strong>适当使用睾酮透皮贴剂：</strong> 一些凝胶利用含有睾酮药物的可蒸发载体发挥作用。厂商建议这种贴剂在早晨使用。施用后，睾酮进入真皮，在一天中缓慢释放。凝胶应避免与其他人接触，尤其是妇女和儿童，包括残留在衣物和其他有可能发生接触的物体上的凝胶。凝胶应仅施用于上臂或肩部，而不应施用于其他部位。施药部位应保持干燥至少2小时。如果施药后会与他人发生肢体接触，也建议在施药后清洗施药部位。</p> <p>表 8-2. 药量滴定与男性化激素治疗的监测</p> <table><thead><tr><th><strong>项目</strong></th> <th><strong>意见</strong></th> <th><strong>基准</strong></th> <th><strong>每3个月*</strong></th> <th><strong>每6个月*</strong></th> <th><strong>每12个月*</strong></th> <th><strong>每年</strong></th> <th><strong>按需</strong></th></tr></thead> <tbody><tr><td><strong>脂质</strong></td> <td>没有支持脂质实时监测的办法；使用临床医生自行决定</td> <td>基于USPSTF</td> <td></td> <td></td> <td></td> <td></td> <td>X</td></tr> <tr><td><strong>A1c或空腹血糖</strong></td> <td>没有支持脂质实时监测的办法；使用临床医生自行决定</td> <td>基于USPSTF</td> <td></td> <td></td> <td></td> <td></td> <td>X</td></tr> <tr><td><strong>雌二醇</strong></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>X</td></tr> <tr><td><strong>总睾酮</strong></td> <td></td> <td></td> <td>X</td> <td>X</td> <td>X</td> <td></td> <td>X</td></tr> <tr><td><strong>性激素结合球蛋白 (SHBG)*</strong>*</td> <td></td> <td></td> <td>X</td> <td>X</td> <td>X</td> <td></td> <td>X</td></tr> <tr><td><strong>白蛋白*</strong>*</td> <td></td> <td></td> <td>X</td> <td>X</td> <td>X</td> <td></td> <td>X</td></tr> <tr><td><strong>血红蛋白与红细胞比容</strong></td> <td></td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td></tr></tbody></table> <ul><li>只适用于疗程第一年</li></ul> <p>** 用于监测机体可利用的睾酮；选择性的监测这种睾酮含量可能对复杂病例有帮助（见文）(<a href="http://www.issam.ch/freetesto.htm" target="_blank" rel="noopener noreferrer">http://www.issam.ch/freetesto.htm)<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>)</p> <p>在考虑临床反应，激素水平监测和安全监测（即血红蛋白和血细胞比容[H＆H]）情况下，应基于患者目标进行药量的向上滴定。临床反应可以通过6个月闭经来进行客观测量[4]。一旦落入正常的男性生理范围内，没有证据证明更高剂量/水平的睾酮会导致进一步雄性化。总睾酮水平的实验室参考范围通常非常宽（大约350-1100ng/dl）；如果睾酮水平仅达到正常男性范围最低标准，并且担心进展缓慢或出现缺乏能量，性欲或者情绪低落的症状，可以在监测副作用的同时合理、缓慢地增加剂量。一旦总睾酮大于实验室报告的参考范围中的中点值，增加剂量是否会对感受到的缓慢进展或情绪症状或其他副作用产生任何积极影响则尚不明确。</p> <p>虽然一些提供者选择忽略激素水平监测，而仅监测临床进展或变化，但如果睾酮水平尚未达到目标范围，则该方法存在男性化程度达不到最优的风险。一项前瞻性研究对刚开始皮下注射环戊丙酸睾酮50-60mg/周，5g/天1％睾酮凝胶或4mg/天睾酮补片的31名跨性别男性进行监测发现6个月后只有21例（68％）达到男性睾酮激素水平，5例（16％）持续月经，且只有9例（29％）的雌二醇水平达到生理男性范围。[5]一些性别酷儿和性别非常规/非二元性别患者可能更愿意将睾酮水平维持在中间范围内。无论选择何种初始剂量方案，滴定剂量都要根据3个月和6个月时测量的睾酮水平确定。一旦激素水平达到特定患者的目标范围，可以改为每年监测一次激素水平。与非跨性别男性中的睾酮替代一样，对于有稳定激素治疗方案的跨性别男性，年度就诊并通过实验室监测激素水平已足够。内分泌学会指南建议每3个月监测一次激素水平。[6]然而在实践中，这是不现实的，并且一旦达到目标剂量这么做也没有太大的意义。[7]在维持阶段测量激素水平的其他原因包括显著的代谢变化，例如糖尿病或甲状腺疾病的发作，显著的体重变化，主观或客观的显著男性化减退，或激素失调可能导致或加剧的新症状，如潮热，骨盆痉挛，出血，或偏头痛。此类患者可能还需要更频繁就诊以治疗这些并发状况。就医频率的增加对于具有复杂心理社会情况的患者也可能是有用的，以允许提供辅助或环绕式（Wraparound）服务。</p> <h3 id="对激素水平的解读的总体意见"><a href="#对激素水平的解读的总体意见" class="header-anchor">#</a> 对激素水平的解读的总体意见</h3> <p>跨性别护理需要特别注意实验室参考范围的解读。许多地方公布了血清雌二醇，总雌激素，游离/总和/生物同质性睾酮总量和性激素结合球蛋白的目标范围。但是，这些具体范围可能因不同的实验室和技术而异。此外，如果患者的注册性别与其激素替代的目标性别不同，则实验室结果报告中提供的参考范围的解释可能不适用。例如，仍然注册为女性的跨性别男性将得到为女性报告的实验室参考范围；很明显，这些范围不适用于使用男性化激素疗法的跨性别男性。性别酷儿或非常规/非二元性别患者的激素水平可能被期望处于男性和女性标准的中间范围。鼓励提供样本的患者咨询当地实验室以获得“男性”和“女性”规范的激素水平参考范围，以保证解释结果的确是根据当前激素性别的参考范围，而不是注册性别。睾酮水平也必须在明确样本是在给药间隔的峰值，谷值或中间周期被提取的情况下作出解释，因为这个值的变化幅度可以非常广泛（如果这种变化引起一系列症状，请见下文和骨盆疼痛和出血指南）。</p> <h3 id="监测睾酮水平-2"><a href="#监测睾酮水平-2" class="header-anchor">#</a> 监测睾酮水平</h3> <p>由于与促性腺激素的脉冲释放有关的水平的快速波动，非跨性别男性中睾酮水平可能难以测量。在接受外源性睾酮的跨性别男性中，睾酮水平可能缺少此类波动（尽管它们可能在给药间隔内变化）。游离睾酮代表未与血清蛋白结合的睾酮部分，并且取决于性激素结合球蛋白（SHBG）的水平。可以测量游离睾酮，但是测定试验不可靠。[8]关于游离与总睾酮水平的作用缺乏共识；总睾酮水平可靠且容易获得，但它们没有描述实际的可利用睾酮水平。机体可利用的睾酮是游离睾酮加上与白蛋白弱结合的睾酮。[9]SHBG在雌激素和甲状腺素的存在下升高。[10]它在雄激素，催乳素和高水平的胰岛素和生长激素的存在下降低。对于跨性别护理，内分泌学会建议监测总睾酮水平。[11]对于复杂病例或者在正常范围总睾酮的情况下存在结果 &lt;11&gt; 或副作用的情况，可利用睾酮的计算也可能有助于指导给药。生物可利用的睾酮可以从总睾酮，白蛋白和SHBG水平计算（ http://www.issam.ch/freetesto.htm ）。生物可利用睾酮的一般参考范围是%3E72ng/dl（2.5nmol/L）。[12-15]</p> <h3 id="监测使用注射睾酮的患者的激素水平"><a href="#监测使用注射睾酮的患者的激素水平" class="header-anchor">#</a> 监测使用注射睾酮的患者的激素水平</h3> <p>虽然患者可能经历诸如偏头痛，骨盆痉挛或情绪波动等周期症状，中期水平通常也足以用于测量注射形式的获得睾酮的患者的激素水平。峰值（注射后1-2天）和谷值可能会显示出激素水平在给药周期内波动；在这种情况下，应考虑改用透皮贴剂，或减少注射间隔（同时减少剂量，以保持随时间推移施用的相同总剂量）。[16,17]</p> <h3 id="监测雌二醇水平-2"><a href="#监测雌二醇水平-2" class="header-anchor">#</a> 监测雌二醇水平</h3> <p>对刚开始睾酮替代治疗的31位跨性别男性的一项为期6个月的预期研究发现，只有9例（29％）达到了生理男性范围的雌二醇水平[18]。实际上，生理女性雌二醇的范围很广，并且在月经周期内变化很大；与生理男性范围可能存在显著重叠。雌二醇可能与骨盆疼痛及症状，持续性月经或情绪不稳有关。尚不清楚使用芳香酶抑制剂（AI）或选择性雌激素受体调节剂（SERM）进行雌激素阻断在控制这些症状或常规给药方案中的作用。本指南的其他部分对骨盆疼痛和持续性月经进行了深入讨论。</p> <h3 id="解释性别相关的非激素实验室结果-2"><a href="#解释性别相关的非激素实验室结果-2" class="header-anchor">#</a> 解释性别相关的非激素实验室结果</h3> <p>碱性磷酸酶（ALP）、血红蛋白（HGB）与红细胞比容（HCT）和肌酐（Cr）水平会随检查者的当前激素状况而变化。一系列因素对这些变化有影响：骨量、肌肉量、肌细胞数量、是否有月经，以及睾酮的红细胞生成效应。许多跨性别男性没有经期，而那些具有男性范围睾酮水平的人会经历红细胞生成效应。因为此类闭经跨性别男性服用睾酮，注册为女性，而血红蛋白/血细胞比容在男性和女性正常下限之间，即使研究报告可能没有表明，也会被认为患有贫血。相反，月经不足和外源性睾酮的存在使得使用血红蛋白/血细胞比容的正常男性范围上限是合理的。由于骨骼和肌肉质量的增加，使用碱性磷酸酶和肌酐的正常男性范围上限也可能适合于跨性别男性。在此情况下，提供者应参考其实验室的男性正常范围。[19]</p> <p>表 8-3. 使用男性化激素治疗的跨性别男性所选用的试验结果的正常下限和上限</p> <table><thead><tr><th><strong>实验指标</strong></th> <th><strong>正常指标下限</strong></th> <th><strong>正常指标上限</strong></th></tr></thead> <tbody><tr><td><strong>肌酐</strong></td> <td>未定义</td> <td>男性指标</td></tr> <tr><td><strong>血红蛋白/血细胞比容</strong></td> <td>若闭经参考男性*</td> <td>男性指标</td></tr> <tr><td><strong>碱性磷酸酶(ALP)</strong></td> <td>未定义</td> <td>男性指标</td></tr></tbody></table> <ul><li>如果月经正常，考虑使用女性最低下限指标</li></ul> <h3 id="基于患者中心目标的个体化药量-2"><a href="#基于患者中心目标的个体化药量-2" class="header-anchor">#</a> 基于患者中心目标的个体化药量</h3> <p>有些患者可能想要更有限的激素效果，或者获得男性化与女性化的混合特征，比如更低沉的嗓音，长出胡须（这两点都是不可逆转的）并保留女性乳房或者其他女性的身体特征。有些患者可能选择进行一段时间的睾酮替代治疗，直到身体发生上述不可逆转的改变，然后停用睾酮，恢复他们身体本身内源性雌性激素控制的状态。在调节剂量和选择何种方法进行药物治疗时，患者可以设立个体化目标，与患者讨论清晰地确定其要达到何种期望和可能发生的未知状况显得尤为重要。需要特别指出的是，要准确地为患者想达到的性征结果选择一种激素方案是不可能的。此外，个体的生理和心理差异导致对于采用相同的给药途径和剂量的患者，血液激素水平和疗效也不尽相同。由此而言，患者最好的办法就是从低剂量开始，缓慢增长，来滴定达到疗效的最适剂量。同时，对激素代替治疗的反应也因个体而异，胡须开始生长，和声音开始变化的程度和时间过长也不同。</p> <p>可能造成男性化的程度和速度不同的预测因素有很多，包括遗传因素及个人身体状态的特殊因素；较早年龄开始激素治疗也可能使男性化进程更快，程度更好，直到达到终点值。更晚开始激素疗程的患者可能会受到更多的限制。患者需要基于这些因素，通过咨询建立对自己身体改变的合理期望，而不是与其他患者的体验进行比较。轶事来源表明最大程度的男性化可能出现在2-5年内。[20]</p> <h3 id="特殊考虑与状况-2"><a href="#特殊考虑与状况-2" class="header-anchor">#</a> 特殊考虑与状况</h3> <p>**<em>骨盆疼痛*<em><strong>和</strong></em></em>持续月经***<em>会在本指南的别处进行讨论</em></p> <p>**性腺切除术后：**因为睾酮的摄入剂量建立在代替生理男性水平的基础上，在性腺切除后不需要减少睾酮摄入的剂量。有些患者在术后会选择降低睾酮剂量，只要剂量足以维持骨密度即可，然而他们需要清楚这样做可能会降低肌肉质量、精力和性欲。</p> <p>术后采用低剂量睾酮替代疗法的患者选择剂量时可以基于卵泡生成素和垂体泌乳素水平确定，通过药量滴定来将其维持在绝经前的水平范围。</p> <p>**红细胞增多：**跨性别男性的血红蛋白与血细胞比容(H&amp;H)应根据其使用的睾酮剂量和绝经状态解释。睾酮水平达到正常男性的跨性别男性如果已经闭经，H&amp;H值范围应参照正常男性。需要注意的是如果患者在实验室的注册性别是女性的话，这个值也许和女性的正常值有所偏差。若已闭经的跨性别男性H&amp;H值高于女性正常上限但低于男性正常下限，提供者需要参照该实验室的正常男性H&amp;H值范围，而不用关注检查结果上H&amp;H过高的标注。对此位跨性别男性，H&amp;H值处于女性下限值与男性上限值之间的情况在检查结果中可能不会被标记为异常，但事实上这可能意味着贫血。依然持续月经并维持低剂量睾酮注射的患者也要谨慎解读自己的H&amp;H值。如果的确患红细胞增多症，跨性别男性应首先检查他们的睾酮水平，包括代谢的峰值，并据此调整睾酮摄入剂量。提高注射频率（保持一定时间范围内的睾酮总量）或改用透皮贴剂可能会降低红细胞增多症的风险。[16]根据升高程度，静脉切开术或献血可能是适当的短期解决方案；在所有情况下，应排除红细胞增多症的其他病理原因。除了肿瘤和心肺疾病之外，跨性别男性需要特别关注肥胖相关的阻塞性睡眠呼吸暂停，并控制烟草使用。</p> <p>**年长的跨性别男性：**对于非跨性别男性，睾酮的替代疗法没有年龄上限。[22]因此，对于跨性别男性的睾酮替代疗法也无法推荐最高终止年龄。在50岁左右非跨性别男性开始更年期的年龄，可以考虑停止激素治疗。无论在这个年龄性腺是否存在，睾酮的逐渐流失将导致肌肉重量、体毛、性欲的减少和减退。</p> <p>**自身免疫：**睾酮与整体免疫抑制有关，自身免疫性疾病在非跨性别女性中比男性更常见[23]。睾酮脱离导致Th1：Th2比率增加[24]。然而，这种关系更为复杂，正如怀孕期间多发性硬化症中出现的矛盾改善所证明的那样。[23]应该告知患有自身免疫疾病的患者，一旦开始进行男性化治疗，他们的病情可能会恶化（或改善）。激素剂量应该从低剂量开始并缓慢增加，以监测恶化症状，并经由任何能够管理自身免疫疾病的专家咨询。</p> <p>**偏头痛：**偏头痛与激素组分和雌激素有明显的关系。鉴于许多服用睾酮的跨性别男性雌激素水平持续存在并可能波动，睾酮治疗可能会使偏头痛恶化。有偏头痛病史的患者应考虑从低剂量开始，并在耐受时向上滴定。透皮睾酮可能是避免任何与注射睾酮相关的潜在周期性效应的更好选择。[25]</p> <p>**精神健康状况：**虽然激素可能导致情绪问题（例如经前焦虑症或产后抑郁症），但这些并不是睾酮治疗与精神健康状况的发生或恶化直接相关的明确证据。事实上，已经发现，开始睾酮治疗会改善跨性别男性的社交功能，减少焦虑和抑郁。[26,27]跨性别男性应该与任何其他人一样接受广泛的鉴别诊断，注意避免与性别焦虑或睾酮治疗有关系的所有症状。由于潜在的周期性水平变化，建议避免注射药物，否则可能导致或加重现有的情绪症状。</p> <p>**对有癌症病史的患者的睾酮替代治疗：**活跃的性激素敏感性癌症是睾酮治疗的绝对禁忌症。对于既往有激素敏感性癌症（比如乳腺癌）病史的患者，建议咨询肿瘤科医生。</p> <p>**脱发：**睾酮替代治疗开始后不久就可能发生脱发现象，这与患者的遗传因素有关。在生理男性中，脱发常常有两种形式：正面和颞部衰退，以及男性型秃发（前额退缩和冠部变薄）。两种形式都可能引起患者的警觉，并且在某些情况下导致停止治疗的愿望。</p> <p>患者应在开始治疗前就其风险、不可预测的本质、程度和时间进行咨询，管理方法类似于非跨性别男性。非处方米诺地尔，5-α还原酶抑制剂和手术方法可以使用。5-α还原酶抑制剂非那雄胺可阻断睾酮向强效雄激素二氢睾酮的转化。[28]每天1mg非那雄胺（保法止™，Propecia™）被批准用于男性型秃发，而5mg每日剂量（保列治™，Proscar™）被批准用于治疗前列腺肥大。[29]副作用可能包括性欲减退或性功能障碍，但对勃起功能的影响（表现为生殖器充血）可能与未经过阴蒂释放术的跨性别男性相关性较低。通常，1mg每日剂量具有最小的性副作用。在睾酮治疗过程中早期对5-α还原酶对跨性别男性的抑制作用的负面影响尚不清楚。与非跨性别男性一样，使用5mg每日剂量的非那雄胺，或使用更有效的5-α还原酶抑制剂度他雄胺，可能导致过度的睾酮阻滞，并导致性副作用和一些男性化的消退。</p> <p>**代谢综合征及相关病症（肥胖，高脂血症，糖耐量异常，多囊卵巢综合征/PCOS）：**心血管和糖尿病的考虑因素在本指南的其他地方有所涉及。多囊卵巢综合征可表现为空腹血糖受损，血脂异常，多毛症，肥胖以及无排卵伴随的寡/闭经。这些特征中的一些（多毛症，少尿或闭经）可能受到跨性别男性的欢迎并且在施用睾酮之前存在。在PCOS存在下，睾酮给药不是禁忌，但应监测患者的高脂血症和糖尿病。<strong>由于睾酮对子宫内膜的萎缩作用（分级：T O M），因此在睾酮存在的情况下，跨性别男性因闭经不被认为具有升高的子宫内膜增生风险。</strong>[30,31]在具有闭经/月经稀发史的跨性别男性中开始使用睾酮之前，进行子宫内膜检测可能是谨慎的。非跨性别男性的睾酮替代治疗与阻塞性睡眠呼吸暂停（OSA）的风险增加有联系。[22]目前尚不清楚睾酮激活后跨性别男性OSA是否增加。然而，睾酮治疗所带来的行为型健康改善可能带来积极的生活方式改变，从而减少肥胖，葡萄糖代谢紊乱或高脂血症。<strong>在包括最严重的病例（糖尿病失控，活动性不稳定冠状动脉疾病）的所有病例中，患者应被告知风险，并且如果仍然需要睾酮治疗，应继续同时进行常规的代谢紊乱和及其后遗症的治疗（分级：X C S）。</strong></p> <p>**痤疮：**面部和身体的痤疮是男性化激素疗法的常见副作用。这种症状的处理方法与非跨性别者的既定做法一致。</p> <p>患者可以放心痤疮在睾酮治疗的第一年趋于达到顶峰，然后下降。[32]维持生理睾酮水平，避免给药间隔过长导致的过高峰值可能有助于减少痤疮。</p> <h3 id="参考文献-8"><a href="#参考文献-8" class="header-anchor">#</a> 参考文献</h3> <ol><li>Light AD, Obedin-Maliver J, Sevelius JM, Kerns JL. Transgender men who experienced pregnancy after female-to-male gender transitioning. Obstet Gynecol. 2014 Dec;124(6):1120– 7.</li> <li>Jacobeit JW, Gooren LJ, Schulte HM. Safety aspects of 36 months of administration of long- acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. Eur J Endocrinol. 2009 Nov 1;161(5):795–8.</li> <li>Mueller A, Kiesewetter F, Binder H, Beckmann MW, Dittrich R. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. J Clin Endocrinol Amp Metab. 2007 Sep;92(9):3470–5.</li> <li>Olson J, Schrager SM, Clark LF, Dunlap SL, Belzer M. Subcutaneous testosterone: an effective delivery mechanism for masculinizing young transgender men. LGBT Health [Internet]. 2014 Jun 26 [cited 2014 Jul 18]; Available from: http://online.liebertpub.com/doi/full/10.1089/lgbt.2014.0018</li> <li>Al-Futaisi AM, Al-Zakwani IS, Almahrezi AM, Morris D. Subcutaneous administration of testosterone. A pilot study report. Saudi Med J. 2006 Dec;27(12):1843–6.</li> <li>Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010 Jun 1;95(6):2536–59.</li> <li>Roberts TK, Kraft CS, French D, Ji W, Wu AHB, Tangpricha V, et al. Interpreting laboratory results in transgender patients on hormone therapy. Am J Med. 2014 Feb;127(2):159–62.</li> <li>Ly LP, Handelsman DJ. Empirical estimation of free testosterone from testosterone and sex hormone-binding globulin immunoassays. Eur J Endocrinol Eur Fed Endocr Soc. 2005 Mar;152(3):471–8.</li> <li>Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007 Feb;92(2):405–13.</li> <li>Serin IS, Ozçelik B, Başbuğ M, Aygen E, Kula M, Erez R. Long-term effects of continuous oral and transdermal estrogen replacement therapy on sex hormone binding globulin and free testosterone levels. Eur J Obstet Gynecol Reprod Biol. 2001 Dec 1;99(2):222–5.</li> <li>Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ, Spack NP, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009 Jun 9;94(9):3132–54.</li> <li>Carnegie C. Diagnosis of Hypogonadism: Clinical assessments and laboratory tests. Rev Urol. 2004;6(Suppl 6):S3–8.</li> <li>Sih R, Morley JE, Kaiser FE, Perry HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997 Jun;82(6):1661–7.</li> <li>Korenman SG, Morley JE, Mooradian AD, Davis SS, Kaiser FE, Silver AJ, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab. 1990 Oct;71(4):963–9.</li> <li>Nelson R, O’Kane D, Heser D, Klee G. A simple and rapid assay for bioavailable- testosterone. Clin Chem. 2001 Jun;47(6):A20–A20.</li> <li>Bui HN, Schagen SEE, Klink DT, Delemarre-van de Waal HA, Blankenstein MA, Heijboer AC. Salivary testosterone in female-to-male transgender adolescents during treatment with intra- muscular injectable testosterone esters. Steroids. 2013 Jan;78(1):91–5.</li> <li>Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999 Oct;84(10):3469–78.</li> <li>Deutsch MB, Bhakri V, Kubicek K. Effects of cross-sex hormone treatment on transgender women and men. Obstet Gynecol. 2015 Mar;125(3):605–10.</li> <li>Roberts TK, Kraft CS, French D, Ji W, Wu AHB, Tangpricha V, et al. Interpreting laboratory results in transgender patients on hormone therapy. Am J Med. 2014 Feb;127(2):159–62.</li> <li>Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, DeCuypere G, Feldman J, et al. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7. Int J Transgenderism. 2012;13(4):165–232.</li> <li>Esteva I, Yahyaoui R, Cano G, Giraldo F, Bergero T, Ruiz de Adana S, et al. Evolution of gonadal axis after sex reassignment surgery in transsexual patients in the Spanish public health system. Int J Transgenderism. 2006 Jun 1;9(2):15–22.</li> <li>Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010 Jun 1;95(6):2536–59.</li> <li>Gold SM, Voskuhl RR. Estrogen and testosterone therapies in multiple sclerosis. In: Progress in Brain Research [Internet]. Elsevier; 2009 [cited 2015 Nov 21]. p. 239–51. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0079612309175167</li> <li>Trigunaite A, Dimo J, Jørgensen TN. Suppressive effects of androgens on the immune system. Cell Immunol. 2015 Apr;294(2):87–94.</li> <li>Chai NC, Peterlin BL, Calhoun AH. Migraine and estrogen. Curr Opin Neurol. 2014 Jun;27(3):315–24.</li> <li>Gómez-Gil E, Zubiaurre-Elorza L, Esteva I, Guillamon A, Godás T, Cruz Almaraz M, et al. Hormone-treated transsexuals report less social distress, anxiety and depression. Psychoneuroendocrinology. 2012 May;37(5):662–70.</li> <li>Meier SLC, Fitzgerald KM, Pardo ST, Babcock J. The effects of hormonal gender affirmation treatment on mental health in female-to-male transsexuals. J Gay Lesbian Ment Health. 2011;15(3):281–99.</li> <li>Rittmaster RS. 5alpha-reductase inhibitors. J Androl. 1997 Dec;18(6):582–7.</li> <li>Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α- reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011 Mar;8(3):872–84.</li> <li>Grynberg M, Fanchin R, Dubost G, Colau J-C, Brémont-Weil C, Frydman R, et al. Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod Biomed Online. 2010 Apr;20(4):553–8.</li> <li>Perrone AM, Cerpolini S, Maria Salfi NC, Ceccarelli C, De Giorgi LB, Formelli G, et al. Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals. J Sex Med. 2009 Nov;6(11):3193–200.</li> <li>Wierckx K, Van de Peer F, Verhaeghe E, Dedecker D, Van Caenegem E, Toye K, et al. Short- and long-term clinical skin effects of testosterone treatment in trans men. J Sex Med. 2014 Jan;11(1):222–9.</li></ol> <blockquote><p>&lt;11&gt;. 译者注：原文如此</p></blockquote> <h2 id="跨性别男性的骨盆疼痛与持续月经"><a href="#跨性别男性的骨盆疼痛与持续月经" class="header-anchor">#</a> 跨性别男性的骨盆疼痛与持续月经</h2> <p>主要作者： Juno Obedin-Maliver, MD, MPH</p> <h3 id="概论-骨盆疼痛"><a href="#概论-骨盆疼痛" class="header-anchor">#</a> 概论：骨盆疼痛</h3> <p>鉴别跨性别男性的骨盆疼痛在临床上比较困难，并且鉴别诊断的结果广泛。持续时间小于六个月的情况考虑为急性发作。慢性盆腔疼痛，即持续超过6个月的下腹部或骨盆持续或间歇性疼痛，则有很大差异。[1]病史是评估和诊断最关键的部分，而病史的关键在于患者对疼痛的详细描述，包括起病，促发和缓解的特征，特性，放射面积，严重程度和时间。网络上有较多疼痛日记可以帮助阐明疼痛模式和特征（参见<a href="http://www.partnersagainstpain.com/printouts/Daily_Pain_Diary.pdf" target="_blank" rel="noopener noreferrer">http://www.partnersagainstpain.com/printouts/Daily_Pain_Diary.pdf<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>）。</p> <p>跨性别男性骨盆疼痛检查的一般方法与非跨性别女性相似。历史收集的解剖学办法认为泌尿科，妇科，胃肠道，肌肉骨骼和心理方面的数据都是至关重要的。具体病因可以是多因素的，例如是否发生胃肠道的术后粘连，或子宫内膜异位症和/或盆底肌肉功能障碍。评估生活质量影响并确定患者认为较好的结果也是至关重要的。大多数评估和治疗指南强调慢性盆腔疼痛可能是一种诊断和治疗的挑战，成功的处理将取决于全面和个体化的评估和多学科护理。[2,3]</p> <h4 id="病因学"><a href="#病因学" class="header-anchor">#</a> 病因学</h4> <p>跨性别男性要考虑的特殊医学病因包括：萎缩性或感染性阴道炎、宫颈炎、膀胱炎，性传播感染，粘连，术后后遗症，肌肉骨骼疾病和神经源性疾病；需要考虑的特殊行为病因包括：抑郁症，情绪创伤史（包括性侵犯或虐待，儿童不良事件），[4]和创伤后应激障碍。睾酮的使用通过诱导低雌激素状态对阴道组织产生剂量依赖性作用，所述低雌激素状态促进萎缩，增加阴道pH并因此增加阴道炎和宫颈炎的风险。此外，跨性别男性可能对此筛查甚至对宫颈炎和性传播感染治疗存在获取途径和利用不足。[5-7]既往手术可能导致粘连，瘢痕组织，膀胱功能障碍或神经损伤，可能导致内脏活动性减少并导致疼痛。[8]目前尚不清楚术后粘连单独引起疼痛可以到达怎样的程度，还是也包括通过诸如收缩或其他器官嵌顿的继发机制。在子宫切除术后有骨盆疼痛但保留一个或两个卵巢/性腺的跨性别男性应进行性腺病理筛查。基因型女性骨骼与睾酮治疗后肌肉质量增加之间的相互作用可能导致姿势举止发生改变。此外，近期和/或历史的性创伤对于性少数群体可能会加剧。与医疗专业人士交谈可能会受到二次创伤；在所有情况下都应采用创伤知情&lt;12&gt;（Trauma-informed）方法。[9]</p> <h4 id="盆腔疼痛病史"><a href="#盆腔疼痛病史" class="header-anchor">#</a> 盆腔疼痛病史</h4> <p>最初的病史应包括月经史，包括发病年龄，月经频率或周期性月经样症状，即使已经闭经，月经持续时间，最后一次月经期，以及闭经多长时间也需要知道，还要对止痛药的使用，以及睾酮给药周期的任何关联性症状进行评定。全面的性生活史，包括评估与其他个体的特定行为，如阴道-阴道，阴道或肛门或接受性阴茎性行为，且认识到许多跨性别男性可能参与阴道性行为。[10]评估怀孕和异位妊娠的潜在风险；与有能力产生精子的伴侣进行阴道性交的跨性别男性有意外怀孕的风险，包括在之前没有月经出血情况下排卵和受孕。还要注意盆腔炎的任何病史。如果有通过开放腹腔镜或阴道方法进行手术的历史，需要特别注意，因为这可能出现疤痕组织和粘连的情况以及随后的症状。注意任何特定的风险，如阑尾破裂或盆腔炎（PID）史。其他历史应包括筛查儿童不良事件，目前的家庭暴力以及药品滥用，包括烟草。</p> <h4 id=""><a href="#" class="header-anchor">#</a></h4> <p>体检</p> <p>{#-5}</p> <p>在检查中需要评估各种腹主动脉器官的受累情况，包括检查肋椎角压痛，腹壁触诊，并特别注意沿先前手术疤痕的任何压痛或沿疤痕或腹壁的一般性点压痛。触诊膀胱以检查局部敏感性，触诊腹部检查内脏器官受累情况。只有在明确指示出明显的阴道分泌物异常或阴道炎的任何证据，并评估阴道组织和子宫颈的一般状况时，才考虑窥镜检查。如果需要进行骨盆检查，应考虑从儿科窥器开始。如果进行双合诊检查，应注意触诊时的任何宫颈，附件或卵巢疼痛。[5]同时评估外阴区域的感觉，采用棉签神经测试（cotton tipped nerve testing）以及锐/钝区分测试（sharp/dull differentiation），并通过闭孔内部触诊检查盆底（两点指检，4点钟至5点钟和7点钟至8点钟方向肌肉触诊；两指在这些位置时的屈曲疼痛表明盆底功能障碍）。如果有指示，还要考虑直肠检查，注意肿块，压痛或硬化粪便。实验室检测包括尿液分析和培养，检查衣原体和淋病，阴道pH，阴道涂片（vaginal wet mount）和KOH测试（KOH prep），并在可能时检查阴道培养物。应考虑妊娠检查，但是部分未与有授精能力的人有性活动的患者可能会因为该检查建议受到冒犯。最好事先向患者解释该检查是标准方案的一部分，如果基于性行为确定不可能怀孕，可以省略妊娠检查。应使用经腹或经阴道超声进行成像；在进行了阴道切除术的男性中，可以选择经直肠超声检查。由于性别焦虑的潜在恶化，一些跨性别男性可能会拒绝阴道超声检查和/或双合诊检查。不应该强迫这些患者进行盆腔检查。在此情况下，通过腹部检查以及实验室和经腹超声检查进行初步检查。</p> <p>特别针对于跨性别男性的评估的关键组成部分包括与睾酮治疗开始相关的疼痛和相关症状的时间，出现“经前”不安的时间（与预期的月经周期相关的症状），即使已经闭经，以及详细的既往手术和相关器官清单。</p> <h4 id="睾酮引起的性交疼痛-阴道炎和宫颈炎"><a href="#睾酮引起的性交疼痛-阴道炎和宫颈炎" class="header-anchor">#</a> 睾酮引起的性交疼痛，阴道炎和宫颈炎</h4> <p>睾酮的使用经常导致雌激素缺乏，阴道组织萎缩，类似于顺性别女性的绝经后状态[11-13]这些发生萎缩的阴道组织意味着组织弹性与皮肤屏障功能下降和对微生物环境改变的易感性增加，这可能导致细菌性阴道疾病，膀胱炎或宫颈炎。[14]此外，变薄的萎缩性阴道组织更容易受到摩擦和性接触造成的创伤性刺激[13]，这可能导致萎缩性性交困难或阴道炎。症状通常被描述为“粗糙”、“砂纸感”、“灼热”或“干燥”的阴道刺激感，针对萎缩的视觉检查显示薄的苍白组织，皱褶的损失，弹性的丧失，脆弱性和干燥。也可以找到充血的深红色阴道组织。细菌性阴道病在雌激素缺乏状态下更常见。涂片，阴道培养，阴道pH和STI检查可以帮助指导治疗。当传染性原因已被排除并且症状局限于膀胱时，应考虑间质性膀胱炎。治疗潜在萎缩的阴道雌激素是有保证的，并且短期疗程内可能成功恢复舒适感。患者可以放心，阴道雌激素的系统性吸收的程度微乎其微，不会干扰睾酮的预期效果。其他治疗方法可能包括阴道润滑剂或阴道保湿剂。[15]</p> <h4 id="睾酮剂量引起的周期性症状"><a href="#睾酮剂量引起的周期性症状" class="header-anchor">#</a> 睾酮剂量引起的周期性症状</h4> <p>使用睾酮的跨性别男性可能会抱怨周期性注射睾酮引起的疼痛，包括骨盆和/或阴道疼痛有关的插入时疼痛（使用阴茎，手指，假阳具等）或性高潮疼痛。睾酮后给药痉挛的病因尚不清楚。在一项横断面研究中，20％的受访者进行子宫切除术后睾酮后痉挛减少，另外22％的受访者不再有“极度出血和痉挛”。[16]有效的方式还有创伤知情护理（Trauma-informed care），以及其他用于慢性骨盆疼痛的治疗，诸如盆底治疗，用无味产品进行阴道润滑，或使用三环类抗抑郁药。</p> <h4 id="共存的心理健康状况"><a href="#共存的心理健康状况" class="header-anchor">#</a> 共存的心理健康状况</h4> <p>与其他疼痛综合征一样，慢性盆腔疼痛患者应评估抑郁症和创伤后应激障碍（PTSD）。这些病症可能同时存在于高达35％的顺性别女性慢性盆腔疼痛患者中。[1]多项研究将不良儿童事件与慢性疼痛和抑郁发生率增加联系起来。原先存在的抑郁症可能会加剧骨盆疼痛。反之，骨盆疼痛和长期处于慢性疼痛状态也可能导致抑郁。经历过性侵犯的人中有很大一部分患有PTSD，许多患有PTSD的人也可能发展为盆底肌肉功能障碍和疼痛。[17,18]骨盆疼痛的存在以及相关的检查和评估可能会引发PTSD，特别是如果这种创伤涉及先前的性侵犯或涉及下腹部和骨盆。这些症状在跨性别男性中可能会更明显，而性别和生殖器官的检查可能特别具有挑战性因为这会触发性别焦虑，导致患者躲避骨盆检查。[19]与心理专家的共同合作可以成为病理生理学评估和治疗的重要辅助手段。</p> <h4 id="药物治疗"><a href="#药物治疗" class="header-anchor">#</a> 药物治疗</h4> <p>最初的管理方法应包括非甾体类消炎药（NSAIDS），并按照指示使用其他疼痛管理药物。改为更均匀的透皮睾酮方案，或添加孕激素如左炔诺孕酮宫内节育器可以解决潜在的激素问题。</p> <h4 id="子宫切除术的作用"><a href="#子宫切除术的作用" class="header-anchor">#</a> 子宫切除术的作用</h4> <p>除了非手术方法以外，在某些情况下，子宫切除术可能在盆腔疼痛的治疗中起作用。**根据患者的偏好和生殖意愿，妇科医生可能会修改他们的治疗方法，考虑比顺性别女性更早地进行子宫切除术（分级：X C S）。**同时，子宫切除术不应被视为万灵药，在某些情况下不能有效改善疼痛。因此，由于目前缺乏基于证据的指导，必须根据具体情况对患有骨盆疼痛的跨性别男性进行评估。进行卵巢切除术的决定应基于骨盆疼痛的病因，并发症的存在，未来的生育意愿以及任何未来停止服用睾酮的计划。</p> <h4 id="对特定症状和综合征的处理"><a href="#对特定症状和综合征的处理" class="header-anchor">#</a> 对特定症状和综合征的处理</h4> <p>如果疼痛来自外阴并且没有可识别的病变或感染，考虑使用2-5％外用利多卡因浸泡棉球局部涂抹并在孔腔过夜残留以缓解疼痛，或根据意愿在性活动前30分钟这样做。</p> <p>如果疼痛来自外阴并且检查与睾酮给药环境中的阴道萎缩一致，则考虑短期使用阴道雌激素，药量和控制方式类似于用于绝经后的非跨性别女性。阴道内使用感觉不适的患者可能被指示在外生殖器使用治疗霜。取决于患者的偏好和处方集的考虑因素，药物选择可以包括药片，治疗霜或环。[20]</p> <p>如果盆底肌肉触诊引发疼痛，可考虑转诊到盆腔诊室物理治疗，进行盆底放松练习，甚至在指导下使用自己或伴侣的手指或按摩工具进行按摩。</p> <p>如果疼痛来自腹部，与腹壁或与腹部瘢痕组织相关，则考虑在疼痛触发点滴注1％利多卡因，重复给药。</p> <p>如果需要经阴道超声检查，可在手术前30分钟考虑口服低剂量苯二氮䓬类药物如劳拉西泮0.5mg，配合手术前10分钟给外阴和阴道施用2-5％利多卡因软膏。这样超声探头进入阴道时一些患者可能感觉更安全，更舒适。这些方法也可以在骨盆检查之前使用。</p> <h3 id="概论-持续性月经和意外阴道流血"><a href="#概论-持续性月经和意外阴道流血" class="header-anchor">#</a> 概论：持续性月经和意外阴道流血</h3> <p>许多跨性别男性选择不进行子宫切除术，卵巢切除术和/或性别肯定的生殖器手术。[19,21,22] 对于没有使用过激素的到达生育年龄的跨性别男性，或使用过睾酮并随后因为不需要的副作用（例如秃顶）停止使用的人，月经应在标准参考范围内：没有月经间出血的21-35天周期，平均持续2-6天，并且平均在49岁时停止。[23]这些范围的变化需要进一步的妇科调查。</p> <p>对于那些使用生理剂量的睾酮的跨性别男性，月经通常会在6个月内停止。月经的停止是由睾酮诱导的排卵抑制（可能是不完全的）和子宫内膜萎缩的结合所驱动的。[12]然而，停止月经的时间可能因人而异。影响月经停止时间的因素可能包括：睾酮剂量，给药途径，睾酮给药频率，卵巢的存在和功能，身体状态，以及子宫或卵巢的其他结构或非结构性医学状况的存在。跨性别男性在开始睾酮之前如果具有异常月经周期史（例如频繁的月经，严重的不规则出血），则可能存在潜在的病理因素，这可能导致服用睾酮停止月经时间延长或途径复杂。因此，对于有子宫内膜增生风险和一定程度的临床怀疑的患者，应考虑睾酮给药的同时评估和消除已知的不规则出血原因；那些之前存在闭经或月经稀发的人可能需要在开始使用睾酮之前评估子宫内膜异常，包括排除与能够产生精子的伴侣频繁性交的跨性别男性怀孕的可能性。</p> <h4 id="病因学-2"><a href="#病因学-2" class="header-anchor">#</a> 病因学</h4> <p>如果患者在维持男性范围睾酮水平6-12个月后依然持续出血并且抑制LH和FSH，可以考虑为异常子宫出血（AUB）。AUB可能与各种结构和非结构原因有关。这些原因可通过国际公认的妇产科联合会（FIGO）PALM-COEIN分类系统进行总结。[24]AUB的结构原因包括：子宫内膜息肉，子宫腺肌病，平滑肌瘤，子宫内膜增生或恶性肿瘤。作为一组病因，这些最好用成像和子宫内膜活检进行评估。尽管先前有提议跨性别男性服用睾酮可能会增加子宫内膜癌的风险[25]，长期数据并不支持这种风险。[26]AUB的非结构性原因包括：妊娠，凝血功能障碍，排卵功能障碍，子宫内膜或医源性原因。虽然骨盆成像的黄金准则是经阴道超声检查，但其他方法如声波-血管造影，经腹超声，CT扫描或MRI也是可行的。应与妇科医生协商调查结构性和非结构性原因。不应该轻易作给跨性别男性执行阴道超声检查或子宫内膜活检的决定，他们也许会觉得这些过程具有侵入性。非侵入性诊断方法，例如在睾酮治疗开始6个月后观察等待诱导闭经，观察孕激素激发后的退缩性出血，或使用经腹入路进行超声检查都可以考虑。</p> <p>有睾酮时的持续性月经也可能与身体状态有关；体内脂肪组织水平更高的患者具有更高的内源性雌激素水平，并通过外周芳构化过程增加睾酮向雌二醇的转化。</p> <h4 id="基于病因学的治疗方法"><a href="#基于病因学的治疗方法" class="header-anchor">#</a> 基于病因学的治疗方法</h4> <p>已经发现增加肌肉睾酮给药剂量和频率（1周和2周）能加快诱导闭经。[27]根据报告，月经停止所需时间为1-13个月[27-31]，决定因素除个别遗传和生理因素外很大程度上与睾酮给药的配方或途径有关。[28]</p> <p>在生理上，闭经诱导率应与睾酮水平增加（对于生理男性范围）以及雄激素治疗中可能降低的雌激素水平相关，然而尽管治疗中雌激素水平升高而睾酮水平仅上升至亚生理性男性水平，许多跨性别男性也达成了闭经。例如，一项针对激素启动治疗的跨性别男性研究发现，参与研究的对象中有84％在6个月时闭经。尽管如此，只有58％达到生理男性总睾酮水平，68％达到生理男性游离睾酮水平。[30]如果持续月经，宜调整激素方案和剂量。口服，注射，植入或宫内（IUD）孕激素的添加可以作为诱导闭经的辅助手段。</p> <p>对于不希望未来生育但不想执行子宫切除术或带有手术并发症的跨性别男性，可以考虑子宫内膜消融[31]。左炔诺孕酮宫内节育系统（IUS/IUD）在生理女性中可显著减少月经量或完全诱发闭经，对于有相关风险者有额外的避孕益处，因为尽管达到男性生理性睾酮水平仍有一些人可排卵。[32]</p> <p>芳香酶抑制剂（AIs）如阿那曲唑（anastrazole）或来曲唑（letrazole）可被认为是用于治疗睾酮治疗中持续月经的患者的短期辅助疗法。芳香酶在人体中全身进行表达，包括卵巢，子宫内膜，皮肤，骨骼，乳房，脑和脂肪组织。AIs已被用于治疗雌激素受体阳性乳腺癌，子宫内膜异位症和诱导排卵。Als也被证明结合其他激素疗法，如孕激素或联合口服避孕药，可以减少阴道出血和骨盆疼痛。[33-35]在生理女性中，用不添加雌激素疗法的Als治疗会导致医学更年期的症状：潮热，关节痛，情绪障碍，疲劳，阴道干涩，骨密度降低和骨折[36]。在跨性别男性同时使用睾酮的情况下，这些症状可能会减弱甚至消失。</p> <p>经卵巢释放的雌激素水平比一般女性生理水平大约低10倍，而睾酮水平在男性范围内时所需的AIs剂量尚不明确。由于AIs已被用于诱导排卵，因此可能有怀孕风险的跨性别男性应考虑避孕。控制体重在所有情况下都对促进健康起重要作用，同时也可以通过减少含有芳香酶的脂肪诱导闭经。</p> <h4 id="有帮助的资源"><a href="#有帮助的资源" class="header-anchor">#</a> 有帮助的资源</h4> <ul><li><ul><li><a href="http://www.pelvicpain.org/" target="_blank" rel="noopener noreferrer">International Pelvic Pain society<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>(国际骨盆疼痛学会): <a href="http://www.pelvicpain.org/" target="_blank" rel="noopener noreferrer">http://www.pelvicpain.org<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a></li> <li><a href="http://moveforwardpt.com/Default.aspx" target="_blank" rel="noopener noreferrer">American Physical Therapy Association<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>(美国物理治疗协会): http://moveforwardpt.com/Default.aspx</li></ul></li></ul> <h3 id="参考文献-9"><a href="#参考文献-9" class="header-anchor">#</a> 参考文献</h3> <ol><li>Abercrombie PD, Learman LA. Providing holistic care for women with chronic pelvic pain. J Obstet Gynecol Neonatal Nurs. 2012 Oct;41(5):668–79.</li> <li>Jarrell JF, Vilos GA, Allaire C, Burgess S, Fortin C, Gerwin R, et al. Consensus guidelines for the management of chronic pelvic pain. J Obstet Gynaecol Can JOGC J Obstétrique Gynécologie Can JOGC. 2005 Aug;27(8):781–826.</li> <li>Miller-Matero LR, Saulino C, Clark S, Bugenski M, Eshelman A, Eisenstein D. When treating the pain is not enough: a multidisciplinary approach for chronic pelvic pain. Arch Womens Ment Health. 2016 Apr;19(2):349–54.</li> <li>Centers for Disease Control and Prevention (CDC). <a href="http://www.cdc.gov/violenceprevention/acestudy/" target="_blank" rel="noopener noreferrer">Adverse Childhood Experiences (ACEs)<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.cdc.gov/violenceprevention/acestudy/" target="_blank" rel="noopener noreferrer">Study<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. Injury Prevention &amp; Control: Division of Violence Prevention. [cited 2016 Apr 26]. Available from: http://www.cdc.gov/violenceprevention/acestudy/</li> <li>Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep Cent Dis Control. 2015 Jun 5;64(RR-03):1–137.</li> <li>Reisner SL, White Hughto JM, Pardee D, Sevelius J. Syndemics and gender affirmation: HIV sexual risk in female-to-male trans masculine adults reporting sexual contact with cisgender males. Int J STD AIDS. 2015 Sep 18;</li> <li>Sevelius J. “There’s no pamphlet for the kind of sex I have:” HIV-related risk factors and protective behaviors among transgender men who have sex with non transgender men. J Assoc Nurses AIDS Care JANAC. 2009 Oct;20(5):398–410.</li> <li>Practice Committee of American Society for Reproductive Medicine in collaboration with Society of Reproductive Surgeons. Pathogenesis, consequences, and control of peritoneal adhesions in gynecologic surgery: a committee opinion. Fertil Steril. 2013 May;99(6):1550–5.</li> <li>Substance Abuse and Mental Health Services Administration (SAMHSA). Trauma-informed approach and trauma-specific interventions [Internet]. 2015 [cited 2016 Mar 25]. Available from: http://www.samhsa.gov/nctic/trauma-interventions</li> <li>Scheim AI, Bauer GR. Sex and gender diversity among transgender persons in Ontario, Canada: results from a respondent-driven sampling survey. J Sex Res. 2015 Jan 2;52(1):1– 14.</li> <li>Miller N, Bédard YC, Cooter NB, Shaul DL. Histological changes in the genital tract in transsexual women following androgen therapy. Histopathology. 1986 Jul;10(7):661–9.</li> <li>Perrone AM, Cerpolini S, Maria Salfi NC, Ceccarelli C, De Giorgi LB, Formelli G, et al. Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals. J Sex Med. 2009 Nov;6(11):3193–200.</li> <li>Kao A, Binik YM, Kapuscinski A, Khalife S. Dyspareunia in postmenopausal women: a critical review. Pain Res Manag J Can Pain Soc J Société Can Pour Trait Douleur. 2008 Jun;13(3):243–54.</li> <li>Stika CS. Atrophic vaginitis. Dermatol Ther. 2010 Oct;23(5):514–22.</li> <li>Weber MA, Kleijn MH, Langendam M, Limpens J, Heineman MJ, Roovers JP. Local oestrogen for pelvic floor disorders: a systematic review. PLoS ONE. 2015 Sep 18;10(9):e0136265.</li> <li>Rachlin K, Hansbury G, Pardo ST. Hysterectomy and oophorectomy experiences of female- to-male transgender individuals. Int J Transgenderism. 2010 Oct 12;12(3):155–66.</li> <li>Postma R, Bicanic I, van der Vaart H, Laan E. Pelvic floor muscle problems mediate sexual problems in young adult rape victims. J Sex Med. 2013 Aug;10(8):1978–87.</li> <li>Wuest J, Merritt-Gray M, Ford-Gilboe M, Lent B, Varcoe C, Campbell JC. Chronic pain in women survivors of intimate partner violence. J Pain Off J Am Pain Soc. 2008 Nov;9(11):1049–57.</li> <li>Rachlin K, Green J, Lombardi E. Utilization of health care among female-to-male transgender individuals in the United States. J Homosex. 2008;54(3):243–58.</li> <li>Minkin MJ, Maamari R, Reiter S. Postmenopausal vaginal atrophy: evaluation of treatment with local estrogen therapy. Int J Womens Health. 2014;6:281–8.</li> <li>Grant JM, Mottet LA, Tanis J, Harrison J, Herman J, Keisling M. <a href="http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf" target="_blank" rel="noopener noreferrer">Injustice at every turn: a<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf" target="_blank" rel="noopener noreferrer">report of the National Transgender Discrimination Survey<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. National Center for Transgender Equality and National Gay and Lesbian Task Force; 2011 [cited 2016 Mar 17]. Available from: http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf</li> <li>Newfield E, Hart S, Dibble S, Kohler L. Female-to-male transgender quality of life. Qual Life Res. 2006 Jun 7;15(9):1447–57.</li> <li>Tom SE, Cooper R, Patel KV, Guralnik JM. Menopausal characteristics and physical functioning in older adulthood in the National Health and Nutrition Examination Survey III. Menopause N Y N. 2012 Mar;19(3):283–9.</li> <li>Munro MG, Critchley HOD, Broder MS, Fraser IS, FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2011 Apr;113(1):3–13.</li> <li>[World Professional Association for Transgender Health (WPATH). Standards of care for the](http://www.wpath.org/uploaded_files/140/files/Standards of Care%2C V7 Full Book.pdf) [health of transsexual, transgender, and gender nonconforming people, 7th Version](http://www.wpath.org/uploaded_files/140/files/Standards of Care%2C V7 Full Book.pdf) [Internet]. WPATH; 2012 [cited 2016 Mar 10]. Available from: [http://www.wpath.org/uploaded_files/140/files/Standards%20of%20Care,%20V7%20Full%20Book.pdf](http://www.wpath.org/uploaded_files/140/files/Standards of Care%2C V7 Full Book.pdf)</li> <li>Wierckx K, Mueller S, Weyers S, Van Caenegem E, Roef G, Heylens G, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med. 2012 Oct 1;9(10):2641–51.</li> <li>Nakamura A, Watanabe M, Sugimoto M, Sako T, Mahmood S, Kaku H, et al. Dose-response analysis of testosterone replacement therapy in patients with female to male gender identity disorder. Endocr J. 2013;60(3):275–81.</li> <li>Pelusi C, Costantino A, Martelli V, Lambertini M, Bazzocchi A, Ponti F, et al. Effects of three different testosterone formulations in female-to-male transsexual persons. J Sex Med. 2014 Dec;11(12):3002–11.</li> <li>Light AD, Obedin-Maliver J, Sevelius JM, Kerns JL. Transgender men who experienced pregnancy after female-to-male gender transitioning. Obstet Gynecol. 2014 Dec;124(6):1120– 7.</li> <li>Deutsch MB, Bhakri V, Kubicek K. Effects of cross-sex hormone treatment on transgender women and men. Obstet Gynecol. 2015 Mar;125(3):605–10.</li> <li>Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ 3rd, Spack NP, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009 Sep;94(9):3132–54.</li> <li>Bauer GR, Redman N, Bradley K, Scheim AI. Sexual health of trans men who are gay, bisexual, or who have sex with men: results from Ontario, Canada. Int J Transgenderism. 2013 Apr;14(2):66–74.</li> <li>Ferrero S, Gillott DJ, Venturini PL, Remorgida V. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reprod Biol Endocrinol RBE. 2011;9:89.</li> <li>Amsterdam LL, Gentry W, Jobanputra S, Wolf M, Rubin SD, Bulun SE. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril. 2005 Aug;84(2):300–4.</li> <li>Ailawadi RK, Jobanputra S, Kataria M, Gurates B, Bulun SE. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril. 2004 Feb;81(2):290–6.</li> <li>Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet Lond Engl. 2005 Jan 1;365(9453):60–2.</li></ol> <blockquote><p>&lt;12&gt;. 译者注：一类照护方法，强调需要考虑患者可能的创伤史及其影响，并采取相应应对措施。</p></blockquote> <h2 id="性别酷儿、性别非常规和性别非二元人群"><a href="#性别酷儿、性别非常规和性别非二元人群" class="header-anchor">#</a> 性别酷儿、性别非常规和性别非二元人群</h2> <p>主要作者： Jennifer Hastings, MD</p> <h3 id="概论-5"><a href="#概论-5" class="header-anchor">#</a> 概论</h3> <p>性别酷儿、性别非常规和性别非二元（GNB）人群不在二元性别叙事中。本章中，将对术语和代词进行简短讨论，之后将概述非二元激素和外科过渡的独特考虑因素。</p> <h3 id="术语"><a href="#术语" class="header-anchor">#</a> 术语</h3> <p>考虑到广义上的性别认同和表达光谱，性别非二元人群可能自我认同为同时为男性和女性；既非男性又非女性；在两种性别之间；在性别光谱之外；或者超越性别二元系统，根本没有性别——自我认同为无性别。有些人可能只是简单地认同为“酷儿”，这是一个可表示尊重的泛称，涵盖了广泛的性别认同、性别表达和性取向。性别非二元人群在性别状态方面与更接近二元性别认同或表达的跨性别者一样真实。非二元性别术语发展迅速；拼写和连字符使用差别很大。性别非二元人群使用的一些术语的其他例子包括&lt;13&gt;[1]:</p> <ul><li>性别流动 gender fluid</li> <li>性别模糊 gender ambiguous</li> <li>泛性别 pangender</li> <li>neutrois</li> <li>gender bender</li> <li>gender blender</li> <li>gender smoothie</li> <li>gender expansive</li> <li>masculine of center</li> <li>feminine of center</li> <li>androgyne</li></ul> <p>性别非二元人群可能选择使用性别中性代词，例如“他们”，“他们”和“他们的”或其他性别中性代词，例如“zie（ze）/hir”，而不是她/她，他/他。</p> <p>与所有跨性别者一样，识别和使用所选名称和代词对于适当的患者护理至关重要。鼓励医疗提供者熟悉性别非二元人群可能使用的代词的多样性。记住图表并不是必需的，如果对于如何使用特定人的代词和共轭的代词有任何疑问，建议要求澄清。性别中性代词的共轭描述如下：</p> <p>表 10-1.代词参考表</p> <table><thead><tr><th><strong>第三人称单数主格</strong></th> <th><strong>第三人称单数宾格</strong></th> <th><strong>第三人称单数属格</strong></th> <th><strong>第三人称单数反身</strong></th></tr></thead> <tbody><tr><td>She</td> <td>Her</td> <td>Her</td> <td>Herself</td></tr> <tr><td>He</td> <td>Him</td> <td>His</td> <td>Himself</td></tr> <tr><td>They</td> <td>Them</td> <td>Their</td> <td>Themselves</td></tr> <tr><td>Ze</td> <td>Zir</td> <td>Zir/Zirs</td> <td>Zirself</td></tr> <tr><td>Xe</td> <td>Xem</td> <td>Xyr/Xyrself</td> <td>Xemself</td></tr> <tr><td>Ze</td> <td>Hir</td> <td>Hir/Hirs</td> <td>Hirself</td></tr> <tr><td>Per</td> <td>Per</td> <td>Per/Pers</td> <td>Perself</td></tr></tbody></table> <p>来源：改编自the University of Alberta Student Union</p> <h3 id="过渡"><a href="#过渡" class="header-anchor">#</a> 过渡</h3> <p>与具有二元跨性别认同的人一样，一部分非二元人群的性别肯定和过渡过程仅限于内在过程或纯粹的社会过程；对于其他人来说，该过程可能涉及各种性别肯定的医学干预和/或外科手术。WPATH护理标准版本7现在更加包含性别非二元认同，并认识到个体化方法的必要性和适当性。[2]</p> <h3 id="性别非二元人群中性别肯定的特殊方法"><a href="#性别非二元人群中性别肯定的特殊方法" class="header-anchor">#</a> 性别非二元人群中性别肯定的特殊方法</h3> <p>激素治疗的方法应该由个体的所需的第二性征特征来指导。策略可包括使用较低剂量的激素或在有限的时间段内使用激素。女性光谱上的非二元人群可以选择仅使用雄激素拮抗剂，和/或以非常低的剂量或短时间使用雌激素。</p> <p>对于男性光谱上的人群，特别是如果不是因月经而烦躁不安的患者，低剂量睾酮可被接受，因为低剂量可能不会阻止月经。如果性别焦虑随月经恶化，睾酮用量可以增加。如果性别非二元个体不希望获得引发月经停止的更高剂量睾酮所导致的男性化程度，则可以探索其他方法。这些可能包括肌内甲羟孕酮，左炔诺孕酮宫内节育系统或依托孕烯植入物，所有这些同时也能提供避孕功能。有时，男性光谱个体可能会选择连续使用复合口服避孕药来停止月经和避孕。停止月经的手术选择可包括子宫烧蚀或子宫切除术。</p> <p>重要的是要记住将生殖和生育考虑作为医学和外科手术方法知情同意的一部分，本指南其他部分将对此进行更详细的讨论。</p> <p>应与性别非二元患者讨论通过任意方案取得特定结果的能力的限制。一些期望的结果组合（例如在没有面部或体毛生长情况下获得更低的声音）可能是无法达到的。</p> <p>性别非二元人群还可以进行各种性别肯定手术和医疗过程，包括胸部重建或隆胸和生殖器外科手术。男性光谱的非二元个体可以选择在进行阴蒂释放术时保留阴道；对于更传统的二元跨性别男性来说，这也是一种选择。女性光谱非二元人可选择阴道成形术但不渴望乳房发育且不追求激素过渡；在此情况下，在性腺切除术后需要激素替代以维持骨骼健康，并且只有在经验丰富并足以胜任的心理健康提供者进行适当评估后才能进行手术。包装、翻折隐藏和束胸等非医疗方法可能是性别非二元人群表达的重要部分。一些性别非二元个体可能同时表现出鲜明对比的男性和女性特征；例如，乳房和面部毛发作为真实表达的一部分。</p> <p>**其它考虑因素：**性别非二元人群的挑战包括缺乏用于医疗记录和法律身份证明（如护照和驾驶执照）的非二元性别标记。倡导团体正在努力挑战二元体系，将非二元性别概念和术语引入法律，医疗，心理健康和教育领域。</p> <p>关于性别非二元体验的更多讨论可以在博客和网站（例如Neutrois Nonsense）[3]和诸如<em>Trans Bodies</em>，<em>Trans Selves</em>等书籍中找到。[4]</p> <h3 id="参考文献-10"><a href="#参考文献-10" class="header-anchor">#</a> 参考文献</h3> <ol><li>Ehrensaft D. 2011 Gender Born, Gender Made: Raising Healthy Gender-Nonconforming Children. New York, NY: The Experiment. 290 p.</li> <li>World Professional Association for Transgender Health (WPATH). Standards of care for the health of transsexual, transgender, and gender non-conforming people, 7th Version [Internet]. WPATH; 2012 [cited 2016 Mar 10]. Available from: [http://www.wpath.org/uploaded_files/140/files/Standards%20of%20Care,%20V7%20Full%](http://www.wpath.org/uploaded_files/140/files/Standards of Care%2C V7 Full Book.pdf) [20Book.pdf](http://www.wpath.org/uploaded_files/140/files/Standards of Care%2C V7 Full Book.pdf)</li> <li>Neutrois Nonsense: <a href="https://neutrois.me/" target="_blank" rel="noopener noreferrer">https://neutrois.me<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> An intimate exploration of identity and finding life wisdom beyond the gender binary.</li> <li>Erikson-Schroth, L. 2014. <em>Trans Bodies, Trans Selves: A Resource for the Transgender Community.</em> New York, NY: Oxford University Press.</li></ol> <blockquote><p>&lt;13&gt;. 译者注：该部分内容中的术语多数在中文语境中没有对应的概念，因此不做翻译</p></blockquote> <h2 id="心血管疾病"><a href="#心血管疾病" class="header-anchor">#</a> 心血管疾病</h2> <p>主要作者： Asa Radix, MD, MPH and Madeline B. Deutsch, MD, MPH</p> <h3 id="概论-6"><a href="#概论-6" class="header-anchor">#</a> 概论</h3> <p>性别是心血管健康预后的自变量。性激素在两性的心血管健康差异中起的作用尚不清楚。2010年Cochrane的分析发现，绝经期后激素疗法与总死亡率、心血管相关死亡率、非致命性心肌梗死或心绞痛、需要进行旁路手术或冠状动脉血管成形术的需求之间无相互作用。[1]该分析发现中风的发病风险略有增加（RR 1.26，95％置信区间 1.11-1.43，可能受到伤害病例数，NMH=164）；然而，2015年Cochrane发现，在绝经后开始激素治疗不足十年的女性亚组中，中风的风险没有增加，这更可能代表跨性别女性。[2]少量研究在考虑到了如烟草使用等风险因素的调整的情况下，调查了在跨性别人群中的激素治疗的心血管疾病风险和负担。较大的研究是回顾性的，并未针对众多共存的风险因素进行调整。前瞻性研究规模较小、期限较短。任何关于激素治疗对心血管疾病和中风可能产生的负面影响的分析，都应该考虑到激素治疗对生活质量和心理社会功能的显著益处。[3-5]</p> <p><strong>一些研究的证据表明，与非跨性别女性相比，使用睾酮的跨性别男性的心血管风险没有变化。[6-8]跨性别女性中的证据不太清楚。一些研究发现，与非跨性别男性相比，心肌梗死和中风的发病率和死亡率增加，但这些研究并未针对包括烟草使用，肥胖和糖尿病在内的多种风险因素进行调整。</strong>[6–8]迄今为止发表的最大规模的研究报告，是一份关于超过1000名荷兰跨性别女性和男性的回顾性队列研究中的死亡率报告，该报告未对包括烟草在内的许多风险因素进行控制。跨性别男性的全因及心血管和脑血管的特异性死亡率与一般荷兰人群无差异。在跨性别女性中，全因死亡率比一般荷兰人群高51％（95％置信区间 47-55），其中绝大多数是由于艾滋病，药物过量和自杀造成的；心血管病死亡风险增加64％（95％置信区间 43-87），但脑血管病死亡率无显著差异[9]。</p> <p>有几个因素可能导致跨性别女性心血管疾病风险升高，例如高吸烟率，肥胖，糖尿病和脂质紊乱以及体力活动减少[7]。较早的研究表明，高剂量（&gt;100mcg/天）的炔雌醇使用者中的发病和死亡率增加，炔雌醇是一种已知会导致血栓形成的合成雌激素，用于口服避孕药，一般剂量仅为20-30mcg/天。[10]对正在进行激素治疗的跨性别的血脂和血压的荟萃分析发现，跨性别女性的甘油三酯平均增加23mg/dl（95％置信区间 5-42），跨性别男性的甘油三酯平均增加31mg（95%置信区间 7-55），收缩血压平均增加1.7mmHg（95％置信区间 0.2至3.3），DHL平均减少6mg/dl （95% 置信区间 0.7-11）；所有其他脂质和血压参数均未显示出统计学上的显著变化。[11]这种统计学上显著的变化效应量较小并且临床意义不明确，特别是对一级预防（primary prevention）而言。</p> <p>激素对跨性别的血脂和血压的影响的直接研究有限。一项对169名奥地利跨性别人群的脂质进行的回顾性研究发现，在五年的时间内，跨性别女性和跨性别男性脂质有分布不良的趋势，但这些变化在大多数情况下都是温和的，而且在一定程度上可以通过透皮雌二醇的使用减轻。[12]对美国31名年轻健康的跨性别女性和17名年轻健康的跨性别男性组成的队列进行的6个月前瞻性研究发现跨性别女性的脂质总体改善不大，跨性别男性的高密度脂蛋白（HDL）轻微减少；虽然具有统计学意义，但效应量较小，临床意义不明确。[12–14]</p> <h3 id="计算风险"><a href="#计算风险" class="header-anchor">#</a> 计算风险</h3> <p>目前的美国心脏协会 - 美国心脏病学会预防和脂质管理指南涉及使用性别特异性计算器来确定风险并指导干预。[14]计算阿司匹林用量也使用了这些计算器用来进行胃肠道出血的风险-效益评估。目前，没有关于使用基于出生性别或使用基于确认性别的风险计算器的建议。考虑到长期暴露在原生荷尔蒙环境下，在随后的生活中过渡的跨性别使用基于原生性别的计算器可能是合理的。然而，随着越来越多的跨性别开始在青春期和青年期开始进行激素治疗，在这些情况下，使用基于被确定的性别的计算器可能更为合适。最终，主要目标是计算他汀类药物治疗或阿司匹林的现实风险-收益比。**根据激素治疗开始的年龄和接触的总时间长度，医疗服务提供者可以选择使用出生性别，改变后性别或者两者的平均值的风险计算器（分级：X C M）。**计算风险的另一个目标是在知情同意过程中提供充分的信息，以便让任何年龄、有或者没有心血管或者脑血管疾病的跨性别，做出明智的关于长期进行激素治疗的决定。</p> <h3 id="降低风险"><a href="#降低风险" class="header-anchor">#</a> 降低风险</h3> <p><strong>对于具有心血管疾病风险或者已经确诊心血管疾病的跨性别女性来说，使用透皮途径的雌激素可能是首选，因为静脉血栓栓塞率较低，并且它和脂质谱或凝血标志物的改变具有较低的相关性（分级：NT O M）。</strong>[15,16] 减少风险的其他可选途径包括戒烟，减轻体重，控制糖尿病和鼓励体育锻炼。理论上，激素治疗的心理社会益处可能通过减轻压力，改善身体形象带来的更健康的生活方式选择，减少烟草使用以及增加体育锻炼，而具有独立的保护性作用。</p> <h3 id="参考文献-11"><a href="#参考文献-11" class="header-anchor">#</a> 参考文献</h3> <ol><li>Main C, Knight B, Moxham T, Gabriel Sanchez R, Sanchez Gomez LM, Roqué i Figuls M, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2013;4:CD002229.</li> <li>Boardman HMP, Hartley L, Eisinga A, Main C, Roqué i Figuls M, Bonfill Cosp X, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;3:CD002229.</li> <li>Newfield E, Hart S, Dibble S, Kohler L. Female-to-male transgender quality of life. Qual Life Res. 2006 Jun 7;15(9):1447–57.</li> <li>Gómez-Gil E, Zubiaurre-Elorza L, Esteva I, Guillamon A, Godás T, Cruz Almaraz M, et al. Hormone-treated transsexuals report less social distress, anxiety and depression. Psychoneuroendocrinology [Internet]. 2011 [cited 2012 Dec 10]; Available from: http://www.sciencedirect.com/science/article/pii/S0306453011002629</li> <li>Colton Meier SL, Fitzgerald KM, Pardo ST, Babcock J. The effects of hormonal gender affirmation treatment on mental health in female-to-male transsexuals. J Gay Lesbian Ment Health. 2011 Jul;15(3):281–99.</li> <li>Gooren LJ, Wierckx K, Giltay EJ. Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern. Eur J Endocrinol. 2014 Jun 1;170(6):809–19.</li> <li>Wierckx K, Elaut E, Declercq E, Heylens G, De Cuypere G, Taes Y, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. Eur J Endocrinol Eur Fed Endocr Soc. 2013 Oct;169(4):471–8.</li> <li>Dhejne C, Oberg K, Arver S, Landén M. An analysis of all applications for sex reassignment surgery in Sweden, 1960-2010: prevalence, incidence, and regrets. Arch Sex Behav. 2014 May 29;</li> <li>Asscheman H, Giltay EJ, Megens JAJ, de Ronde W, van Trotsenburg MAA, Gooren LJG. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011 Jan 25;164(4):635–42.</li> <li>van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf). 1997 Sep;47(3):337–42.</li> <li>Elamin MB, Garcia MZ, Murad MH, Erwin PJ, Montori VM. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clin Endocrinol (Oxf). 2010 Jan;72(1):1–10.</li> <li>Ott J, Aust S, Promberger R, Huber JC, Kaufmann U. Cross-sex hormone therapy alters the serum lipid profile: a retrospective cohort study in 169 transsexuals. J Sex Med. 2011 Aug;8(8):2361–9.</li> <li>Deutsch MB, Bhakri V, Kubicek K. Effects of cross-sex hormone treatment on transgender women and men. Obstet Gynecol. 2015 Mar;125(3):605–10.</li> <li>Stone NJ, Robinson J, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Nov 12;01.cir.0000437738.63853.7a.</li> <li>Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, * AV, Hovatta O, Hamsten A, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost. 2001;85(4):619–25.</li> <li>Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007 Feb;115(7):840–5.</li></ol> <h2 id="糖尿病"><a href="#糖尿病" class="header-anchor">#</a> 糖尿病</h2> <p>主要作者： Linda Wesp, MSN, NP-C</p> <p>对跨性别患者进行糖尿病筛查的建议（无论激素状态如何）和现行国家指南没有差异。</p> <p>性别肯定激素治疗对糖尿病风险或疾病过程的影响尚不明确。一项荷兰病例对照研究指出，与非跨性别男性和女性的年龄对照组相比，跨性别男性和跨性别女性中2型糖尿病的患病率增加，但该研究并未针对其他风险因素进行调整。[1]一个对激素替代治疗对跨性别女性和跨性别男性的胰岛素抵抗的影响的研究发现，跨性别女性可能会出现胰岛素抵抗标志物的增加，而跨性别男性则没有变化。[2]一些来自非跨性别男性的数据表明，睾酮会降低胰岛素抵抗。[3]未进行激素治疗的跨性别男性中，多囊卵巢综合征（PCOS）发病率是否增加的数据相互矛盾。虽然非跨性别女性PCOS患者需要密切监测由于明显的胰岛素抵抗引起的糖尿病发展[4,5]，但一旦激素环境因添加睾酮而改变，这种风险是否仍然存在尚不清楚。虽然胰岛素抵抗可作为告知风险的有效替代指标，但使用糖尿病诊断作为终点的临床结局研究尚未进行。</p> <p>另一个角度来说，年轻健康的跨性别人群常常会仅以获得激素治疗或手术为目的寻求医疗护理。进行全面初级护理时，非跨性别患者的风险辨别因素相比于跨性别患者（例如肥胖，PCOS，代谢综合征，空腹血糖受损或糖尿病）将会更早被识别。这可以被视为改善健康的机会，特别是对心血管风险可能增加的跨性别女性。但是，应注意避免让性别肯定治疗依赖于对这些健康问题的严格控制。存在着大量的例子，控制不良的糖尿病跨性别患者在开始激素替代治疗后后，自我护理改善并导致血红蛋白A1c的下降。</p> <p>尚未对跨性别患者的糖尿病治疗进行具体研究。睾酮药品说明书建议进行监测，因为接受睾酮的糖尿病患者的血糖可能会降低。在开始或调整激素治疗时，对空腹血糖和血红蛋白A1c等指标加强监测是合理的。虽然WPATH护理标准建议在开始激素治疗之前“合理控制”糖尿病等疾病，但没有提出绝对的标准。对血糖的潜在不良影响应和激素治疗的益处相权衡。寻求性别肯定手术的糖尿病患者代表了一个特殊的群体，他们需要积极治疗以使血糖控制正常化。生殖器手术和乳房/胸部手术涉及微血管技术。通过更好的血糖控制，可以改善愈合，避免感染，改进功能和美观性。虽然糖尿病本身可能不是这些手术的禁忌症，但建议外科医生和进行糖尿病治疗的医疗提供者之间进行认真协调。[6]</p> <h3 id="参考文献-12"><a href="#参考文献-12" class="header-anchor">#</a> 参考文献</h3> <ol><li>Wierckx K, Elaut E, Declercq E, Heylens G, De Cuypere G, Taes Y, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. Eur J Endocrinol Eur Fed Endocr Soc. 2013 Oct;169(4):471–8.</li> <li>Elbers JM., Giltay EJ, Teerlink T, Scheffer PG, Asscheman H, Seidell JC, et al. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf). 2003;58(5):562–71.</li> <li>Jones TH. Effects of testosterone on Type 2 diabetes and components of the metabolic syndrome. J Diabetes. 2010 Sep;2(3):146–56.</li> <li>Baba T, Endo T, Ikeda K, Shimizu A, Honnma H, Ikeda H, et al. Distinctive features of female-to-male transsexualism and prevalence of gender identity disorder in Japan. J Sex Med. 2011 Jun;8(6):1686–93.</li> <li>Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. J Clin Endocrinol Metab. 2008 Apr;93(4):1408–11.</li> <li>Ellsworth WA, Colon GA. Management of medical morbidities and risk factors before surgery: smoking, diabetes, and other complicating factors. Semin Plast Surg. 2006 Nov;20(4):205–13.</li></ol> <h2 id="骨骼健康和骨质疏松"><a href="#骨骼健康和骨质疏松" class="header-anchor">#</a> 骨骼健康和骨质疏松</h2> <p>主要作者： Asa Radix, MD, MPH and Madeline B. Deutsch, MD, MPH</p> <h3 id="概论-7"><a href="#概论-7" class="header-anchor">#</a> 概论</h3> <p>由于现存的非跨性别人群的骨质疏松症的筛查建议变化很广，包括对非跨性别男性的骨质疏松筛查缺乏共识，以及没有美国国家级别的筛查频率建议，因此对跨性别人群的骨质疏松症的筛查建议的适应改编是复杂的。</p> <p>骨质疏松症的筛查目前基于年龄和性别，并且基于风险因素因人而异。有许多生活方式、基因、内分泌、血液、类风湿和自身免疫疾病，以及药物，会导致骨质疏松症。已知的骨质疏松症的风险因素包括高加索人或亚洲人种、高龄、酒精&gt;10次/周、低体重指数（BMI）、吸烟、慢性皮质类固醇使用、性腺机能减退、类风湿性关节炎、甲状旁腺功能亢进、活动受限、维生素D缺乏和HIV感染。[1,2]</p> <h3 id="跨性别女性骨质疏松症的风险"><a href="#跨性别女性骨质疏松症的风险" class="header-anchor">#</a> 跨性别女性骨质疏松症的风险</h3> <p>在一项研究中，研究人员发现，跨性别女性具有可能导致骨质疏松症风险增加的因素，独立并且存在先于激素使用。如体力活动水平减少，肌肉重量和握力降低，以及维生素D水平降低。[3]调查使用激素的跨性别女性的骨密度研究表明，激素开始后骨密度的变化，减小、增高或者不变三种结果皆有。[4-11]结果的差异可能是由于使用的方案（一些人在开始激素治疗之前使用了一段时间非对抗性雄激素拮抗剂）和随访时间长度不同。已知的骨质疏松症的风险因素包括在性腺切除术后激素的使用不足或使用雄激素拮抗剂的同时未使用雌激素或使用雌激素不足。GnRH类似物也可能导致骨矿物质密度的短期下降（即GnRH类似物没有和雌激素联用，并且当使用雌激素时，或停用拮抗剂时骨密度恢复正常）。</p> <h3 id="跨性别男性骨质疏松症的风险"><a href="#跨性别男性骨质疏松症的风险" class="header-anchor">#</a> 跨性别男性骨质疏松症的风险</h3> <p>到目前为止，大多数已发表的研究显示，使用睾酮的跨性别男性的骨矿物质密度没有变化或增加。这一人群中骨质疏松症的风险因素包括未进行合适的激素替代治疗时，在患者45岁以前进行的卵巢切除术[4,6,9-13]。</p> <h3 id="目前非跨性别人群的筛查指南"><a href="#目前非跨性别人群的筛查指南" class="header-anchor">#</a> 目前非跨性别人群的筛查指南</h3> <p>对于非跨性别人群，目前没有一致的最佳筛查频率的指导方案。WHO指南建议每10年一次。最近美国NIH资助的一项研究表明，正常骨密度或轻度骨质减少的筛查间隔约为15年，中度骨质减少的筛查间隔为5年，晚期骨质减少的筛查间隔为1年。跨性别的筛查间隔也可以基于这些建议。所有专业组织都建议对65岁以上的所有非跨性别女性进行筛查。有些人建议对有风险因素的人进行早期筛查。部分较旧的指南建议在70岁以后的非跨性别男性或有风险因素的人中筛查，而另一部分以及较新的指南则没有对男性的建议。</p> <h3 id="跨性别女性和男性的筛查建议"><a href="#跨性别女性和男性的筛查建议" class="header-anchor">#</a> 跨性别女性和男性的筛查建议</h3> <p>没有足够的证据来指导跨性别女性或男性的骨密度测试的建议。<strong>跨性别者（不论出生性别）应在65岁时开始进行骨密度筛查。对于已确定骨质疏松症危险因素的患者，应考虑50至64岁之间的筛查。对于经历过性腺切除术并且至少有5年没有激素替代史的跨性别（不论出生性别），也应考虑进行骨密度测试，无论年龄大小（分级：X C W）。</strong></p> <h3 id="筛查方式"><a href="#筛查方式" class="header-anchor">#</a> 筛查方式</h3> <p>髋关节和腰椎的双能X射线吸收测定法（DEXA）。</p> <h3 id="特殊考虑因素"><a href="#特殊考虑因素" class="header-anchor">#</a> 特殊考虑因素</h3> <p>目前还没有研究确定临床医生应该使用出生性别还是被确认的性别来评估骨质疏松症，如使用FRAX®工具时（ http://www.shef.ac.uk/FRAX/ ）。虽然一些研究人员在骨质量通常在成年早期开始激素的跨性别个体中达到顶峰的假设下使用出生性别，但应根据具体情况对其进行评估，直至有更多数据可用。随着在跨性别人群中青春期或青春期后不久进行激素过渡的趋势增加，这一假设将进一步复杂化。在风险评估工具中进行比较时的性别可以基于激素开始的年龄和激素的暴露时间长短。在某些情况下，同时使用男性和女性计算器并使用中间值来评估风险可能是合理的。</p> <p>较弱的证据表明，无性腺状态导致骨质疏松症风险增加，但缺乏长期研究。[14]<strong>没有性腺并且未进行激素替代治疗的跨性别者，应遵循无性腺或绝经后妇女的筛查和预防指南，不论出生性别或性别认同（分级：X C W）。</strong></p> <p>应给予以下建议来减轻骨质疏松的风险因素，包括戒烟，纠正低维生素D水平，维持钙摄入量符合现行非跨性别指南，负重活动和节制饮酒。</p> <h3 id="参考文献-13"><a href="#参考文献-13" class="header-anchor">#</a> 参考文献</h3> <ol><li>National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. [Internet]. 2013 [cited 2016 Feb 4]. Available from: http://nof.org/files/nof/public/content/file/917/upload/481.pdf</li> <li>Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012 Jun;97(6):1802–22.</li> <li>Van Caenegem E, Taes Y, Wierckx K, Vandewalle S, Toye K, Kaufman J-M, et al. Low bone mass is prevalent in male-to-female transsexual persons before the start of cross- sex hormonal therapy and gonadectomy. Bone. 2013 May;54(1):92–7.</li> <li>Wierckx K, Mueller S, Weyers S, Van Caenegem E, Roef G, Heylens G, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med. 2012 Oct 1;9(10):2641–51.</li> <li>Lapauw B, Taes Y, Simoens S, Van Caenegem E, Weyers S, Goemaere S, et al. Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone. 2008 Dec;43(6):1016–21.</li> <li>Ruetsche AG, Kneubuehl R, Birkhaeuser MH, Lippuner K. Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross- sectional study. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2005 Jul;16(7):791–8.</li> <li>Reutrakul S, Ongphiphadhanakul B, Piaseu N, Krittiyawong S, Chanprasertyothin S, Bunnag P, et al. The effects of oestrogen exposure on bone mass in male to female transsexuals. Clin Endocrinol (Oxf). 1998 Dec 1;49(6):811–4.</li> <li>van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf). 1997 Sep;47(3):337–42.</li> <li>Meriggiola MC, Armillotta F, Costantino A, Altieri P, Saad F, Kalhorn T, et al. Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals. J Sex Med. 2008 Oct 1;5(10):2442–53.</li> <li>Mueller A, Haeberle L, Zollver H, Claassen T, Kronawitter D, Oppelt PG, et al. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals. J Sex Med. 2010 Sep 1;7(9):3190–8.</li> <li>Schlatterer K, Auer DP, Yassouridis A, von Werder K, Stalla GK. Transsexualism and osteoporosis. Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc. 1998;106(4):365–8.</li> <li>Van Caenegem E, Wierckx K, Taes Y, Dedecker D, Van de Peer F, Toye K, et al. Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy. J Clin Endocrinol Metab. 2012 Jul;97(7):2503–11.</li> <li>Turner A, Chen TC, Barber TW, Malabanan AO, Holick MF, Tangpricha V. Testosterone increases bone mineral density in female-to-male transsexuals: a case series of 15 subjects. Clin Endocrinol (Oxf). 2004 Nov;61(5):560–6.</li> <li>Garcia C, Lyon L, Conell C, Littell RD, Powell CB. Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy. Gynecol Oncol. 2015 Sep;138(3):723–6.</li></ol> <h2 id="跨性别健康和hiv"><a href="#跨性别健康和hiv" class="header-anchor">#</a> 跨性别健康和HIV</h2> <p>主要作者： Tonia Poteat, PhD, MPH, PA-C</p> <h3 id="概论-8"><a href="#概论-8" class="header-anchor">#</a> 概论</h3> <p>HIV的筛查，预防和护理的一般准则对跨性别没有差别；但是，<strong>跨性别人群的HIV服务应该满足这一人群的特定生理，心理和社会需求。</strong>[1]改编自针对男男性接触者（MSM）或非跨性别女性开发的实践的艾滋病预防和护理计划，未能解决独特的结构性的因素和不公平现象，这些因素和现象增加了艾滋病的风险并为跨性别人群护理产生了障碍。例如，许多跨性别女性（特别是年轻人，少数人种/少数民族和无证件的个人）经历了交叉性歧视（intersecting discrimination）&lt;14&gt; 和高（肉体或精神）创伤率、不稳定的住房、贫困、监禁和失业，这些都对艾滋病风险，检测和持续护理产生负面影响。</p> <p>由于缺乏通常用于性别肯定激素治疗的雌激素形式的数据，对使用女性激素的跨性别女性的抗逆转录病毒治疗（ART）的使用建议变得复杂；因此，有必要从使用复方口服避孕药的研究中推断出药物-药物相互作用的数据。跨性别男性的艾滋病数据很少，可能是由于艾滋病病毒感染率低得多。然而，与男性发生性关系的跨性别男性的艾滋病风险的证据正在增加[2-4]。</p> <p>根据美国疾病控制中心（CDC）和美国预防服务工作组（USPSTF）的国家指南，建议对HIV进行普遍筛查，所有跨性别者都应至少接受一次HIV筛查。在对所有患者进行初步筛查后，重复筛查基于HIV风险评估。**有效的风险评估需要有获得涵盖解剖学特异性性行为的准确性生活史的能力。**具有阴茎的跨性别女性应当被问及插入性交以及接受性交。尽管接受阴道成形术的跨性别女性接受阴道性交获得HIV的风险尚不清楚，但具有阴道的跨性别女性和跨性别男性应该被问及阴道性交和肛门性交。与男性生殖器重建相关的风险，如阴茎成形术或阴蒂释放术尚不清楚。使用开放式的问题，不预先假设解剖结构和伴侣的性或性别可能提供最多的信息。</p> <h3 id="预防"><a href="#预防" class="header-anchor">#</a> 预防</h3> <p>避孕套仍然是艾滋病预防的主要手段。然而，因为勃起程度降低，使用避孕套对使用激素的跨性别女性可能会困难。跨性别女性也可能缺乏动机在性行为中商讨使用安全套，特别是那些从事性工作的人。[5]安全套在已经接受阴茎成形术的跨性别男性中的作用尚不清楚，可能取决于具体的解剖学结构和所使用的手术方法。“女性”安全套可能是可以接受阴道接受性交的跨性别男性的一种选择。</p> <p>较新的生物医学艾滋病预防干预措施增加了降低艾滋病风险的选择。目前有两类药物可供非HIV感染者用于预防艾滋病病毒感染：1）暴露前预防（PrEP）；2）非职业性暴露后预防（nPEP）。</p> <h4 id="暴露前预防-prep"><a href="#暴露前预防-prep" class="header-anchor">#</a> 暴露前预防（PrEP）</h4> <p>每日口服PrEP（由替诺福韦地索普西富马酸盐（TDF）300毫克和恩曲他滨（FTC）200毫克组成的固定剂量复方制剂）已被证明安全有效的降低MSM，非跨性别异性恋和注射药品人群获得HIV的风险。疾病预防控制中心（CDC）已公布了针对艾滋病病毒感染高风险人群使用PrEP的详细临床指南。[6]</p> <p>对来自PrEP大型多国随机对照试验的数据进行的子分析表明，在跨性别女性中PrEP在按规定服用时能有效预防HIV。然而，在跨性别女性中的意向治疗分析（“intent-to-treat” analysis）没有发现效力。[7]重要的是，在研究的PrEP组中发生血清转化的所有跨性别女性在他们的血液中都没有可检测到的TDF，这表明他们没有按规定服用药物。TDF/FTC与激素治疗之间没有已知的药物-药物相互作用，也没有任何已知的PrEP与激素治疗联用的禁忌症。为了有效地啮合跨性别女性，PrEP计划应使用包含跨性别的营销策略，解决社区对TDF与激素治疗之间药物相互作用的忧虑，并确保服务由了解跨性别健康的提供者提供。[8]</p> <h4 id="非职业性暴露后预防-npep"><a href="#非职业性暴露后预防-npep" class="header-anchor">#</a> 非职业性暴露后预防（nPEP）</h4> <p>在跨性别群体中使用nPEP应遵循非跨性别的指导原则。与PrEP一样，社交营销和宣传活动应针对跨性别人群进行相应调整。</p> <h3 id="治疗hiv的同时进行激素治疗"><a href="#治疗hiv的同时进行激素治疗" class="header-anchor">#</a> 治疗HIV的同时进行激素治疗</h3> <p>HIV及其治疗并非激素治疗的禁忌症。事实上，在HIV治疗的背景下提供激素治疗可以改善护理的参与度和留存率[9]以及依从性和病毒载量。[10,11]世界卫生组织[12]以及美国卫生部和人类服务部[13]建议所有HIV感染者接受抗逆转录病毒治疗，不论HIV载量或CD4计数如何。[14]</p> <p>雌激素的代谢通过细胞色素P450酶系统，因此与ART药物存在潜在的药物-药物相互作用。关于这些相互作用的信息基于避孕背景下的研究，并且通常包含炔雌醇而不是推荐用于女性化的17-β雌二醇。在跨性别护理的背景下，没有关于激素和抗逆转录病毒药物之间药物相互作用的数据。然而，<strong>根据现有数据，大多数ART可能可以安全地与雌激素一起使用，但有两个例外：不推荐使用安普那韦（Agenerase）和未加强的福沙那韦（Lexiva）与雌激素共同给药，由于安普那韦血清浓度会发生降低。</strong>[13]</p> <p>有限的数据表明，非核苷类逆转录酶抑制剂（NNRTIs），利托那韦（RTV）-加强蛋白酶抑制剂（PIs）或可比司他（Cobicistat）与整合酶链抑制剂（INSTIs）可能对某些激素避孕药的血液水平有影响。在炔雌醇和核苷逆转录酶抑制剂（NRTI），CCR5拮抗剂，融合抑制剂或非增强的INST之间没有已知的药物-药物相互作用。相互作用在炔雌醇，炔诺酮或诺孕酯的血液水平降低或增加之间变化。这种相互作用可能潜在地导致激素功效降低或增加激素副作用。</p> <p>跨性别女性可能优先考虑激素治疗而不是其他护理；如果认为这些症状是由于ART引起的，这些症状可能导致ART依从性降低。在开始或改变抗逆转录病毒治疗时，考虑监测雌二醇水平和/或根据雌激素性症状的发展或变化进行经验性给药或方案调整。</p> <p>有关ART与雄性激素或其他用作女性化抗雄激素的药物之间相互作用的数据有限。目前，ART与雄激素（例如睾酮）或抗雄激素（例如螺内酯）之间没有有记载的相互作用。</p> <h3 id="激素治疗和艾滋病相关机会性感染和预防的管理"><a href="#激素治疗和艾滋病相关机会性感染和预防的管理" class="header-anchor">#</a> 激素治疗和艾滋病相关机会性感染和预防的管理</h3> <p>由于HIV而免疫抑制的患者可能需要治疗或预防机会性感染。最常见的是每天使用甲氧苄氨嘧啶-磺胺甲恶唑（TMP-SMX）预防PCP肺炎。螺内酯和TMP-SMX之间有导致高钾血症的明显的相互作用，医院门诊和死亡案例已经详细的在非跨性别病人中描述了该相互作用。当这些药物联合使用时，建议保持较高的怀疑指数，并经常监测血清电解质和肾功能。尤其建议老年患者避免使用这种组合。[15,16]</p> <h3 id="参考文献-14"><a href="#参考文献-14" class="header-anchor">#</a> 参考文献</h3> <ol><li>Sevelius JM, Keatley J, Gutierrez-Mock L. HIV/AIDS programming in the United States: considerations affecting transgender women and girls. Womens Health Issues Off Publ Jacobs Inst Womens Health. 2011 Nov;21(6 Suppl):S278–82.</li> <li>Meier SC, Pardo ST, Labuski C, Babcock J. Measures of clinical health among female-to- male transgender persons as a function of sexual orientation. Arch Sex Behav. 2013 Apr;42(3):463–74.</li> <li>Light AD, Obedin-Maliver J, Sevelius JM, Kerns JL. Transgender men who experienced pregnancy after female-to-male gender transitioning. Obstet Gynecol. 2014 Dec;124(6):1120–7.</li> <li>Reisner SL, White Hughto JM, Pardee D, Sevelius J. Syndemics and gender affirmation: HIV sexual risk in female-to-male trans masculine adults reporting sexual contact with cisgender males. Int J STD AIDS. 2015 Sep 18;</li> <li>Poteat T, Wirtz AL, Radix A, Borquez A, Silva-Santisteban A, Deutsch MB, et al. HIV risk and preventive interventions in transgender women sex workers. Lancet. 2015 Jan 17;385(9964):274–86.</li> <li><a href="http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf" target="_blank" rel="noopener noreferrer">Preexposure prophylaxis for the prevention of HIV in the United States – 2014: A clinical<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf" target="_blank" rel="noopener noreferrer">practice guideline<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>. Centers for Disease Controal and Prevention, U.S. Public Health Service. [Internet]. Available from: http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf</li> <li>Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, et al. <a href="http://linkinghub.elsevier.com/retrieve/pii/S2352301815002064" target="_blank" rel="noopener noreferrer">HIV pre-<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://linkinghub.elsevier.com/retrieve/pii/S2352301815002064" target="_blank" rel="noopener noreferrer">exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>. Lancet HIV [Internet]. 2015 Nov [cited 2015 Nov 12]; Available from: http://linkinghub.elsevier.com/retrieve/pii/S2352301815002064</li> <li>Sevelius JM, Keatley J, Calma N, Arnold E. “I am not a man”: Trans-specific barriers and facilitators to PrEP acceptability among transgender women. In Florida; 2015.</li> <li>Sevelius JM, Patouhas E, Keatley JG, Johnson MO. Barriers and facilitators to engagement and retention in care among transgender women. living with human immunodeficiency virus. Ann Behav Med Publ Soc Behav Med. 2014 Feb;47(1):5–16.</li> <li>Sevelius JM, Carrico A, Johnson MO. Antiretroviral therapy adherence among transgender women living with HIV. J Assoc Nurses AIDS Care JANAC. 2010 Jun;21(3):256–64.</li> <li>Sevelius JM, Saberi P, Johnson MO. Correlates of antiretroviral adherence and viral load among transgender women living with HIV. AIDS Care. 2014;26(8):976–82.</li> <li>World Health Organization (WHO). <a href="http://www.who.int/hiv/pub/guidelines/keypopulations/en/" target="_blank" rel="noopener noreferrer">Consolidated guidelines on HIV prevention, diagnosis,<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.who.int/hiv/pub/guidelines/keypopulations/en/" target="_blank" rel="noopener noreferrer">treatment and care for key populations<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. WHO. [cited 2016 Jan 29]. Available from: http://www.who.int/hiv/pub/guidelines/keypopulations/en/</li> <li>Panel on Antiretroviral Guidelines for Adults and Adolescents. <a href="https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf" target="_blank" rel="noopener noreferrer">Guidelines for the use of<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf" target="_blank" rel="noopener noreferrer">antiretroviral agents in HIV-1-infected adults and adolescents<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>. Department of Health and Human Services [Internet]. [cited 2016 Jan 29]. Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf</li> <li><a href="http://www.who.int/hiv/pub/guidelines/en/" target="_blank" rel="noopener noreferrer">World Health Organization (WHO) Guidelines: HIV<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. WHO. [cited 2014 Dec 3]. Available from: http://www.who.int/hiv/pub/guidelines/en/</li> <li>Antoniou T, Gomes T, Mamdani MM, Yao Z, Hellings C, Garg AX, et al. Trimethoprim- sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. BMJ. 2011;343:d5228.</li> <li>Antoniou T, Hollands S, Macdonald EM, Gomes T, Mamdani MM, Juurlink DN, et al. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. CMAJ Can Med Assoc J J Assoc Medicale Can. 2015 Mar 3;187(4):E138– 43.</li></ol> <blockquote><p>&lt;14&gt;. 译者注：指在多个不同领域处于边缘和受歧视的地位而受到的总体性的歧视</p></blockquote> <h2 id="跨性别健康和丙型肝炎"><a href="#跨性别健康和丙型肝炎" class="header-anchor">#</a> 跨性别健康和丙型肝炎</h2> <p>主要作者： Tonia Poteat, PhD, MPH, PA-C</p> <h3 id="概论-9"><a href="#概论-9" class="header-anchor">#</a> 概论</h3> <p>虽然没有证据表明跨性别是丙型肝炎的独立危险因素，但一些跨性别亚群体中风险可能会增加。跨性别者中HIV感染和注射药物的比例较高，跨性别者可能会注射激素或软组织填充物，如硅胶。[1]分享或使用受污染的针头，注射器或小瓶是血源性病原体（包括丙型肝炎）感染的可能危险因素，尽管跨性别人群中针头共用的实际流行率被认为较低。[2,3]尽管如此，使用注射激素的跨性别者的患者教育应涵盖仅使用无菌注射器一次而不共享的建议。</p> <p>根据现行指南，提供者应筛查所有跨性别人群的丙型肝炎风险因素，并对确定存在风险的人进行抗体筛查。所有注射软组织填充物的跨性别者都应接受丙型肝炎筛查。</p> <h3 id="慢性hcv和激素治疗"><a href="#慢性hcv和激素治疗" class="header-anchor">#</a> 慢性HCV和激素治疗</h3> <p>慢性丙型肝炎不是激素治疗的禁忌症。雌激素和睾酮均经历肝脏代谢，因此建议对肝功能进行常规监测。然而，这两种激素都与肝损伤或肝功能检查异常无关。慢性丙型肝炎感染患者的肝功能监测应按疾病分期和风险因素的阶段指导原则进行。非口服形式的激素治疗避免首先通过肝脏代谢，可能是肝病患者的首选，但没有具体证据支持这一建议。[4]</p> <p>肝功能障碍和恶性肿瘤已经被注意到和口服甲基睾酮一起出现。然而，大多数国家不再使用甲基睾酮，不应再将其作为激素替代治疗方案的一部分。在非跨性别男性的10年安全性研究中，美国境外可获得的口服十一酸睾酮胶囊与肝功能障碍无关。[5]没有关于患有慢性病毒性肝炎同时接受激素疗法的跨性别个体的临床结局的公开数据。</p> <h3 id="慢性hcv治疗和激素治疗"><a href="#慢性hcv治疗和激素治疗" class="header-anchor">#</a> 慢性HCV治疗和激素治疗</h3> <p>美国肝病研究协会建议对所有慢性HCV感染患者进行治疗，但由于共症状况预期寿命较短的患者除外[6]。用于治疗丙型肝炎的抗病毒药物根据HCV基因型，疾病分期和HCV治疗史而有所不同；大多数通过与口服雌激素相同的细胞色素P450途径代谢。[7]下表总结了雌激素和丙型肝炎抗病毒药物之间目前已知的药物相互作用。</p> <p>表 15-1. 雌激素与HCV抗病毒药物之间的相互作用</p> <table><thead><tr><th><strong>避孕药和激素替代疗法</strong></th> <th><strong>波普瑞韦</strong></th> <th><strong>达卡他韦</strong></th> <th><strong>雷迪帕韦/索非布韦</strong></th> <th><strong>OBV/P</strong></th> <th><strong>OBV/PTV/r</strong></th> <th><strong>西咪匹韦</strong></th> <th><strong>索非布韦</strong></th> <th><strong>特拉匹韦</strong></th></tr></thead> <tbody><tr><td><strong>地索高诺酮(去氧孕烯)</strong></td> <td><strong>?</strong></td> <td><strong>√</strong></td> <td><strong>√</strong></td> <td><strong>?</strong></td> <td><strong>?</strong></td> <td><strong>√</strong></td> <td><strong>√</strong></td> <td><strong>?</strong></td></tr> <tr><td><strong>地诺孕素</strong></td> <td><strong>?</strong></td> <td><strong>√</strong></td> <td><strong>√</strong></td> <td><strong>?</strong></td> <td><strong>?</strong></td> <td><strong>√</strong></td> <td><strong>√</strong></td> <td><strong>?</strong></td></tr> <tr><td><strong>屈螺酮</strong></td> <td><strong>X</strong></td> <td><strong>√</strong></td> <td><strong>√</strong></td> <td><strong>√</strong></td> <td><strong>√</strong></td> <td><strong>?</strong></td> <td><strong>√</strong></td> <td><strong>?</strong></td></tr> <tr><td><strong>雌二醇</strong></td> <td><strong>?</strong></td> <td><strong>√</strong></td> <td><strong>√</strong></td> <td><strong>?</strong></td> <td><strong>?</strong></td> <td><strong>√</strong></td> <td><strong>√</strong></td> <td><strong>?</strong></td></tr> <tr><td><strong>炔雌醇</strong></td> <td><strong>?</strong></td> <td><strong>√</strong></td> <td><strong>√</strong></td> <td><strong>X</strong></td> <td><strong>X</strong></td> <td><strong>√</strong></td> <td><strong>√</strong></td> <td><strong>?</strong></td></tr> <tr><td><strong>炔诺酮</strong></td> <td><strong>?</strong></td> <td><strong>√</strong></td> <td><strong>√</strong></td> <td><strong>?</strong></td> <td><strong>?</strong></td> <td><strong>√</strong></td> <td><strong>√</strong></td> <td><strong>?</strong></td></tr></tbody></table> <p><strong>说明：</strong></p> <p><strong>X</strong> = 这些药物不应该被同时给药</p> <p><strong>?</strong> = 潜在的相互作用 – 可能需要密切监测，改变药物剂量或给药时间</p> <p><strong>√</strong> = 没有显著的临床相互作用预期</p> <p><strong>缩略语：</strong></p> <p>OBV/PTV/r = 奥比他韦/帕利普韦/利托那韦</p> <p>OBV/PTV/r+DSV = 奥比他韦/帕利普韦/利托那韦+达沙布韦.</p> <p>表取自 <a href="http://www.hep-druginteractions.org/" target="_blank" rel="noopener noreferrer">HEP Drug Interactions Checker<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> (<a href="http://www.hep-druginteractions.org/interactions.aspx" target="_blank" rel="noopener noreferrer">http://www.hep-druginteractions.org/interactions.aspx)<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>)</p> <p>雌二醇与奥比他韦/帕利普韦/利托那韦、达沙布韦或特拉匹韦的共同给药可能会增加雌二醇暴露；然而尚未对共同给药进行研究。发现炔雌醇与波普瑞韦或特拉匹韦共同给药会降低雌激素水平[8]。在使用OBV/PTV/r服用炔雌醇的顺性别女性中观察到升高的肝酶，不建议同时使用（无论有无DSV）。总之，炔雌醇与奥比他韦/帕利普韦/利托那韦禁忌。没有证据表明HCV抗病毒药物和17-β雌二醇之间存在潜在的相互作用，因此提供者应考虑在使用雌二醇的患者中避免使用OBV/PTV/r（无论有或没有DSV）[8]。在开始或停止HCV治疗时，应密切监测雌激素治疗中的跨性别女性。</p> <h3 id="参考文献-15"><a href="#参考文献-15" class="header-anchor">#</a> 参考文献</h3> <ol><li>Reback CJ, Fletcher JB. HIV prevalence, substance use, and sexual risk behaviors among transgender women recruited through outreach. AIDS Behav. 2014 Jul;18(7):1359–67.</li> <li>Herbst JH, Jacobs ED, Finlayson TJ, McKleroy VS, Neumann MS, Crepaz N, et al. Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. AIDS Behav. 2008 Jan;12(1):1–17.</li> <li>Wallace PM, Rasmussen S. Analysis of adulterated silicone: implications for health promotion. Int J Transgenderism. 2010 Oct 12;12(3):167–75.</li> <li>Knezevich EL, Viereck LK, Drincic AT. Medical management of adult transsexual persons. Pharmacotherapy. 2012 Jan;32(1):54–66.</li> <li>Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl. 1994 Jun;15(3):212–5.</li> <li>AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatol Baltim Md. 2015 Sep;62(3):932–54.</li> <li>Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015 Jul;63(1):20–9.</li> <li>University of Liverpool. HEP Drug Interaction Checker [Internet]. HEP Drug Interactions. [cited 2016 May 24]. Available from: http://www.hep-druginteractions.org/</li></ol> <h2 id="跨性别者与性传播疾病-sti"><a href="#跨性别者与性传播疾病-sti" class="header-anchor">#</a> 跨性别者与性传播疾病（STI）</h2> <p>主要作者： Tonia Poteat, PhD MPH PA-C</p> <h3 id="概论-10"><a href="#概论-10" class="header-anchor">#</a> 概论</h3> <p>国家指南中有针对如何获取性行为史，及根据性别及风险组区分的性传播疾病（STI）筛查频率的推荐。[1]2015年疾病预防控制中心指南及2015年性病治疗指南确实将跨性别男性和女性作为特殊人群对待，并建议基于当前解剖和性行为，关注患者症状与常见性传播疾病一致的程度，以及根据过往史及性行为对缺乏症状的性传播疾病进行筛查。[2]然而这些指南并不包括特定的筛查或间隔建议。本章介绍的是在跨性别人群中筛查性传播感染时的具体考虑因素。</p> <p>对确诊的性传播感染的处理建议与非跨性别者无异。筛查间隔应基于风险设定，每3个月应对高风险人群（多个性伴侣，无套性行为，性交易/性工作者，醉酒性行为）进行筛查。</p> <p>实践中，跨性别者可能因害怕歧视，[3]遇到对跨性别健康训练不足的提供者，[4]或对就诊或检查的个人不适[5]而回避接受筛查程序和体检。对于临床医生来说，建立信任和尊重的关系，并清楚解释明确露骨问题和实施各部分检查的原因非常重要。</p> <h3 id="性行为史与风险评估"><a href="#性行为史与风险评估" class="header-anchor">#</a> 性行为史与风险评估</h3> <p>临床医生应根据患者的性行为和当前的解剖学结构评估性传播疾病（STI）的风险。由于跨性别群体在激素使用，性别肯定手术程序和性行为模式方面存在差异，因此提供者应避免对患者是否存在特定生理结构，性取向及性行为做出任何假设。解剖学结构及性行为可随时间变化；因此评估可能影响STI风险的上述变化至关重要。为促进相互尊重关系，应使用患者首选术语来指代生理部位。</p> <p>芬威指南（Fenway Guide）提供了包括以下问题的性风险评估建议：</p> <ul><li>你目前有性生活吗？过去一年内你有多少性伴侣？</li> <li>你在与谁发生性关系？（包括伴侣的性别和生理条件）</li> <li>你进行的是何种性行为？性行为时使用何部位？</li> <li>你采取何种性传播疾病感染保护措施？（多久使用一次安全套/屏障？是否使用HIV暴露前预防药物？）</li> <li>如有的话，你患过何种性传播疾病？上一次查出性传播疾病的时间？</li> <li>你的性伴侣被诊断过患有任何性传播疾病吗？</li> <li>你在进行性行为时服用酒精或任何药物吗？</li> <li>你是否以性交换取过金钱，药物或住处？</li></ul> <p>这些问题是完整性史的组成部分，包括性关系类型，性生活频率，初次性行为年龄，性行为期间服药或酗酒，性工作史，性虐待史和性功能。[7]</p> <h3 id="体检与性传播疾病筛查"><a href="#体检与性传播疾病筛查" class="header-anchor">#</a> 体检与性传播疾病筛查</h3> <p>对于跨性别人群（HIV，乙型肝炎和丙型肝炎，梅毒）的血清学筛查推荐在建议或技术上与非跨性别人群无异。</p> <p>许多跨性别者都遭受过暴力对待，包括性暴力。[3]因此，提供者在进行筛查时，如有可能应在创伤知情（trauma-informed）的情况下进行陪护。[8]该方法基于使患者感到可控，包括：在患者还穿戴整齐时给予问候；解释检查内容及原因；提供信息，选择及决定权。[9]一些跨性别患者可能更愿意自行收集自身样本，以使检查过程感觉可控。</p> <p>自行收集的阴道和直肠拭子以及尿液样本用于对淋病，衣原体和滴虫的核酸扩增检查时，与由医疗提供者收集的样本具有相同的敏感性和特异性。[1]体检应侧重于现存并可能因性史而受到感染的器官。</p> <p>经阴道成形术（阴茎皮内翻或结肠阴道成形术）的跨性别女性没有子宫颈，因此不适合筛查宫颈人乳头瘤病毒（HPV）。一些手术方法使用尿道组织，这可能导致衣原体或淋病等黏膜感染。尽管可能存在梅毒性下疳，疱疹或软下疳等病变，完整且翻转的阴茎皮肤被这些病原体感染的风险尚不清楚。当出现症状而获临床指示时，应进行体检和适当的筛查。在跨性别女性中创建的新阴道的生理结构与先天性阴道的不同之处在于其为盲端，子宫颈或周围的穹窿阙如，并且朝向可能更靠后部。因此，使用肛门镜可能是解剖学上更合适的视检方法。可插入肛门镜并移除套管针，可见的阴道壁则在肛门镜拔出时在其周围收缩。没有证据可引导决定对跨性别女性进行常规骨盆检查以筛查前阴茎皮肤的疣或病变等病症。</p> <p>经阴道成形术的跨性别女性保留前列腺组织，因此对出现疑似症状且具有性生活的跨性别女性的诊断中，应包括感染性前列腺炎的检查。没有证据表示，可对未出现症状的经阴道成形术的跨性别女性进行常规性衣原体筛查，尽管考虑对有风险因素的跨性别女性进行尿液筛查是合理的。经阴茎皮内翻的女性中，与尿液检测相反，阴道淋病和衣原体标本检测的作用尚不明确。提供者应考虑是否进行阴道检查，但应视尿液检测为必要步骤。</p> <p>对于有子宫和输卵管且接受阴道性交的跨性别男性，盆腔炎的发生存在差异。阴道萎缩与睾酮的使用有关；因此，在具有阴道的跨性别男性中，使用润滑剂和小窥镜可能分别适用于盆腔和窥镜检查。一些跨性别男性在子宫成形术后保留明显阴道，可能需要根据性行为史进行阴道筛查。</p> <p>宫颈癌和人乳头瘤病毒（HPV）的筛查在本指南其他位置有所涉及。</p> <h3 id="参考文献-16"><a href="#参考文献-16" class="header-anchor">#</a> 参考文献</h3> <ol><li>Workowski KA, Bolan GA, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep Cent Dis Control. 2015 Jun 5;64(RR-03):1–137.</li> <li>Centers for Disease Control and Prevention (CDC). <a href="http://www.cdc.gov/std/tg2015/default.htm" target="_blank" rel="noopener noreferrer">2015 STD Treatment Guidelines<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. [cited 2016 Mar 25]. Available from: http://www.cdc.gov/std/tg2015/default.htm</li> <li>Grant JM, Mottet LA, Tanis J, Harrison J, Herman J, Keisling M. <a href="http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf" target="_blank" rel="noopener noreferrer">Injustice at every turn: a<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf" target="_blank" rel="noopener noreferrer">report of the National Transgender Discrimination Survey<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. National Center for Transgender Equality and National Gay and Lesbian Task Force; 2011 [cited 2016 Mar 17]. Available from: http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf</li> <li>Lambda Legal. <a href="http://www.lambdalegal.org/health-care-report" target="_blank" rel="noopener noreferrer">When Health Care Isn’t Caring: Lambda Legal’s Survey of Discrimination<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.lambdalegal.org/health-care-report" target="_blank" rel="noopener noreferrer">Against LGBT People with HIV<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>. [Internet]. New York, NY; 2010 [cited 2016 Mar 25]. Available from: http://www.lambdalegal.org/health-care-report</li> <li>Bates CK, Carroll N, Potter J. The challenging pelvic examination. J Gen Intern Med. 2011 Jun;26(6):651–7.</li> <li>Gelman M, van Wagenen A, Potter J. Principles for Taking an LGBTQ-Inclusive Health History and Conducting a Culturally Competent Physical Exam. In: Fenway Guide to Lesbian, Gay, Bisexual, and Transgender Health. 2nd ed. Philadelphia: American College of Physicians; 2015.</li> <li>Daskalakis DC, Radix A, Mayer G. Sexual Health of LGBTQ People. In: Fenway Guide to Lesbian, Gay, Bisexual, and Transgender Health. 2nd ed. Philadelphia: American College of Physicians; 2015.</li> <li>Substance Abuse and Mental Health Services Administration (SAMHSA). <a href="http://www.samhsa.gov/nctic/trauma-interventions" target="_blank" rel="noopener noreferrer">Trauma-<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.samhsa.gov/nctic/trauma-interventions" target="_blank" rel="noopener noreferrer">Informed Approach and Trauma-Specific Interventions<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. 2015 [cited 2016 Mar 25]. Available from: http://www.samhsa.gov/nctic/trauma-interventions</li> <li>Raja S, Hasnain M, Hoersch M, Gove-Yin S, Rajagopalan C. Trauma informed care in medicine: current knowledge and future research directions. Fam Community Health. 2015 Sep;38(3):216–26.</li></ol> <h2 id="睾丸和阴囊疼痛及相关问题"><a href="#睾丸和阴囊疼痛及相关问题" class="header-anchor">#</a> 睾丸和阴囊疼痛及相关问题</h2> <p>主要作者： Barry Zevin, MD</p> <h3 id="概论-11"><a href="#概论-11" class="header-anchor">#</a> 概论</h3> <p>阴囊相关疾病的发病率尚不清楚，但之前并非罕见。跨性别女性阴囊疼痛的一个常见原因是“翻折隐藏”，通过穿着紧身约束衣物使出现女性化的生殖器轮廓。翻折隐藏包括手动将睾丸向上移动到腹股沟管中，而后将阴茎和阴囊皮肤固定在双腿之间并向后朝向肛门，然后使用紧身内衣，胶带或称为<em>gaff</em>的特殊服装来保持此体位。许多跨性别女性认为这种做法是促进性别认同的，即使在晚上睡觉时也可能保持。由此产生的疼痛可能是创伤性的，机械性的或神经性的。长时间翻折阴茎也可导致尿液反流和前列腺感染的症状，如附睾-睾丸炎，前列腺炎或膀胱炎。长时间接近肛门的压缩尿道口也可能成为感染通道。与开始激素治疗相关的疼痛是常见症状，但此症状的病因尚不清楚。</p> <p>急性阴囊疼痛需要进行检查以排除需紧急治疗的其他情况。通过体检排除肿瘤，疝气，鞘膜积液或其他疼痛原因是合适的。如有需要，应进行适当成像检查。[1,2]</p> <h3 id="治疗方法"><a href="#治疗方法" class="header-anchor">#</a> 治疗方法</h3> <p>如有需要，需对扭转，感染（尤其是淋病和衣原体感染），腹股沟疝和隐匿性创伤造成的急性阴囊疼痛进行检查。如未发现需紧急治疗的病症，以非甾体抗炎药（NSAID）治疗可能有效。[2]</p> <p>咨询和指导实施更安全的翻折隐藏方法可能是对被认为与这种做法有关的疼痛的最有效缓解。其中可包括缩短翻折时间或降低紧绷程度。在医学上需要时准备进行性别重置手术，包括睾丸切除术和阴道成形术，也可使此问题最小化。</p> <p>针对非跨性别男性慢性坐骨神经痛的疗法，通常建议实施抗生素治疗（在尝试诊断病因后）并且不鼓励将睾丸切除术作为最后手段。此疗法可能不适合跨性别女性。患者通常会出现性别焦虑，并可能因进行睾丸切除术而得到缓解（与非跨性别男性相反，其在需要进行单侧睾丸切除术时常表现抗拒）；在此些情况下，疗法中睾丸切除术的优先级会提高更多。当未需睾丸切除术时，治疗神经性疼痛的药物可能起作用。与开始激素治疗相关的疼痛通常是良性的，可自发改善，并且可以依期望安心治疗。[1,3]</p> <p>所有提供者都应意识到对生殖器的体检可能会对跨性别女性造成创伤，必要时须敏感谨慎。提供者不应轻视跨性别者的睾丸疼痛症状，也不应先行持有任何认为此问题的跨性别女性患者都希望切除睾丸的观点。</p> <h3 id="参考文献-17"><a href="#参考文献-17" class="header-anchor">#</a> 参考文献</h3> <ol><li>Keoghane SR, Sullivan ME. Investigating and managing chronic scrotal pain. BMJ. 2010;341:c6716.</li> <li>Williams DH. How to manage testicular/groin pain: medical and surgical ladder. Urology Times [Internet]. 2014 Jul 24 [cited 2016 Jan 29]; Available from: http://urologytimes.modernmedicine.com/urology-times/content/tags/christopher-m- gonzalez/how-manage-testiculargroin-pain-medical-and-surgic</li> <li>Levine L. Chronic orchialgia: evaluation and discussion of treatment options. Ther Adv Urol. 2010 Oct;2(5-06):209–14.</li></ol> <h2 id="无定形硅胶和其他填充物使用"><a href="#无定形硅胶和其他填充物使用" class="header-anchor">#</a> 无定形硅胶和其他填充物使用</h2> <p>主要作者： Barry Zevin, MD and Madeline B. Deutsch, MD, MPH</p> <h3 id="概论-12"><a href="#概论-12" class="header-anchor">#</a> 概论</h3> <p>医用级硅胶起源于第二次世界大战后开发的飞机润滑剂；美国陆军员工注意到库存桶装陶氏™200硅胶润滑剂消失，从而追查到一些医疗提供者注射该材料。到20世纪60年代，陶氏化学™推出了纯化的医用有机硅（Dow 360），用作注射器润滑剂和药用载体。随后Dow 360的超说明书用药造成了许多不良后果，到20世纪70年代，已经通过了一些禁止开展此类注射的法律。[1]到20世纪90年代，一种更粘稠的有机硅材料（Silikon-1000）已被FDA批准用于玻璃体注射，且软组织注射被认为是“可接受的超说明书用药”。[1]医学上无定形硅胶注射的恰当使用包括由经训练的医生反复以&lt;0.1cc剂量注射，目的是导致局部纤维形成反应及胶原蛋白生长，最终导致皮下轮廓的变化。[2]此方法已在对HIV相关脂肪营养不良的治疗中得到描述。[2]</p> <p>在跨性别健康的背景下，“硅胶注入”实际上是指许多软组织填充物中的任一种，通常由无资质或不道德的医疗提供者注射。注入物的实际成分通常未知，且可能不是医用级别的；注射物质可能包括航空润滑剂，轮胎密封剂，窗口填缝剂，矿物油，甲基丙烯酸酯，凡士林或其他物质。[3]在无监督注射的情况下，注射量（1-3升或更多）远超获许可的医疗提供者可实施注射的量。此外，这些注射也可能缺乏消毒或预防栓塞的措施。许多跨性别女性可能从大型注射行为（“群体注射”）中获取大容量注入物。[4]在一些跨性别女性人群中，注入频率估计在20％至50％以上[5,6]。美国国外的数据来源包括秘鲁利马40%的跨性别女性[3]，和泰国一些大城市中68%的跨性别女性[7]。虽然软组织注入的大多数数据和先例都来自跨性别女性，但在跨性别男性中使用也是理论上可行的。</p> <h3 id="寻求软组织注入的动机"><a href="#寻求软组织注入的动机" class="header-anchor">#</a> 寻求软组织注入的动机</h3> <p>接受注入的动机可能包括对立即改变身体以缓解性别焦虑的强烈需求，特别是在其他治疗方式不可行，无法获取或被视为低效或缓慢的情况。即时结果可能会鼓励群体成员在出现任何不利影响迹象之前向同类推荐该过程。对跨性别女性使用硅胶的定性研究发现了此流行现象的四个因素：自我形象不佳，对硅胶的误解，在公共场合的不适（注入硅胶后快速且大范围的女性化改变有助于跨性别女性融合于人群或“过关”），及难以获取医保。[8]其他影响因素包括社群中缺乏总体的风险意识，同侪压力，为生存而女性化以支撑性工作，以及为保留勃起功能而实现无激素女性化的能力。[9]</p> <h3 id="并发症及不良反应"><a href="#并发症及不良反应" class="header-anchor">#</a> 并发症及不良反应</h3> <p>并发症可根据发病时间（即时，早期，延迟/后期）和影响部位（局部，远端，全身）进行分类。[10-12]</p> <p>硅胶和其他物质的即时不良反应包括硅胶栓塞，出血，疼痛和局灶性糜烂和坏死。局部皮肤也可能出现丘疹和过敏反应。肺部的硅胶栓塞可能导致成人呼吸窘迫综合征（ARDS）甚至死亡。一些患者由于此情况而出现多系统衰竭，伴有严重残疾，包括失去四肢等后遗症[11,13-18]。</p> <p>注入后数天或数周的早期不良反应包括由于常见皮肤和软组织病原体以及非典型分枝杆菌感染的炎性结节，并且可能出现波动。非炎症性结节也可能导致疼痛，瘙痒和色素沉着异常[18,19]。血管神经性水肿也可能出现。</p> <p>注射后数周至数年发生的长期不良反应包括硅胶移动以及相关的疼痛或畸形。可能发生局部或远端炎症性和非炎性结节；有些可能演变成无菌脓肿或瘘管。可能出现硅胶肉芽肿，伴有疼痛，肿胀，溃疡，淋巴结病及可能的全身性症状。活组织检查显示异物肉芽肿，伴有白色空泡和周边炎症细胞。这些病变的发病机制可能包括T细胞活化和生物膜的存在。其他潜在的并发症包括继发性淋巴水肿，毛细血管扩张和持续性红斑。[18]</p> <p>主要的全身并发症包括全身炎症反应综合征（SIRS）/ARDS，败血症，栓塞，过敏性肺炎，免疫重建炎症综合征（IRIS）或高钙血症[14,18,20]。由于直接的占位效应（mass effect），也可能出现器官衰竭。</p> <h3 id="诊断"><a href="#诊断" class="header-anchor">#</a> 诊断</h3> <p>详细病史可帮助识别任何先前的软组织注射或使用的风险因素。患者可能对于表述先前的医疗程序犹豫不决。超声，CT或MRI可能是有用的辅助手段。乳房X线成像术可能对以前填充过的乳房无效。对于有大量注射史的患者，软组织超声检查可能是指导注射治疗梅毒，淋病，HIV（恩夫韦肽）或疫苗的有效工具。[21]</p> <p>**预防：**尚未对防止医学上无监督使用软组织填充物的最佳实施方法进行研究。可能减少无资质硅胶注射流行的策略包括：对跨性别女性进行风险和使用替代品的教育，以及提供更常规的性别认同治疗，如激素治疗和手术。利用同伴倡导或促进健康的群体层面干预措施可能比提供者的干预措施更有效。</p> <p>**治疗方法：**对软组织注射相关的急性紧急情况的成功治疗需快速识别并应用重症监护。由于患者对寻求护理犹豫不决，或报告其接受了软组织注射，以及提供者未能识别紧急情况并了解必要的治疗，因此可能出现延迟。</p> <p>对大多数并发症的处理是支持性和症状驱动的。由于额外的抗炎特性，米诺环素在感染方面有作为一线抗生素的前景。[12]可能需要使用手术切除和重建皮瓣/移植物。[22]对于无定形硅胶在整个乳房中出现扩散的患者，可能需要进行完整的乳房切除术和乳房重塑。[23,24]其他可行的方法包括病灶内皮质类固醇注射，局部用咪喹莫特或每周两次依那西普25mg皮下注射。[19]。吸脂术在过去已有叙述，但不太可能利于患者。[25]</p> <h3 id="参考文献-18"><a href="#参考文献-18" class="header-anchor">#</a> 参考文献</h3> <ol><li>Chasan PE. The history of injectable silicone fluids for soft-tissue augmentation. Plast Reconstr Surg. 2007 Dec;120(7):2034–40.</li> <li>Narins RS, Beer K. Liquid injectable silicone: a review of its history, immunology, technical considerations, complications, and potential. Plast Reconstr Surg. 2006 Sep;118(3 Suppl):77S – 84S.</li> <li>Silva-Santisteban A, Raymond HF, Salazar X, Villayzan J, Leon S, McFarland W, et al. Understanding the HIV/AIDS epidemic in transgender women of Lima, Peru: results from a sero-epidemiologic study using respondent driven sampling. AIDS Behav. 2012;1–10.</li> <li>Wallace PM, Rasmussen S. Analysis of adulterated silicone: implications for health promotion. Int J Transgenderism. 2010 Oct 12;12(3):167–75.</li> <li>Xavier JM, Bobbin M, Singer B, Budd E. A needs assessment of transgendered people of color living in Washington, DC. Int J Transgenderism. 2005;8(2-3):31–47.</li> <li>Nemoto T, Operario D, Keatley J. Health and social services for male-to-female transgender persons of color in San Francisco. Int J Transgenderism. 2005;8(2-3):5–19.</li> <li>Guadamuz TE, Wimonsate W, Varangrat A, Phanuphak P, Jommaroeng R, McNicholl JM, et al. HIV prevalence, risk behavior, hormone use and surgical history among transgender persons in Thailand. AIDS Behav. 2011;15(3):650–8.</li> <li>Wallace PM. Finding self: A qualitative study of transgender, transitioning, and adulterated silicone. Health Educ J. 2010 Sep 21;0017896910384317.</li> <li>Wilson E, Rapues J, Jin H, Raymond HF. The use and correlates of illicit silicone or “fillers” in a population-based sample of transwomen, San Francisco, 2013. J Sex Med. 2014 Jul;11(7):1717–24.</li> <li>Shvartsbeyn M, Rapkiewicz A. Silicon-associated subcutaneous lesion presenting as a mass: a confounding histopathologic correlation. Hum Pathol. 2011 Sep;42(9):1364–7.</li> <li>Clark RF, Cantrell FL, Pacal A, chen W, Betten DP. Subcutaneous silicone injection leading to multi-system organ failure. Clin Toxicol. 2008 Jan;46(9):834–7.</li> <li>Silva MM, Modolin M, Faintuch J, Yamaguchi CM, Zandona CB, Cintra W, et al. Systemic inflammatory reaction after silicone breast implant. Aesthetic Plast Surg. 2011 Mar 18;35(5):789–94.</li> <li>Bartsich S, Wu JK. Silicon emboli syndrome: A sequela of clandestine liquid silicone injections. A case report and review of the literature. J Plast Reconstr Aesthet Surg. 2010 Jan;63(1):e1–3.</li> <li>Hariri LP, Gaissert HA, Brown R, Ciaranello A, Greene RE, Selig MK, et al. Progressive granulomatous pneumonitis in response to cosmetic subcutaneous silicone injections in a patient with HIV-1 infection: case report and review of the literature. Arch Pathol Lab Med. 2012;136(2):204–7.</li> <li>Price EA, Schueler H, Perper JA. Massive systemic silicone embolism: a case report and review of literature. Am J Forensic Med Pathol. 2006 Jun;27(2):97–102.</li> <li>Smith SW, Graber NM, Johnson RC, Barr JR, Hoffman RS, Nelson LS. Multisystem organ failure after large volume injection of castor oil. Ann Plast Surg. 2009 Jan;62(1):12–4.</li> <li>Hage JJ, Kanhai RC, Oen AL, van Diest PJ, Karim RB. The devastating outcome of massive subcutaneous injection of highly viscous fluids in male-to-female transsexuals. Plast Reconstr Surg. 2001 Mar;107(3):734–41.</li> <li>Styperek A, Bayers S, Beer M, Beer K. Nonmedical-grade injections of permanent fillers: medical and medicolegal considerations. J Clin Aesthetic Dermatol. 2013 Apr;6(4):22–9.</li> <li>Paul S, Goyal A, Duncan LM, Smith GP. Granulomatous reaction to liquid injectable silicone for gluteal enhancement: review of management options and success of doxycycline. Dermatol Ther. 2015 Apr;28(2):98–101.</li> <li>Visnyei K, Samuel M, Heacock L, Cortes JA. Hypercalcemia in a male-to-female transgender patient after body contouring injections: a case report. J Med Case Reports. 2014;8:71.</li> <li>Gabrielli E, Ferraioli G, Ferraris L, Riva A, Galli M, Filice C, et al. Enfuvirtide administration in HIV-positive transgender patient with soft tissue augmentation: U.S. evaluation. New Microbiol. 2010 Jul;33(3):263–5.</li> <li>Loustau HD, Mayer HF, Catterino L. Dermolipectomy of the thighs and buttocks to solve a massive silicone oil injection. Aesthetic Plast Surg. 2008 Aug 14;33(4):657–60.</li> <li>Cárdenas-Camarena L. Managing the mammary gland infiltrated with foreign substances: different surgical alternatives. Ann Plast Surg. 2009 Jun;62(6):621–6.</li> <li>Echo A, Otake LR, Mehrara BJ, Kraneburg UM, Agrawal N, Da Lio AL, et al. Surgical management of silicone mastitis: case series and review of the literature. Aesthetic Plast Surg. 2013 Aug;37(4):738–45.</li> <li>Zandi I. Failure to remove soft tissue injected with liquid silicone with use of suction and honesty in scientific medical reports. Plast Reconstr Surg. 2000;105(4):1555.</li></ol> <h2 id="跨性别人群的生育选项"><a href="#跨性别人群的生育选项" class="header-anchor">#</a> 跨性别人群的生育选项</h2> <p>主要作者： Paula Amato, MD</p> <h3 id="概论-13"><a href="#概论-13" class="header-anchor">#</a> 概论</h3> <p>跨性别者和非跨性别者一样具有相同的生殖愿望。尽管数据有限，但没有证据表明跨性别父母的孩子会以任何独特的方式受到伤害。[1]<strong>建议在过渡之前，向所有跨性别者提供关于过渡对其生育能力的影响以及生育能力保存和生殖选项的建议（分级：T O S）。</strong>[2,3]</p> <p>外源性激素和性腺切除术（切除睾丸或卵巢）对生育能力有明显影响。在已经开始过渡并保留其性腺的跨性别者中的生殖通常涉及停止外源激素，尽管在激素疗法存在下可以继续排卵和精子发生。如果一个人没有经历过性腺切除术，并且如果初步评估表明没有排卵或精子发生，那么在停止激素治疗一段时间后可能恢复生育能力。有趣的是，恢复生育的时间可能在3-6个月之间，但有些人可能会经历永久性的生育能力丧失，或需要如下所述的辅助技术。</p> <p><strong>因为在接受激素治疗的跨性别者中，不育不是绝对的或普遍的，所有有性腺并进行可能导致怀孕的性行为的跨性别者应该被告知需要避孕。单独的激素替代治疗不是一种可靠的避孕方法，睾酮是妊娠期禁忌的致畸因子。目前尚不清楚妊娠前跨性别男性的睾酮冲洗期有多长（分级：X C S）。</strong></p> <p>保留生育能力的选择可能包括精子，卵母细胞，胚胎，卵巢组织或睾丸组织冷冻保存。[4]这些类似于经历性腺毒性癌症治疗或由于社会原因而选择性保留生育能力的男性和女性可用的选项。</p> <p>辅助生殖可能包括全方位的生育服务。长期激素暴露是否给正在接受辅助生殖程序的患者带来任何独特的医疗风险，或者对生殖细胞和未来后代的任何长期影响目前都是未知的。应该告知使用生育能力保存或辅助生殖方法的跨性别患者目前尚缺乏结果的相关数据。</p> <h3 id="跨性别女性的生殖选项"><a href="#跨性别女性的生殖选项" class="header-anchor">#</a> 跨性别女性的生殖选项</h3> <p>在跨性别女性中，研究表明睾丸长期接触雌激素与睾丸损伤有关[2]。然而，长期雌激素治疗后精子发生的恢复尚未得到很好的研究。[2]跨性别女性保留生育能力最成功的选择是在激素治疗开始前对精子进行冷冻保存。枸橼酸氯米芬或hCG注射有时用于刺激精子发生。最近报道的几例子宫移植到非跨性别女性的病例代表了未来潜在的选择，但这项技术仍处于初期阶段。</p> <h3 id="跨性别男性的生殖选项"><a href="#跨性别男性的生殖选项" class="header-anchor">#</a> 跨性别男性的生殖选项</h3> <p>外源性睾酮长期治疗对卵巢功能的影响尚不清楚。睾酮治疗通常会导致无排卵状态和闭经。这在停止睾酮治疗后通常是可逆的，并且在长期睾酮治疗后的怀孕已有报道。</p> <p>跨性别男性的生育保存选择包括卵母细胞冷冻保存，胚胎冷冻保存和卵巢组织冷冻保存。之后可以使用患者的子宫或通过转移到女性伴侣或其他妊娠载体中将冻融的卵母细胞或胚胎用于妊娠建立。虽然缺乏可靠的数据，但已经开始过渡的跨性别男性已经能够停止睾酮治疗并接受精子或IVF的授精，并将胚胎移植到患者的子宫，女性伴侣或其他妊娠载体身上。</p> <p>最近发表的一份报告调查了开始使用睾酮后经历了怀孕的跨性别男性。[5]80%在恢复睾酮后6个月内恢复月经。7％的人进行了生育治疗。睾酮和非睾酮使用者的产科结局相似，但目前尚不清楚参与睾酮使用的受试者是否在受孕时和怀孕期间接受睾酮。该研究的参与者也表达了对更多支持性资源的渴望，并且报告医疗提供者缺乏对跨性别患者生育能力的认识和知识。三分之一的怀孕是无计划的，但目前尚不清楚这些意外怀孕中有多少发生在正在使用睾酮的情况下。然而，这些发现凸显了一些患者对避孕的需求。</p> <p>卵巢组织冷冻保存目前仍被认为是实验性的。全世界已经报道了几例在自体移植冷冻保存的卵巢组织后的活产。[6,7]然而，尚未报道任何在冻融卵巢组织碎片来源的卵母细胞的体外成熟情况下的活产。通过干细胞技术创建生殖细胞的研究也在进行中。</p> <p>还应告知所有患者这些辅助生殖选项费用昂贵且通常不在保险范围内。应为那些寻求或需要此类服务的追求生殖选项的跨性别者提供心理健康咨询和支持。</p> <h3 id="儿童和青少年的生育能力保存"><a href="#儿童和青少年的生育能力保存" class="header-anchor">#</a> 儿童和青少年的生育能力保存</h3> <p>建议跨性别儿童和青少年及其监护人在开始青春期抑制和激素替代治疗之前，了解和咨询有关保留生育能力的方案。在已经开始先天性青春期的儿童中，保留生育能力的选择包括精子、卵母细胞和胚胎冷冻保存。目前，未经历过先天性青春期（并且可能使用过激素替代治疗）的儿童尚无法保存生殖细胞。</p> <p>使用促性腺激素释放激素（GnRH）类似物的长期青春期抑制通常是可逆的，并且不应该在停止时损害青春期的恢复，尽管大多数接受青春期抑制的儿童继续开始激素替代治疗而不经历先天性青春期。</p> <p>关于青春期抑制的进一步讨论以及在法定成年年龄之前进行性腺切除术的决定包含在跨性别儿童和青少年的指南中。</p> <h3 id="参考文献-19"><a href="#参考文献-19" class="header-anchor">#</a> 参考文献</h3> <ol><li>Ethics Committee of the American Society for Reproductive Medicine. Access to fertility services by transgender persons: an Ethics Committee opinion. Fertil Steril. 2015 Nov;104(5):1111–5.</li> <li>Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ 3rd, Spack NP, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009 Sep;94(9):3132–54.</li> <li>World Professional Association for Transgender Health (WPATH). [Standards of care for](http://www.wpath.org/uploaded_files/140/files/Standards of Care%2C V7 Full Book.pdf) [the health of transsexual, transgender, and gender non-conforming people, 7th Version](http://www.wpath.org/uploaded_files/140/files/Standards of Care%2C V7 Full Book.pdf) [Internet]. WPATH; 2012 [cited 2016 Mar 10]. Available from: [http://www.wpath.org/uploaded_files/140/files/Standards%20of%20Care,%20V7%20Full%](http://www.wpath.org/uploaded_files/140/files/Standards of Care%2C V7 Full%) 20Book.pdf</li> <li>TʼSjoen G, Van Caenegem E, Wierckx K. Transgenderism and reproduction. Curr Opin Endocrinol Diabetes Obes. 2013 Dec;20(6):575–9.</li> <li>Light AD, Obedin-Maliver J, Sevelius JM, Kerns JL. Transgender men who experienced pregnancy after female-to-male gender transitioning. Obstet Gynecol. 2014 Dec;124(6):1120–7.</li> <li>Donnez J, Silber S, Andersen CY, Demeestere I, Piver P, Meirow D, et al. Children born after autotransplantation of cryopreserved ovarian tissue. a review of 13 live births. Ann Med. 2011;43(6):437–50.</li> <li>Dittrich R, Hackl J, Lotz L, Hoffmann I, Beckmann MW. Pregnancies and live births after 20 transplantations of cryopreserved ovarian tissue in a single center. Fertil Steril. 2015 Feb;103(2):462–8.</li></ol> <h2 id="跨性别人群中癌症筛查的一般方法"><a href="#跨性别人群中癌症筛查的一般方法" class="header-anchor">#</a> 跨性别人群中癌症筛查的一般方法</h2> <p>主要作者： Madeline B. Deutsch, MD, MPH</p> <p>长期随访病例对照研究未发现接受激素治疗的转诊患者与对照组相比癌症发病率存在差异，但这些研究存在许多局限性。[1,2]缺乏足够的证据来确定跨性别者整体以及器官特异性的癌症风险是否增加或减少。初级护理提供者应根据现行指南对所有跨性别患者进行基于器官的常规癌症筛查，作为综合初级护理的一个组成部分。**通常，如果个体具有特定的身体部位或器官，并且基于风险因素或症状符合筛查标准，则无论激素使用如何都应进行筛查（分级：X C S）。**因此，持续和彻底地了解医疗和手术史对于确定个体患者的筛查需求至关重要。</p> <h3 id="参考文献-20"><a href="#参考文献-20" class="header-anchor">#</a> 参考文献</h3> <ol><li>Wierckx K, Elaut E, Declercq E, Heylens G, De Cuypere G, Taes Y, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. Eur J Endocrinol Eur Fed Endocr Soc. 2013 Oct;169(4):471–8.</li> <li>Wierckx K, Mueller S, Weyers S, Van Caenegem E, Roef G, Heylens G, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med. 2012 Oct 1;9(10):2641–51.</li></ol> <h2 id="跨性别女性中的乳腺癌筛查"><a href="#跨性别女性中的乳腺癌筛查" class="header-anchor">#</a> 跨性别女性中的乳腺癌筛查</h2> <p>主要作者： Madeline B. Deutsch, MD, MPH</p> <h3 id="概论-14"><a href="#概论-14" class="header-anchor">#</a> 概论</h3> <p>由于在非跨性别女性中对乳腺癌筛查缺乏共识，因此筛查建议如何适用于跨性别女性的问题颇为复杂。现有的建议在每一个关键考虑因素中都有很大差异，并且随医疗组织兴趣和地域的不同存在差异。[1-7]</p> <p>理想的乳腺癌筛查建议可以最大限度地减少死亡率和漏诊，同时避免过度筛查，以避免不必要的后续检查，情绪困扰以及潜在的侵入性活检和其他程序的固有风险。值得注意的是，阳性预测值（PPV）定义为筛查结果为阳性时实际患病的概率（与假阳性相反），因此会随着特定人群中疾病的流行率下降而下降。</p> <h3 id="跨性别女性中的乳腺癌风险"><a href="#跨性别女性中的乳腺癌风险" class="header-anchor">#</a> 跨性别女性中的乳腺癌风险</h3> <p>在跨性别女性中，可能导致乳腺癌风险降低的因素包括可能较少的终生或周期性暴露于雌激素的时间，以及在某些情况下会缺乏或极少接触孕酮。然而，跨性别女性中致密乳房的发病率高，这是一项与乳腺癌的独立风险因素，而且是乳房X线照相检查中假阴性率增加的预测因素；荷兰对50名跨性别女性的研究发现，60％的人在乳房X线照相检查中呈现“致密”或“非常致密”的乳房。[8]</p> <p>关于跨性别女性的现有回顾性数据有矛盾的发现。已经报道了两项回顾性的基于人群的跨性别女性乳腺癌研究；两者均仅报告了作为常规临床护理的一部分被检测到的乳腺癌病例，而不是通过结构化的、广泛的筛查计划。在一个中心接受治疗的2,307名荷兰跨性别女性的回顾性研究发现，与荷兰非跨性别女性一般人群155/100,000人年的发病率相比，估计发病率为4.1/100,000人年。[9]对美国退伍军人管理医疗保健系统中3,566名跨性别女性接受治疗的回顾性研究共发现3例，从而可以得到与非跨性别女性相比不显著的标准化发病率：0.7（95%置信区间 0.03-5.57）；而与非跨性别男性相比，标准化发病率显著：33.3（95%置信区间21.9-45.1）。[10]目前尚不清楚有多少乳腺癌病例在这两个人群中未被发现，然后因其他原因而无法得到随访或死亡（已知在跨性别女性中较高）。[11]</p> <p>跨性别女性的乳腺癌数据仅限于上述研究以及若干病例报告，并且总体上可以确定风险不高，且可能低于非跨性别女性人群。</p> <h3 id="考虑开始筛查的年龄"><a href="#考虑开始筛查的年龄" class="header-anchor">#</a> 考虑开始筛查的年龄</h3> <p>仅有的50岁以下女性进行乳房X线照相术的大规模研究在英国基于160,921名女性进行，结果发现整体乳腺癌死亡率无差异。[12]鉴于50岁以前进行筛查得到的无差别结果和跨性别女性中可能较低的发病率，建议在50岁之前不要开始对跨性别女性的乳房X射线检查。</p> <h3 id="使用女性化激素的时长"><a href="#使用女性化激素的时长" class="header-anchor">#</a> 使用女性化激素的时长</h3> <p>跨性别女性在接触雌激素的长度以及接触孕激素的不同程度方面与非跨性别女性不同。因此，建议不论年龄大小，都不要在使用女性化激素5年以内对跨性别女性开始筛查。一些医疗提供者可能会选择与患者讨论风险和未知因素，并延迟筛查至女性化激素使用达到10年后，无论年龄大小。请注意，50岁以上的跨性别女性在使用雌激素至少5-10年之前不符合筛查标准。</p> <h3 id="筛查频率"><a href="#筛查频率" class="header-anchor">#</a> 筛查频率</h3> <p>针对非跨性别女性的现有建议中筛查频率不一。与发病年龄一样，鉴于跨性别女性的发病率可能较低，**一旦达到50岁和5-10年的女性化激素使用标准，建议每2年进行一次乳房X射线检查。医疗提供者和患者应参与包括过度筛查的风险和个体风险因素评估（分级：T O W）的讨论。**当用于跨性别女性时，诸如GAIL方法等风险分数计算器可能是不可靠的。</p> <h3 id="筛查方式-2"><a href="#筛查方式-2" class="header-anchor">#</a> 筛查方式</h3> <p>**乳房X线照相筛查是跨性别女性乳腺癌筛查的主要推荐方式。**跨性别女性经常关注她们的乳房外观和发育，并且可能经常进行未经指导的自我检查。早期乳房发育可能与乳房疼痛，压痛和结节有关联。</p> <p>跨性别女性可能会因这些症状要求进行乳房检查，或者可能会发现乳房检查起到性别肯定的作用。因此，提供者可能会考虑定期进行临床乳房检查，和/或与患者针对对乳房的一般性关注和乳房健康进行讨论，但与非跨性别女性一样，不推荐跨性别女性以[13]临床医师正式进行或自行进行的乳房检查达到乳腺癌筛查的目的。</p> <h3 id="特殊考虑因素-2"><a href="#特殊考虑因素-2" class="header-anchor">#</a> 特殊考虑因素</h3> <p>与非跨性别女性一样，临床医生可以在具有显著家庭危险因素的患者中选择降低开始筛查的年龄，所需接触雌性激素的年数或筛查间隔。具有暗示（或已知）BRCA突变的家族史的跨性别女性应该转介进行遗传咨询。没有数据可用于指导在发现具有BRCA突变的跨性别女性中使用雌激素。有BRCA突变的非跨性别男性患乳腺癌风险的数据较为有限，BRCA-1的数据表明终生风险为1.2-5.8％[14-16]，而BRCA-2的数据表明终生风险为6.8％。具有BRCA突变的非跨性别女性的风险要高得多，终生风险为78％。[14,17]目前尚不清楚具有BRCA-1突变并使用雌激素的跨性别女性是否具有高于非跨性别男性的风险，以及接触雌激素的开始年龄和总时长可能起什么作用。一个具有BRCA-1突变的跨性别女性的单个病例报告涉及在知情同意下继续使用雌激素。[18]</p> <p>一项针对在美国大型城市社区健康中心患者接受治疗的1263名跨性别女性的回顾性队列研究发现，年龄在50到74岁之间且有至少5年激素治疗史的跨性别人群按照指南接受乳房X射线检查的可能性显著低于非跨性别群体（AOR = 0.53；95％置信区间 0.31-0.91）。[19]需要进一步研究以了解构成这种差异的障碍和其他因素。</p> <h3 id="参考文献-21"><a href="#参考文献-21" class="header-anchor">#</a> 参考文献</h3> <ol><li><a href="http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/breast-cancer-screening" target="_blank" rel="noopener noreferrer">U.S. Preventive Services Task Force: Final Update Summary Breast Cancer Screening<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. [cited 2016 Jan 28]. Available from: http://www.uspreventiveservicestaskforce.org/ Page/Document/UpdateSummaryFinal/breast-cancer-screening</li> <li><a href="http://canadiantaskforce.ca/ctfphc-guidelines/2011-breast-cancer/" target="_blank" rel="noopener noreferrer">Canadian Task Force on Preventative Care: Screening for Breast Cancer<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> (2011) [Internet]. [cited 2016 Jan 28]. Available from: http://canadiantaskforce.ca/ctfphc-guidelines/2011-breast-cancer/</li> <li>American College of Obstetricians-Gynecologists. Practice bulletin no. 122: Breast cancer screening. Obstet Gynecol. 2011 Aug;118(2 Pt 1):372–82.</li> <li>American Academy of Family Physicians (AAFP): <a href="http://www.aafp.org/patient-care/clinical-recommendations/all/breast-cancer.html" target="_blank" rel="noopener noreferrer">Breast Cancer<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. [cited 2016 Jan 28]. Available from: http://www.aafp.org/patient-care/clinical-recommendations/all/breast-cancer.html</li> <li><a href="http://www.cancer.org/healthy/findcancerearly/cancerscreeningguidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer" target="_blank" rel="noopener noreferrer">American Cancer Society Guidelines for the Early Detection of Cancer<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. [cited 2016 Jan 28]. Available from: http://www.cancer.org/healthy/findcancerearly/cancerscreeningguidelines/ american-cancer-society-guidelines-for-the-early-detection-of-cancer</li> <li><a href="http://www.acr.org/~/media/ACR/Documents/AppCriteria/Diagnostic/BreastCancerScreening.pdf" target="_blank" rel="noopener noreferrer">American College of Radiology: ACR Appropriateness Criteria (Breast Cancer Screening)<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. [cited 2016 Jan 28]. Available from: http://www.acr.org/~/media/ACR/Documents/AppCriteria/Diagnostic/BreastCancerScreening.pdf</li> <li>American Cancer Society recommendations for early breast cancer detection in women without breast symptoms [Internet]. [cited 2016 Jan 28]. Available from: http://www.cancer.org/ cancer/breastcancer/moreinformation/breastcancerearlydetection/breast-cancer-early-detection-acs-recs</li> <li>Weyers S, Villeirs G, Vanherreweghe E, Verstraelen H, Monstrey S, Van den Broecke R, et al. Mammography and breast sonography in transsexual women. Eur J Radiol. 2010 Jun;74(3):508–13.</li> <li>Gooren LJ, van Trotsenburg MAA, Giltay EJ, van Diest PJ. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med. 2013 Dec;10(12):3129–34.</li> <li>Brown GR, Jones KT. Incidence of breast cancer in a cohort of 5,135 transgender veterans. Breast Cancer Res Treat. 2015 Jan;149(1):191–8.</li> <li>Asscheman H, Giltay EJ, Megens JAJ, de Ronde W, van Trotsenburg MAA, Gooren LJG. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011 Jan 25;164(4):635–42.</li> <li>Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years’ follow-up: a randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1123–32.</li> <li>Oeffinger KC, Fontham EH, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the american cancer society. JAMA. 2015 Oct 20;314(15):1599–614.</li> <li>Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002 Sep 18;94(18):1365–72.</li> <li>Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2007 Dec 5;99(23):1811–4.</li> <li>Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol Off J Am Soc Clin Oncol. 2004 Feb 15;22(4):735–42.</li> <li>Byrd LM, Shenton A, Maher ER, Woodward E, Belk R, Lim C, et al. Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2008 Jun;17(6):1535–42.</li> <li>Colebunders B, T’Sjoen G, Weyers S, Monstrey S. Hormonal and surgical treatment in trans-women with BRCA1 mutations: a controversial topic. J Sex Med. 2014 Oct;11(10):2496–9.</li> <li>Bazzi AR, Whorms DS, King DS, Potter J. Adherence to mammography screening guidelines among transgender persons and sexual minority women. Am J Public Health. 2015 Nov;105(11):2356–8.</li></ol> <h2 id="跨性别女性中的前列腺和睾丸癌考虑因素"><a href="#跨性别女性中的前列腺和睾丸癌考虑因素" class="header-anchor">#</a> 跨性别女性中的前列腺和睾丸癌考虑因素</h2> <p>主要作者： Linda Wesp, MSN, NP-C</p> <h3 id="前列腺癌"><a href="#前列腺癌" class="header-anchor">#</a> 前列腺癌</h3> <p>有不同激素使用和手术史的跨性别女性患有前列腺癌的病例被报道。[1-3]大多数前列腺癌病例发生在50岁以后开始激素治疗的个体中；这些病例实际上可能是隐匿性肿瘤，这种肿瘤在激素治疗开始之前就已存在[4]。比利时经过阴道成形术的320名跨性别女性队列中，前列腺特异抗原（PSA）检查和经阴道超声检查以及前列腺的阴道指检显示PSA水平和前列腺体积低于相应年龄的非跨性别男性。[5]一些抗雄激素，如5-α还原酶抑制剂也被证实可以降低PSA。[6]除雌激素暴露外，切除性腺可能会降低患前列腺癌和良性前列腺肥大的风险[4,5]。</p> <p>无论如何，初级保健提供者应该继续意识到跨性别女性，即使是那些经历过性腺切除术的人，患有前列腺癌的可能性。在跨性别女性中进行前列腺癌筛查的决定应基于非跨性别男性的指导原则。如果指示前列腺检查，可以考虑通过直肠和新阴道方法。经过阴道成形术的跨性别女性前列腺位于阴道壁前方，通过新阴道的进行指检可能更有效。[5]应该注意的是，当PSA检查在具有低睾酮水平的跨性别女性中进行时，将正常上限降低至1.0ng/ml可能是适当的。[4]</p> <h3 id="睾丸癌"><a href="#睾丸癌" class="header-anchor">#</a> 睾丸癌</h3> <p>文献中报道了一例睾丸癌[7]。雄激素抑制可能会降低风险。不建议非跨性别男性进行常规睾丸癌筛查，并且没有证据表明在跨性别女性中需要此筛查。对于使用治疗剂量的雌激素以及雄激素拮抗剂而仍然有持续性睾酮升高的跨性别女性，应对睾丸肿瘤进行评估，方式有体检及检查人绒毛膜促性腺激素（hCG），甲胎蛋白（AFP）和乳酸脱氢酶（LDH）水平，及可能的阴囊超声波检查。</p> <h3 id="参考文献-22"><a href="#参考文献-22" class="header-anchor">#</a> 参考文献</h3> <ol><li>Miksad RA, Bubley G, Church P, Sanda M, Rofsky N, Kaplan I, et al. Prostate cancer in a transgender woman 41 years after initiation of feminization. JAMA. 2006 Nov 15;296(19):2316–7.</li> <li>Turo R, Jallad S, Prescott S, Cross WR. Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy. Can Urol Assoc J J Assoc Urol Can. 2013 Aug;7(7-8):E544–6.</li> <li>Dorff TB, Shazer RL, Nepomuceno EM, Tucker SJ. Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient. Clin Genitourin Cancer. 2007 Jun;5(5):344–6.</li> <li>Trum HW, Hoebeke P, Gooren LJ. Sex reassignment of transsexual people from a gynecologist’s and urologist’s perspective. Acta Obstet Gynecol Scand. 2015 Jun;94(6):563–7.</li> <li>Weyers S, De Sutter P, Hoebeke S, Monstrey G, ’T Sjoen G, Verstraelen H, et al. Gynaecological aspects of the treatment and follow-up of transsexual men and women. Facts Views Vis ObGyn. 2010;2(1):35–54.</li> <li>Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol. 2006 Sep;176(3):868–74.</li> <li>Wolf-Gould CS, Wolf-Gould CH. A transgender woman with testicular cancer: a new twist on an old problem. LGBT Health. 2015 Dec 24;</li></ol> <h2 id="跨性别男性的乳腺癌筛查"><a href="#跨性别男性的乳腺癌筛查" class="header-anchor">#</a> 跨性别男性的乳腺癌筛查</h2> <p>主要作者： Madeline B. Deutsch, MD, MPH</p> <p>未经过双侧乳房切除术或仅经过乳房缩小术的跨性别男性，应根据现行的非跨性别女性指南进行筛查。没有可靠的证据来指导接受乳房切除术的跨性别男性的筛查。由于大多数或几乎所有乳房组织被接触，因此用于评估可触及病变的乳房X线照相术可能技术上不可行，并且可能需要诸如超声或MRI之类的替代方案。乳房切除术后残留的乳房组织中乳腺癌的风险尚不明确。获得明确的手术史十分重要，因为一些患者可能仅进行了乳房缩小术。一些外科医生进行常规术前乳房X射线检查。一些指南建议在乳房切除术后的跨性别男性每年进行胸壁检查；然而该建议并非循证的，并且与通常非跨性别女性的临床检查排除因素（the move away）相冲突。</p> <p>诊断体检可能会让患者产生抱怨。<strong>临床医生应与已经接受双侧乳房切除术的跨性别男性进行对话，让他们了解与残留乳房组织相关的未知风险，以及乳房X线照相术可能的技术限制（分级：X C S）。</strong></p> <h2 id="跨性别男性的宫颈癌筛查"><a href="#跨性别男性的宫颈癌筛查" class="header-anchor">#</a> 跨性别男性的宫颈癌筛查</h2> <p>主要作者： Katherine T. Hsiao, MD, FACOG</p> <h3 id="概论-15"><a href="#概论-15" class="header-anchor">#</a> 概论</h3> <p>跨性别男性有患宫颈癌的风险。宫颈癌是全球第三大常见癌症[1]；其中99％以上是由人乳头瘤病毒（hr-HPV）的几种高风险致癌菌株感染之一引起的。[2]通过骨盆检查获得子宫颈涂片检查可能对跨性别患者具有挑战性。宫颈癌的筛查不充分与跨性别者在医疗保健方面面临的文化敏感性障碍有关。[3]跨性别男性比非跨性别女性更不愿意接受宫颈癌筛查。[4]从未或很少接受宫颈癌筛查的人如果被慢性hr-HPV感染，发展为恶性肿瘤，发病率和死亡率的风险最高。[5]</p> <p>据报告与非跨性别男性发生性关系的跨性别男性（trans MSM）在与伴侣口交，阴道和肛交期间不持续使用安全套，且患有hr-HPV感染和未检测到疾病进展的风险增加[6,7]。9至26岁之间的HPV疫苗接种可以显著降低宫颈癌，口腔癌和肛门癌的发病率[8-10]。非跨性别男性可以接受HPV疫苗接种，如果医疗机构提供这些服务，74％自我认定为同性恋或双性恋者的非跨性别男性愿意接种疫苗。[11,12]</p> <h3 id="筛查建议"><a href="#筛查建议" class="header-anchor">#</a> 筛查建议</h3> <p><strong>宫颈癌筛查绝不应成为睾酮治疗的必要条件。跨性别男性的宫颈癌筛查，包括筛查间隔和开始和结束筛查的年龄，遵循美国癌症协会，美国阴道镜检查和宫颈病理学会（ASCCP），美国临床医学会，病理学家，美国预防服务工作组（USPSTF）和世界卫生组织认可的对非跨性别女性的建议（分级：X C S）。</strong>[13-15]与非跨性别女性一样，21岁以下的跨性别男性不应该进行子宫颈涂片检查，不管他们开始性生活的年龄有多长。[13]与非跨性别女性相比，跨性别男性的子宫颈涂片检查坏片的可能性要高10倍，这与进行睾酮治疗的时间长度正相关。[16]如果注意到阴道和/或宫颈组织的红斑，则在排除睾酮介导的萎缩性宫颈阴道炎之前，需要评估通常的炎症原因。炎症可能使宫颈组织的细胞学评估模糊并导致结果不理想。此外，这类检查申请还应表明任何睾酮的使用和是否闭经，以方便病理学家可以准确地解释细胞形态。</p> <h3 id="改善患者体验"><a href="#改善患者体验" class="header-anchor">#</a> 改善患者体验</h3> <p>促进更具支持性和敏感的环境包括使用文化敏感的语言，在脱衣之前与患者交谈，并仅要求患者从腰部向下更衣。痛苦的宫颈涂片检查经历可能导致患者逃避前来接受筛查和阴道镜检查。[17]一些轶事技术可以减轻患者的疼痛，比如儿科窥镜可以使子宫颈可见，并可以减少检查的不适；然而，重要的是避免使用过短的窥器以使其需要过大的外部压力来使宫颈可见。将臀部移动到检查台的末端并鼓励患者骨盆松弛也可以增加舒适度并改善子宫颈的可见性。如果检查者注意到紧张或焦虑，花时间进行口头放松练习可能会有所帮助。温水可以用于在插入之前润滑狭窄的窥器，以最小化患者的不适和不安而不损害涂片结果；在窥器的外部使用少量的水基润滑剂可以减少患者的不适，同时最大限度地降低样品不符合标准的风险。[18,19]应避免过量的润滑剂；关于过量润滑剂对涂片结果的影响的研究结果相互冲突。一些临床医生发现，通过首先将一根或两根手指放在阴道中并且在要求患者弯曲和放松他们的骨盆底肌肉的同时从后面施加压力来插入窥器会让患者感到更加舒适。指检（非双合诊检查）也可以帮助确定子宫颈的位置并最小化窥器检查期间的操作。对无症状的患者进行标准的双合诊检查可能不会增加临床价值，并可能增加患者的不适。[20]减少不适的其他方法可包括允许患者自己插入窥器或使用镜子观察这个过程，在检查前给予口服苯二氮䓬类药物，或在检查前一周使用阴道雌激素。</p> <p>初步研究显示，与临床医生获得的样本相比，自行收集的HPV阴道样本同样有价值。这种方法对跨性别男性来说可能更容易接受。[21,22]未来HPV初步筛查对于跨性别男性也可以利用非阴道来源的标本；支持尿液HPV与宫颈HPV一致性的研究代表了一种潜在的非阴道分类方法。</p> <h3 id="参考文献-23"><a href="#参考文献-23" class="header-anchor">#</a> 参考文献</h3> <ol><li>Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Apr;61(2):69–90.</li> <li>Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep;189(1):12–9.</li> <li>Rachlin K, Green J, Lombardi E. Utilization of health care among female-to-male transgender individuals in the United States. J Homosex. 2008;54(3):243–58.</li> <li>Peitzmeier SM, Khullar K, Reisner SL, Potter J. Pap test use is lower among female-to- male patients than non-transgender women. Am J Prev Med. 2014 Dec;47(6):808–12.</li> <li>Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer. 2000 May 15;88(10):2283–9.</li> <li>Sevelius J. “There’s no pamphlet for the kind of sex I have”: HIV-related risk factors and protective behaviors among transgender men who have sex with nontransgender men. J Assoc Nurses AIDS Care JANAC. 2009 Oct;20(5):398–410.</li> <li>Herbst JH, Jacobs ED, Finlayson TJ, McKleroy VS, Neumann MS, Crepaz N, et al. Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. AIDS Behav. 2008 Jan;12(1):1–17.</li> <li>Moscicki A-B. Impact of HPV infection in adolescent populations. J Adolesc Health Off Publ Soc Adolesc Med. 2005 Dec;37(6 Suppl):S3–9.</li> <li>Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008 Nov 15;113(10 Suppl):3036–46.</li> <li>Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):626–9.</li> <li>Reiter PL, McRee A-L, Kadis JA, Brewer NT. HPV vaccine and adolescent males. Vaccine. 2011 Aug 5;29(34):5595–602.</li> <li>Reiter PL, Brewer NT, McRee A-L, Gilbert P, Smith JS. Acceptability of HPV vaccine among a national sample of gay and bisexual men. Sex Transm Dis. 2010 Mar;37(3):197–203.</li> <li>Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012 May;62(3):147–72.</li> <li>Moyer VA, U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012 Jun 19;156(12):880–91, W312.</li> <li>World Health Organization. Cervical Cancer Screening in Developing Countries: Report of a WHO Consultation. World Health Organization; 2002. 90 p.</li> <li>Peitzmeier SM, Reisner SL, Harigopal P, Potter J. Female-to-male patients have high prevalence of unsatisfactory Paps compared to non-transgender females: implications for cervical cancer screening. J Gen Intern Med. 2014 May;29(5):778–84.</li> <li>Brooks SE, Gordon NJ, Keller SJ, Thomas SK, Chen TT, Moses G. Association of knowledge, anxiety, and fear with adherence to follow up for colposcopy. J Low Genit Tract Dis. 2002 Jan;6(1):17–22.</li> <li>Hathaway JK, Pathak PK, Maney R. Is liquid-based pap testing affected by water-based lubricant? Obstet Gynecol. 2006 Jan;107(1):66–70.</li> <li>Holton T, Smith D, Terry M, Madgwick A, Levine T. The effect of lubricant contamination on ThinPrep (Cytyc) cervical cytology liquid-based preparations. Cytopathol Off J Br Soc Clin Cytol. 2008 Aug;19(4):236–43.</li> <li>Bates CK, Carroll N, Potter J. The challenging pelvic examination. J Gen Intern Med. 2011 Jun;26(6):651–7.</li> <li>Jacobson DL, Womack SD, Peralta L, Zenilman JM, Feroli K, Maehr J, et al. Concordance of human papillomavirus in the cervix and urine among inner city adolescents. Pediatr Infect Dis J. 2000 Aug;19(8):722–8.</li> <li>Sellors JW, Lorincz AT, Mahony JB, Mielzynska I, Lytwyn A, Roth P, et al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. Can Med Assoc J. 2000;163(5):513–8.</li></ol> <h2 id="跨性别男性卵巢癌和子宫内膜癌的考虑因素"><a href="#跨性别男性卵巢癌和子宫内膜癌的考虑因素" class="header-anchor">#</a> 跨性别男性卵巢癌和子宫内膜癌的考虑因素</h2> <p>主要作者： Linda Wesp, MSN, NP-C</p> <h3 id="子宫内膜癌"><a href="#子宫内膜癌" class="header-anchor">#</a> 子宫内膜癌</h3> <p>外源性睾酮的施用，及其通过芳香化而生成雌激素，以及由睾酮诱导的可能的无排卵状态，可能产生“非对抗性的”（unopposed）雌激素的激素环境。这就产生了子宫内膜增生或癌症的理论风险。尽管存在这种理论风险，但文献中仅存在一例子宫内膜样腺癌的病例报告。[1]两项研究表明，子宫内膜增生的风险较低，并且在睾酮治疗时，跨性别男性通常都会发生子宫内膜萎缩。一项观察性研究发现近半数（45％）跨性别睾酮治疗者在子宫切除术术后常规检查的组织学报告中发现子宫内膜萎缩。[2]另一项病例对照研究在至少使用雄激素一年后行子宫切除术的跨性别男样本性和绝经前和绝经后女性样本上比较组织病理学检查结果，发现跨性别男性有与绝经后女性相似的子宫内膜萎缩[3]。</p> <p>一些资料建议闭经的跨性别男性进行子宫内膜监测，每年进行盆腔超声检查，但这一建议并非基于证据，也可能是不切实际的，因为据报告跨性别男性由于医护者对跨性别缺乏文化理解而不愿接受妇科医疗护理。[4]</p> <p>**因此，不推荐使用睾酮的跨性别男性对子宫内膜癌进行常规筛查。应分析先前因睾酮诱导停经患者不明原因的阴道出血（在没有错过或改变睾酮剂量的情况下）（分级：X C M）。**对于这些患者，应当给予教育说明他们需要向他们的医护人员告知不明原因的阴道出血。</p> <p>**子宫切除术作为子宫内膜癌的一级预防措施，目前不被推荐（分级：X C M）；**为了消除宫颈癌筛查的需要，考虑子宫切除术可以逐案讨论，并注意到子宫切除术在减少性别焦虑中的作用，并考虑到手术风险和不可逆的不孕。</p> <h3 id="卵巢癌"><a href="#卵巢癌" class="header-anchor">#</a> 卵巢癌</h3> <p>虽然在跨性别男性中有几例卵巢癌病例报告[5,6]，但没有证据表明服用睾酮会增加风险。</p> <p>睾酮导致卵巢发生类似于多囊卵巢综合征（PCOS）的皮质层和鞘的增厚，但组织学上窦卵泡计数存在差异。[2,7]一些研究表明一些服用睾酮的跨性别男性PCOS患病率增加。[8-10]虽然历史上存在关于使用睾酮对跨性别男性患卵巢癌风险增加的担忧，但这些担忧主要基于睾酮引起PCOS样卵巢的不准确前提。此外，最近的数据驳斥了患有PCOS的非跨性别女性卵巢癌的存在增加风险的看法[11]。</p> <p>从初级保健的角度来看，在对于不超过平均风险的任何个体（即，已知的遗传或个人/家庭风险因素）中，没有可用于卵巢癌筛查的有效筛查算法。跨性别男性也同样应根据病史和现状考虑是否进行卵巢咨询和筛查。虽然在跨性别男性中单性或双侧卵巢切除术可以作为性别焦虑或病理过程管理的一部分执行，但不推荐常规卵巢切除术作为卵巢癌的一级预防措施。需要盆腔检查者如果已经接受了阴道切除但保留一个或两个卵巢/性腺，可通过经直肠或经腹超声检查进行评估。</p> <h3 id="参考文献-24"><a href="#参考文献-24" class="header-anchor">#</a> 参考文献</h3> <ol><li>Urban RR, Teng NNH, Kapp DS. Gynecologic malignancies in female-to-male transgender patients: the need of original gender surveillance. Am J Obstet Gynecol. 2011 May;204(5):e9–12.</li> <li>Grynberg M, Fanchin R, Dubost G, Colau J-C, Brémont-Weil C, Frydman R, et al. Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod Biomed Online. 2010 Apr;20(4):553–8.</li> <li>Perrone AM, Cerpolini S, Maria Salfi NC, Ceccarelli C, De Giorgi LB, Formelli G, et al. Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals. J Sex Med. 2009 Nov;6(11):3193–200.</li> <li>Reisner SL, Perkovich B, Mimiaga MJ. A mixed methods study of the sexual health needs of New England transmen who have sex with nontransgender men. AIDS Patient Care STDs. 2010 Aug;24(8):501–13.</li> <li>Dizon DS, Tejada-Berges T, Koelliker S, Steinhoff M, Granai CO. Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. Gynecol Obstet Invest. 2006;62(4):226–8.</li> <li>Hage JJ, Dekker JJ, Karim RB, Verheijen RH, Bloemena E. Ovarian cancer in female-to- male transsexuals: report of two cases. Gynecol Oncol. 2000 Mar;76(3):413–5.</li> <li>Gooren LJG, Giltay EJ. Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. J Sex Med. 2008 Apr;5(4):765–76.</li> <li>Balen AH, Schachter ME, Montgomery D, Reid RW, Jacobs HS. Polycystic ovaries are a common finding in untreated female to male transsexuals. Clin Endocrinol (Oxf). 1993 Mar;38(3):325–9.</li> <li>Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. J Clin Endocrinol Metab. 2008 Apr;93(4):1408–11.</li> <li>Baba T, Endo T, Honnma H, Kitajima Y, Hayashi T, Ikeda H, et al. Association between polycystic ovary syndrome and female-to-male transsexuality. Hum Reprod Oxf Engl. 2007 Apr;22(4):1011–6.</li> <li>Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014 Oct;20(5):748–58.</li></ol> <h2 id="跨性别及性别非常规人群的心理健康"><a href="#跨性别及性别非常规人群的心理健康" class="header-anchor">#</a> 跨性别及性别非常规人群的心理健康</h2> <p>主要作者： lore m. dickey, PhD; Dan H. Karasic, MD; Nathaniel G. Sharon, MD</p> <h3 id="初级护理下的心理健康"><a href="#初级护理下的心理健康" class="header-anchor">#</a> 初级护理下的心理健康</h3> <p>对于所有的跨性别患者而言，心理健康护理对于良好的身体健康状况至关重要，都应在初级护理中给予体现。跨性别者通常因病态化及遭到虐待而抗拒与心理健康提供者接触。[1,2]表明心理健康问题时，初级护理可为跨性别者提供更安全的环境，并且相比于常规心理医疗更易于获取。每次治疗都应含有患者的心理健康历史记录及对突出心理健康问题的评估。相应的检测应包括跨性别患者的首要心理健康问题、环境与社会压力因素及性别相关需求。确认有需要时，也应将患者转诊至合适的跨性别心理医疗服务机构。</p> <p>不应自动认为跨性别者存在的心理健康问题必定与性别认同相关。跨性别者可能出于多种因素而寻求心理健康护理；除与性别认同相关或由此产生的问题外，跨性别人士患有心境障碍及其他精神疾病的几率与常人相仿。部分跨性别患者可能寻求性别相关的特别协助，而其他患者也会因抑郁、焦虑及其他无关性别认同的临床症状求助。</p> <p>考虑到众多跨性别患者受到过来自人际关系和社会/医护的复杂创伤，在初级护理的实施中应运用创伤知情（trauma informed）的护理方法。对所有医护人员和服务提供者而言，培训此种护理方法可提升治疗的参与度及改善健康状况。[4] Machtinger及其同事在最近一篇文献中叙述了提供此类初级护理的理论体系[5]，体系模型的建立则基于有创伤经历的女性的医护需求。模型提出了建立初级护理环境的需求，患者的发现/检测，服务提供者对患者需求的反应，以及在所有规模的服务机构建立支持此类护理方法的机构理念。Machtinger及其同事亦说明，为了提倡强调创伤护理及患者反应的全面病史检测，有必要建立互相信任的环境。能够在保证患者隐私的场所与服务提供者对话，则是十分关键的。</p> <h3 id="跨性别人群对心理健康的主要需求"><a href="#跨性别人群对心理健康的主要需求" class="header-anchor">#</a> 跨性别人群对心理健康的主要需求</h3> <p>通常意义上，跨性别及非常规性别人士对心理健康的需求分为以下三种。</p> <ul><li><ul><li><ul><li><ol><li>性别认同的探索。这类包括决定个人的准确性别认同，在此性别认同下达成自我接纳与个性化，以及在外界环境中逐步实现此认同的个人方式的探索。这也可包括多种对性别认同医护治疗过程的准备和评估。</li> <li>出柜和社会性别过渡，包括向家人、朋友及同事出柜，处理约会及人际关系，并且寻求应对在可能恐跨的环境下作为跨性别者生活的方法。</li> <li>可能与性别认同无关的常规心理健康需求。跨性别者经历的心理疾病种类包括心境障碍，广泛性焦虑症，物质滥用及创伤后应激障碍（PTSD）。[6]</li></ol></li></ul></li></ul></li></ul> <p>跨性别人士可能在意识到性别认同与生理性别不符，或无法承受身心性别不一致带来的焦虑时，向医疗机构寻求医护服务。不同患者出现此意识的年龄，以及开始寻求医护的年龄均有很大区别。不应认为较晚出现这样的意识，或较晚开始寻求医护是个体“跨性别程度浅”的体现。[1]</p> <p>因无法如同女/男同性恋及双性恋（LGB）人士隐藏自身的性取向，跨性别人士的出柜过程会较LGB人士困难。跨性别人士社会角色和生理过渡的性质决定，如非他们选择搬迁或“隐形（即不泄露跨性别身份）”生活，则必须向他人出柜。出柜过程可能耗时且难以启齿。在此过程中如能得到支持，跨性别者会更加明确自己的性别认同；相反，缺乏支持或被虐待、骚扰、边缘化，被强调生理性别状态，或被试探性重复询问个人问题可能使跨性别者陷入痛苦。</p> <p>支持跨性别人士出柜及自我探索过程的方法包括强调自我认同，探索并完善自我意识，由此作为与不支持自己的伙伴、朋友、亲戚或同事接触时的后盾，也为忽略并排除日常生活中潜在的隐性无意识恐跨/敌视信息提供所需的帮助。</p> <p>跨性别人士患有心境障碍、双相情感障碍、精神分裂症等疾病的概率与常人相仿，同时在某些情况下由于长期承受作为少数群体的压力和歧视而有更高的潜在患病几率。[7]Hendricks和Testa将Meyer的少数群体压力模型延用到了跨性别人士群体中。该模型表示最近期和最远期的困境会增加个人患有精神疾病的可能性。与之相关的亦有Nedal提出“微歧视”的研究。与Hendricks和Testa强调关注心境障碍相似，Nedal的研究也指出跨性别人士患精神疾病的风险有所增加。</p> <p>针对跨性别者例行的初级护理随诊须包括对伴随出现的心理健康问题，治疗记录，自杀、自残行为记录、创伤后应激障碍症状以及物质滥用的监测。初级护理提供者处理跨性别患者的心理健康问题（例如抑郁、焦虑）时应当与其他患者无异。任何超出例行实施范围的主要心理健康问题都需转至针对跨性别者的心理医疗机构。需要时，应将患者转至药物滥用干预机构，包括针对与之同时出现的精神疾病的双重诊断机构。对任何抱有自杀念头的患者，所有初级医疗机构都应有明确的自杀干预反应计划。<a href="http://www.translifeline.org/" target="_blank" rel="noopener noreferrer">Trans Lifeline<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>是一个由跨性别者组成且为之服务的危机干预热线，可包含在患者的安全方案中。</p> <p>跨性别者寻求心理健康护理时，需要文化背景上能够胜任，即对性别认同概念有最基本的了解的人提供服务[1]。不应该由跨性别患者向其服务提供者介绍心理或生理健康的需求。</p> <h3 id="环境与社会的考虑"><a href="#环境与社会的考虑" class="header-anchor">#</a> 环境与社会的考虑</h3> <p>环境与社会压力会严重影响心理健康。相比于非跨性别者，跨性别者更有可能生活贫穷，遭遇就业歧视和暴力对待。[12]跨性别者也有更高几率失去家庭或流离失所。当跨性别者身份与其他诸如种族、民族或社会经济地位重合时，则更有可能遭遇对生活打击。有色跨性别女性有极高的比率面对社会地位与健康状况的不平等现象。[13-16]无论如何，初级医疗的例行随诊都应评估患者在居住及工作环境下的住房、食物、经济和安全状况。如条件允许，则应在初级医疗范围内提供个案管理。跨性别者可能因难以适应环境压力而诱发抑郁、焦虑和创伤反应等次生疾病。通过推荐针对个人及群体患者的治疗与支持，也可帮助建立保护性环境因素，而非加重许多患者承受的极端痛苦。[17-18]</p> <h3 id="对性别焦虑的诊断"><a href="#对性别焦虑的诊断" class="header-anchor">#</a> 对性别焦虑的诊断</h3> <p>根据《精神疾病诊断与统计手册第五版》（DSM-5），个人可因自身性别认同与生理性别不符，且临床上因此遭受显著痛苦或有社会/职业角色错位感，而被诊断具有精神疾病“性别焦虑”。然而，获得性别焦虑诊断可能被理解为病态化。[19]该问题也因对曾经实施过某种性别过渡而不再感到显著痛苦或有社会/职业角色错位感的患者缺乏诊断标准，而变得更复杂。在一些个例中，心理健康护理会被从患者的医疗方案中抽出独立对待。由于唯一现行的ICD10性别焦虑诊断标准被归类于心理健康范畴，进而在此类个例中患者可能无法在医疗方面受益。在ICD11中建立更广泛、更有价值的诊断标准的工作尚在进行中。部分州的保险计划不包括性别焦虑相关的医疗护理，即使此类护理在医学上是极其必要的[20]。在禁止削除医保项目的州，或是在个人保险包括跨性别相关护理情况下，若用保险支付必要的医药和手术治疗费用可能需要性别焦虑的诊断。</p> <h3 id="性别认同的特殊考虑"><a href="#性别认同的特殊考虑" class="header-anchor">#</a> 性别认同的特殊考虑</h3> <p>不同的性别认同与性别表达并非疾病[21]。然而，一些跨性别人士会出于自己的性别认同而寻求心理健康护理。通常情况下，这些跨性别人士因在社会及环境中遇到的极大困难而痛苦，从而寻求医护以处理上述压力因素。跨性别人士也会由于身心性别不一致带来的痛苦，或是为讨论以不同性别身份生活的社会及医疗渠道而寻求医疗服务。</p> <p>跨性别患者会频繁与初级医护提供者讨论开始跨性别激素治疗。<strong>在未进行初始心理健康评估的情况下，有经验的初级医疗护理提供者可能以知情同意原则自行开始对患者提供激素治疗（分级：T O S）。</strong>[22]知情同意包括向患者表明进行激素治疗的医学、社会风险以及受益情况。为此设置一次单独的预约就诊有助于确保患者有足够时间审视所需信息及提出任何问题。为满足所有患者的健康素养需求，“知情同意”需经患者本人亲自确认。</p> <p>世界跨性别健康专业协会（WPATH）出版的医护标准（Standards of Care, SOC）[23]概述了开始激素治疗的过程。根据SOC，患者须经有经验的临床医生——初级医护者或心理健康专家评估后方能开始激素治疗。该评估确认患者的确存在性别焦虑，并具有知情同意的能力。知情同意原则中关于治疗的风险及受益不仅应包括医学风险/益处，也应包括潜在的社会风险/益处（如就业、人际关系及住房等方面的风险），以及应对并减轻上述风险的方式。治疗方案并不一定需要开始医疗干预，但鼓励表明任何该过程中可能出现的问题。[23]SOC也倾向于更具灵活性并基于个体实际情况施行。[23]心理医护人员不再具有“看门人”的角色也允许患者与医护人员建立开放且利于治疗的关系。</p> <p>如果患者因精神疾病导致知情同意能力遭到损害，则应进一步评估患者的心理健康状况，并在开始跨性别激素治疗前治疗其精神疾病。SOC建议在开始激素治疗前稳定患者的精神疾病病情，但某些情况下对性别焦虑的治疗最好与精神疾病和物质滥用的治疗同时进行。[24]</p> <p>某些首次寻求初级医疗的患者可能已经开始摄入激素。在已有医师处方的情况下，后续激素治疗无需对患者心理健康进行评估。与患者讨论其后续护理目标后，应继续跨性别激素治疗并按标准维持身体条件评估和实验室评估。</p> <p>鼓励服务提供者查看SOC中概述的其作为心理健康医护者的任务。SOC概述了心理健康服务提供者诸如评估、咨询和药品管理的作用。[23]SOC要求在对跨性别者实施特定手术前，包括胸部和生殖器手术，由心理健康专家进行一到两次评估。SOC给出了每种手术的要求和评估量表，并且心理健康服务提供者可在线上获取此类评估的培训。[25]对所需评估项目的解释及相关的“推荐信”详见表1。鼓励服务提供者注意未针对跨性别者设计的评估方法。</p> <p>历史上，术前评估过程的重点在于诊断性别焦虑，确认患者提供知情同意的能力，以及评估某些特定标准（即服用激素的时长）。然而性别肯定手术后的恢复可能复杂且步骤繁多，还需要评估整体心理社会功能和支持，健康素养，自我保健能力和社会支持结构。此外还需向患者提供对基本手术步骤的教学，并填补评估过程中检测出的缺陷。此类需求也因包括无医保的贫困人士等更广泛的群体获得手术机会而增加。关于上述全部治疗过程，包括WPATH评估过程的框架已被提出（见表1）。[26]该框架包括评估心理社会功能，社会支持体系，健康素养，居住和交通状况以及术后阶段紧急医护的获取。</p> <p>表26-1. 性别肯定医护所需评估（即“推荐信”）</p> <p>除表中所需之外的程序不需正式评估过程，但如同任何手术一样，某些情况下可能会指明需要评估和准备。某些情况下，需要来自依照知情同意原则启动激素治疗的服务提供者的评估和推荐。</p> <table><thead><tr><th><strong>手术类型</strong></th> <th><strong>单次评估</strong></th> <th><strong>二次评估</strong></th> <th><strong>时间标准</strong></th></tr></thead> <tbody><tr><td><strong>隆胸</strong></td> <td>X</td> <td></td> <td>推荐12个月激素治疗，但不必需</td></tr> <tr><td><strong>乳房切除</strong></td> <td>X</td> <td></td> <td></td></tr> <tr><td><strong>性腺切除/子宫切除</strong></td> <td></td> <td>X</td> <td>除有禁忌，否则需12个月激素治疗</td></tr> <tr><td><strong>阴道成形术/阴茎成形术</strong></td> <td></td> <td>X</td> <td>除有禁忌，否则需12个月激素治疗并以与性别认同一致的身份生活至少12个月</td></tr></tbody></table> <p>图 26-1. 围手术期评估，准备和护理导航的框架</p> <p>改编自: Deutsch MB. Gender- affirming Surgeries in the Era of Insurance Coverage: Developing a Framework for Psychosocial Support and Care Navigation in the Perioperative Period. J Health Care Poor Underserved; May 2016.</p> <p>心理咨询可成为跨性别者护理中的一个重要部分。对于在开始激素治疗前寻求心理咨询或心理治疗的跨性别者而言，疗程或阶段的数量没有最低要求。[23]如上所说，服务提供者必须注意患者寻求医护的原因，并且不应假设问题仅于性别焦虑直接相关。重要的是，意识到患者有任何悲伤与失落的经历均是正常的。无论原因如何，患者生活中任何一次转变都可能包含失落经历。</p> <p>最后，一些精神健康服务提供者在为跨性别者管理精神药品方面训练有素且具有资质。与心理咨询相似，当跨性别患者同时出现与药品对应的心理问题时，这也可作为护理中一个重要部分。在一些州内，心理学专家拥有处方权。但在绝大部分州，此类服务由精神医师，初级医护人员，执业护士或医师助理提供&lt;15&gt;。</p> <h3 id="降低危害"><a href="#降低危害" class="header-anchor">#</a> 降低危害</h3> <p>一些跨性别患者可能未经初始医疗评估或监督，由其他途径，如互联网或街头获取激素。无论患者是否有能力或希望接受与性别相关的精神/心理评估，SOC都规定服务提供者可继续对独立开始进行HRT的患者进行治疗。[23]医护人员可根据降低危害的原则提供治疗。当患者表明在无医师监督下继续使用药物的决定时，建议接受他们的自行医护并开具恰当的激素药物。拒绝护理可能导致患者继续独立治疗，并可能造成危害。</p> <h3 id="寻找心理健康提供者"><a href="#寻找心理健康提供者" class="header-anchor">#</a> 寻找心理健康提供者</h3> <p>向患者推荐文化资质上胜任的服务提供者可能具挑战性，部分原因是缺乏相关训练。[27,28]尽管近些年来情况有改善，但这依然可能具有挑战性。大城市拥有的LGBT健康中心和可向跨性别者提供合格护理的人员，已成为可信任的护理资源。通常在这些城市有心理健康提供者的联系网络。对居住在农村环境或国内保守地区的跨性别者，寻找可推荐的提供者可能更加困难。[16]一些提供者会允许远程心理健康服务。然而确保提供者在患者接受服务的权限范围内拥有资质，也十分重要。</p> <p>应鼓励患者联系可能的提供者，并准备提出问题以确保提供者能够满足其需求。一些提供者会提供免费初始咨询，这对于患者也有机会确认提供者是否适合自己。美国各州的提供者名单可以从WPATH网站找到。[29]</p> <h3 id="合作护理"><a href="#合作护理" class="header-anchor">#</a> 合作护理</h3> <p>鼓励心理健康提供者建立交叉领域的关系。特别是寻求性别认同医疗过程的跨性别者会需要来自多个提供者的护理。其中可能包括初级护理医生，内分泌专家及外科医生。</p> <h3 id="总结"><a href="#总结" class="header-anchor">#</a> 总结</h3> <p>跨性别者应该从具有文化资质的提供者获得心理健康服务。跨性别认同护理假定患者理解自己的经历与认同。提供者应以文化谦逊的态度对待每位患者，并注意避免根据先前患者，经历或先入为主的概念做出假设或预测。提供者应以尊重的态度对待所有患者。</p> <h3 id="参考文献-25"><a href="#参考文献-25" class="header-anchor">#</a> 参考文献</h3> <ol><li>American Psychological Association. Guidelines for Psychological Practice With Transgender and Gender Nonconforming People. Am Psychol. 2015 Dec;70(9):832–64.</li> <li>Lev AI. Transgender emergence: therapeutic guidelines for working with gender-variant people and their families. New York, NY: Haworth Clinical Practice. New York, NY: Haworth Press; 2004.</li> <li>Carmel T, Hopwood R, dickey lm. Mental health concerns. In: Trans Bodies, Trans Selves: A Resource for the Transgender Community. Oxford University Press; 2014.</li> <li>Richmond KA, Burnes T, Carroll K. Lost in trans-lation: Interpreting systems of trauma for transgender clients. Traumatology. 2012;18(1):45–57.</li> <li>Machtinger EL, Cuca YP, Khanna N, Rose CD, Kimberg LS. From treatment to healing: the promise of trauma-informed primary care. Womens Health Issues Off Publ Jacobs Inst Womens Health. 2015 Jun;25(3):193–7.</li> <li>American Psychiatric Association, American Psychiatric Association, DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. Arlington, Va.: American Psychiatric Association; 2013.</li> <li>Bockting WO, Miner MH, Swinburne Romine RE, Hamilton A, Coleman E. Stigma, mental health, and resilience in an online sample of the U.S. transgender population. Am J Public Health. 2013 May;103(5):943–51.</li> <li>Meyer IH. Prejudice, social stress, and mental health in lesbian, gay, and bisexual populations: conceptual issues and research evidence. Psychol Bull. 2003 Sep;129(5):674–97.</li> <li>Hendricks ML, Testa RJ. A conceptual framework for clinical work with transgender and gender nonconforming clients: an adaptation of the Minority Stress Model. Prof Psychol Res Pract. 2012;43(5):460–7.</li> <li>Nadal KL, Davidoff KC, Davis LS, Wong Y. Emotional, behavioral, and cognitive reactions to microaggressions: Transgender perspectives. Psychol Sex Orientat Gend Divers. 2014;1(1):72–81.</li> <li>Trans Lifeline - (877) 565-8860 - Transgender Crisis Hotline [Internet]. Trans Lifeline. [cited 2016 Mar 25]. Available from: http://www.translifeline.org/</li> <li>Grant JM, Mottet LA, Tanis J, Harrison J, Herman J, Keisling M. <a href="http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf" target="_blank" rel="noopener noreferrer">Injustice at every turn: a<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf" target="_blank" rel="noopener noreferrer">report of the National Transgender Discrimination Survey<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. National Center for Transgender Equality and National Gay and Lesbian Task Force; 2011 [cited 2016 Mar 17]. Available from: http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf</li> <li>Bauer GR, Hammond R, Travers R, Kaay M, Hohenadel KM, Boyce M. “I don’t think this is theoretical; this is our lives”: how erasure impacts health care for transgender people. J Assoc Nurses AIDS Care JANAC. 2009 Oct;20(5):348–61.</li> <li>Hanssmann C, Morrison D, Russian E, Shiu-Thornton S, Bowen D. A community-based program evaluation of community competency trainings. J Assoc Nurses AIDS Care JANAC. 2010 Jun;21(3):240–55.</li> <li>Shipherd JC, Mizock L, Maguen S, Green KE. Male-to-female transgender veterans and VA health care utilization. Int J Sex Health. 2012;24(1):78–87.</li> <li>Walinsky D, Whitcomb D. Using the ACA Competencies for counseling with transgender clients to increase rural transgender well-being. J LGBT Issues Couns. 2010;4:160–75.</li> <li>Singh A. <a href="http://tmt.sagepub.com/content/early/2010/05/04/1534765610369261" target="_blank" rel="noopener noreferrer">“Just Getting Out of Bed Is a Revolutionary Act”: The Resilience of Transgender<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://tmt.sagepub.com/content/early/2010/05/04/1534765610369261" target="_blank" rel="noopener noreferrer">People of Color Who Have Survived Traumatic Life Events<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>. Traumatology [Internet]. 2010 May 7 [cited 2016 Mar 24]; Available from: http://tmt.sagepub.com/content/early/2010/05/04/1534765610369261</li> <li>Singh AA, Hays DG, Watson LS. Strength in the face of adversity: resilience strategies of transgender individuals. J Couns Dev. 2011 Winter;89(1):20–7.</li> <li>Winters K. Gender madness in American Psychiatry: Essays from the struggle for dignity. GID Reform Advocates. 2008;</li> <li>National Center for Transgender Equality. <a href="http://www.transequality.org/know-your-rights/medicare" target="_blank" rel="noopener noreferrer">Know your rights: Medicare<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. National Center for Transgender Equality. 2015 [cited 2016 Mar 25]. Available from: http://www.transequality.org/know-your-rights/medicare</li> <li>World Professional Association for Transgender Health (WPATH). [WPATH de-](http://www.wpath.org/uploaded_files/140/files/de-psychopathologisation 5-26-10 on letterhead.pdf) [psychopathologisation statement](http://www.wpath.org/uploaded_files/140/files/de-psychopathologisation 5-26-10 on letterhead.pdf) [Internet]. 2010 May [cited 2016 Mar 25]. Available from: [http://www.wpath.org/uploaded_files/140/files/de-psychopathologisation%205-26-](http://www.wpath.org/uploaded_files/140/files/de-psychopathologisation 5-26-) 10%20on%20letterhead.pdf</li> <li>Deutsch MB. Use of the informed consent model in the provision of cross-sex hormone therapy: a survey of the practices of selected clinics. Int J Transgenderism. 2012 May;13(3):140–6.</li> <li>Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, DeCuypere G, Feldman J, et al. Standards of Care for the Health of Transsexual, Transgender, and Gender- Nonconforming People, Version 7. Int J Transgenderism. 2012;13(4):165–232.</li> <li>Karasic DH. Transgender and gender nonconforming patients. In: Lim RF, editor. Clinical manual of cultural psychiatry (2nd ed). Arlington, VA: American Psychiatric Publishing; 2015. p. 397–410.</li> <li>Karasic DH. <a href="http://www.lgbthealtheducation.org/lgbt-education/continuing-education/" target="_blank" rel="noopener noreferrer">Mental health care and assessment of transgender adults<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. 2015 [cited 2016 Mar 24]. Available from: http://www.lgbthealtheducation.org/lgbt- education/continuing-education/</li> <li>Deutsch MB. Gender-affirming surgeries in the era of insurance coverage: developing a framework for psychosocial support and care navigation in a perioperative period. J Health Care Poor Underserved. 2016;27:1–6.</li> <li>Obedin-Maliver J, Goldsmith ES, Stewart L, White W, Tran E, Brenman S, et al. Lesbian, gay, bisexual, and transgender–related content in undergraduate medical education. JAMA J Am Med Assoc. 2011;306(9):971–7.</li> <li>Pickering DL, Leinbauhg T. Counselor self-efficacy with transgendered clients: Implications for training. [Ohio]: Ohio University; 2005.</li> <li>World Professional Association for Transgender Health (WPATH). <a href="http://www.wpath.org/uploaded_files/140/custom/find_a_provider.cfm?CFID=31626&amp;CFTOKEN=5b8f32ffd04104a5-701FE4B3-A261-C027-A80A16B51AF6F946" target="_blank" rel="noopener noreferrer">WPATH - Find a<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.wpath.org/uploaded_files/140/custom/find_a_provider.cfm?CFID=31626&amp;CFTOKEN=5b8f32ffd04104a5-701FE4B3-A261-C027-A80A16B51AF6F946" target="_blank" rel="noopener noreferrer">Provider<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. 2016 [cited 2016 Mar 25]. Available from: http://www.wpath.org/uploaded_files/140/custom/find_a_provider.cfm?CFID=31626&amp;CFT OKEN=5b8f32ffd04104a5-701FE4B3-A261-C027-A80A16B51AF6F946</li> <li>Ducheny K, Hendricks ML, Keo-Meier C. TGNC-affirmative interdisciplinary care. In: Handbook of trans-affirmative counseling and psychological practice. Washington, DC: American Psychological Association.</li></ol> <blockquote><p>&lt;15&gt;. 译者注：在我国，只有精神科医师有处方权</p></blockquote> <h2 id="男性化胸部手术的术后护理与常见问题"><a href="#男性化胸部手术的术后护理与常见问题" class="header-anchor">#</a> 男性化胸部手术的术后护理与常见问题</h2> <p>主要作者： Eric D. Wang, MD; Esther A. Kim, MD</p> <h3 id="概论-16"><a href="#概论-16" class="header-anchor">#</a> 概论</h3> <p>跨性别男性最常用的男性化胸部手术技术包括通过乳晕切除术以及乳房下乳房切除术与游离乳头移植术进行的皮下乳房切除术。无论采用何种方法，男性胸部手术的目标都是塑造与对患者胸部的身体状态相匹配的自然男性化胸部。不幸的是，暂无已达成共识的手术方案。手术技术不仅取决于整形外科医生的个人经验和患者的特定偏好，还取决对患者的术前身体状态，乳房大小、形状以及皮肤质量的评估。</p> <p>术前胸部可简化为以下四个部分：乳房和皮下组织，皮肤包膜（skin envelope），乳头，最终切口。[5]乳腺组织切除对获取男性化胸部形状是必要的。这与针对乳腺癌实施的乳房切除术，以及针对乳腺增生实施的皮下乳房切除术在解剖学，目标及实施方法上显著不同。为获得紧绷且美观的男性胸部，可能根据乳房组织的体积，术前下垂程度和皮肤弹性，需要对外侧皮肤进行显著切除。乳头-乳晕复合体（NAC）同样需要调整大小，重塑和重新定位，以在血液供应的限制下匹配男性对应的比例。最后，切口和皮肤切除须使疤痕的产生达到最不明显的大小，位置和方向。</p> <p>由于有不同的考虑和约束因素，已有大量的技术改进和算法提出；并且都可以归入两大类技术。对较小且较少下垂的乳房，通过NAC周围或穿过NAC的单个切口可在每个乳房周围进行皮下乳房切除术，切除新月形或圆环形的皮肤。然而对较大或下垂的乳房，由于难以在解剖学意义上重定位乳头及实施必要的皮肤切除，此方法则更为困难。在此情况下，每个乳房都须双切口，以去除腺体组织和皮下脂肪并通过乳房下切口重新接合，而乳头通过单独的椭圆形切口保留。如果无法基于血管蒂转移NAC，则也可选择游离乳头移植。</p> <p>手术过程本身通常需要2-4小时，取决于使用的技术。大部分患者需要过夜或是短期住院。[1]手术使用全身麻醉。在术后门诊就诊前通常会留下引流管。本文作者倾向于在术后1-2周内使用引流管并穿着压迫胸部服装。</p> <p>一般而言，接受男性化胸部手术的跨性别男性很少发生并发症。4-9％的患者在早期需要再次手术，通常用于血肿清除和感染，总并发症发生率为12％[1,2]。术后并发症分为早期（术后2周内）和后期（2~4周后）。跨性别男性化胸部手术的数据有限，且发表的数据在稳健性上较乳房缩小整形和男性乳腺增生手术差，因此，从这些领域中可获得的更广泛文献中提取的数据补充了手术并发症的数据。</p> <h3 id="初级和紧急护理条件下的术后护理"><a href="#初级和紧急护理条件下的术后护理" class="header-anchor">#</a> 初级和紧急护理条件下的术后护理</h3> <p>尽管大多数早期并发症很少危及生命，但应迅速引起手术整形外科医生的注意并参考自身经验。某些早期并发症（特别是血肿，血清肿和乳头并发症）会导致持久畸形并影响美观，可通过及时干预避免。</p> <p>若患者出现延迟并发症及自觉特定区域不美观，也应转至外科医生。最常见的患者投诉与术后瘢痕形成，轮廓畸形，乳头外观或变色有关。一年内愈合和重塑的过程应得到患者的辅助。在考虑可选的修正措施之前，患者应在医学，心理和社会方面表现稳定，并抱有现实的期望。</p> <h3 id="皮瓣和切口并发症及疤痕"><a href="#皮瓣和切口并发症及疤痕" class="header-anchor">#</a> 皮瓣和切口并发症及疤痕</h3> <p>男性化胸部手术需通过抬高薄皮瓣以切除多余的皮肤和软组织。所以这些皮瓣的血液供应很脆弱。这会导致早期并发症，表现为一定程度的伤口分离，伤口愈合延迟或皮瓣坏死，估计接受缩胸手术人群内的发病率约为5％[7]。</p> <p>早期切口和皮瓣并发症的风险因素包括高BMI（&gt;30），高血压，既往乳房切口和乳房组织切除量。可能最重要也是在非紧急手术之前可改变的因素是术前吸烟。[7,8]应建议患者在手术前4周完全戒烟，考虑到戒烟的困难性质，患者在推荐进行此类手术之前就应考虑戒烟。</p> <p>作为延迟并发症，形成无法接受的瘢痕也是跨性别男性担心的问题。手术的目标之一就是尽量减少疤痕的出现并控制其位置。伤口的延迟愈合会导致色素沉着异常的宽疤痕，比理想的细纹疤痕更明显。一般而言，手术切口的瘢痕可以由术后伤口护理的一些基本原理得到改善。首先，通过限制术后活动来减少伤口上的机械应力和张力，对于减少瘢痕宽度是至关重要的。切口上的张力可导致微小的伤口破裂，导致瘢痕形成过多或变宽。应当告知患者，切口在治愈的早期阶段外观最差，此阶段最长可达10周，在此后的数月至一年内开始重塑并好转。在此重塑期间，色素沉着过度或色素减退也会导致更明显的疤痕。因此，我们建议术后一年内避免阳光下暴露切口，或在愈合切口处采取强力的遮光措施。此外发现压迫瘢痕可减少肥厚性瘢痕形成，尽管其机制尚不清楚。这可以通过温和疤痕按摩（术后不早于2周开始），束胸或粘贴硅胶和薄片实现。[9]如果疤痕护理无法改善外观至可接受水平，则有时需进行手术瘢痕切除和修正。</p> <h3 id="血肿-血清肿"><a href="#血肿-血清肿" class="header-anchor">#</a> 血肿/血清肿</h3> <p>在所有种类缩胸手术的患者中，约有1-2%患者出现术后血肿，通常在术后早期出现[8]。在跨性别患者的某些亚组的报告中，出现几率高达5-11％[1-3]。通过精细的手术止血方法和对合并症（凝血病，高血压，以及停止持续抗凝和使用某些草药）的优化可以预防血肿。血肿表现为不对称的肿胀和疼痛，有时还伴有瘀斑。一般而言，大多数血肿需清除，因为它们可在绷紧的外部皮肤上施加物理压力，从而可能损害皮瓣活性，并且还可能导致术后胸部畸形。其他并发症可包括钙化或血肿感染。在对血肿进行重新检测及消除手术时，通常不会发现任何分散的出血血管。小型液化血肿可以经皮吸出或排出。</p> <p>血清肿和积油囊肿是在手术部位的积液，在手术期间常通过放置闭合的抽吸引流管以排空，并结合术后穿着粘附压力衣物。这些囊肿偶尔可在手术引流管移除后持续存在或复发，并需要排空以防止皮瓣或切口受损。手术引流管移除的时间取决于引流输出速度，且应与外科医生一同做出决定。</p> <p>大型积油囊肿由脂肪坏死引起，随时间的推移会导致轮廓不规则和钙化，可通过抽吸和/或手术修正解决。</p> <h3 id="感染"><a href="#感染" class="header-anchor">#</a> 感染</h3> <p>感染是男性化胸部手术后罕见的早期并发症。[1,8]通常会表现为局部蜂窝组织炎，一般可用短程口服抗生素治疗。如果与持续的术后感染相关，则可能需要排出下面的积液。</p> <h3 id="乳头-乳晕复合体和乳头移植并发症"><a href="#乳头-乳晕复合体和乳头移植并发症" class="header-anchor">#</a> 乳头-乳晕复合体和乳头移植并发症</h3> <p>无论乳头-乳晕复合体是否保留在皮肤蒂上（如在皮下乳房切除术中），或作为游离移植物，都存在乳头愈合相关的早期和晚期并发症。两种方法的预期结局都包括乳头敏感度降低，麻木或感觉异常。使用这两种技术的患者均报告，随时间出现不同程度的感觉恢复。两种技术都会导致一定程度的色素减退，乳头突出减少，以及罕见的乳头缺失并发症；这些风险随游离移植而变得更明显。严格遵守术后指导及乳头敷料可帮助确保使用任一种技术获得良好效果，[1,2]即描述的整体乳头缺失率为1％或更低。区分患者术后的全层乳头坏死和预期下的浅表皮肤蜕皮[6]也十分重要。可能需要通过乳头重建和修正程序来恢复乳头的外观。在二次手术过程中也可以调整乳头位置和大小。这些通常是初始愈合阶段完成后即可实施的次要程序。</p> <h3 id="轮廓不规则"><a href="#轮廓不规则" class="header-anchor">#</a> 轮廓不规则</h3> <p>多个已发表系列文献中，患者寻求二次胸壁手术最常见的代表性原因有轻微的胸壁轮廓畸形或不对称，包括在切口末端发现的多余组织（“狗耳”）。[3,6]这些可以通过门诊手术切除。此外，其他轮廓畸形或不对称可通过吸脂或脂肪移植解决。</p> <p>据大量已发表的男性化胸部手术文献，总的为改善美观性的进行修正手术的比率高达32％[2]。</p> <h3 id="乳腺癌风险"><a href="#乳腺癌风险" class="header-anchor">#</a> 乳腺癌风险</h3> <p>应告知跨性别男性，雄激素激素治疗和胸壁塑形术（包括皮下乳房切除术）无法消除乳腺癌发展的风险，特别是那些由于家族史而患乳腺癌风险较高的患者。胸壁轮廓塑形具有本质不同的目标和技术，不同医师间的技术相关差异，而不应被视为降低风险的程序。不同手术者描述了各种技术，已确认了残留乳房组织的存在。[1,3,6]由于美容乳房切除术的方法不同于乳腺癌治疗中使用的方法，所有接受胸部手术的患者都应进行基线乳房X射线检查，以防止术中或手术的意外病理发现。这些指南的其他部分讨论了皮下乳房切除术后持续进行的乳腺癌检查。</p> <h3 id="参考文献-26"><a href="#参考文献-26" class="header-anchor">#</a> 参考文献</h3> <ol><li>Wolter A, Diedrichson J, Scholz T, Arens-Landwehr A, Liebau J. Sexual reassignment surgery in female-to-male transsexuals: an algorithm for subcutaneous mastectomy. J Plast Reconstr Aesthetic Surg JPRAS. 2015 Feb;68(2):184–91.</li> <li>Monstrey S, Selvaggi G, Ceulemans P, Van Landuyt K, Bowman C, Blondeel P, et al. Chest-wall contouring surgery in female-to-male transsexuals: a new algorithm. Plast Reconstr Surg. 2008 Mar;121(3):849–59.</li> <li>Berry MG, Curtis R, Davies D. Female-to-male transgender chest reconstruction: a large consecutive, single-surgeon experience. J Plast Reconstr Aesthetic Surg JPRAS. 2012 Jun;65(6):711–9.</li> <li>Cregten-Escobar P, Bouman MB, Buncamper ME, Mullender MG. Subcutaneous mastectomy in female-to-male transsexuals: a retrospective cohort-analysis of 202 patients. J Sex Med. 2012 Dec;9(12):3148–53.</li> <li>Hage JJ, van Kesteren PJ. Chest-wall contouring in female-to-male transsexuals: basic considerations and review of the literature. Plast Reconstr Surg. 1995 Aug;96(2):386– 91.</li> <li>Monstrey SJ, Ceulemans P, Hoebeke P. Sex reassignment surgery in the female-to- male transsexual. Semin Plast Surg. 2011 Aug;25(3):229–44.</li> <li>Henry SL, Crawford JL, Puckett CL. Risk factors and complications in reduction mammaplasty: novel associations and preoperative assessment. Plast Reconstr Surg. 2009 Oct;124(4):1040–6.</li> <li>Hall-Findlay EJ, Shestak KC. Breast reduction. Plast Reconstr Surg. 2015 Oct;136(4):531e – 44e.</li> <li>Broughton G, Rohrich R. Wounds and scars. Sel Read Plast Surg. 2005;10(7).</li></ol> <h2 id="女性化隆胸成形术的术前和术后护理"><a href="#女性化隆胸成形术的术前和术后护理" class="header-anchor">#</a> 女性化隆胸成形术的术前和术后护理</h2> <p>主要作者： Eric D. Wang, MD; Esther A. Kim, MD</p> <h3 id="概论-17"><a href="#概论-17" class="header-anchor">#</a> 概论</h3> <p>与非跨性别女性相同，跨性别女性的隆胸术包括基于植体的隆胸成形术。将由硅胶壳与盐水或粘性硅胶填充物组成的假体植体置于乳房组织（腺下植体）下方或胸肌下（胸肌下植体）。</p> <p>雌激素和抗雄激素治疗的启动刺激跨性别女性乳房组织的发育。由于没有确凿证据表明隆胸前女性化激素治疗的最佳时间长度，一些来源建议在手术前至少进行6个月的激素治疗，以促进激素相关的乳房发育。[1,2]实际上，若使激素促进乳房发育更可能最大化，则至少需2-3年时间。</p> <p>植体，方法种类和植入位置的选择取决于该跨性别女性的术前身体状态和愿望，应与有资质的乳房或整形外科医生协商。如有足够的乳房和皮下组织覆盖植体，可首选腺下植入植体，并避免出现可见的植体接缝和波纹。使用盐水植入物时，或者没有足够的软组织掩盖植体的形状时，胸肌下植入植体可能是首选。[3]除美观方面的考虑以及外科医生和患者的偏好之外，并无客观的结局数据支持应使用盐水还是硅胶填充物。[4]由于许多跨性别女性乳房发育不足，因此使用胸肌下植入为典型方法。</p> <p>在全身麻醉下，隆胸手术通常作为“当天”的门诊手术进行；手术时间约2小时。术后数周内恢复相当迅速，但有些患者可能会出现长时间的酸痛，肿胀和轻度瘀伤。手术沿新的乳房下皱襞切口，并在上述的腺下或胸肌下平面产生用于植入的空间。切口用数层缝合线封闭，从而患者感受通常足够好而在手术当晚就可回家。</p> <p>手术结果通常比较持久，并且女性化隆胸术的并发症很少见。[2]并发症通常分为早期（少于2-4周）或后期并发症（超过4周）。具体到跨性别女性的隆胸手术数据有限；某些数据则根据非跨性别女性的手术数据推断而来。在一项研究中，75％的跨性别女性在长期随访报告中对基于植体的隆胸术感到满意，大多数不满意与主观上的美学效果（主要是乳房大小不足），而不是技术上的手术并发症有关。[5]</p> <h3 id="初级和紧急护理中的术后并发症"><a href="#初级和紧急护理中的术后并发症" class="header-anchor">#</a> 初级和紧急护理中的术后并发症</h3> <p>如有对于术后早期并发症的任何担忧（详见下文），应尽快转介至手术医生。</p> <p>整形手术转诊也适用于在隆胸术后，较晚出现与先前隆胸相关的乳房症状或客观不适（例如肿胀，疼痛，红斑，显著畸形/不对称和植入物漏气）的患者。良性和恶性乳腺肿瘤的鉴别诊断始终不同，且应进行适当的检查。在转诊之前，乳腺癌筛查结果应当是最新的。如果根据病史或检查怀疑有积液或植入物破裂，在寻求整形外科医疗前用超声波或MRI进行确认是有帮助的。</p> <p>主观上对前一次隆胸术不满意的跨性别女性可能需要进行二次手术咨询或转诊至另一位整形外科医生。对隆胸术选择性的二次修正并不罕见。在任何关于胸部手术的转诊前，患者应在医学，心理和社会方面表现稳定（若进行乳腺癌筛查，则需最新结果），并抱有现实的期望。</p> <h3 id="性别肯定女性化乳房成形手术的麻醉并发症"><a href="#性别肯定女性化乳房成形手术的麻醉并发症" class="header-anchor">#</a> 性别肯定女性化乳房成形手术的麻醉并发症</h3> <p>除标准麻醉并发症外，应评估接受女性化乳房成形术的患者静脉血栓栓塞的危险因素，并根据个体危险因素采取适当的物理和化学预防措施。围手术期内雌激素治疗的管理和雌激素的静脉血栓栓塞风险在本方案的其他部分讨论。</p> <h3 id="血肿"><a href="#血肿" class="header-anchor">#</a> 血肿</h3> <p>血肿通常在隆胸术后早期（1-2周内）出现，通常表现为局部或单侧肿胀，并伴有手术部位疼痛和瘀伤。迟发性血肿在没有乳房创伤的情况下很罕见。[6]</p> <p>为防止术后早期出现血肿，必须严格遵守术后护理方案。具体上，应建议患者避免剧烈活动以及胸部可能受到外部创伤的情况。此外，严格遵医嘱（特别是遵守抗凝血剂，抗血小板和某些草药，以及抗高血压药物方面的要求）可以降低术后血肿的发生率。</p> <p>无论是否更换假体植入物，一般都通过手术再次探查，在确定出血源的情况下排出及重新闭合治疗血肿。偶尔可以控制预防小型血肿。未经治疗的大型血肿可导致继发性并发症，如感染，包膜挛缩或植体错位[7]。</p> <h3 id="血清肿"><a href="#血清肿" class="header-anchor">#</a> 血清肿</h3> <p>预计无菌的术后积液会在假体周围形成，并且通常在早期恢复期后被重吸收。[6]除非有理由怀疑伴随感染或者积液有引起切口破裂和植体暴露的危险，否则无需担心或需要对术后早期积液的进一步放射学评估。整形外科文献中没有证据支持在隆胸成形术中引流管的常规使用。一般情况下延迟血清肿是异常的，应由整形外科医生进行评估。[4]</p> <h3 id="感染-2"><a href="#感染-2" class="header-anchor">#</a> 感染</h3> <p>感染较为罕见，且通常作为隆胸术后早期（1-4周）并发症出现。感染的严重程度可从轻度切口蜂窝组织炎到假体周围化脓感染。假体周围感染中最常见的病原体是皮肤菌群，因此，外科医生会采取大量避免污染的措施。[8]</p> <p>多数情况下，术后感染会对抗生素治疗产生反应。然而，一旦患者有时间愈合并完全清除感染，大部分作者会建议在未能解决的情况下移除植入物，并在6-12个月内进行延迟的二次隆胸术。[3]</p> <h3 id="切口并发症"><a href="#切口并发症" class="header-anchor">#</a> 切口并发症</h3> <p>切口瘢痕形成是隆胸术的晚期并发症。患者应注意进行适当的疤痕护理，包括术后早期避免阳光直射。深色或油性皮肤，或既有增生性瘢痕或瘢痕疙瘩形成既往史的患者也应注意这些并发症的风险增加。</p> <p>一般而言，通过遵循术后伤口护理的一些基本原则，可以改善手术切口的瘢痕形成。首先，通过限制术后活动来减少伤口上的机械应力和张力对于减少瘢痕宽度至关重要。切口上的张力可导致微小的伤口破裂，导致瘢痕形成过多或变宽。应当告知患者，切口在治愈的早期阶段外观最差，此阶段最长可达10周，在此后的数月至一年内开始重塑并好转。在此重塑期间，色素沉着过度或色素减退也会导致更明显的疤痕。因此，我们建议术后一年内避免阳光下暴露切口，或在愈合切口处采取强力的遮光措施。此外发现压迫瘢痕可减少肥厚性瘢痕形成，尽管其机制尚不清楚。这可以通过温和疤痕按摩（术后不早于2周开始），束胸或粘贴硅胶及薄片实现[9]。</p> <h3 id="植体破裂"><a href="#植体破裂" class="header-anchor">#</a> 植体破裂</h3> <p>盐水植体的硅胶壳破裂可通过漏气或乳房体积减小立即识别。在2000年代后期之前植入的植体含有液态硅凝胶，因壳破裂和浸出而易于泄漏。潜在的并发症包括乳房畸形，炎症和疼痛。目前可用的硅胶乳房植入物（第4代或第5代植入物，也称为粘性凝胶植入物）即使在植体外壳破裂的情况下也不允许无定形硅胶从植体中逸出。因此硅胶植体破裂通常难以发现。对疑似的植体破裂可通过MRI确认。一项关于种植体完整性的MRI长期研究发现，当前一代硅胶植入物的90％以上在10年内完好无损。[11]</p> <p>美国食品药物管理局（FDA）2011年的一份报告建议最初在植入后3年对无症状的硅胶植入物破裂进行常规MRI筛查，此后每半年一次，[12]尽管没有证据支持此建议且MRI可能不在保险覆盖内。[13]患者应该接受关于该建议的术前咨询，以及理解其客观证据支持的缺乏性。</p> <h3 id="植体错位和包膜挛缩"><a href="#植体错位和包膜挛缩" class="header-anchor">#</a> 植体错位和包膜挛缩</h3> <p>随着乳房适应乳房植体的放置和老化，植体可能会发生错位。植体表面预计形成非病理性包膜。</p> <p>病理性纤维化囊的形成，或称为包膜挛缩，可导致植体的明显坚硬感或移位，乳房变形，甚至与植体相关的乳房疼痛。一旦出现症状或畸形，则需要移除植体及手术切除包膜。现代植体的包膜挛缩率低于10％，但仍需长期随诊[3]。乳房植体或假体周围包膜的形成与结缔组织疾病之间没有任何联系。[3]虽然美国食品和药物管理局建议每3年用MRI筛查有机硅植入物破裂，但在未出现症状（疼痛，畸形）的情况下，此做法并无证据支持，因为对于偶然及无明显症状的植入物破裂，推荐方法是非手术观察。</p> <h3 id="尺寸不足及美观畸形"><a href="#尺寸不足及美观畸形" class="header-anchor">#</a> 尺寸不足及美观畸形</h3> <p>一项关于进行过隆胸术的跨性别女性的研究发现，16%的患者因尺寸不足而做过二次隆胸。这也构成了大部分对隆胸术不满意的情况。</p> <p>患者可能会出现许多影响美观的并发症而导致不满，并需要修复手术和二次隆胸。这些并发症通常是手术和患者解剖技术结合的结果。其中部分并发症可包括植体外露及植体折叠或波纹，出现在使用盐水植入物，或患者的软组织不足以覆盖植入物的情况下。其他患者可出现与瘢痕形成或与（胸肌下植体）胸肌作用下随时间移位相关的不对称。这些畸形需要通过二次修正隆胸手术解决。</p> <h3 id="乳房肿块"><a href="#乳房肿块" class="header-anchor">#</a> 乳房肿块</h3> <p>本指南的其他部分涵盖了跨性别女性中乳腺癌的流行病性及其筛查。对于需要筛查，或进行乳房X射线超声检查的跨性别女性，对乳房植体进行上述两种检查均可。但乳房X射线检查无法检测出植体相关的并发症，例如植体破裂。[14]</p> <h3 id="乳房软组织注入"><a href="#乳房软组织注入" class="header-anchor">#</a> 乳房软组织注入</h3> <p>尽管自体脂肪移植在整形外科手术中正被逐步接受，[15]但其在跨性别女性中的应用尚不广泛或未充分描述。本指南的其他部分详细介绍了无资质提供者的硅胶及其他物质注入。</p> <h3 id="参考文献-27"><a href="#参考文献-27" class="header-anchor">#</a> 参考文献</h3> <ol><li>World Professional Association for Transgender Health (WPATH). [Standards of care for](http://www.wpath.org/uploaded_files/140/files/Standards of Care%2C V7 Full Book.pdf) [the health of transsexual, transgender, and gender non-binary people, 7th Version](http://www.wpath.org/uploaded_files/140/files/Standards of Care%2C V7 Full Book.pdf) [Internet]. WPATH; 2012 [cited 2016 Mar 10]. Available from: [http://www.wpath.org/uploaded_files/140/files/Standards%20of%20Care,%20V7%20Full%20Book.pdf](http://www.wpath.org/uploaded_files/140/files/Standards of Care%2C V7 Full Book.pdf)</li> <li>Kanhai RC, Hage JJ, Asscheman H, Mulder JW. Augmentation mammaplasty in male-to- female transsexuals. Plast Reconstr Surg. 1999 Aug;104(2):542–9; discussion 550–1.</li> <li>Thorne CH. An evidence-based approach to augmentation mammaplasty. Plast Reconstr Surg. 2010 Dec;126(6):2184–8.</li> <li>Lista F, Ahmad J. Evidence-based medicine: augmentation mammaplasty. Plast Reconstr Surg. 2013 Dec;132(6):1684–96.</li> <li>Kanhai RC, Hage JJ, Mulder JW. Long-term outcome of augmentation mammaplasty in male-to-female transsexuals: a questionnaire survey of 107 patients. Br J Plast Surg. 2000 Apr;53(3):209–11.</li> <li>Thorne CH. Breast Augmentation. In: Grabb and Smith’s plastic surgery. Lippincott Williams &amp; Wilkins; 2013.</li> <li>Williams C, Aston S, Rees TD. The effect of hematoma on the thickness of pseudosheaths around silicone implants. Plast Reconstr Surg. 1975 Aug;56(2):194–8.</li> <li>Brand KG. Infection of mammary prostheses: a survey and the question of prevention. Ann Plast Surg. 1993 Apr;30(4):289–95.</li> <li>Broughton G, Rohrich R. Wounds and scars. Sel Read Plast Surg. 2005;10(7).</li> <li>Walker PS, Walls B, Murphy DK. Natrelle saline-filled breast implants: a prospective 10- year study. Aesthetic Surg J Am Soc Aesthetic Plast Surg. 2009 Feb;29(1):19–25.</li> <li>Cunningham B. The Mentor Core Study on Silicone MemoryGel Breast Implants. Plast Reconstr Surg. 2007 Dec;120(7 Suppl 1):19S – 29S; discussion 30S – 32S.</li> <li>U.S. Food and Drug Administration, Center for Devices and Radiological Health. FDA Update on the Safety of Silicone Gel-Filled Breast Implants. 2011 Jun.</li> <li>McCarthy CM, Pusic AL, Kerrigan CL. Silicone breast implants and magnetic resonance imaging screening for rupture: do U.S. Food and Drug Administration recommendations reflect an evidence-based practice approach to patient care? Plast Reconstr Surg. 2008 Apr;121(4):1127–34.</li> <li>Weyers S, Villeirs G, Vanherreweghe E, Verstraelen H, Monstrey S, Van den Broecke R, et al. Mammography and breast sonography in transsexual women. Eur J Radiol. 2010 Jun;74(3):508–13.</li> <li>Eaves FF, Haeck PC, Rohrich RJ. ASAPS/ASPS Position statement on stem cells and fat grafting. Plast Reconstr Surg. 2012 Jan;129(1):285–7.</li></ol> <h2 id="阴道成形术-术后并发症及护理"><a href="#阴道成形术-术后并发症及护理" class="header-anchor">#</a> 阴道成形术，术后并发症及护理</h2> <p>主要作者： Toby Meltzer, MD</p> <h3 id="概论-18"><a href="#概论-18" class="header-anchor">#</a> 概论</h3> <p>最常见的阴道成形技术是由阴茎翻转术经适当改变而来。在此技术中，直肠和尿道之间形成阴道穹窿，即与非跨性别女性盆底（Kegel）肌肉之间相同的位置，阴道内衬则由阴茎皮肤产生。进行睾丸切除术，使用阴囊皮肤创建阴唇，而阴蒂由龟头的一部分形成。前列腺留在原位以避免诸如尿失禁和尿道狭窄等并发症。</p> <p>此外，前列腺具有性敏感度，并且与“g点”在解剖学上等效。通过适当地定位切口并精细闭合可以极小心地控制阴道成形术所造成的外部疤痕。典型阴道深度为15厘米（6英寸），且一般在12-16厘米（5-6.5英寸）范围内；相比之下，非跨性别女性的典型阴道深度在9-12厘米（3.5至5英寸）之间。在先前包皮环切的情况下，可能需要进行皮肤移植，通常来源于阴囊。如果阴茎和阴囊之间的皮肤不足以达成12cm（5英寸）深度，则可使用来自臀部，下腹部或大腿内侧的移植皮肤。使用标准技术可以最小化或隐藏供体部位形成的瘢痕。由于阴茎翻转方法不会产生阴道黏膜，阴道不会自我润滑，在进行扩张或插入式性行为时需要使用外部润滑剂。</p> <p>阴囊皮肤有丰富的毛囊，除非提前去除毛发，否则可以将有稀疏毛发生长的皮肤移植到人工阴道内。一些外科医生会依靠在手术时腐蚀皮肤使之变薄和烧灼可见毛囊的方法，处理所有可见的毛发。然而由于毛发分阶段生长，手术时此方法可能无法充分处理休眠毛囊。防止阴道毛发生长的最佳方法是进行阴囊电解，间隔8-12周进行至少三次完全脱毛，取决于电解师使用偏好和毛发类型分布。外科医师应向患者提供除毛区域的图解。</p> <p>若只通过单个阶段（“单期”阴道成形术）在位于阴囊皮肤间的的阴茎皮肤上实施阴茎翻转成形术，常见结果为大阴唇间隔过远。单次手术后也可能出现阴蒂包皮（除体重较重患者）或小阴唇大小不足。尽管单次手术的程序可能不同，但依作者经验，先前提到的缺陷是常见的。这种局限可归结于阴茎翻转方法的固有性质和有限的血液供应。在站立或腿合拢的姿势下，大多数结果似乎可接受；但若通过直接检查或接触检查，上述缺陷将是显而易见的。为了充分弥补此类缺陷，作者认为需要进行二次手术。二次阴唇成形术提供了使大阴唇更接近中线，即解剖学上的正确位置，提供足够大小的阴蒂包皮并修正小阴唇的机会。此外，许多自变量可影响治疗和最终结果。具体而言，二次手术还允许外科医生处理愈合上的差异，例如尿道修正，任何阴道蹼状疤痕或长期不对称的矫正，或修复不满意的疤痕。这些修正会改善患者的术后功能性及最终结局，否则问题可能无法由其他方式解决。</p> <h3 id="术后即时考虑"><a href="#术后即时考虑" class="header-anchor">#</a> 术后即时考虑</h3> <p>术中应在阴道内填塞纱布或放置支架装置，并保持5-7天。移除上述装置后应指导患者进行阴道扩张，通常由外科医生提供扩张器；扩张时间安排因外科医生而异。表1列举了术后指导的示例，表2则显示了阴道扩张指南及示例扩张时间表。</p> <p>表 29-1. 阴道成形术后护理指南</p> <table><thead><tr><th><strong>关注方面</strong></th> <th><strong>护理指南</strong></th></tr></thead> <tbody><tr><td><strong>活动</strong></td> <td>6周内避免剧烈运动；3个月内避免游泳或骑行</td></tr> <tr><td><strong>就坐</strong></td> <td>术后一个月内，就坐可能感到不适，但并非不安全。建议采用环形圈垫缓解手术部位压力</td></tr> <tr><td><strong>洗浴</strong></td> <td>首次术后就诊后即可淋浴，须保证手术部位干燥。术后8周内不可沐浴或浸入水中。</td></tr> <tr><td><strong>阴道肿胀</strong></td> <td>阴道肿胀较为常见，通常于术后6-8周后缓解。长期保持站姿或坐姿会加剧肿胀。术后一周内，每小时在会阴部位冰敷20分钟可有助于缓解部分肿胀感。</td></tr> <tr><td><strong>性行为</strong></td> <td>除另行建议外，可在术后3个月后恢复性行为。</td></tr> <tr><td><strong>会阴部卫生</strong></td> <td>与会阴部有任何接触前都应洗手。应每日冲洗或清洗会阴。清洗时须由前部至后部擦拭，以避免被肛门区域细菌感染。避免穿过紧衣物；摩擦可能引起细菌转移。</td></tr> <tr><td><strong>阴道分泌物</strong></td> <td>预计术后4-6周内阴道分泌物呈黄褐色。流血及点状出血预计在术后8周内出现。用洗液及水冲洗应有助于减少此类情况。洋甘菊或薰衣草洗液也可帮助清洁新阴道。</td></tr> <tr><td><strong>烟草/吸烟</strong></td> <td>术后一个月内避免吸烟或使用烟草，因为会干扰愈合进程。</td></tr> <tr><td><strong>饮食/恶心/便秘</strong></td> <td>应从流质饮食开始，逐渐适应至可承受的日常饮食。可开具止吐药防止恶心。麻醉止痛药可能导致便秘；采用多库酯®等大便软化剂可预防便秘。</td></tr> <tr><td><strong>疼痛缓解</strong></td> <td>术后疼痛较为常见，可使用止痛药缓解。应按处方服用止痛药，并可随时换用泰诺®强效镇痛药（Tylneol® Extra Strength）。</td></tr> <tr><td><strong>扩张</strong></td> <td>阴道扩张是术后恢复的重要部分。可在术后阶段向患者提供阴道扩张器及其使用指南。</td></tr></tbody></table> <p><em>来源：Brownstein＆Crane 手术服务</em></p> <h4 id="扩张指南"><a href="#扩张指南" class="header-anchor">#</a> 扩张指南</h4> <p><em>来源：Brownstein＆Crane 手术服务</em></p> <p>请注意扩张时间表可能因人而异</p> <ul><li>插入阴道前，确保扩张器洁净。</li> <li>用温水和杀菌皂清洗扩张器。彻底清洗后用洁净的纸巾或布擦干。</li> <li>插入前使用Sugrilube或K-Y润滑剂。仅使用水性润滑剂。</li> <li>避免使用硅胶性润滑剂。</li> <li>将扩张器以45度角轻插入阴道直至耻骨下方，然后继续直向内插入。</li> <li>预计感受到少许阻力和疼痛。如阻力过大或出现剧痛，应立即停止。</li> <li>将扩张器插入阴道最深处（直到有中等阻力或压力感），并停留10分钟。应插入扩张器直至阴道外仅剩1-2个白点。</li> <li>自移除填充物起3个月内，每天扩张3次。</li> <li>开始扩张3个月后可使用下一尺寸扩张器。下一尺寸也应使用3个月。</li> <li>扩张频率：术后0-3月内3次/日，10分钟/次；术后3-6月内1次/日，10分钟/次；6个月后2-3次/周，10分钟/次；9个月后1-2次/周。</li> <li>如阴道感觉过紧，应增加扩张频率。</li> <li>每次扩张后应使用水和肥皂清洁阴道管道。</li></ul> <p>表 29-2. 扩张时间表示例</p> <table><thead><tr><th><strong>术后月份</strong></th> <th><strong>扩张器颜色</strong></th> <th><strong>扩张器直径</strong>&lt;16&gt;</th> <th><strong>频率</strong></th></tr></thead> <tbody><tr><td><strong>0-3</strong></td> <td><strong>紫色</strong></td> <td>1又1/8英寸</td> <td>每日3次</td></tr> <tr><td><strong>3-6</strong></td> <td><strong>蓝色</strong></td> <td>1又1/4英寸</td> <td>每日1次</td></tr> <tr><td><strong>6-9</strong></td> <td><strong>绿色</strong></td> <td>1又3/8英寸</td> <td>隔日1次</td></tr> <tr><td><strong>9-12</strong></td> <td><strong>橙色</strong></td> <td>1又1/2英寸</td> <td>每周1-2次</td></tr></tbody></table> <p><em>来源：Brownstein＆Crane 手术服务</em></p> <p>术后直接风险包括出血，感染，皮肤或阴蒂坏死，缝合线裂开，尿潴留或阴道脱垂。直肠，尿道或膀胱的瘘管通常在早期出现。</p> <p>急性出血通常来自尿道，最通常情况下可通过局部压迫控制。如果无法通过局部压迫止血，则仅在尿道内放置较大的导管（20F）可止血。如有必要，在出血部位周围放置缝线（已放置导管）可在绝大多数情况下止血。通过阴道或缝合线自发排出局部血肿并非罕见。因血肿液化，这通常发生在手术后一周或更长时间。出血血液的典型外观较暗且陈旧，并无凝块出现。尽管这会使患者害怕，但并不需治疗。</p> <p>生殖器和会阴有极好的血液供应，因此感染应为罕见，并且很少需广谱抗生素以外的其他药物。皮肤蜕皮或脱落也很少见，应采取保守治疗。缝合线可能发生断裂，最常见于扩张时对会阴后部的压迫和拉伸。缝合线断裂应用抗生素软膏保守治疗，大多数情况下会愈合且无后果。不应因此停止扩张，这在此阶段至关重要。术后即时阶段未充分扩张可能导致严重的阴道狭窄。因其为受污染创口，故不应立即尝试二次闭合裂口，否则可能导致闭合失败。某些情况下，裂口会在后部形成蹼状疤痕，在后期阶段可轻易修正。</p> <p>术后可能发生部分或完全阴蒂坏死，应采用抗菌软膏进行保守治疗。大多数情况下，神经血管束和部分阴蒂仍然存在，并通常保持良好的敏感性。</p> <p>肿胀和/或暂时性外围神经损伤（神经性瘫痪）引起的尿潴留应更换导管进行5-7天治疗。此症状几乎完全是暂时的，应用盐酸坦索罗辛（哈乐®）会有帮助。早期的阴道狭窄非常罕见。</p> <p>患者可能会损失一部分移植皮肤并经阴道排出。此现象通常发生在手术后至少2周，并且通常是因阴道移植皮肤过多产生。其并无伴随出血，且脱落的皮肤似乎无法自生。</p> <p>术后恢复通常较为平静，且患者应持续扩张阴道。一个较为严重的并发症是整个阴道皮肤内衬被排出，其通常在早期发生（术后第一周内）并常至少伴有一些出血。这尽管罕见，但在大多数情况下是灾难性的，患者需要手术干预，通常须一年后重塑阴道。</p> <h3 id="术后延期-后期维护及考虑"><a href="#术后延期-后期维护及考虑" class="header-anchor">#</a> 术后延期/后期维护及考虑</h3> <p>严格遵守扩张方案对术后愈合及阴道深度和周长的维持至关重要。在最初愈合期后，必须在术后至少一年内定期坚持扩张。应定期检查阴道的深度和宽度，逐渐缩减扩张次数。如果通过患者报告或临床检查发现阴道深度或宽度减小，则应增加扩张计划。如果患者由于不适感而扩张困难，则用3cc注射器或有阴道抗真菌剂的涂药器在扩张器前部滴注润滑剂可能有帮助。患者可能对水性润滑剂中的防腐剂敏感；通常只需更换润滑剂品牌即易解决。</p> <p>扩张不足导致的阴道周长减小通常可由增加扩张频率弥补；阴道深度减小则较难仅通过扩张解决。持续的疼痛或其他扩张问题应与外科医生讨论。其他可能引起疼痛或扩张不足的原因包括骨盆入口过小或肌肉和阴道痉挛。解决方法包括但不限于注射肉毒杆菌毒素，移除阴道入口蹼状疤痕，和/或转至专门治疗骨盆疼痛和盆底问题的物理治疗师。</p> <p>阴道以皮肤为衬里，在正常情况下，皮肤菌群和一些阴道菌群在此繁殖；一项在术后出现及未出现阴道异味和分泌物的跨性别女性中的研究发现，最常见菌群包括金黄色葡萄球菌，链球菌，肠球菌，棒状杆菌，动弯杆菌和拟杆菌属。只在30名跨性别女性中的1人发现了乳酸杆菌，未发现念珠菌。阴道症状的出现与任一特定菌种之间没有相关性。[1]这些研究结果表明，跨性别女性出现阴道分泌物和异味不太可能是由于与非跨性别女性相同的原因，如菌群失调或念珠菌症等；事实上，黏膜的缺乏与低pH值也符合本研究中罕见乳酸杆菌和无念珠菌的发现。在大多数情况下，分泌物很可能是皮脂，死皮或角蛋白碎片，以及存留的精液或润滑剂。</p> <p>由于阴道不含黏膜，应常用肥皂水冲洗清洁应以保持卫生。在初期，患者应在频繁扩张期间每天冲洗阴道。扩张频率降低后，冲洗可以减少到每周2-3次。如果异味或分泌物持续存在，应检查病变或肉芽组织。如菌群过度生长或失调，2-3天内在水中使用醋或25％聚维酮碘溶液可能有帮助，之后患者可以恢复以肥皂和水清洁。如果分泌物和异味依然存在，实施5天的阴道甲硝唑疗程是合理的。</p> <p>尽管并无证据支持，考虑每年骨盆视觉检查以对病变，肉芽组织或不应出现的深度和周长减少进行筛查是合理的。由于阴道是皮肤衬里的，因此存在发生与阴茎和阴囊皮肤（鳞状细胞，基底细胞，黑色素瘤）上相同皮肤癌的风险。其他皮肤病（如牛皮癣）也会影响阴道，应进行类似治疗。如果需要，可在阴道内进行前列腺检查，因为直肠入路可能会被新存在于直肠和前列腺之间的阴道壁所阻挡。</p> <p>一种更罕见的阴道成形术是使用结肠或小肠壁组成阴道穹窿。该技术具有减少扩张需求，阴道深度增加并可自然进行自润滑的优点。然而此方法需要腹部手术，且存在严重甚至危及生命的并发症的风险。结肠方法的主要手术指征是对上述阴茎翻转成形术的修正。由于分泌物是消化性的，因此存在恶臭和频繁分泌的风险，并且分泌物不仅在受到唤起时，更会长期出现。可能有必要长期穿着内裤衬垫或护垫。术后治疗中菌群繁殖过度（转移性结肠炎）较为常见，并且分泌物可能呈绿色。肠皮阴道衬里的耐受度也不如皮瓣。肠道组织的使用也使阴道具有患肠疾病的风险，包括炎症性肠病（IBD），动静脉畸形（AVM）或肿瘤；应指导进行此类病症的筛查或诊断评估。</p> <h3 id="瘘管"><a href="#瘘管" class="header-anchor">#</a> 瘘管</h3> <p>最常见的瘘管是直肠阴道瘘。这些通常发生在阴道口5cm内的中线，几乎完全来自直肠手术损伤。小瘘管可能只通过排气，而较大的瘘管可以让粪便排出阴道。出于卫生考虑可能需要手术临时转移结肠造口。应继续扩张以避免阴道闭合，且应在至少6个月内修复瘘管。</p> <p>尿道阴道瘘以尿液从阴道泄漏的形式出现。大多数病例不需要或不需即刻干预，并且多数情况下患者仍然可以自制。应告知患者，尤其在性交后他们更容易受到尿路感染。通常情况下，性交后迅速排尿和/或用果汁或蔓越莓片酸化尿液可做到充足预防性护理。膀胱和阴道之间的瘘管是最罕见的，也最难控制。膀胱中的导尿管会导出大部分（但非全部）尿液；通常需外科手术。</p> <h3 id="肉芽组织"><a href="#肉芽组织" class="header-anchor">#</a> 肉芽组织</h3> <p>阴道中的肉芽组织是延迟愈合的结果，并较为常见。术后早期阶段频繁扩张的需求会通过对肉芽区域造成反复创伤而加剧此问题。多数情况下，这会由于频繁扩张的需求随时间下降而逐步愈合。如症状持续，定期用硝酸银治疗和局部类固醇乳膏（去炎松®）治疗，或医用级蜂蜜（麦卢卡蜂蜜）可加速愈合。可以将硝酸银滴加到肉芽区域，直至观察到烧灼，产生灰色结痂和凝结。可以在扩张器的尖端涂上类固醇乳膏或蜂蜜。长期来看，阴茎皮肤内衬的阴道应极为耐用。</p> <h3 id="尿路感染-uti"><a href="#尿路感染-uti" class="header-anchor">#</a> 尿路感染（UTI）</h3> <p>由于在阴道成形术期间尿道缩短，尿路感染并不罕见。通常情况下适当的卫生和润湿措施可充分预防尿路感染。对患有复发性尿路感染的患者，应进行尿道狭窄检查。一个简单的诊断测试是试图将16F导管通入膀胱以排除狭窄，包括球部尿道后或尿路口狭窄。黏膜瓣引起尿道口过大的患者需要精细的卫生和预防措施。由于前列腺退化，大多数患者会在较长时间内感到存留较多尿液能力降低。极少数人甚至可能会出现急迫性尿失禁。托特罗定®或达非那新®等膀胱松弛剂对此病例有帮助。</p> <h3 id="阴道敏感度与性高潮"><a href="#阴道敏感度与性高潮" class="header-anchor">#</a> 阴道敏感度与性高潮</h3> <p>在手术过程中不应切断重要的感觉神经，因此阴道成形术后不应对阴道敏感性产生不良影响。在2002年发表的一项结局研究中，作者治疗的86%的患者可产生性高潮。[2]尽管先前快感缺失的患者可能在术后出现高潮，术前功能也是一个重要的指标。长期的雌激素/抗雄激素治疗和睾丸切除术可能共同导致一些患者性欲下降，在其他指南中已有讨论。</p> <h3 id="参考文献-28"><a href="#参考文献-28" class="header-anchor">#</a> 参考文献</h3> <ol><li>Weyers S, Verstraelen H, Gerris J, Monstrey S, dos Santos Lopes Santiago G, Saerens B, et al. Microflora of the penile skin-lined neovagina of transsexual women. BMC Microbiol. 2009;9(1):102.</li> <li>Lawrence AA. Factors associated with satisfaction or regret following male-to-female sex reassignment surgery. Arch Sex Behav. 2003 Aug;32(4):299–315.</li></ol> <blockquote><p>&lt;16&gt;. 译者注：直径分别约28.6mm, 31.8mm, 34.9mm, 38.1mm</p></blockquote> <h2 id="阴茎成形术和阴蒂释放术-概述和术后考虑"><a href="#阴茎成形术和阴蒂释放术-概述和术后考虑" class="header-anchor">#</a> 阴茎成形术和阴蒂释放术——概述和术后考虑</h2> <p>主要作者： Curtis Crane, MD</p> <h3 id="概论-19"><a href="#概论-19" class="header-anchor">#</a> 概论</h3> <p>对跨性别男性的阴茎成形术涉及到选用数种手术中的一种来制作阴茎；术中可使用独立或带蒂的皮瓣，术中使用的皮瓣通常取自手臂（前臂径向游离皮瓣成形术，RFF）或大腿前侧（大腿前侧带蒂皮瓣成形术，ALT）。在使用游离皮瓣的手术中，组织与供血部位一同从供体部位被完全移除，然后将其供血与转移部位的受体供血匹配。在带蒂皮瓣手术中，整台手术中组织将不会被切断供血。手术可以使用上述任何一种方法，将供体皮肤卷成管状结构并移植到腹股沟区域。为了使发生瘘管的风险最小化，通常在子宫切除术和阴道切除术（或阴道黏膜消融术）后进行阴茎成形术。也可以使用皮肤皮瓣进行阴囊成形术。阴囊成形术可以在有或没有睾丸植入物的情况下进行。可以使用内颊或阴道的黏膜进行尿道连接，并且可以选择放置勃起植入物。通常整个阴茎成形术过程涉及多阶段手术，早期阶段的手术在完成整个阴茎成形术的成形过程之前使皮肤移植物得以重塑局部的供血系统。根据手术方法不同，人造阴茎可能有也可能没有性快感。</p> <h3 id="与阴茎成形术相关的风险"><a href="#与阴茎成形术相关的风险" class="header-anchor">#</a> 与阴茎成形术相关的风险</h3> <p>任何手术都存在常见的一些风险，包括感染，出血，周围组织损伤和疼痛。针对跨性别男性的阴茎成形术，存在皮瓣损失、尿道并发症、伤口破裂、盆腔流血或疼痛、膀胱或直肠损伤、触感缺失、需要长期进行引流，或需要进一步手术的风险。在组织供体部位，存在诸如难看的疤痕、伤口破损、肉芽组织形成、灵活性下降、血肿、疼痛和触感下降等风险。如果患者在术后出院并且不在当地，他们应当在术后第一年内每三个月在其初级护理提供者处就诊一次。</p> <p>下面列出了一些最常见的并发症。不同的技术和方法可以具有不同的并发症，不同的外科医生也可能有不同的并发症发生率；了解不同外科医生的执行的手术程序，他们的经验，执行这些程序的频率以及并发症发生率是有帮助的。</p> <h3 id="游离或带蒂皮瓣阴茎成形术后直接或早期-一个月内的-并发症"><a href="#游离或带蒂皮瓣阴茎成形术后直接或早期-一个月内的-并发症" class="header-anchor">#</a> 游离或带蒂皮瓣阴茎成形术后直接或早期（一个月内的）并发症</h3> <p><strong>伤口感染</strong>通常在手术后的最初几周内发生，可以表现为蜂窝组织炎、真菌感染或两者都有。抗生素和抗真菌霜通常足以治疗。在某些情况下，可能需要静脉注射抗生素。</p> <p><strong>伤口破裂</strong>是常见的并且通常发生在多条缝合线相交的点（即阴囊-阴囊连接处和阴茎基部）。大多数伤口破裂问题可以通过局部伤口护理（更换由湿至干敷料法，wet to dry dressing changes）来控制，从而使伤口通过2期愈合&lt;17&gt;（Secondary intention）康复。一些伤口破裂可能需要清创，并且极少数可能需要皮肤移植或进一步的外科手术来闭合伤口。</p> <p><strong>导尿管问题</strong>体现为导管堵塞或膀胱痉挛。此类问题通过确保管道中没有扭结或扭曲，冲洗导管和抗痉挛药物（抗胆碱能药物）来处理。在导尿管中的尿路感染（UTI）可以发生并呈现出一系列症状，包括尿液混浊，尿液恶臭，膀胱痉挛增加或导管周围渗漏。这些症状可能会或可能不会出现发烧或其他全身症状。如果患者没有出现一系列此类症状，即使尿液分析（UA）和尿培养（UCx）显示与感染一致的实验室检查结果，也不太可能是真正的UTI。</p> <p><strong>皮瓣损失</strong>很少见，并且通常由于技术错误（错位的显微外科缝线或血管蒂扭结/压缩）而发生。皮瓣损失通常在最初的72小时内出现，如果早期（几小时内）被识别，可以通过紧急返回手术室来挽救。返回手术室时，将压迫血管蒂的血肿引流，修复动脉或静脉吻合，或者在某些情况下用球囊导管进行机械血栓切除术或将组织纤溶酶原激活物（tPA）灌注到皮瓣中可以避免皮瓣丢失。即使采取这些措施，也可能出现部分或完全的皮瓣损失。</p> <p>高凝状态可使患者在手术和皮瓣损失后易于凝血。在皮瓣血栓形成的情况下，应考虑未确诊的凝血障碍，如凝血因子V Leiden，抗磷脂综合征，凝血酶原基因突变G20210A，抗凝血酶III缺乏，蛋白C和S缺乏，以及高同型半胱氨酸血症。</p> <p><strong>盆腔或腹股沟血肿</strong>可能发生，可通过引流处理，或可能需要手术引流。虽然用普通肝素或低分子肝素（Lovenox）预防深静脉血栓形成可能会使患者血肿形成的风险更高，但必须权衡这种风险与深静脉血栓形成和肺栓塞的风险。存在风险评估模型以帮助确定个体化的围手术期抗凝方式。[1]虽然这些风险评估通常由外科医生进行，但了解个体患者血栓栓塞或围手术期出血风险增加的初级护理提供者应在手术前通知外科医生。</p> <p><strong>直肠损伤</strong>是一种罕见但严重的并发症。该手术的阴道切除术部分涉及在阴道后壁和直肠前壁之间形成一个平面。剪刀划伤或烧灼伤可能造成此类损伤。直肠壁的无意伤害可以急性地（可被立即得知和修复）或亚急性地（几天到几周）出现。在亚急性期中识别直肠损伤可以基于发热，寒战，不适或（更明显的）败血症症状等全身症状。手术野中直肠的部分在腹膜外，所以腹痛或腹膜征是异常的。从会阴切口，阴囊或阴茎底部排出粪便表明在直肠壁和皮肤之间有瘘管形成。这种伤口需要住院治疗，并需要普通外科参与护理计划。可能需要短期结肠造口术来转移粪便流并使瘘管闭合。可能需要冲洗盆腔脓肿并闭合直肠瘘，可能需要2期伤口愈合。</p> <h3 id="游离或带蒂皮瓣阴茎成形术后长期并发症"><a href="#游离或带蒂皮瓣阴茎成形术后长期并发症" class="header-anchor">#</a> 游离或带蒂皮瓣阴茎成形术后长期并发症</h3> <p><strong>尿道狭窄</strong>通常在手术后6-12个月出现，伴有弱流症状，排尿困难，有时伴有瘘管继发于远端梗阻。这将需要通过扩张或尿道成形术进行外科手术。</p> <p><strong>伤口收缩和瘢痕形成</strong>是皮肤切割时出现的并发症，但它们发生的程度在患者之间变化很大。有些患者比其他患者更容易形成疤痕。随着伤口内的肌成纤维细胞在最初的2-9天内变得活跃，所有瘢痕都随时间而收缩。[2]伤口挛缩是减少缺损尺寸，减少必须愈合的有效表面积的自然机制。然而，伤口挛缩可导致周围组织扭曲和轮廓缺陷。通过2期愈合关闭的伤口显示出比1期愈合更多的挛缩。</p> <p><strong>瘢痕</strong>可能呈细线状，也可以变宽或变得肥厚，甚至可以超越瘢痕的边界（瘢痕疙瘩）。通过切除和重新闭合可以成功地修复肥厚性疤痕，减少皮肤张力，以减少复发。瘢痕疙瘩很少发生，通常发生在倾向于瘢痕疙瘩形成的人群中。单纯切除和闭合后瘢痕疙瘩的复发率非常高（至少70％）。类固醇注射剂，硅胶敷料和压缩敷料，以及放射疗法已被作为治疗方式提供，会给复发率带来有限改善。</p> <p><strong>肉芽组织</strong>常见于供体位置周围和皮瓣内部。其外观体现了成纤维细胞和小血管的过度增殖。根据需要，大多数肉芽组织可以通过周期性局部施用硝酸银来在几次就诊内得到处理。硝酸银可导致处理组织的暗斑，其可持续数周至数月。然而，肉芽组织很少需要更多的治疗。</p> <p><strong>阴茎头冠扁平化</strong>（Corona flattening）有时会出现，可能需要在第二阶段手术（通常是阴茎和睾丸植入）的同时进行修复手术。</p> <h3 id="勃起植入物"><a href="#勃起植入物" class="header-anchor">#</a> 勃起植入物</h3> <p>在阴茎成形大约九个月后，患者可以放置阴茎植入物以获得能插入的硬度。目前，没有专门为跨性别患者制作的FDA批准的植入物。因此，为具有勃起功能障碍的非跨性别男性制作的植入物可刚性固定到耻骨上。并发症可能包括感染和侵蚀。</p> <p><strong>感染</strong>是阴茎植入物最常见的并发症。术前和术后抗生素以及术中无菌技术可降低风险。如果植入物被感染，通常必须将其移除。六个月后可以更换新植入物。</p> <p><strong>侵蚀</strong>是指植入物通过阴茎或尿道的皮肤突出。在阴茎中保留感觉，以及避免过大的植入物降低了侵蚀的风险。与感染一样，植入物的侵蚀需要手术移除。</p> <h3 id="排尿困难"><a href="#排尿困难" class="header-anchor">#</a> 排尿困难</h3> <p>如果最近完成阴茎成形术的患者出现排尿困难，最好的方法是进行尿培养。尿液分析几乎没有价值，因为在正常患者在术后几个月内都可以检测到白细胞和红细胞。如果尿培养呈阳性，应使用培养特异性抗生素治疗感染。如果结果为阴性，最可能的原因是尿道狭窄，应由执行阴茎成形术的外科医生评估，或者在无法进行时由当地泌尿科医生进行评估。</p> <h3 id="阴蒂释放术"><a href="#阴蒂释放术" class="header-anchor">#</a> 阴蒂释放术</h3> <p>阴蒂释放术（metoidioplasty, metaoidioplasty）是一个希腊词，意为“向男性生殖器”。睾酮会导致阴蒂生长；阴蒂释放术仅使用局部组织（无移植）创造一个较小的1至3英寸阴茎，其周长约为拇指的大小。患者可能选择将尿道置于阴茎中，但并非所有患者都选择这样做。也可以从大阴唇创造阴囊，并且可以同时进行阴道切除术。</p> <p>因为阴蒂释放术是一个较短的过程，偶尔子宫切除术与阴蒂释放术同时进行。一些外科医生可能会使用组织扩张器来制造阴囊，而其他人则认为没有必要。睾丸植入物通常在第二阶段中大约4个月后放置。虽然阴茎大小不足以接受阴茎植入物，但可以勃起，因为该过程使用先天具有的阴蒂和其他生殖器组织。</p> <p>与阴蒂释放术相关的并发症与游离皮瓣阴茎成形术非常相似（除皮瓣损失，因为没有使用皮瓣）。伤口破裂，感染，尿道狭窄和瘘管均见于与游离皮瓣成形术类似的解剖部位，尽管在阴蒂释放术中发生率较低。在阴蒂释放术中不会发生诸如阴茎头冠扁平化的风险，因为在阴蒂释放术中阴茎头冠不需要成形。并发症的处理类似于阴茎成形术部分。</p> <h3 id="参考文献-29"><a href="#参考文献-29" class="header-anchor">#</a> 参考文献</h3> <ol><li>Pannucci CJ, Bailey SH, Dreszer G, Fisher Wachtman C, Zumsteg JW, Jaber RM, et al. Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients. J Am Coll Surg. 2011 Jan;212(1):105–12.</li> <li>Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol. 2007 Mar;127(3):526–37.</li></ol> <blockquote><p>&lt;17&gt;. 译者注：指伤口边缘不清晰（通常由于难以闭合或缝合，或组织损失过多）情况下的康复。</p></blockquote> <h2 id="子宫切除术"><a href="#子宫切除术" class="header-anchor">#</a> 子宫切除术</h2> <p>主要作者： Juno Obedin-Maliver, MD, MPH</p> <h3 id="概论-20"><a href="#概论-20" class="header-anchor">#</a> 概论</h3> <p>WPATH认为，同时进行或不进行输卵管切除术/卵巢切除术的子宫切除术，在医学上是选择寻求这种手术的跨性别男性的性别肯定外科治疗的必要组成部分。[1]目前尚不清楚有多少跨性别男性为性别肯定或在性别焦虑的情况下希望接受子宫切除术。在国家跨性别歧视调查中，接受调查的跨性别男性有21％接受了子宫切除术。[2]58％的人希望在未来的某个时间进行子宫切除术，21％的人不希望进行子宫切除术。目前尚不清楚已经接受过子宫切除术的人与未来希望手术的人有什么区别，尽管很可能在于护理和经济上的考虑。生殖欲望如何影响他们做出接受子宫切除术或卵巢切除术的决定也不清楚。</p> <p>此外，本研究尚不清楚这些子宫切除术中有多少比例是由于医学病理状况而非性别焦虑，因为子宫切除术是最常见的非产科外科手术之一。</p> <p>一项针对134名跨性别男性的研究报告了子宫切除术的多种适应证，大多数手术都是针对性别肯定进行的。在该研究中，58％的患者因器官与目前的性别认同不一致而接受了子宫切除术，47％为进一步的身体男性化，43％为促进法律文件的变更，37％为避免将来的妇科预约。然而，同样的研究还指出，对于许多人来说，这种手术在59％的情况下被视为“预防性”手术，26%的情况下因先前存在的医疗问题进行，特别是22％的“肿瘤，囊肿，子宫肌瘤或子宫内膜异位症”以及22％为了阻止子宫重度出血和痉挛。[3]由于用于性别肯定的子宫切除术最近才得到广泛而明确的保险覆盖且仍在发展中，共存的性别焦虑可能促进了一些在病理状况的情况下进行子宫切除术的决定。</p> <h3 id="手术方法"><a href="#手术方法" class="header-anchor">#</a> 手术方法</h3> <p>尚未有跨性别男性的子宫切除手术方法最佳实践的研究。子宫切除术可以在腹部，通过腹腔镜或在阴道进行。根据现有证据，美国妇产科医师大会已经指出，对于适合这种方法的患者，阴道方法具有并发症和失血最少，恢复最快的优点，是最具成本效益的。[4]对于跨性别男性，阴道子宫切除术还具有不留腹部疤痕的好处。初始数据[5,6]支持阴道子宫切除术适用于跨性别男性的观点。许多其他研究指出，腹腔镜子宫切除术作为子宫切除术侵入性次小的形式也是可行的，并且可以在没有其他并发症的情况下成功完成。[7–11]</p> <p>子宫切除术已成功与同一天在同一手术室进行的其他性别肯定手术相结合，包括阴道切除术，乳房切除术和生殖器重建术，包括阴蒂释放术和阴茎成形术。[10,12]子宫切除术本身并没有很大差异，但并行手术和切口长度的一些修正可能因跨性别者的目标而异。例如，如果接受子宫切除术的跨性别男性将来没有进行阴道性交的计划，那么可以在更外部闭合阴道断端，从而减少阴道口的残留。类似地，如果不需要阴道口，只要不计划将来使用阴道黏膜进行生殖器重建手术（用于尿道延长等），可以进行阴道切除术（去除阴道黏膜组织）和阴道闭合术（闭塞阴道管）。最后，考虑是否在手术时保留或移除卵巢和输卵管也是个人决定，并且基于对患者期望，未来生育能力，外源性（类固醇）激素给药计划，以及其他可由卵巢去除（子宫内膜异位症等）辅助或加剧的疾病的考虑。</p> <p>虽然WPATH护理标准规定在子宫切除术之前需要进行两次心理健康评估，但这在学术上[7]和实践中[13]受到了挑战；因非跨性别女性可能由于出现同等或更少引人注意的症状，而在没有类似限制的情况下接受子宫切除术。</p> <h3 id="参考文献-30"><a href="#参考文献-30" class="header-anchor">#</a> 参考文献</h3> <ol><li>World Professional Association for Transgender Health (WPATH). Standards of care for the health of transsexual, transgender, and gender nonconforming people, 7th Version [Internet]. WPATH; 2012 [cited 2016 Mar 10]. Available from: [http://www.wpath.org/uploaded_files/140/files/Standards%20of%20Care,%20V7%20Full%](http://www.wpath.org/uploaded_files/140/files/Standards of Care%2C V7 Full%) 20Book.pdf</li> <li>Grant JM, Mottet LA, Tanis J, Harrison J, Herman J, Keisling M. Injustice at every turn: a report of the National Transgender Discrimination Survey [Internet]. National Center for Transgender Equality and National Gay and Lesbian Task Force; 2011 [cited 2016 Mar 17]. Available from: http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf</li> <li>Rachlin K, Hansbury G, Pardo ST. Hysterectomy and oophorectomy experiences of female-to-male transgender individuals. Int J Transgenderism. 2010 Oct 12;12(3):155–66.</li> <li>Committe on Gynocologic Practice. ACoOa. <a href="http://www.acog.org/-/media/Committee-Opinions/Committee-on-Gynecologic-Practice/co444.pdf?dmc=1&amp;ts=20141105T0749303173" target="_blank" rel="noopener noreferrer">Committee Opinion No. 444: Choosing the<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.acog.org/-/media/Committee-Opinions/Committee-on-Gynecologic-Practice/co444.pdf?dmc=1&amp;ts=20141105T0749303173" target="_blank" rel="noopener noreferrer">Route of Hysterectomy for Benign Disease<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>. [Internet]. ACOG; 2011 [cited 2016 Mar 20]. Available from: http://www.acog.org/-/media/Committee-Opinions/Committee-on- Gynecologic-Practice/co444.pdf?dmc=1&amp;ts=20141105T0749303173</li> <li>Obedin-Maliver J, Light A, DeHaan G, Steinauer J, Jackson R. Vaginal hysterectomy as a viable option for female-to-male transgender men: Obstet Gynecol. 2014 May;123:126S – 127S.</li> <li>Kaiser C, Stoll I, Ataseven B, Morath S, Schaff J, Eiermann W. [Vaginal hysterectomy and bilateral adnexectomy for female to male transsexuals in an interdisciplinary concept] Vaginale Hysterektomie und beidseitige Adnexektomie in interdisziplinärem Konzept bei Frau zu Mann – Transsexualismus. Handchir · Mikrochir · Plast Chir. 2011 Aug;43(04):240–5.</li> <li>O’Hanlan KA, Dibble SL, Young-Spint M. Total laparoscopic hysterectomy for female-to- male transsexuals. Obstet Gynecol. 2007 Nov;110(5):1096–101.</li> <li>Bartos P, Struppl D, Popelka P. [Role of total laparoscopic hysterectomy in genital reconstruction in transsexuals]. Ceska Gynekol Ceska Lek Spolecnost J Ev Purkyne. 2001 May;66(3):193–5.</li> <li>Chapin DS. Laparoscopically assisted vaginal hysterectomy in female-to-male transsexuals. Plast Reconstr Surg. 1993 Apr;91(5):962.</li> <li>Ergeneli MH, Duran EH, Ozcan G, Erdogan M. Vaginectomy and laparoscopically assisted vaginal hysterectomy as adjunctive surgery for female-to-male transsexual reassignment: preliminary report. Eur J Obstet Gynecol Reprod Biol. 1999 Nov;87(1):35–7.</li> <li>Perrone AM, Scifo MC, Martelli V, Casadio P, Morselli PG, Pelusi G, et al. Hysterectomy and bilateral salpingoovariectomy in a transsexual subject without visible scarring. Diagn Ther Endosc. 2010;2010.</li> <li>Ott J, van Trotsenburg M, Kaufmann U, Schrögendorfer K, Haslik W, Huber JC, et al. Combined hysterectomy/salpingo-oophorectomy and mastectomy is a safe and valuable procedure for female-to-male transsexuals. J Sex Med. 2010 Jun;7(6):2130–8.</li> <li>Weiss E, Green J. Transgender patients care. Am J Obstet Gynecol. 2014 Aug;211(2):185–6.</li></ol> <h2 id="束胸、包装和翻折隐藏"><a href="#束胸、包装和翻折隐藏" class="header-anchor">#</a> 束胸、包装和翻折隐藏</h2> <p>主要作者： Madeline B. Deutsch, MD, MPH</p> <p>**翻折隐藏（Tucking）**使得裆部轮廓明显光滑。在这种实践中，会将睾丸（如果存在的话）移入腹股沟管，并使阴茎和阴囊在会阴区域向后移动。然后穿着紧身内衣或称为<em>gaffe</em>的特殊内衣来保持这种形状。在某些情况下，可能会使用粘合剂或甚至胶带。除了局部皮肤影响外，这种做法还可能导致尿道损伤或感染，以及其他地方的睾丸疾病。</p> <p>**包装（Packing）**是将阴茎假体置于一个人的内衣中的过程，既改善外观又可减少性别焦虑。</p> <p>**束胸（Binding）**涉及使用紧身运动文胸，衬衫，绷带或特制粘合剂，以提供平坦的胸部轮廓。在一些乳房较大的人中，可能使用多层织物，并且可能限制呼吸。长期束胸可能导致乳房疼痛，局部皮肤刺激或真菌感染。</p> <h2 id="脱毛"><a href="#脱毛" class="header-anchor">#</a> 脱毛</h2> <p>主要作者： Cecily Reeves, PhD, FNP-C/PA-C; Madeline B. Deutsch, MD, MPH; Jeannine Wilson Stark, LE, CPE</p> <h3 id="概论-21"><a href="#概论-21" class="header-anchor">#</a> 概论</h3> <p>对多余毛发的处理由于许多原因通常对跨性别者造成挑战。此类障碍包括接触有跨性别相关经验的美容服务提供者，交通，价格以及关于选项、风险和益处的困惑。[1,2]虽然跨性别者的脱毛保险范围正在扩大，但仍然不一致，可能是患者和提供者的沮丧和焦虑的一个重要来源。[3,4]</p> <p>跨性别男性、跨性别女性以及其他性别非常规个体可能寻求服务；每个患者的护理计划最好根据他们的个人需求和过渡目标进行个性化。跨性别女性通常寻求在面部，颈部以及生殖器区域（作为阴道成形术的术前准备）去除毛发。[5,6]跨性别男性通常寻求在前臂或大腿未来移植部位减少毛发以准备阴茎成形术。[5,7]虽然物理除毛（拔毛、使用蜡类产品或Epi-Lady型装置&lt;18&gt;）和脱毛剂（化学品）能临时去除毛发，但许多人寻求永久性毛发减少/去除方式：激光脱毛（LHR）和电解脱毛（EHR）。[8,9]与任何转诊护理一样，理想情况是与经验丰富、易于接触且在跨性别社区有良好声誉的从业者建立良好关系。</p> <h3 id="方法与利弊"><a href="#方法与利弊" class="header-anchor">#</a> 方法与利弊</h3> <p>毛发生长周期由三个连续阶段组成，包括毛发生长期，过渡期和休止期每根毛发都处于自己的发展阶段。每个阶段的时长可以根据位置而变化，从身体上的一个月到两个月的生长期，到头皮上的两到六年。头发生长的模式也可能因性别和种族而异。[10]以下两种方法的有效性在一定程度上依赖于毛发生长周期的时间，在毛发处于生长期时会取得最理想的效果。两者都需要多次脱毛过程；由于有效率约为85-90％，激光脱毛和电解脱毛的组合可能为许多人提供最佳效果。为获得持续的效果通常需要终生的脱毛处理。[10-12]</p> <p><strong>激光脱毛</strong>：激光的使用被认为是一种“医疗程序”，提供选择性地以深色粗毛为目标的光照。[13]深色头发中的色素会吸收光线，从而产生热量，从轴向下传播以破坏毛囊。它可以处理更大的表面积，比EHR更省时。治疗通常每4-8周进行一次，取决于治疗位置，因为毛发生长周期因面积而异。安全性和有效性可能因所使用的平台（二极管，红宝石，掺钕钇铝石榴石；[Nd:YAG]等），患者皮肤类型和头发特征而异。LHR通常对薄，浅，红，金发或白发无效。波长为1064（Nd:YAG）是对黑皮肤个体安全的唯一波长（Fitzpatrick皮肤类型5或6）。[9,11]</p> <p>LHR已获FDA批准用于永久<em>减少</em>毛发。在接受治疗之前，患者需要由医疗提供者（NP/PA/MD等）进行评估；关于激光操作员资格和执照的规定因美国州而异，有些州要求注册护士。[10]</p> <p>与使用选择性光热疗法的任何基于光的治疗一样，过热可导致发红，水疱，烧伤，以及随后的过度或低色素沉着。[14-16]其中大多数是罕见的和暂时的；但是，任何有瘢痕瘤病史的患者（可在低能见度区域做测试）都应该小心，LHR禁用于可能因光照暴露而发炎的情况，如红斑狼疮[17]。有单纯疱疹爆发病史的患者应该注意到光刺激发病的可能性（在治疗区域）并且需准备用于自我治疗的抗病毒药物。</p> <p>使用光敏药物时应避免治疗（见表[18]）。不要治疗活动性感染区域。众所周知，闪光灯会引起易感患者的癫痫发作，因此应对患者进行筛查。[19]面部护理需要紧闭双眼，以防止视网膜暴露和损伤。</p> <p>在非面部身体治疗期间可使用保护性的、用于特定波长的护目镜。[20]</p> <p>激光脱毛的相关禁忌症：</p> <ul><li>病史：黑色素瘤，痣，可疑病变，瘢痕瘤形成，愈合问题，活动性感染，开放性病变，荨麻疹，疱疹病变，唇疱疹，治疗区域纹身或永久性化妆，近期使用异喹啉，四环素，或最近一年使用圣约翰草，自身免疫性疾病如狼疮、硬皮病、白癜风。[17,18]</li> <li>虽然不是治疗的禁忌症，但以下药物可能会导致毛发生长增加：青霉素，环孢菌素，皮质类固醇，氟哌啶醇，苯妥英，甲状腺药物。[18]</li></ul> <p><strong>电解脱毛</strong>通过非常细的探针的电流来破坏单个毛囊的根部。电解脱毛有三种类型：电化学（直流电流产生化学反应）、热解（透热疗法：产生热量的短波）和混合（电化学和热解的组合）。[21]由于电解涉及根部的直接机械破坏，因此它可用于所有毛发颜色和皮肤类型。根据患者的疼痛耐受性，治疗通常是每周一次并持续长达1小时。每次针对单根毛发进行治疗的方式耗时而昂贵，但是当用于治疗对激光脱毛缺乏反应的毛发时非常有效。较新的技术/脱毛器（27MHz频率）进行治疗时更加舒适，并且可能比旧型号机器（14MHz频率）更安全。随着频率的增加，产生的热量也会增加，从而提高效率。[22]电解被FDA批准用于永久<em>移除</em>毛发。在美国，电解医师在其实践中获得许可并独立开展医疗实践。</p> <p>与激光脱毛相关的一些风险同样适用于电解脱毛：发红，色素变化，以及避免活动性皮炎或感染的区域。[23]患有心脏起搏器的患者进行热解治疗较为安全，但应在治疗前与心脏病专家讨论。家用激光或电解设备尚未证明有效并可能造成伤害。[24]</p> <h3 id="脱毛过程中的疼痛管理"><a href="#脱毛过程中的疼痛管理" class="header-anchor">#</a> 脱毛过程中的疼痛管理</h3> <p>在任何一种脱毛过程中都会有一些不适。[25]每个患者最好单独评估，以确定疼痛管理的最佳方法。对每种治疗的反应可以根据治疗的位置，水合程度，焦虑和压力而变化。创造一个舒缓的环境、使患者安心、深呼吸、合适的设备方向、使用“测试点”、冷敷预处理和非处方止痛药（对乙酰氨基酚）可能都有帮助。最好在治疗前后避免立即使用非甾体类消炎药&lt;19&gt;，以尽量减少瘀伤的风险。麻醉剂通常不需要使用，但在某些情况下可能是适当的。</p> <h4 id="局部麻醉剂"><a href="#局部麻醉剂" class="header-anchor">#</a> 局部麻醉剂</h4> <p>含利多卡因的产品（单独或复合形式）在治疗开始时和患者需要时可以向患者提供。局部麻醉剂减少与手术相关的疼痛且副作用最小。必须特别注意特定的解剖位置，覆盖的总表面积和麻醉皮肤接触的持续时间。局部麻醉剂可在治疗前15-45分钟应用，通常在手术期间或手术后取出。[26-30]使用EMLA（利多卡因2.5％和普鲁卡因2.5％）可能效果有限，主要是由于在预处理阶段期间需要长时间起效和需要闭塞屏障。20％苯佐卡因，8％利多卡因和4％丁卡因（BLT）的组合是常见且有效的。该准备工作仅应由持照医疗服务提供者或护士进行，因为过量使用会产生毒性。</p> <h3 id="参考文献-31"><a href="#参考文献-31" class="header-anchor">#</a> 参考文献</h3> <ol><li>Roberts TK, Fantz CR. Barriers to quality health care for the transgender population. Clin Biochem. 2014 Jul;47(10-11):983–7.</li> <li>Radix AE, Lelutiu-Weinberger C, Gamarel KE. Satisfaction and healthcare utilization of transgender and gender non-conforming individuals in NYC: a community-based participatory study. LGBT Health. 2014 Dec;1(4):302–8.</li> <li>Human Rights Campaign. <a href="http://www.hrc.org/resources/finding-insurance-for-transgender-related-healthcare/" target="_blank" rel="noopener noreferrer">Finding Insurance for Transgender-Related Healthcare<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. Human Rights Campaign. [cited 2016 Mar 22]. Available from: http://www.hrc.org/resources/finding-insurance-for-transgender-related-healthcare/</li> <li>Transgender Law Center. <a href="http://www.transgenderlaw.org/resources/tlchealth.htm" target="_blank" rel="noopener noreferrer">Recommendations for Transgender Health Care<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. [cited 2016 Mar 22]. Available from: http://www.transgenderlaw.org/resources/tlchealth.htm</li> <li>Ginsberg BA, Calderon M, Seminara NM, Day D. A potential role for the dermatologist in the physical transformation of transgender people: A survey of attitudes and practices within the transgender community. J Am Acad Dermatol. 2016 Feb;74(2):303–8.</li> <li>San Francisco Department of Public Health (SFDPH). <a href="https://www.sfdph.org/dph/comupg/oprograms/THS/eligibility.asp" target="_blank" rel="noopener noreferrer">Patient Education for Vaginoplasty<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. Transgender Health Services. [cited 2016 Mar 22]. Available from: https://<a href="http://www.sfdph.org/dph/comupg/oprograms/THS/eligibility.asp" target="_blank" rel="noopener noreferrer">www.sfdph.org/dph/comupg/oprograms/THS/eligibility.asp<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a></li> <li>San Francisco Department of Public Health (SFDPH). <a href="https://www.sfdph.org/dph/comupg/oprograms/THS/eligibility.asp" target="_blank" rel="noopener noreferrer">Patient Education for Phalloplasty<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. Transgender Health Services. [cited 2016 Mar 22]. Available from: https://<a href="http://www.sfdph.org/dph/comupg/oprograms/THS/eligibility.asp" target="_blank" rel="noopener noreferrer">www.sfdph.org/dph/comupg/oprograms/THS/eligibility.asp<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a></li> <li>Haedersdal M, Wulf HC. Evidence-based review of hair removal using lasers and light sources. J Eur Acad Dermatol Venereol JEADV. 2006 Jan;20(1):9–20.</li> <li>Sadighha A, Mohaghegh Zahed G. Meta-analysis of hair removal laser trials. Lasers Med Sci. 2009 Jan;24(1):21–5.</li> <li>Shenenberger DW, Utecht LM. Removal of unwanted facial hair. Am Fam Physician. 2002 Nov 15;66(10):1907–11.</li> <li>Battle EF. Advances in laser hair removal in skin of color. J Drugs Dermatol JDD. 2011 Nov;10(11):1235–9.</li> <li>Somani N, Turvy D. Hirsutism: an evidence-based treatment update. Am J Clin Dermatol. 2014 Jul;15(3):247–66.</li> <li>Mayo Clinic. <a href="http://www.mayoclinic.org/tests-procedures/laser-hair-removal/basics/definition/prc-20019438" target="_blank" rel="noopener noreferrer">Laser hair removal<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. Tests and Procedures. [cited 2016 Mar 22]. Available from: http://www.mayoclinic.org/tests-procedures/laser-hair- removal/basics/definition/prc-20019438</li> <li>Bashour M. <a href="http://emedicine.medscape.com/article/843831-overview%23a4" target="_blank" rel="noopener noreferrer">Laser Hair Removal<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. 2016 [cited 2016 Mar 22]. Available from: <a href="http://emedicine.medscape.com/article/843831-overview" target="_blank" rel="noopener noreferrer">http://emedicine.medscape.com/article/843831-overview#a4<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a></li> <li>Lim SPR, Lanigan SW. A review of the adverse effects of laser hair removal. Lasers Med Sci. 2006 Sep;21(3):121–5.</li> <li>Liew SH. Laser hair removal: guidelines for management. Am J Clin Dermatol. 2002;3(2):107–15.</li> <li>WebMD. <a href="http://www.webmd.com/lupus/features/lupus-skin-care-makeup" target="_blank" rel="noopener noreferrer">Lupus Health Center<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. WebMD. [cited 2016 Mar 22]. Available from: http://www.webmd.com/lupus/features/lupus-skin-care-makeup</li> <li>Levine JI. <a href="https://www.vitiligosupport.org/newsletters/fall2012/medication.pdf" target="_blank" rel="noopener noreferrer">Photosensitizing medication list<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. 2008 [cited 2016 Mar 22]. Available from: https://<a href="http://www.vitiligosupport.org/newsletters/fall2012/medication.pdf" target="_blank" rel="noopener noreferrer">www.vitiligosupport.org/newsletters/fall2012/medication.pdf<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a></li> <li>Epilepsy Foundation. <a href="http://www.epilepsy.com/learn/triggers-seizures/photosensitivity-and-seizures" target="_blank" rel="noopener noreferrer">Photosensitivity and Seizures<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. Epilepsy Foundation. [cited 2016 Mar 22]. Available from: http://www.epilepsy.com/learn/triggers- seizures/photosensitivity-and-seizures</li> <li>Parver DL, Dreher RJ, Kohanim S, Zimmerman P, Garrett G, Devisetty L, et al. Ocular injury after laser hair reduction treatment to the eyebrow. Arch Ophthalmol Chic Ill 1960. 2012 Oct;130(10):1330–4.</li> <li>American Electrology Association. FAQs about permanent hair removal [Internet]. [cited 2016 Mar 22]. Available from: http://www.electrology.com/faqs-about-permanent-hair- removal/</li> <li>American Institute of Education: <a href="https://www.aielectrology.com/news_9.shtml" target="_blank" rel="noopener noreferrer">Electrology Program. What’s Your Frequency?<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="https://www.aielectrology.com/news_9.shtml" target="_blank" rel="noopener noreferrer">Electrolysis and Electrology<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>. [Internet]. [cited 2016 Mar 22]. Available from: https://<a href="http://www.aielectrology.com/news_9.shtml" target="_blank" rel="noopener noreferrer">www.aielectrology.com/news_9.shtml<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a></li> <li>WebMD. Electrolysis for Removing Hair [Internet]. [cited 2016 Mar 22]. Available from: http://www.webmd.com/beauty/hair-removal/electrolysis-for-removing-hair</li> <li>Hession MT, Markova A, Graber EM. A review of hand-held, home-use cosmetic laser and light devices. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2015 Mar;41(3):307–20.</li> <li>Aimonetti J-M, Ribot-Ciscar E. Pain management in photoepilation. J Cosmet Dermatol. 2015 Nov 21;</li> <li>Chiang YZ, Al-Niaimi F, Madan V. Comparative efficacy and patient preference of topical anaesthetics in dermatological laser treatments and skin microneedling. J Cutan Aesthetic Surg. 2015 Sep;8(3):143–6.</li> <li>Eidelman A, Weiss JM, Lau J, Carr DB. Topical anesthetics for dermal instrumentation: a systematic review of randomized, controlled trials. Ann Emerg Med. 2005 Oct;46(4):343– 51.</li> <li>Sobanko JF, Miller CJ, Alster TS. Topical anesthetics for dermatologic procedures: a review. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2012 May;38(5):709–21.</li> <li>Cohen JL. Pain management with a topical lidocaine and tetracaine 7%/7% cream with laser dermatologic procedures. J Drugs Dermatol JDD. 2013 Sep;12(9):986–9.</li> <li>U.S. Food and Drug Administration (FDA). <a href="http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm079047.htm" target="_blank" rel="noopener noreferrer">Topical Anesthetics<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. [cited 2016 Mar 22]. Available from: http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm079047.htm</li></ol> <blockquote><p>&lt;18&gt;. 译者注：一类电动拔毛器</p> <p>&lt;19&gt;. 译者注：如阿司匹林、布洛芬、对乙酰氨基酚等，原文如此。</p></blockquote> <h2 id="跨性别者语音与交流-嗓音健康和考虑因素"><a href="#跨性别者语音与交流-嗓音健康和考虑因素" class="header-anchor">#</a> 跨性别者语音与交流——嗓音健康和考虑因素</h2> <p>主要作者： Sarah Schneider, MS, SLP-CC; Mark Courey, MD</p> <h3 id="概论-22"><a href="#概论-22" class="header-anchor">#</a> 概论</h3> <p>语音和交流是人类日常生活的一个重要方面。在跨性别社区中，当性别认同与语音/交流风格之间存在明显不一致时，语音和交流往往成为最重要的问题。语音和交流与性别[1]和文化密切相关。[2]这些包括音调、语调、响度和重音模式、语音质量、共鸣、清晰度、语速、语言和非语言交流。[3,4]据报道，改变与性别相关的语音和交流方面可减少性别焦虑，改善心理健康和生活质量。[1]</p> <p>有许多资源可以帮助跨性别者识别交流特征从而开发更具性别特征的交流方式。这些可能包括声乐教练，戏剧专业人士，歌唱教师和运动专家。[3]<strong>受过专业训练的语言病理学家（SLP）最适合帮助改善整体嗓音健康和效率</strong>，以及与跨性别者的语音和交流相关的行为改变。[1-3,5]喉科专业的耳鼻喉科医生熟练掌握声带手术技术（声学外科），可以作为语音治疗的辅助手段。</p> <h3 id="语音症状"><a href="#语音症状" class="header-anchor">#</a> 语音症状</h3> <p>跨性别人群可能会具有与性别过渡无关的语音质量变化或疲劳的语音症状。[2]这可能是非器质性的，器质性的，医源性的或特发性的（表1）。在开始语音治疗之前重要的一点是，由语言学家和语音训练的语言病理学家完成全面的语音评估，包括与性别过渡相关的语音和交流需求。</p> <p>评估应包括彻底的喉部检查，包括频闪喉镜检查，以评估与声音产生相关结构的解剖学和生理学状况。</p> <p>表 34-1.常见语音症状和诊断</p> <table><thead><tr><th><strong>来源</strong></th> <th><strong>诊断</strong></th> <th><strong>语音症状</strong></th></tr></thead> <tbody><tr><td><strong>器质性</strong></td> <td>声带结节、息肉、囊肿、肉芽肿、疤痕</td> <td>粗糙、气息声、音调中断、语音疲劳、发声困难</td></tr> <tr><td></td> <td></td> <td></td></tr> <tr><td></td> <td></td> <td></td></tr> <tr><td><strong>非器质性</strong></td> <td>肌肉紧张障碍</td> <td>粗糙、语音疲劳、发声困难</td></tr> <tr><td></td> <td></td> <td></td></tr> <tr><td></td> <td></td> <td></td></tr> <tr><td><strong>医源性</strong></td> <td>声带运动损伤、疤痕</td> <td>粗糙、气息声、音调上升、语音疲劳、发声困难</td></tr> <tr><td></td> <td></td> <td></td></tr> <tr><td></td> <td></td> <td></td></tr> <tr><td><strong>特发性</strong></td> <td>声带瘫痪/麻痹</td> <td>气息声、语音疲劳、发声困难</td></tr> <tr><td></td> <td></td> <td></td></tr> <tr><td></td> <td></td> <td></td></tr></tbody></table> <p>存在语音和交流问题的跨性别者的首要治疗目标是帮助其以高效和安全的方式实现性别一致的声音。治疗应该是患者特异性的，可以通过行为治疗和医疗/外科手术来完成。</p> <h3 id="声音女性化"><a href="#声音女性化" class="header-anchor">#</a> 声音女性化</h3> <p>一项关于跨性别女性自我认知的研究发现沟通满意度的最大贡献因素是声音。[6]语音产生的组成部分包括音调、共鸣、语调和强度。</p> <h4 id="音调"><a href="#音调" class="header-anchor">#</a> 音调</h4> <p>音调可被视为语音和随后的性别识别的最重要因素。[2,7,8]使语音被识别为女性的强标记是在大约140到300Hz的范围内平均为180Hz的说话音调。[9,10]平均非跨性别女性音调约为225Hz，而平均非跨性别男性音调约为125Hz。被认为是性别中性的音调范围通常在155-185Hz之间。[11]已经证明，增加说话音调会影响语音女性化的程度。[9,12,13]然而，增加音调到女性范围并不一定会导致听者将说话者视为女性。[7,14]研究表明其他声音特征，如说话音调范围，语调，共鸣和语音质量在女性气质的感知中扮演不同的角色。[5]同样地，音调底线（pitch floor，音调范围的最低值）和通常说话音调与该最低值的接近度被认为会影响声音的男性化程度，而不仅仅是说话音调。[14]</p> <h4 id="共鸣"><a href="#共鸣" class="header-anchor">#</a> 共鸣</h4> <p>通过共振峰（谐波）频率研究，文献中关于共鸣作用的看法存在一些差异。谐波频率是基频的倍数；任何给定声音的共振峰频率的组合和配置决定了它的“音调”。咽部的长度和鼻窦的大小能影响声带共鸣，与非跨性别女性相比，经历过男性青春期的跨性别女性个体的上述尺寸被固定在更大的水平。一份报告提出了共鸣在说话者性别的感知识别中起到主要作用。[10]然而，另一项研究报告发现音调和共鸣的组合有助于感知女性气质。[4,15]</p> <h4 id="语调"><a href="#语调" class="header-anchor">#</a> 语调</h4> <p>语调，即说话中的音调变化是语音女性化的行为干预的推荐组成部分。在一项研究中，在性别之间观察到的总体语调模式没有显著差异。被确定为女性的跨性别参与者在话语中具有比其他群体更大的向上语调模式和更大的半音范围。被误认为男性的跨性别女性比正确识别的女性和跨性别女性具有更少的向上和更多的向下语调模式。[16]</p> <p><strong>强度和其他语音特征有助于感知性别</strong></p> <p>使用较低的声音强度[13,17]、避免气泡音[13]和增加气息声[9,17]可以促进语音女性化。</p> <h4 id="行为治疗"><a href="#行为治疗" class="header-anchor">#</a> 行为治疗</h4> <p>语音产生的组成部分主要通过行为语音治疗来解决。研究表明除了作为女性生活的时间外，接受语音治疗课程的数量可以预示行为治疗的效果。[18]</p> <p>两种常见的语音治疗技术包括流式发声（flow phonation）和共振语音治疗（resonant voice therapy）。流式发声的目的是在声音产生过程中平衡呼出气流，以提高发声效率，并有助于改变气息和强度。共振语音治疗的重点是在口腔中感受到声音的能量或振动从而改变共振同时实现轻松发声。[19]据报道，用于跨性别女性时，口腔共振疗法可通过改变共振来增加女性气质，从而更接近女性共振，同时音调自发升高。[4]声音功能练习（vocal function exercises），一种系统性生理声音练习项目，旨在加强和平衡喉部肌肉组织，并实现气流和肌肉力量之间的平衡，[20]似乎并没有改善跨性别女性的治疗效果。[18]</p> <p>尤其在音调和共鸣方面，报告显示有与听众对语音治疗后的性别认知相关的长期收益。[15]语音治疗也被证明可以产生显著影响听众对女性气质的感知的变化；然而恰在治疗完成后的女性气质被认为比15个月后更高。[21]具有不同声音目标的跨性别女性可能会选择在所有时间中或仅在特定情境中使用女性交流模式。[1,17]上面提到的女性气质随着时间的减弱，以及女性声音的不同应用可能反映了语音治疗后维持程序的意义。虽然在这方面需要进行进一步研究，但周期性“检入”和重新校准语音可能有必要。</p> <p>研究表明，跨性别女性在语音治疗后的声音得到改善，大多数人对效果感到满意。[17,21]如果在行为治疗过程中没有达到预期的结果，可以考虑手术治疗。[22]此时，外科手术干预主要针对音调改变。单独改变音调对听众来说不足以准确识别性别[7,14]，不应被视为语音女性化的初始或唯一治疗方法。</p> <h4 id="激素治疗对嗓音的影响"><a href="#激素治疗对嗓音的影响" class="header-anchor">#</a> 激素治疗对嗓音的影响</h4> <p>跨性别女性的激素治疗虽然导致睾酮水平降低与黄体酮和雌激素水平升高，但并未被认为对声音或女性声音的感知有显著影响。[23]声音音调是声带整体大小和质量的函数，英语文献中没有正式研究表明青春期后男性的激素改变会显著改变声音音调。在男性青春期，暴露于睾酮会导致喉部肌肉，软骨和黏膜肥大。这导致青春期男性中发生的特征性语音变化。</p> <p>虽然消除睾酮会导致一定程度的黏膜和肌肉变薄，但这种效果需要数年时间并且不能逆转由先前暴露引起的显著肥大。因此，与声带质量和大小相关的音调仍较低，并且一旦发生这些变化，雄激素消除对声音的总体影响很小。这与暴露于雄激素用于治疗医学病症的女性中所见的一致。一旦发生暴露并且声音音调降低，雄激素的消除通常不会与音调的显著重新升高相关联。因此，如果行为干预不能使患者对声音特征的满意度持续改善，则可以考虑手术。</p> <h4 id="手术考虑"><a href="#手术考虑" class="header-anchor">#</a> 手术考虑</h4> <p>如前所述，当患者产生声音时，声音的音调与整体声带质量和声带的张力有关。我们都可以自愿增加声带的张力来提升音调。然而，这需要持续的肌肉力量。通过注意力，训练和时间，这种增加的努力可能变得习惯。然而，即使是成功的患者也常常在一天结束时抱怨需要努力发声和/或疲劳的感觉。因此，手术设计通过改变声带张力，质量或两者来提高音调。当人工拉伸或拉紧时生物结构松弛的趋势代表了对语音修改的外科手术方法的重大挑战。此外，试图通过伤害声带的振动部分来改变张力或减小整体声带质量的程序有可能在声带的脆弱组织中引起负面改变，由于其必须在高频率下振动以产生正常的声音。</p> <h4 id="延长声带的手术尝试"><a href="#延长声带的手术尝试" class="header-anchor">#</a> 延长声带的手术尝试</h4> <p>报告的音调升高的最早手术方法之一是环甲接近术（criothyroid approximation），或4型甲状腺成形术，最初在20世纪70年代开发。在这种手术中，使用缝合线将甲状软骨前部接近环状软骨从而将声带置于永久性增加的张力下。一项为期一年的纵向报告显示，接受此手术的11名患者（其中只有1名是跨性别者）在术后立即达到最初的预期水平。[24]然而，虽然音调确实在一年内保持升高，但是与刚完成手术时相比音调较低，理论上认为长期声带张力导致组织松弛或缝合线穿过软骨。这引出了对最初描述的手术的修改建议：要么通过改变缝线放置的方法[25]，要么通过将甲状腺划伤到环状软骨。[26]其他案例系列已经发现类似的初步改善结果，同时其益处随着时间的推移而减弱。</p> <p>永久性延长声带以增加张力的其他尝试也产生了类似的结果。[27,28]这些修改提出将声带前部向前拉，而不将环状软骨固定在甲状腺上。理论上的优点是患者能够进一步调节音调。然而这样的方法并没有达成此结果，并且在患者长期随访中结果不一。</p> <h4 id="减少声带质量和长度的手术尝试"><a href="#减少声带质量和长度的手术尝试" class="header-anchor">#</a> 减少声带质量和长度的手术尝试</h4> <p>1982年，Donald等人[29]提出减少声带大小的手术方法：通过打开喉头，去除前三分之一的声带并缝合喉头，在声带的前部之间形成粘连（web）。这种手术的优点是能够与减少喉颈部突出的手术同时进行。[30]虽然没有给出随访的长度，Donald报告了3名患者中的音调的成功提升和患者的满意。该程序已被其他外科医生修改，并通过闭合喉部和舌骨而缩短咽部。在一系列94名患者中（其中74名患者被随访约1年或更长时间），这些作者报告音调从术前平均的139Hz提高到196Hz。并发症相对罕见且短暂。[31]虽然很有希望，但在整体声音质量和声音范围方面，结果有些不可预测。此外，虽然手术通常具有良好的耐受性，但它确实使气道处于危险之中并且需要在颈部前部皮肤处进行外部切口。</p> <h4 id="通过在声带制造瘢痕增加张力的手术尝试"><a href="#通过在声带制造瘢痕增加张力的手术尝试" class="header-anchor">#</a> 通过在声带制造瘢痕增加张力的手术尝试</h4> <p>如前所述，确定声音音调的声带振动速率受声带质量（随着质量减小，振动速率或音调增加）和张力（随着张力增加振动和音调增加）的影响。这导致外科医生试图通过使声带表面或声带的前部留下瘢痕来增加张力以缩短可用于振动的部分来提高音调。这些类型的手术的主要优点是它们可以通过口腔完成，颈部没有切口，耐受性良好，并且不会使患者的呼吸处于显著的风险中。主要的缺点是愈合和瘢痕产生可能不可预测且手术的效果不一。</p> <p>Wendler在1989年提出了这种手术的初步报告。[32]该程序，后来被称为Wendler声门成形术，相对容易执行。声带前部的黏膜或皮肤被去除。这可以使用CO2激光器或传统的不接电源仪器来完成；然后将声带的前方缝合在一起。这个程序的其它变化形式在来自其他中心的多个小患者系列中复现了结果。[12,22,33,34]一般来说，音调显著提高，但整体音调范围和声音响度水平降低。在所有患者中，术后声音粗糙程度略有增加，并且当在50岁以上的患者中进行手术时，这更加明显。如果愈合没能产生所需的瘢痕，也可以重复该过程，并且可以在其他类型的手术失败的患者中进行。[35]</p> <p>最后，一些外科医生试图在声带的顶部/上表面产生瘢痕，或作为单独的手术[36]或作为Wendler声门成形术的辅助手段。[37]这些尝试尚未显示出相比单独进行声门成形术更可靠的结果或益处，因此最好避免。</p> <h3 id="声音男性化"><a href="#声音男性化" class="header-anchor">#</a> 声音男性化</h3> <p>与跨性别女性相比，接受语音评估和治疗的跨性别男性要少得多。这可能与跨性别男性因激素治疗而经历的音调降低有关。[38,39]因此，跨性别男性中对嗓音治疗的需求可能被低估了。[40]激素诱导的音调改变并不总是没有问题，并且仍然不清楚在所有情况下是否足以将说话者识别为男性。[38,39]研究支持语音和沟通应该成为语音治疗的目标。[2,5,40-42]</p> <h4 id="音调-2"><a href="#音调-2" class="header-anchor">#</a> 音调</h4> <p>使用激素疗法，最终降低的音调可在1年后的某个时间实现。根据对这种治疗的反应，据报道，大约75％的跨性别男性通过电话被确定为男性。[42]这使得四分之一的跨性别男性可能不会被视为男性。感知到的声音的男性气质不仅与音调有关，而且与习惯性音调与音调或最低音调的接近程度有关。[5]通过语言病理学家进行行为干预，说话音调可以进一步减少35Hz，且音调不稳定、语音疲劳等问题可得到解决。[40]</p> <h4 id="共鸣-2"><a href="#共鸣-2" class="header-anchor">#</a> 共鸣</h4> <p>建议将增加胸腔共鸣作为语音治疗的目标。[2]在语音产生过程中实现均衡共鸣有助于提高整体声音效率，并且可能在语音治疗后跨性别者语音状况的改善中发挥作用。共鸣的这些变化进一步得到了数据的支持，这些数据表明在激素治疗的第一年期间，伴随行为干预，共振峰频率（共鸣的声学相关值）发生了变化。[5]</p> <h4 id="语调-2"><a href="#语调-2" class="header-anchor">#</a> 语调</h4> <p>在一项研究中，在4个性别组之间观察到的总体语调模式没有显著差异（12名非跨性别男性，12名非跨性别女性，6名跨性别男性，14名跨性别女性）。然而，被误认为男性的跨性别女性比正确识别的女性和跨性别女性具有更少的向上和更多的向下语调模式。[16]对于跨性别男性来说，建议减少音调变化，同时避免声音单调。[2]</p> <h4 id="强度"><a href="#强度" class="header-anchor">#</a> 强度</h4> <p>在研究文献中没有充分记录跨性别男性的声强。然而，考虑到增加气息声[9,17]和使用较低的声音强度[13,17]有助于语音女性化，减少气息声和避免柔和的声音可能使得声音更男性化。</p> <h4 id="行为治疗-2"><a href="#行为治疗-2" class="header-anchor">#</a> 行为治疗</h4> <p>虽然音调主要通过激素疗法解决，其次通过语音疗法解决，但声音产生的其他组成部分主要通过行为语音治疗来解决。</p> <p>流式发声和共振声音治疗是两种常见的语音治疗技术。流式发声的目标是在语音产生期间平衡呼出气流，使用呼吸作为实现发声效率的动力源。共振语音治疗的重点是在口腔内经历声音的能量或振动时实现轻松的发声。[19]这些技术的结合可以最大化产生跨性别男性的目标音调，共鸣，语调和强度；然而这一点仍需要有效数据来支持。</p> <p>跨性别光谱中的部分群体只寻求一定程度的语音男性化，并希望在语音和交流中具有灵活性。[5]虽然文献支持语音治疗在语音男性化中的作用，[40,41]但这是一个需要进一步关注的领域。考虑到这一点，语音治疗应该是患者特异性和有生理学基础的，以便以有效和安全的方式实现患者和治疗目标。</p> <h4 id="睾酮激素治疗对嗓音的影响"><a href="#睾酮激素治疗对嗓音的影响" class="header-anchor">#</a> 睾酮激素治疗对嗓音的影响</h4> <p>在服用外源性雄激素4到5个月后，90％的跨性别男性将达到可接受的语音效果，将音调降低到性别中性或男性范围。[38]在多个小系列报告中，平均说话音调从190-200Hz的女性范围下降到100-140Hz的可接受的男性范围。[5,43]然而，尽管由于雄激素的作用导致增厚从而导致音调降低，在某些情况下，必须通过行为疗法来学习男性说话模式。10％或更多的患者在过渡过程中会因无法通过改变喉部产生有效的发声，或者无法自然采用男性说话模式，而遇到困难。[44]这些患者通常会向经过认证的有管理跨性别语音问题的个人经验的语言病理学家进行咨询。</p> <h4 id="手术考虑-2"><a href="#手术考虑-2" class="header-anchor">#</a> 手术考虑</h4> <p>由于激素疗法和行为疗法可以有效地帮助90％的跨性别男性获得可接受声音，因此在该组中很少表现出手术干预。然而，如果需要，可以进行旨在减小声带张力的松弛成形术。同样的手术也用于音调过高的男性患者，使用原始方法[45]足以导致音调降低，而如果按照其他作者的描述进行修改则会导致更大的降低。典型的音调降低在100Hz的范围内，并且通常导致患者获得可接受的男性声音音调。然而，由于干预后声带的张力不太可控，因此声音通常被认为更粗糙且音量更小。[46]</p> <h3 id="参考文献-32"><a href="#参考文献-32" class="header-anchor">#</a> 参考文献</h3> <ol><li>Shelagh Davies, Joshua M. Goldberg. Clinical aspects of transgender speech feminization and masculinization. Int J Transgenderism. 2006 Sep 1;9(3-4):167–96.</li> <li>Thornton J. Working with the transgender voice: The role of the speech and language therapist. Sexologies. 2008 Oct;17(4):271–6.</li> <li>Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, DeCuypere G, Feldman J, et al. Standards of Care for the Health of Transsexual, Transgender, and Gender- Nonconforming People, Version 7. Int J Transgenderism. 2012;13(4):165–232.</li> <li>Carew L, Dacakis G, Oates J. The effectiveness of oral resonance therapy on the perception of femininity of voice in male-to-female transsexuals. J Voice. 2007 Sep;21(5):591–603.</li> <li>Davies S, Papp VG, Antoni C. Voice and communication change for gender nonconforming individuals: Giving Voice to the Person Inside. Int J Transgenderism. 2015 Jul 3;16(3):117–59.</li> <li>Byrne LA, Dacakis G, Douglas JM. Self-perceptions of pragmatic communication abilities in male-to-female transsexuals. Adv Speech Lang Pathol. 2003 Jan 1;5(1):15–25.</li> <li>Dacakis G. The role of voice therapy in male-to-female transsexuals. Curr Opin Otolaryngol Head Neck Surg. 2002 Jun;10(3):173–7.</li> <li>Dacakis G, Davies S, Oates JM, Douglas JM, Johnston JR. Development and preliminary evaluation of the transsexual voice questionnaire for male-to-female transsexuals. J Voice Off J Voice Found. 2013 May;27(3):312–20.</li> <li>Gorham-Rowan M, Morris R. Aerodynamic analysis of male-to-female transgender voice. J Voice Off J Voice Found. 2006 Jun;20(2):251–62.</li> <li>King RS, Brown GR, McCrea CR. Voice parameters that result in identification or misidentification of biological gender in male-to-female transgender veterans. Int J Transgenderism. 2012 May 1;13(3):117–30.</li> <li>Adler RK, Hirsch S, Mordaunt M. Voice and communication therapy for the transgender/transsexual client: a comprehensive clinical guide. Plural Publishing; 2012. 577 p.</li> <li>JC Casado, C ÓConnor, MS Angulo, JA Adrián. Wendler glottoplasty and voice-therapy in male-to-female transsexuals: results in pre and post-surgery assessment. Acta Otorrinolaringol Esp [Internet]. 2015 May [cited 2016 Mar 18]; Available from: http://europepmc.org/abstract/med/26028541</li> <li>Holmberg EB, Oates J, Dacakis G, Grant C. Phonetograms, aerodynamic measurements, self-evaluations, and auditory perceptual ratings of male-to-female transsexual voice. J Voice Off J Voice Found. 2010 Sep;24(5):511–22.</li> <li>Gelfer MP, Schofield KJ. Comparison of acoustic and perceptual measures of voice in male-to-female transsexuals perceived as female versus those perceived as male. J Voice Off J Voice Found. 2000 Mar;14(1):22–33.</li> <li>Hancock AB, Garabedian LM. Transgender voice and communication treatment: a retrospective chart review of 25 cases. Int J Lang Commun Disord R Coll Speech Lang Ther. 2013 Jan;48(1):54–65.</li> <li>Hancock A, Colton L, Douglas F. Intonation and gender perception: applications for transgender speakers. J Voice Off J Voice Found. 2014 Mar;28(2):203–9.</li> <li>Oates J, Dacakis G. Transgender voice and communication: research evidence underpinning voice intervention for male-to-female transsexual women. Perspect Voice Voice Disord. 2015 Jul 1;25(2):48.</li> <li>Gelfer MP, Van Dong BR. A preliminary study on the use of vocal function exercises to improve voice in male-to-female transgender clients. J Voice Off J Voice Found. 2013 May;27(3):321–34.</li> <li>Verdolini K. Resonant voice therapy. In: Voice Therapy: Clinical Studies. San Diego, CA: Singular; 2000. p. 46–61.</li> <li>Stemple JC, Lee L, D’Amico B, Pickup B. Efficacy of vocal function exercises as a method of improving voice production. J Voice Off J Voice Found. 1994 Sep;8(3):271–8.</li> <li>Gelfer MP, Tice RM. Perceptual and acoustic outcomes of voice therapy for male-to- female transgender individuals immediately after therapy and 15 months later. J Voice Off J Voice Found. 2013 May;27(3):335–47.</li> <li>Anderson JA. Pitch elevation in trangendered patients: anterior glottic web formation assisted by temporary injection augmentation. J Voice Off J Voice Found. 2014 Nov;28(6):816–21.</li> <li>Edgerton MT. The surgical treatment of male transsexuals. Clin Plast Surg. 1974 Apr;1(2):285–323.</li> <li>Isshiki N, Taira T, Tanabe M. Surgical alteration of the vocal pitch. J Otolaryngol. 1983 Oct;12(5):335–40.</li> <li>Lee S, Liao T, Hsieh T. Extralaryngeal approach in functional phonosurgery. Tokyo; 1986 p. 482–3.</li> <li>Sataloff RT. Professional voice: the science and art of clinical care. 2nd ed. San Diego, CA: Singular Publishing Group; 1997.</li> <li>LeJeune FE, Guice CE, Samuels PM. Early experiences with vocal ligament tightening. Ann Otol Rhinol Laryngol. 1983 Oct;92(5 Pt 1):475–7.</li> <li>Tucker HM. Anterior commissure laryngoplasty for adjustment of vocal fold tension. Ann Otol Rhinol Laryngol. 1985 Dec;94(6 Pt 1):547–9.</li> <li>Donald PJ. Voice change surgery in the transsexual. Head Neck Surg. 1982 Jun;4(5):433–7.</li> <li>Kunachak S, Prakunhungsit S, Sujjalak K. Thyroid cartilage and vocal fold reduction: a new phonosurgical method for male-to-female transsexuals. Ann Otol Rhinol Laryngol. 2000 Nov;109(11):1082–6.</li> <li>Thomas JP, Macmillan C. Feminization laryngoplasty: assessment of surgical pitch elevation. Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol - Head Neck Surg. 2013 Sep;270(10):2695–700.</li> <li>Proceedings of the Union of the European Phoniatricians. 1989; Salsomaggiore, Italy.</li> <li>Gross M. Pitch-raising surgery in male-to-female transsexuals. J Voice Off J Voice Found. 1999 Jun;13(2):246–50.</li> <li>Remacle M, Matar N, Morsomme D, Veduyckt I, Lawson G. Glottoplasty for male-to- female transsexualism: voice results. J Voice Off J Voice Found. 2011 Jan;25(1):120–3.</li> <li>Mastronikolis NS, Remacle M, Biagini M, Kiagiadaki D, Lawson G. Wendler glottoplasty: an effective pitch raising surgery in male-to-female transsexuals. J Voice Off J Voice Found. 2013 Jul;27(4):516–22.</li> <li>Orloff LA, Mann AP, Damrose JF, Goldman SN. Laser-assisted voice adjustment (LAVA) in transsexuals. The Laryngoscope. 2006 Apr;116(4):655–60.</li> <li>Geneid A, Rihkanen H, Kinnari TJ. Long-term outcome of endoscopic shortening and stiffening of the vocal folds to raise the pitch. Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol - Head Neck Surg. 2015 Dec;272(12):3751–6.</li> <li>Cosyns M, Van Borsel J, Wierckx K, Dedecker D, Van de Peer F, Daelman T, et al. Voice in female-to-male transsexual persons after long-term androgen therapy. The Laryngoscope. 2014 Jun 1;124(6):1409–14.</li> <li>Azul D. Transmasculine people’s vocal situations: a critical review of gender-related discourses and empirical data. Int J Lang Commun Disord. 2015 Jan 1;50(1):31–47.</li> <li>Söderpalm E, Larsson A, Almquist S-Å. Evaluation of a consecutive group of transsexual individuals referred for vocal intervention in the west of Sweden. Logoped Phoniatr Vocol. 2004 Mar 1;29(1):18–30.</li> <li>McNeill EJM. Management of the transgender voice. J Laryngol Otol. 2006 Jul;120(07):521–3.</li> <li>Dahl M, Feldman J, Goldberg JM, Jaberi A, Bockting WO, Knudson G. Endocrine therapy for transgender adults in British Columbia: suggested guidelines. Vanc BC Vanc Coast Health Auth Dep Public Health Retrieved January. 2006;1:2005.</li> <li>Damrose EJ. Quantifying the impact of androgen therapy on the female larynx. Auris Nasus Larynx. 2009 Feb;36(1):110–2.</li> <li>Van Borsel J, De Cuypere G, Rubens R, Destaerke B. Voice problems in female-to-male transsexuals. Int J Lang Commun Disord R Coll Speech Lang Ther. 2000 Sep;35(3):427– 42.</li> <li>Nakamura K, Tsukahara K, Watanabe Y, Komazawa D, Suzuki M. Type 3 thyroplasty for patients with mutational dysphonia. J Voice Off J Voice Found. 2013 Sep;27(5):650–4.</li> <li>Hoffman MR, Devine EE, Remacle M, Ford CN, Wadium E, Jiang JJ. Combined type IIIB with bilateral type I thyroplasty for pitch lowering with maintenance of vocal fold tension. Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol - Head Neck Surg. 2014 Jun;271(6):1621–9.</li></ol> <h2 id="美国跨性别人群的医保覆盖问题"><a href="#美国跨性别人群的医保覆盖问题" class="header-anchor">#</a> 美国跨性别人群的医保覆盖问题</h2> <p>主要作者： Andre A. Wilson, MS; Jamison Green, PhD</p> <h3 id="概论-23"><a href="#概论-23" class="header-anchor">#</a> 概论</h3> <p>自20世纪80年代以来在美国发布的保险计划通常包含广泛的书面排除，禁止支付与“易性症”，“变性治疗”，“性别认同障碍”或“跨性别护理”相关的护理。在某些情况下，提供者或诊所管理者以及保险公司内的理赔管理人员将以最广泛的理解解释这些排他性陈述，认为跨性别者不应接受任何医疗护理。当人们身体不适或受伤时，与这种困难作斗争的负担是护理的重大障碍。这种困难导致很高比例的跨性别者避免寻求所需医疗护理。[1]</p> <h3 id="保险和健康福利计划的复杂性"><a href="#保险和健康福利计划的复杂性" class="header-anchor">#</a> 保险和健康福利计划的复杂性</h3> <p>保险政策受美国50个州分别监管；因此，例如，在一个州实行的Anthem Blue Cross政策的内容可能与另一个州的同一运营商实行的政策有很大不同，尽管这些计划最初可能看起来是等同的。此外，许多在美国拥有私人保险的人通过其雇主获得保险，许多大型雇主能够协商其保险范围以包括或排除特定护理。这些是“健康福利计划”，严格来说并非“保险计划”，尽管它们对于注册会员可能看起来相同。这种健康福利计划通常被称为“ERISA计划”（在某些情况下称为“自我保险计划”），通常受1974年联邦雇员退休收入保障法的监管。这些ERISA计划由同样提供个人或小型团体计划的保险公司实行和管理，但雇主支付所有护理的直接费用。因此，ERISA计划在所涵盖的内容方面具有更大的灵活性，具体取决于雇主的任务和意图。在非ERISA计划中（在某些情况下称为“完全资助”计划），保险公司承担其承保个人或团体不会花费超过保费和自付额带来的收入的风险。由于激励（指员工招聘和留任由雇主处理）进一步减少，非ERISA计划可能不太能够灵活地增加覆盖范围或处理需要根据具体情况分析的场景。</p> <p>虽然由特定运营商（如Aetna，United Health，Anthem BCBS等）提供保险或管理的计划通常彼此间差异很大，但是由于运营商努力使内部流程标准化，方法中也经常存在相似性。大多数运营商现在已经发布了自己的内部指南，专门针对跨性别相关的医疗保健，特别是外科手术。这些指导原则（名称不一，如医疗政策或承保位置）阐明了特定医疗条件将涵盖哪些服务，并且通常适用于运营商发布的所有保险产品。但是，它们可能不适用于一些ERISA监管的健康福利计划，因为大型雇主有能力就自己的员工健康计划进行谈判。</p> <p>因此，特定健康计划所涵盖的内容不仅会因州而且会因雇主而异。一些大公司选择在其ERISA计划下提供跨性别健康福利，目的如最大限度地招募人才、提供公正和平等的工作场所、或通过提供人们需要的服务来控制医疗保健成本。这些大型雇主选择实施提供更多可获得的机会的医疗指南，例如覆盖更广泛的所需医疗服务。较小的企业，依赖于保险公司承担风险（并且其风险与其他小型雇主合并），可能没有能力与运营商谈判以将跨性别健康福利包含在内。但是，较小的雇主可以向其运营商代表咨询覆盖跨性别健康福利的可行性和每个成员每月的成本，因为此类覆盖在全国越来越普遍。</p> <h3 id="获得覆盖-改变范式"><a href="#获得覆盖-改变范式" class="header-anchor">#</a> 获得覆盖：改变范式</h3> <p>从20世纪60年代到90年代，在某些情况下，一些非常执着的个人，常常是在医疗保健提供者的支持下，能够获得福利金支付。</p> <p>然而，系统性改革直到2000年才开始，当时提倡者说服旧金山市和县在城市和县级员工用于医疗保险可以选择的五个计划中至少一个里取消对跨性别医疗福利的排除。前五年的利用率数据显示，在大型团体计划中纳入医学上必要的性别肯定护理时，计划成本几乎没有增加。由于得到这样的结果，人权运动中的企业平等指数将跨性别健康福利状况纳入在内，该指数旨在评估公司对LGBT员工和客户关系的态度。[2]</p> <h3 id="私有和公共保险改革"><a href="#私有和公共保险改革" class="header-anchor">#</a> 私有和公共保险改革</h3> <p>截至2015年，越来越多的雇主提供跨性别健康福利计划，许多州和哥伦比亚特区的保险专员已颁布法规，禁止出售歧视跨性别人士的保险计划。[3]此外，2014年5月30日，美国卫生和公共服务部发布了一项裁决：长期以来医疗保险对“变性手术程序”的排除已不再有效，因此提供的服务可以根据当地的覆盖范围确定。[4]随后，一些州已经开始修改他们的医疗补助计划，以提供将跨性别涵盖在内的医疗保健。[5]具体的医疗补助政策可以从各个州的医疗补助监管机构获得。目前（截至2015年），Medicare与Mediaid服务中心（CMS）正在制定新的国家保险决定，其中包括在Medicare计划中纳入性别肯定护理。</p> <p>私人医疗保险产品通常由州保险部（State Department of Insurance）或管理式医疗部（Department of Managed Care）管理（部门命名法可能因州而异）；具体政策和承保范围详情可从各州政府机构获得。</p> <h3 id="性别特异性过程中的拒绝赔付"><a href="#性别特异性过程中的拒绝赔付" class="header-anchor">#</a> 性别特异性过程中的拒绝赔付</h3> <p>在一些自动化系统中，例如，如果患者在电子病历（EMR）中被指定为“女性”，并且输入的治疗或程序代码用于保险覆盖范围专门针对被指定为男性的身体的护理（如前列腺超声），该索赔可能会被自动拒绝。对于一些在EMR中被指定为男性的人来说，情况恰恰相反：他们需要专门为被指定为女性者提供的护理。如果患者的计划文件或其州法规规定跨性别护理已经涵盖（或者这一护理不受性别限制），患者可能需要医生办公室的支持，通知运营商或管理员该患者是跨性别者，并且该申诉不应被拒绝。如果在这种情况下没有跨性别护理的规定，则提供者有必要向运营商要求覆盖特定的治疗或诊断。</p> <h3 id="推翻性别不匹配-code-45"><a href="#推翻性别不匹配-code-45" class="header-anchor">#</a> 推翻性别不匹配：Code 45</h3> <p>所有联邦政府资助的医疗机构（如大多数医院）都在其编码实践中接受了关于使用Code 45（以及KX修饰符）的指导，并且所有Medicare行政承包商都需要处理此代码，[6]这一代码可以取消推翻（override）性别不匹配状况。</p> <p>但是，并不是所有医院或运营商的系统都实现了这一代码；在这些情况下，使用Code 45可能会导致退回索赔，或者直接拒绝索赔。</p> <h3 id="歧视申诉"><a href="#歧视申诉" class="header-anchor">#</a> 歧视申诉</h3> <p>美国卫生和公众服务部（HHS）的民权办公室已经发布了指导，不能仅仅基于性别就拒绝提供预防性服务，从而使得如疾病预防控制中心提供了覆盖跨性别女性的乳房X射线检查。2015年5月，CMS发布了次级监管指南，明确了平价医疗法案（ACA）提供的预防服务，无论个人的性别认同，出生时性别分配或性别记录如何。经ACA修订的公共卫生服务法第2713条要求大多数健康计划涵盖某些预防性服务，不论性别如何。[7,8]随着时间的推移，其他性别不匹配问题的解决方案有望根据包含在平价医疗法案（来自美国卫生和公共服务部）第1557节所载的新法规的实施基于性别的非歧视条款的指导得到开发。[7]与此同时，鼓励那些因性别特异性服务的性别不匹配而遭受拒绝的人向HHS民权办公室提出申诉。[8]</p> <h3 id="拒绝赔付与歧视"><a href="#拒绝赔付与歧视" class="header-anchor">#</a> 拒绝赔付与歧视</h3> <p>许多跨性别者经历对其跨性别过渡相关服务的拒绝赔付。更多人从未接受过正式的拒绝赔付，因为他们的保险计划包含特定于跨性别的排除条款，而医生从未提交文书以事先授权此类服务。许多人打电话给他们的保险公司，并被告知服务将不予承保，并且在此基础上从不尝试提出索赔。跨性别者及其健康服务提供者应该意识到，除非他们得到书面形式的拒绝，否则拒绝并不有效，也无法上诉。更重要的是，具有良好记录的索赔的跨性别者越来越多地在他们的诉求中取得成功。鼓励个人积极与医疗服务提供者合作，确保申诉文件包含个性化的，广泛的文档以说明服务必要性和适当性。此类呼吁还应包括对性别过渡进程的全面和详细的概述，包括支持所要求的具体服务的作用和证据。除了为不知情的审查者提供背景之外，这些全面的文件还传达了个人将坚持提出诉求直至最后阶段的意图，这可能是非常有说服力的。</p> <p>随着时间推移，预计这些问题将由于新的法规指导实施基于性别的非歧视条款而逐渐得到解决，这些条款将在未来几个月内由HHS发布。[9]与此同时，鼓励其健康计划包含基于性别的歧视条款的个人，包括跨性别特定排除，向HHS民权办公室提出投诉。[8]虽然并非美国的每项健康计划目前都受到ACA第1557条的管制，但ACA确实规定了他们必须提供的基本健康福利（Essential Health Benefits）且不得基于性别进行歧视。</p> <p>表 35-1. 在美国可用的医保覆盖</p> <table><thead><tr><th><strong>保险类型</strong></th> <th><strong>一般特点和注意事项</strong></th></tr></thead> <tbody><tr><td><strong>ACA/医保市场计划</strong></td> <td>ACA（平价医疗法案）覆盖没有资格获得Medicaid或Medicare，以及没有通过雇主提供保险或可能是自由职业人士的个人和家庭。在HHS实施第1557条之前，只有法律禁止对保险产品中的跨性别人群进行歧视的州可能会提供包含跨性别的计划。要查看您所在的州是否属于其中之一，请访问www.transequality.org[10]或www.transgenderlawcenter.org查看有关健康保险的最新信息。[11]然而，即使在目前禁止保险计划中的跨性别排除的几个州，部分或全部市场计划仍可能保留排除。</td></tr> <tr><td><strong>完全资助的雇主计划(ERISA)</strong></td> <td>此类计划是小企业可用的团体计划，有时可能包括向符合标准的个人提供的计划。完全资助意味着该计划的购买者支付额外费用来支付医疗服务提供者和保险公司提供的服务费用。</td></tr> <tr><td><strong>自我保险的雇主计划(非ERISA)</strong></td> <td>此类计划为保险公司管理的团体计划，使用与其他计划相同的提供者网络和索赔处理机制，但雇主自己支付所有费用，因此雇主承担所有风险。这些计划不受联邦ERISA法规的国家监管，该法规为计划的雇主/客户提供了更多的余地来申请他们想要的功能和覆盖水平，包括跨性别特定护理。其中一些计划有自己的内部医疗指南，可以覆盖过渡所需的所有医疗服务。</td></tr> <tr><td><strong>健康维护组织(HMO)</strong></td> <td>此类由州监管的组织提供保险和医疗服务。在某些情况下，可用的服务可能不包括跨性别特异性护理，但许多HMO正在努力提供有效的跨性别护理。截至2015年12月，包括哥伦比亚特区在内的13个州在这些健康计划中禁止跨性别排除（注意禁止排除与强制包含不同），执行情况因州而异。有关各州的信息，请访问www.transequality.org或www.transgenderlawcenter.org。</td></tr> <tr><td><strong>Medicaid</strong></td> <td>此类是州营（部分由联邦资金资助）的安全网计划，向接受计划愿意支付的金额的提供者提供支付（通常远低于私人保险将支付的金额）。Medicaid覆盖符合要求的低收入人群，家庭和儿童，孕妇，老年人和残疾人。一些州开始从医疗补助计划中删除针对跨性别医疗的排除。要查看您所在的州是否属于其中之一，请访问www.transequality.org或www.transgenderlawcenter.org查看有关健康保险的最新信息。</td></tr> <tr><td><strong>Medicare</strong></td> <td>这是涵盖65岁以上人群和65岁以下残疾人的联邦计划。HHS在2014年5月裁定，“变性手术”的全面排除不再适用，因为有医学证据表明此类护理在进行时是适当的，有效的，不再是实验性外科手术，也不是单纯的整形手术。目前的覆盖范围通过本地覆盖范围确定（Local Coverage Determination，LCD）逐案决定。</td></tr> <tr><td><strong>铁路Medicare</strong></td> <td>根据该计划，在铁路工作至少10年的人可以通过铁路指定的管理员以优惠的价格获得Medicare B部分服务。可通过Medicare与Medicaid服务中心根据LCD提供跨性别特定服务。</td></tr> <tr><td><strong>TRICARE</strong></td> <td>这是不符合Medicare资格的美国现役军人及其家属和退休人员的健康福利管理计划。当跨性别者不允许公开服役时，跨性别特定服务不被提供。此政策可能会在2016年中期发生变化。</td></tr> <tr><td><strong>工会计划</strong></td> <td>在某些州，一些工会可能有跨性别政策；请联系工会福利办公室/部门。一些工会在国家一级有决议要求消除跨性别排除。虽然对成员工会没有约束力，但这些可能有助于工会成员争取公平福利。</td></tr> <tr><td><strong>退伍军人管理</strong></td> <td>跨性别退伍军人可以获得定期医疗护理，包括激素治疗。目前限制或禁止跨性别特异性外科手术，尽管这可能随着美国军方考虑跨性别服役成员的作用而改变。</td></tr></tbody></table> <h3 id="参考文献-33"><a href="#参考文献-33" class="header-anchor">#</a> 参考文献</h3> <ol><li>Grant JM, Mottet LA, Tanis J, Harrison J, Herman J, Keisling M<a href="http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf" target="_blank" rel="noopener noreferrer">. Injustice at every turn: a<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf" target="_blank" rel="noopener noreferrer">report of the National Transgender Discrimination Survey<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. National Center for Transgender Equality and National Gay and Lesbian Task Force; 2011 [cited 2016 Mar 17]. Available from: http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf</li> <li>Herman JL. <a href="http://escholarship.org/uc/item/5z38157s" target="_blank" rel="noopener noreferrer">Costs and Benefits of Providing Transition-related Health Care Coverage in<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://escholarship.org/uc/item/5z38157s" target="_blank" rel="noopener noreferrer">Employee Health Benefits Plans: Findings from a Survey of Employers<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>. eScholarship [Internet]. 2013 Sep 1 [cited 2016 Mar 24]; Available from: http://escholarship.org/uc/item/5z38157s</li> <li>National Center for Transgender Equality. Map: <a href="http://www.transequality.org/issues/resources/map-state-health-insurance-rules" target="_blank" rel="noopener noreferrer">Transgender Health Insurance Laws<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. National Center for Transgender Equality; Issues and Resources. 2015 [cited 2016 Mar 24]. Available from: http://www.transequality.org/issues/resources/map-state- health-insurance-rules</li> <li>Green J. Transsexual surgery may be covered by medicare. LGBT Health. 2014 Dec;1(4):256–8.</li> <li>National Center for Transgender Equality. <a href="http://www.transequality.org/know-your-rights/healthcare" target="_blank" rel="noopener noreferrer">Healthcare Rights and Transgender People<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [<a href="http://www.transequality.org/know-your-rights/healthcare" target="_blank" rel="noopener noreferrer">Internet]. National Center for Transgender Equality: Know Your Rights; Healthcare<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>. 2014 [cited 2016 Mar 24]. Available from: http://www.transequality.org/know-your- rights/healthcare</li> <li>Center for Medicare and Medicaid Services (CMS) and Medicare Learning Network (MLN). <a href="https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/MM6917.pdf" target="_blank" rel="noopener noreferrer">MLN Matters® Number MM6917: Instructions Regarding the Processing of Inpatient<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/MM6917.pdf" target="_blank" rel="noopener noreferrer">Claims for Gender/Procedure Conflict<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. MLN Matters: Information for Medicare Fee-for-Service Health Care Professionals; 2010 [cited 2016 Mar 24]. Available from: https://<a href="http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-" target="_blank" rel="noopener noreferrer">www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> MLN/MLNMattersArticles/downloads/MM6917.pdf</li> <li>U.S. Department of Health and Human Services (HHS): Office for Civil Rights (OCR). <a href="http://www.hhs.gov/civil-rights/for-individuals/section-1557/nondiscrimination-health-programs-and-activities-proposed-rule/index.html" target="_blank" rel="noopener noreferrer">Nondiscrimination in Health Programs and Activities Proposed Rule - Section 1557 of the<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.hhs.gov/civil-rights/for-individuals/section-1557/nondiscrimination-health-programs-and-activities-proposed-rule/index.html" target="_blank" rel="noopener noreferrer">Affordable Care Ac<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>t [Internet]. HHS.gov. 2015 [cited 2016 Mar 24]. Available from: http://www.hhs.gov/civil-rights/for-individuals/section-1557/nondiscrimination-health- programs-and-activities-proposed-rule/index.html</li> <li>U.S. Department of Health and Human Services (HHS): Office for Civil Rights (OCR). <a href="http://www.hhs.gov/ocr/filing-with-ocr/index.html" target="_blank" rel="noopener noreferrer">Filing with OCR<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. HHS.gov. 2015 [cited 2016 Mar 24]. Available from: http://www.hhs.gov/ocr/filing-with-ocr/index.html</li> <li>Office for Civil Rights (OCR<a href="http://www.hhs.gov/civil-rights/for-individuals/section-1557/summary/index.html" target="_blank" rel="noopener noreferrer">). Section 1557 - Summary<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. HHS.gov. 2015 [cited 2016 Mar 24]. Available from: http://www.hhs.gov/civil-rights/for-individuals/section- 1557/summary/index.html</li> <li>National Center for Transgender <a href="http://www.transequality.org/" target="_blank" rel="noopener noreferrer">Equality<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. National Center for Transgender Equality. [cited 2016 Mar 24]. Available from: http://www.transequality.org/</li> <li>Transgender Law Center | <a href="http://transgenderlawcenter.org/" target="_blank" rel="noopener noreferrer">Making Authentic Lives Possible<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. [cited 2016 Mar 24]. Available from: http://transgenderlawcenter.org/</li></ol> <h2 id="法定与身份证件"><a href="#法定与身份证件" class="header-anchor">#</a> 法定与身份证件</h2> <p>主要作者： Dan Karasic, MD</p> <p>“法定性别”的概念很复杂，但为简单起见，该术语将用于本讨论。世界跨性别健康专业协会倡导一类简单的行政程序来改变法律身份证件以匹配个体认同的性别。[1]虽然包括阿根廷，丹麦，马耳他和爱尔兰在内的一小部分（但正在增长）的国家的法律赋予法律性别的自决权，但在大多数国家都需要卫生专业人员的参与，如果“改变性别”是法律所允许的。[2]</p> <p>根据美国联邦法律，在某些州，改变法律性别不需要手术，但健康专业人员必须证明他们的患者已经接受对性别过渡“必要的”医疗或心理治疗。[3]在完成这项文书工作时，健康专业人员应该意识到没有特定的临床治疗（如激素或手术）对所有跨性别者都是“必要的”，并且反映性别与一个人性别认同一致的法律文件，能够帮助就业，安全旅行和其他日常生活所必须的方面，以及便于获得医疗保健，从而有助于患者的健康。</p> <p>在某些司法管辖区，对改变法律性别有手术要求。根据法律，健康提供者可能有余地，因为对于所有跨性别者而言，没有特别的手术是“必要的”。一些跨性别者无法在其所来自的州或国家更改出生证明，但仍可能在其美国护照，社保卡和驾驶执照上更改其性别标记。[4]</p> <p>跨性别者可能会在他们的法定性别和性别特异性的医疗护理之间发生冲突，例如宫颈癌或前列腺疾病的筛查。虽然州法律可能有所不同，但在某些情况下，提供者可能有必要联系保险公司并解释性别特异性的服务拒绝的具体情况。一旦法律文件发生变更，患者应确保在其保险公司和医疗服务提供者处更新其法定姓名和性别，以防止由于信息不匹配被拒绝服务。</p> <p>名称的法律变更在大部分司法管辖区是与性别无关的过程；在大多数司法管辖区，跨性别者的名称变更过程与非跨性别者的名称变更过程相同。</p> <p><a href="http://travel.state.gov/content/passports/en/passports/information/gender.html" target="_blank" rel="noopener noreferrer">美国国务院护照指南<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [5]: http://travel.state.gov/content/passports/en/passports/information/gender.html</p> <p>社保管理局指南 [6]: https://secure.ssa.gov/apps10/poms.nsf/lnx/0110212200</p> <p>全国跨性别平等中心设有一个资源中心，其中包含与美国各州更改身份证件的指导方针的链接[3]：http：//www.transequality.org/documents</p> <p>有关在欧洲更改性别身份文件的信息，请访问tgeu.org。[7]</p> <h3 id="参考文献-34"><a href="#参考文献-34" class="header-anchor">#</a> 参考文献</h3> <ol><li><p>WPATH Public Policy Committee, Green J. WPATH <em>Statement on Legal Recognition of Gender Identity</em> [Internet]. 2015 [cited 2016 Mar 24]. Available from: <a href="http://www.wpath.org/uploaded_files/140/files/WPATH%20Statement%20on%20Legal%20Recognition%20of%20Gender%20Identity%201-19-15.pdf" target="_blank" rel="noopener noreferrer">http://www.wpath.org/uploaded_files/140/files/WPATH%20Statement%20on%20Legal%20Recognition%20of%20Gender%20Identity%201-19-15.pdf<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a></p></li> <li><p>The Open Society Foundations, Byrne J. <a href="https://www.opensocietyfoundations.org/sites/default/files/license-to-be-yourself-20140501.pdf" target="_blank" rel="noopener noreferrer">License to be Yourself: Laws and advocacy for<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="https://www.opensocietyfoundations.org/sites/default/files/license-to-be-yourself-20140501.pdf" target="_blank" rel="noopener noreferrer">legal gender recognition of trans people<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. New York, NY; 2014 May [cited 2016 Mar 24]. Available from: https://<a href="http://www.opensocietyfoundations.org/sites/default/files/license-to-be-" target="_blank" rel="noopener noreferrer">www.opensocietyfoundations.org/sites/default/files/license-to-be-<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> yourself-20140501.pdf</p></li> <li><p>National Center for Transgender Equality. <a href="http://www.transequality.org/documents" target="_blank" rel="noopener noreferrer">ID Documents Center<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. National Center for Transgender Equality. 2016 [cited 2016 Mar 24]. Available from: http://www.transequality.org/documents</p></li> <li><p>Lambda Legal. <a href="http://www.lambdalegal.org/know-your-rights/transgender/changing-your-documents-resources" target="_blank" rel="noopener noreferrer">Resources for Changing Your Documents<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. Lambda Legal: Know Your Rights. [cited 2016 Mar 24]. Available from: http://www.lambdalegal.org/know-your- rights/transgender/changing-your-documents-resources</p></li> <li><p>U.S. Department of State; Bureau of Consular Affairs. <a href="http://travel.state.gov/content/passports/en/passports/information/gender.html" target="_blank" rel="noopener noreferrer">Gender Transition Applicants<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. U.S. Passports and International Travel. [cited 2016 Mar 24]. Available from: http://travel.state.gov/content/passports/en/passports/information/gender.html</p></li> <li><p>U.S. Social Security Administration. <a href="https://secure.ssa.gov/apps10/poms.nsf/lnx/0110212200" target="_blank" rel="noopener noreferrer">Program Operations Manual System (POMS): RM<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="https://secure.ssa.gov/apps10/poms.nsf/lnx/0110212200" target="_blank" rel="noopener noreferrer">10212.200 - Changing Numident Data for Reasons other than Name Change<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. Official Social Security Website. 2013 [cited 2016 Mar 24]. Available from: https://secure.ssa.gov/apps10/poms.nsf/lnx/0110212200</p></li> <li><p><a href="http://tgeu.org/" target="_blank" rel="noopener noreferrer">Transgender Europe<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> (TGEU) [Internet]. [cited 2016 Mar 24]. Available from: http://tgeu.org/</p></li></ol> <h2 id="性别隔离体系"><a href="#性别隔离体系" class="header-anchor">#</a> 性别隔离体系</h2> <p>主要作者： Dan Karasic, MD</p> <p><strong>性别隔离体系中的指导原则是赋予人们使用与其性别认同最相符的设施和项目的自主权。这包括使用洗手间设施，住院和住宿床位，以及与所体验性别一致的更衣室（分级：X C S）</strong>。当可以获得且个体偏好时，可以使用无性别设施，但服务不应取决于此类设施的可获得性。</p> <p>根据最近的州和联邦法规，依据其性别认同获得相应项目的合法权利已经扩大。根据加利福尼亚州等一些州的法律，学校必须允许学生使用与其性别认同相符的设施和项目。[1]根据加利福尼亚州法律，学生应该能够根据自己的性别认同选择设施，或者使用非公用设施。学生应该能够根据性别认同参加体育项目和使用体育设施。应使用其偏好的名称和代词称呼学生，并根据数据系统中保存的性别认同信息列出。教育部根据第九条规定，学生必须能够根据自己的性别认同参加项目和使用设施。[2]</p> <p>美国卫生和公众服务部现在要求庇护所和其他住房方案根据其性别认同向跨性别者提供住房和其他住宿和服务。[3]</p> <p>WPATH SOC 7讨论机构环境&lt;20&gt;中人群的照护问题，指出性别过渡照护的所有方面都应该为生活在机构中的人提供，并指出根据外生殖器进行的性别隔离可能是不恰当的，并使跨性别者面临受害的风险。[4]</p> <h3 id="参考文献-35"><a href="#参考文献-35" class="header-anchor">#</a> 参考文献</h3> <ol><li>California School Boards Association (CSBA). <a href="http://www.aclu-il.org/wp-content/uploads/2014/06/CSBA-Final-Guidance-03-2014.pdf" target="_blank" rel="noopener noreferrer">Final Guidance: AB1266, Transgender and<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.aclu-il.org/wp-content/uploads/2014/06/CSBA-Final-Guidance-03-2014.pdf" target="_blank" rel="noopener noreferrer">Gender Nonconforming Students, Privacy, Programs, Activities &amp; Facilities<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. 2014 Mar [cited 2016 Mar 25]. Available from: http://www.aclu-il.org/wp-content/uploads/2014/06/CSBA-Final- Guidance-03-2014.pdf</li> <li>U.S. Department of Education; <a href="https://timedotcom.files.wordpress.com/2014/12/faqs-title-ix-single-sex-201412.pdf" target="_blank" rel="noopener noreferrer">Office for Civil Rights. Questions and Answers on Title IX<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="https://timedotcom.files.wordpress.com/2014/12/faqs-title-ix-single-sex-201412.pdf" target="_blank" rel="noopener noreferrer">and Single-Sex Elementary and Secondary Classes and Extracurricular Activities<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. 2014 [cited 2016 Mar 25]. Available from: https://timedotcom.files.wordpress.com/2014/12</li></ol> <p>/faqs-title-ix-single-sex-201412.pdf</p> <ol><li>U.S. Department of Housing and Urban Development (HUD). <a href="https://www.regulations.gov/%23!documentDetail%3BD%3DHUD_FRDOC_0001-4281" target="_blank" rel="noopener noreferrer">FR–5863–P–01 Equal<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="https://www.regulations.gov/%23!documentDetail%3BD%3DHUD_FRDOC_0001-4281" target="_blank" rel="noopener noreferrer">Access in Accordance With an Individual’s Gender Identity in Community Planning and<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="https://www.regulations.gov/%23!documentDetail%3BD%3DHUD_FRDOC_0001-4281" target="_blank" rel="noopener noreferrer">Development Programs.<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> Regulations.gov - Proposed Rule Document [Internet]. 2016 [cited 2016 Mar 25]. Available from: https://<a href="http://www.regulations.gov/" target="_blank" rel="noopener noreferrer">www.regulations.gov/#!documentDetail;D=HUD_FRDOC_0001-<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> 4281</li> <li>World Professional Association for Transgender Health (WPATH). [Standards of care for](http://www.wpath.org/uploaded_files/140/files/Standards of Care%2C V7 Full Book.pdf) [the health of transsexual, transgender, and gender nonconforming people, 7th Version](http://www.wpath.org/uploaded_files/140/files/Standards of Care%2C V7 Full Book.pdf) [Internet]. WPATH; 2012 [cited 2016 Mar 10]. Available from: [http://www.wpath.org/uploaded_files/140/files/Standards%20of%20Care,%20V7%20Full%20Book.pdf](http://www.wpath.org/uploaded_files/140/files/Standards of Care%2C V7 Full Book.pdf)</li></ol> <blockquote><p>&lt;20&gt;. 译者注：WPATH SOC中提及的机构环境指监狱等。</p></blockquote> <h2 id="无家可归的跨性别者个体"><a href="#无家可归的跨性别者个体" class="header-anchor">#</a> 无家可归的跨性别者个体</h2> <p>主要作者： Barry Zevin, MD</p> <h3 id="概论-24"><a href="#概论-24" class="header-anchor">#</a> 概论</h3> <p>参与美国跨性别歧视情况调查的跨性别人群中，有五分之一表示经历过无家可归的情况。无家可归通常由以下原因造成：逃离非宽容家庭，被赶出家门，由于歧视丢掉工作，或因为歧视/自身残疾无法就业。此调查中，经历过无家可归的受调查者中，大部分尝试去无家可归者收容所的人受到过收容所员工或居住者的困扰，29%的人被直接遣离，22%的人被居住者或员工性骚扰。[1]很多跨性别个体发现医疗护理和社会服务提供者对跨性别问题和需求不甚了解。针对无家可归者的社会服务机构有必要在此领域有足够的知识水平，因为他们更易于接触到跨性别人群。[2]美国无家可归病人医护网络在该领域提供了高质量的培训。[2-4]</p> <p>经常有无家可归的跨性别人群反映公共场所尤其是无家可归者收容所内的歧视和侵害。[5]虽然联邦和其他法规禁止歧视[6]，很多人由于此类歧视依然难以表现他们自我认同的性别，如果收容所是性别隔离的，最好的办法也许是先以私密、非歧视的方式收集性别认同信息，然后询问住宿偏好。大部分个体倾向于根据他们生活中或自我认同的性别被安排住宿，然而在一些情形下一些人出于安全或者其他考虑，可能会希望被根据出生性别安排住宿。最好的收容所经办指南已经出台。[7-8]</p> <p>功能残疾（functional disability）在无家可归跨性别人群中非常普遍。很多无家可归的跨性别个体由于此类问题无法工作。性别焦虑本身就可导致严重抑郁，焦虑和自杀倾向。[9]童年不良经历、损失和创伤可能导致创伤后应激障碍和其他持续性问题。身体侵害，酒精及药物使用也可能造成慢性身体问题。教育机会的错失和工作机会的缺失会导致学习掌握新技能的能力低下。这些问题常常导致工作能力的长期缺失。一些人可能符合社会保障中的残疾标准，这可能是他们摆脱无家可归困境的唯一途径。详细记录此类功能残疾会对这些个体有所帮助。[10]</p> <h3 id="无家可归状态与性别肯定治疗"><a href="#无家可归状态与性别肯定治疗" class="header-anchor">#</a> 无家可归状态与性别肯定治疗</h3> <p>激素疗法和跨性别手术，若患者有意愿，医疗上被认为是治疗性别焦虑所必需的。在一些案例中，无家可归的境况被作为了这些医疗服务的排除条件之一。大部分案例中需要激素疗法的个体表现高度积极，在无家可归的压力下依然可以遵从治疗和监测。为无家可归者提供医疗护理的机构已经成功地对很多患者进行了激素治疗。[3]对于那些寻求胸部，乳房，生殖器或其他性别确定手术的患者，无家可归也并非与为手术做计划相矛盾。对于这类手术，良好预后所需的居住安定程度，因手术流程和个人情况而异。医疗暂憩护理&lt;21&gt;项目（medical respite program）可帮助一些患者从某些手术静养恢复。由于往往从申请到手术需要一年或更久的等待期，这段时间就是努力稳定住房条件的时机。对于手术的愿景和承诺，对于之前流离失所的人来说往往是一个非常强的驱动力。一些患者可能会对于手术，恢复和后期护理的艰苦考验，或者他们稳定居住的可能性有不合实际的想法和认识。这些个体需要与主要护理提供者，心理健康服务提供者，护理指导员&lt;22&gt;（care navigator）等方面努力协作，从而达成术后良好预后所需的稳定性。在手术前的教育和准备过程中应注意避免患者产生这样的影响：护理者对住所稳定性的担心带有歧视意味或只是主观认为的困境。[11]</p> <h3 id="预防-2"><a href="#预防-2" class="header-anchor">#</a> 预防</h3> <p>对于流离失所的预防，依赖于降低在家庭，工作和其他社会环境中的歧视，并为跨性别个体提供平等的机会。帮助无法工作的人得到残疾人资格是摆脱无家可归状况的重要途径。防治无家可归的危害可以通过采用最佳的处理实践，和教育针对无家可归者的社会服务提供者达成。尽管在这一领域大量研究已经启动，仍需更多的研究，以使得最佳处理实践的发展变化被知晓，从而进一步实践这些变化。</p> <h3 id="参考文献-36"><a href="#参考文献-36" class="header-anchor">#</a> 参考文献</h3> <ol><li>Grant JM, Mottet LA, Tanis J, Harrison J, Herman J, Keisling M<a href="http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf" target="_blank" rel="noopener noreferrer">. Injustice at every turn: a<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf" target="_blank" rel="noopener noreferrer">report of the National Transgender Discrimination Survey<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. National Center for Transgender Equality and National Gay and Lesbian Task Force; 2011 [cited 2016 Mar 17]. Available from: http://www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf</li> <li>O’Sullivan A, Apodaca E, Caughlan J, Roberts LC, Hale A, Hines L, et al. <a href="http://www.nhchc.org/wp-content/uploads/2011/09/transgendered.pdf" target="_blank" rel="noopener noreferrer">Crossing to<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.nhchc.org/wp-content/uploads/2011/09/transgendered.pdf" target="_blank" rel="noopener noreferrer">Safety: Transgender Health &amp; Homelessness. Healing Hands<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> (A publication of the HCH Clinicians’ Network) [Internet]. 2002 Jun [cited 2016 Mar 17];6(4). Available from: http://www.nhchc.org/wp-content/uploads/2011/09/transgendered.pdf</li> <li>Klein P, Wenzel C, Ammerman S, Aytch M. <a href="http://www.nhchc.org/wp-content/uploads/2014/12/practice-transformation.pdf" target="_blank" rel="noopener noreferrer">Practice Transformation: Improving Access to<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.nhchc.org/wp-content/uploads/2014/12/practice-transformation.pdf" target="_blank" rel="noopener noreferrer">Care and Quality of Care for Unstably Housed Transgender and Gender-Nonconforming<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.nhchc.org/wp-content/uploads/2014/12/practice-transformation.pdf" target="_blank" rel="noopener noreferrer">Persons<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. National HCH Conference; [cited 2016 Mar 17]. Available from: http://www.nhchc.org/wp-content/uploads/2014/12/practice-transformation.pdf</li> <li>HCH Clinicians’ Network. <a href="https://www.nhchc.org/wp-content/uploads/2015/02/hh-transgender-final-2-24-15.pdf" target="_blank" rel="noopener noreferrer">“Seeing People as They See Themselves”: Health Care and<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="https://www.nhchc.org/wp-content/uploads/2015/02/hh-transgender-final-2-24-15.pdf" target="_blank" rel="noopener noreferrer">Access for Transgender Individuals Experiencing Homelessness<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>. Healing Hands[Internet]. 2015 Winter [cited 2016 Mar 17];19(1). Available from: https://<a href="http://www.nhchc.org/wp-content/uploads/2015/02/hh-transgender-final-2-24-15.pdf" target="_blank" rel="noopener noreferrer">www.nhchc.org/wp-content/uploads/2015/02/hh-transgender-final-2-24-15.pdf<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a></li> <li>Mottet L, Ohle J. Transitioning Our Shelters: Making Homeless Shelters Safe for Transgender People. J Poverty. 2006 May 22;10(2):77–101.</li> <li>U.S. Department of Housing and Urban Development (HUD). <a href="https://www.hudexchange.info/resources/documents/Notice-CPD-15-02-Appropriate-Placement-for-Transgender-Persons-in-Single-Sex-Emergency-Shelters-and-Other-Facilities.pdf" target="_blank" rel="noopener noreferrer">Appropriate Placement for<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="https://www.hudexchange.info/resources/documents/Notice-CPD-15-02-Appropriate-Placement-for-Transgender-Persons-in-Single-Sex-Emergency-Shelters-and-Other-Facilities.pdf" target="_blank" rel="noopener noreferrer">Transgender Persons in Single-Sex Emergency Shelters and Other Facilities<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. 2015 Feb [cited 2016 Mar 17]. Available from: https://<a href="http://www.hudexchange.info/resources/documents/Notice-CPD-15-02-Appropriate-Placement-for-" target="_blank" rel="noopener noreferrer">www.hudexchange.info/resources/documents/Notice-CPD-15-02-Appropriate-Placement-for-<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> Transgender-Persons-in-Single-Sex-Emergency-Shelters-and-Other-Facilities.pdf</li> <li>Massachusetts Transgender Political Coalition Policy Committee. <a href="http://www.masstpc.org/wp-content/uploads/2012/10/Shelter-for-all-Genders.pdf" target="_blank" rel="noopener noreferrer">Shelter for all genders:<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.masstpc.org/wp-content/uploads/2012/10/Shelter-for-all-Genders.pdf" target="_blank" rel="noopener noreferrer">best practices for homeless shelters, services, and programs in Massachusetts in serving<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.masstpc.org/wp-content/uploads/2012/10/Shelter-for-all-Genders.pdf" target="_blank" rel="noopener noreferrer">transgender adults and gender non-conforming guests<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. 2013 [cited 2016 Mar 17]. Available from: http://www.masstpc.org/wp-content/uploads/2012/10/Shelter-for-all- Genders.pdf</li> <li>The FTM Safer Shelter Project Research Team. <a href="http://www.wellesleyinstitute.com/wp-content/uploads/2011/11/invisible-men.pdf" target="_blank" rel="noopener noreferrer">Invisible Men: FTMs and Homelessness<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.wellesleyinstitute.com/wp-content/uploads/2011/11/invisible-men.pdf" target="_blank" rel="noopener noreferrer">in Toronto<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. Wellesley Institute; 2008 Jun [cited 2016 Mar 17]. Available from: http://www.wellesleyinstitute.com/wp-content/uploads/2011/11/invisible-men.pdf</li> <li>Clements-Nolle K, Marx R, Katz M. Attempted suicide among transgender persons: The influence of gender-based discrimination and victimization. J Homosex. 2006;51(3):53–69.</li> <li>O’Connell JJ, Zevin BD, Quick PD, Anderson SF, Perret YM, Dalton M, et al. <a href="http://www.nhchc.org/wp-content/uploads/2012/02/DocumentingDisability2007.pdf" target="_blank" rel="noopener noreferrer">Documenting<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.nhchc.org/wp-content/uploads/2012/02/DocumentingDisability2007.pdf" target="_blank" rel="noopener noreferrer">Disability: Simple Strategies for Medical Providers<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> [Internet]. Health Care for the Homeless Clinician’s Network; 2007 Sep [cited 2016 Mar 17]. Available from: http://www.nhchc.org/wp-content/uploads/2012/02/DocumentingDisability2007.pdf</li> <li>Deutsch MB. Gender-affirming surgeries in the era of insurance coverage: developing a framework for psychosocial support and care navigation in a perioperative period. J Health Care Poor Underserved. 2016;27:1–6.</li> <li>National Health Care for the Homeless Council. <a href="http://www.nhchc.org/wp-content/uploads/2014/10/in-focus_transgender_sep2014_final.pdf" target="_blank" rel="noopener noreferrer">Gender Minority &amp; Homelessness:<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a> <a href="http://www.nhchc.org/wp-content/uploads/2014/10/in-focus_transgender_sep2014_final.pdf" target="_blank" rel="noopener noreferrer">Transgender Population<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>. Focus Q Res Rev Natl HCH Counc [Internet]. 2014 Aug [cited 2016 Mar 17];3(1). Available from: http://www.nhchc.org/wp-content/uploads/2014/10/in- focus_transgender_sep2014_final.pdf</li> <li>Fletcher JB, Kisler KA, Reback CJ. Housing status and HIV risk behaviors among transgender women in Los Angeles. Arch Sex Behav. 2014 Nov;43(8):1651–61.</li></ol> <blockquote><p>&lt;21&gt;. 译者注：一类对有健康状况的无家可归者提供短期收容疗养的项目。</p> <p>&lt;22&gt;. 译者注：指在医院环境外为有需求人员选择和获取医疗服务提供指导的人员</p></blockquote> <h2 id="跨性别和性别非常规儿童和青少年的健康考虑因素"><a href="#跨性别和性别非常规儿童和青少年的健康考虑因素" class="header-anchor">#</a> 跨性别和性别非常规儿童和青少年的健康考虑因素</h2> <p>主要作者： Johanna Olson-Kennedy, MD; Stephen M. Rosenthal, MD; Jennifer Hastings, MD; Linda Wesp, MSN, NP-C</p> <h3 id="概论-25"><a href="#概论-25" class="header-anchor">#</a> 概论</h3> <p>跨性别者和性别非常规（TGNC）青少年的照护是一个快速发展的医学领域，并且在专业人士中引起争议。理所当然的是，跨性别成年人作为跨性别青少年开始，而且如果在儿童期或青春期就被识别，可能会从早期获得激素拮抗剂和/或激素替代治疗中获益。虽然关于青春期抑制和青春期使用激素替代治疗的影响的数据很少，但来自荷兰的可信结果表明这种方法可以改善青少年的生活质量，减少性别焦虑。[1]确定跨性别青少年采用的最佳实践的主要挑战在于每个人的发育都不同。虽然儿童有青春期开始的标准范围，[2]儿童开始表达性别焦虑的经历或主张与出生时的指定性别不同的性别认同的年龄变化很大。跨性别青少年护理的提供者应该擅长满足在其过程中任何阶段接受护理的年轻人的需求。对跨性别青少年的照顾不一定限于儿科内分泌学家。普通儿科医生，青少年医学专家，家庭医学，医学/儿科，以及执业护士，医师助理和其他人都有资格为跨性别青少年提供高质量的护理。</p> <h3 id="为青少年创造积极的空间"><a href="#为青少年创造积极的空间" class="header-anchor">#</a> 为青少年创造积极的空间</h3> <p>文化敏感性和意识始于前台员工和其他成为与父母和患者初始接触点的员工。工作人员和提供者询问和一致使用适当的代词和名称是创建在文化上有敏感性和热情环境的第一步，也是最重要的一步。专业人员可以在父母和看护人在场的情况下对姓名和代词的恰当使用进行建模。</p> <p>越来越多的年轻人表现出非二元或性别酷儿身份，更倾向于使用性别中性的代词作为更准确的描述方式。医疗提供者，父母，朋友和家庭成员与性别中立的代词斗争并且无意中拒绝非二元身份的情况并不少见。无论他们的非二元认同仅仅是得到更二元化的身份的中间步骤，或者成为他们性别认同探索的终点，他们的认同都是有效的并且需要被尊重。</p> <h3 id="精神健康支持"><a href="#精神健康支持" class="header-anchor">#</a> 精神健康支持</h3> <p>精神健康专业人员在跨性别和性别非常规青少年的护理中起着至关重要的作用。甚至在披露与出生时的指定性别不同的真实性别认同之前，跨性别青少年常常就会出现抑郁，焦虑，社交孤立，行为问题，学校中的困难状况（school struggles）和自杀意念等症状。[3]通常年轻人在提供与表型性别转变相关的护理之前很久就开始接受精神卫生服务。不幸的是，由于很少有心理健康服务提供者在跨性别和性别非常规青少年的护理方面经验丰富，因此不准确的建议并不少见。不应寻求心理健康支持，以说服接受性别认同与出生时指定的性别一致，而应该为年轻人提供一个安全和热情的空间来讨论和探索他们的性别以及任何可能存在的心理健康挑战。虽然历史上精神卫生专业人员一直负责认定他们的跨性别和性别非常规来访者的性别，但这种方法正在迅速失去支持，并且正在被支持性模式取代，而不是成为获得照护的看门人。[4]精神卫生专业人员在帮助青少年学会表达他们的性别经验，以及确定他们围绕性别与出生时分配的性别不一致的需求方面发挥重要作用。治疗师应该花时间与年轻人一起收集关于他们与性别有关的经历，以及年轻人的支持系统如何处理的历史信息。此外，如果需要，治疗师可以帮助青少年制定有关披露，自我接纳，跨性别身份整合，亲密伴侣关系和社会转型的策略。治疗师可以帮助青少年澄清他们希望从青春期抑制，激素替代治疗和/或手术中获得的东西。</p> <p>心理健康服务提供者在教育父母、家庭成员、学校和其他人关于跨性别和性别非常规青少年的需求，以及在多个领域为这些年轻人辩护方面也发挥着重要作用。治疗师还可以与父母密切合作，帮助他们了解孩子的体验以及可能从父母和/或照顾人需要什么。许多跨性别和性别非常规青少年，和任何年龄段经历重大生活改变的大多数人一样，将受益于青春期抑制期间和激素替代治疗管理最初几年中（以及或许更长时间）的持续治疗。尽管被了解和接受程度越来越高，但跨性别青少年可能会遭遇跨性别恐惧及其不良后果，因此可能从持续支持中受益。要求参与治疗以获取与身体性别过渡相关的护理既不成功，也不促进年轻人和治疗师之间的诚实沟通。应强烈推荐治疗方案，并与青年人进行常规讨论；但由于缺乏熟练的性别心理健康专业人员，因此由于经济或地理位置原因跨性别和性别非常规青少年及其家庭并不总能获得这些资源。越来越多的擅长支持跨性别和性别非常规青少年的治疗师正在提供在线或电话治疗，以帮助解决这些困难的情况。此外，青少年经常因与性别无关的原因而获得精神健康治疗，例如社交焦虑，抑郁，自残等。虽然这些症状与性别焦虑重叠，但仍有许多精神健康专业人员熟悉这些特殊挑战。精神卫生服务提供者提出的问题也可以由经验丰富，有资格并有时间与青年进行此类讨论的其他医疗服务提供者解决。如果没有可用或无法获得的心理健康专业人员，这通常是必需的。</p> <h3 id="青春期前性别非常规儿童"><a href="#青春期前性别非常规儿童" class="header-anchor">#</a> 青春期前性别非常规儿童</h3> <p>在过去的五年中，有儿童的家庭越来越普遍地要求就接触性别非常规儿童的最佳方式提出建议。年仅18个月的儿童已经清楚地了解了他们的性别认同和性别表达偏好。大多数父母都不知道如何最好地帮助他们的孩子，并可能寻求专业人士的建议；通常是精神科医生或儿科医生。在这个发展阶段，没有必要进行医疗干预。对于幼儿，必须做出决定以创造促进健康成长和发展的安全环境。对于一些孩子来说，这可能包括社会过渡-改变外表（衣服，发型）以及可能的名称和代词以匹配其内在性别。</p> <p>尽管仍然存在关于哪些性别非常规儿童将继续进入拥有跨性别身份和/或性别焦虑的青春期和成年期的不确定性，先前的研究中已经注意到，性别焦虑的强度增加是未来跨性别身份的预测因素。这一发现很容易引起混淆：因为安全因素或缺乏基本语言来表达感受而抑制性别焦虑的年轻人同样可能持续到成年，然而并不会在很小的时候表现出来。临床经验表明，正是那些儿童在寻求社会过渡——被视为和作为与被指派性别不同的性别生活的机会——时最为难以忍受。社会过渡已经变得越来越普遍，最近的一项研究报告称，其所坚称的性别受到支持的跨性别儿童具有良好的心理健康状况。[5]儿童的社会转型可能在后勤方面较为复杂，最好由包括家庭，医疗服务提供者，心理健康治疗师甚至律师在内的支持团队提供便利。该团队可以在学校，体育运动和其它方面共同为孩子提供辩护，以便性别非常规儿童能够安全地参与这些活动。心理健康治疗师可以在父母和其他家庭成员关于性别非常规儿童的教育以及他们对支持和爱的需求方面发挥重要作用。</p> <h3 id="跨性别青少年的医疗保健"><a href="#跨性别青少年的医疗保健" class="header-anchor">#</a> 跨性别青少年的医疗保健</h3> <p>通过定义两个不同的青少年群体可以简化护理方法：青春期前或青春期早期发育阶段（Tanner 2-3），以及那些在后期阶段或完成阶段的人（Tanner 4-5）。这两个队列通常需要不同的医疗干预措施；抑制内源性青春期，和/或使用激素替代治疗来发育男性化或女性化的特征。</p> <h3 id="早期青春期中的内源性青春期抑制"><a href="#早期青春期中的内源性青春期抑制" class="header-anchor">#</a> 早期青春期中的内源性青春期抑制</h3> <p>患有性别焦虑的青少年在其内源性青春期过程开始时经常会出现严重创伤。[6]青春期开始时性别焦虑的情况并非罕见。第二性征的发展会巩固对于那些性别认同与出生时指定性别不一致的人的所不期望的身体发育过程。由于跨性别青少年频繁面临心理健康挑战，包括焦虑，抑郁，社会隔离，自我伤害，吸毒和酗酒，许多医疗服务提供者视早期治疗为挽救生命。</p> <p>对于那些处于跨性别男性光谱的年轻人来说，青春期伴随约10岁时乳房发育时开始，尽管一项大型横断面研究表明，10％的白种人，23％的非西班牙裔黑人和近15％的西班牙裔人在7岁前发生Tanner 2乳房发育。[7]对于那些处于跨性别女性光谱的年轻人来说，青春期的第一个迹象是睾丸体积增大到4毫升以上，大约平均发生年龄为11岁。与先天性青春期相关的不良继发性特征的发展可能具有深刻的负面心理社会影响，并且对许多人来说是极度痛苦的根源。</p> <p>荷兰阿姆斯特丹自由大学（VU）医学中心性别鉴定诊所的一个专家团队率先制定了一项方案，该方案提出了延迟或完全避免因不必要的内源性青春期过程而导致的不期望的第二性征特征的可能性。[8]这种护理模式包括使用促性腺激素释放激素（GnRH）类似物（在美国最常见的有醋酸亮丙瑞林或组氨瑞林），一类几十年来用于延缓中枢性性早熟儿童青春期发育的药物。[9]GnRH类似物提供可逆干预，允许青少年暂时缓解不良的、可能造成创伤的内源性青春期。虽然数据稀少，但来自荷兰的初步结果表明，青少年（12岁及以上）青春期抑制期间行为问题和一般心理功能得到改善。[10]</p> <p>为了避免产生不期望的第二性征，理想情况下GnRH类似物应在青春期的早期阶段开始使用（Tanner 2-3）。[11]对于处于青春期发育后期的青少年来说，使用GnRH类似物可以起到诱导闭经的作用，或者阻止持续发育不期望的第二性征。此外，GnRH类似物是跨性别女性青少年雌激素治疗的有效补充，因为在生理剂量下单独使用雌激素通常不足以抑制睾酮的产生（见下文）。青少年不能无限期地单独留在GnRH类似物上，因为骨矿化依赖于性类固醇的存在。虽然临床上越来越普遍，但在青春期早期和&lt;12岁时对跨性别青少年施用的GnRH类似物的影响尚未有发表。虽然罕见，但报道使用GnRH类似物的副作用可能包括骨矿物质密度的获取减少，体重增加，注射部位的脓肿（如果使用注射形式），阴道不规则出血和情绪不稳定。</p> <h3 id="获得治疗的同意"><a href="#获得治疗的同意" class="header-anchor">#</a> 获得治疗的同意</h3> <p>当父母对他们的跨性别和性别非常规孩子有不一致的看法，或者孩子由法院监护时，会出现其他挑战。如果父母双方仍为孩子做出医疗决策，那么医疗和心理健康服务提供者的任务就是帮助父母双方了解医疗干预的必要性。这个过程并不总是直截了当，可能需要花费很多时间，有时需要法律援助的参与。对于儿童福利制度中的年轻人，法官可以下令进行医疗干预，包括激素替代治疗的管理。</p> <h3 id="gnrh类似物的剂量"><a href="#gnrh类似物的剂量" class="header-anchor">#</a> GnRH类似物的剂量</h3> <p>醋酸亮丙瑞林可以通过每日直至每3至4个月进行一次注射给药。[12]组氨瑞林通过随时间释放的植入物给药，该植入物通过外科手术插入上臂的下侧，可持续使用12至36个月。</p> <p>对于开始不期望的青春期的儿童而言接受体检可能会非常紧张。提供者应努力与儿童建立临床关系，以便在进行生殖器检查之前培养信任。提供者应该在评估青春期进展时讨论生殖器检查（针对有睾丸者）和胸部检查（针对有卵巢者）的重要性。使用手机，设备，书籍和其他东西在这些检查中分散儿童注意力的技术可以使检查更易被接受。显著的对生殖器和胸部的不安在年轻人中很常见，对第二性征特征检查的厌恶不应成为开展青春期抑制的障碍。事实上，提供者应考虑推迟生殖器或胸部检查至复诊，直至有希望建立良好关系。在极端情况下，提供者应该考虑创造性的方法，例如首先获得实验室检查结果以确认青春期开始，并在更好地建立关系后在随诊中进行生殖器和/或胸部检查。</p> <h3 id="监测使用gnrh类似物的青少年"><a href="#监测使用gnrh类似物的青少年" class="header-anchor">#</a> 监测使用GnRH类似物的青少年</h3> <p>用于确定下丘脑 - 垂体 - 性腺轴是否被GnRH类似物抑制的血液测试应在开始每月剂量后6-8周或在开始每3个月给药后8周进行。对于那些有植入物的人，应在植入后8周进行用于评估疗效的血液水平检查。血液检查包括超敏感性LH/FSH/总睾酮（在有睾丸者中）或雌二醇（在有卵巢者中）。有证据表明LH/FSH水平不一定是GnRH类似物植入物抑制的可靠指标，因此更准确的充分抑制评估可能需要促性腺激素对皮下亮丙瑞林醋酸盐刺激试验的反应。[13]虽然目前的指南建议每三个月进行一次实验室检查，以评估对下丘脑 - 垂体 - 性腺（HPG）轴的充分抑制，[11]对于跨性别和性别非常规儿童，重复抽血可能是昂贵的，并且会造成创伤。每3至4个月应通过临床检查评估下丘脑 - 垂体 - 性腺（HPG）轴的抑制状况，包括身高和体重；而每年检查血清超敏感性LH，FSH，雌二醇/睾酮水平，肾和肝功能，脂质，葡萄糖，胰岛素和糖基化血红蛋白，在临床上被认为是适当的。如果有关于青春期阻滞剂功效的临床问题，可以更频繁地考虑检查超敏感性儿科FSH/LH和性类固醇水平。</p> <p>如果孩子参与临床或研究试验，将会进行更全面和频繁的实验室检查。</p> <p>关于骨密度的基线信息存在潜在的益处，尽管在GnRH类似物施用之前和期间尚无关于获得骨密度测定的必要性的共识。如果存在非创伤性骨折或骨质疏松症的家族史，建议进行基线筛查。为了优化骨骼健康，提供者应确保摄入足够的钙，并应监测维生素D水平（25-OH）和补充剂（如果有指示）。还应鼓励负重活动。应在随访时评估青春期的身体变化。</p> <p>与正在接受青春期抑制的年轻人进行的后续对话应该包括对持续抑制内源性青春期的愿望的评估。虽然极为罕见，但一些年轻人可能想要停止GnRH类似物并体验其内源性青春期。对于仍然存在性别焦虑，并有兴趣向前推进男性化或女性化的年轻人，可以在GnRH类似物中添加激素替代治疗。</p> <h3 id="激素替代治疗"><a href="#激素替代治疗" class="header-anchor">#</a> 激素替代治疗</h3> <p>激素替代治疗可以添加到GnRH类似物治疗中，以帮助跨性别青少年中女性化或男性化特征的发育。<strong>虽然目前的内分泌学会指南建议在16岁左右开始激素替代治疗，[11]但是一些专科诊所和专家现在建议根据发展状况而不是年龄，基于个体状况决定开始激素替代治疗。（分级：X C S）。</strong>[12] 支持在16岁之前考虑激素起始的因素包括：</p> <ol><li>使用GnRH类似物的时间长度。对于青春期早期抑制内源性青春期的青年，等到16岁时加入激素意味着潜在的5-7年间隙，在此期间骨密度维持在青春期前的比率。这可能会影响峰值骨矿物质密度，并使青年处于相对骨质减少/骨质疏松症的风险之中。</li> <li>在高中最后几年或大学早期经历青春期会带来多重潜在挑战。青春期青少年发生的情绪剧变通常发生在11或12岁。对于那些在那个年龄时情绪不稳定的年轻人来说，他们是在受父母/看护人监管的相对受保护的环境中这样做的，并且没有机动车，毒品，酒精和成人（或几乎成人）同伴与性伴侣等潜在的危险。在高中环境下具有未性成熟的11岁外貌可能会带来情感和社交方面的挑战，这种挑战会因性别焦虑而加剧。</li> <li>来自荷兰的现有数据表明，那些进入青春期时具有性别焦虑的青少年不太可能恢复与出生时指定性别一致的性别认同。[10]</li></ol> <p>意识到一个人的性别认同<strong>不需要</strong>直至青春期或成年早期才能获得的认知能力，也不需要额叶完全髓鞘化。对非跨性别参与者的性别研究发现，儿童在五岁或六岁之前就已经意识到自己的性别，而且往往更早。[14]</p> <h3 id="青春期后青少年的诱导闭经"><a href="#青春期后青少年的诱导闭经" class="header-anchor">#</a> 青春期后青少年的诱导闭经</h3> <p>**通常，跨性别男性青少年尚未准备好或尚未达到开始睾酮治疗的适当年龄，但会对诱导闭经感兴趣。GnRH类似物可用于这种情况，但由于经济和其他原因，通常难以获得，并且如果没有激素替代治疗，这些药物就不能无限期使用。诱发闭经的其他机制包括连续给予复合口服避孕药，以及仅使用孕激素的长效可逆避孕药（LARC），如醋酸去甲羟孕酮注射液，左炔诺孕酮宫内避孕器（IUD）或依托孕烯棒植入物（分级：NT R M）。**释放黄体酮的宫内节育器可能导致大约一半的使用者闭经。[15]请注意，一些跨性别男性青少年对使用“女性”激素感到不适，即使是用于诱导闭经也是如此。可以告知青少年单独使用孕激素几乎没有任何女性化作用。在决策过程中，仔细考虑个体需求至关重要。</p> <h3 id="在跨性别青少年中使用激素替代治疗的准备"><a href="#在跨性别青少年中使用激素替代治疗的准备" class="header-anchor">#</a> 在跨性别青少年中使用激素替代治疗的准备</h3> <p>在开始使用激素替代治疗之前，提供者应该审查患者对其表型性别转变中激素使用的期望。对年轻人来说，对激素替代治疗应有现实的期望，并了解激素能够和不能达到的目标，这一点很重要。如果年龄在18岁以下，GnRH类似物和激素替代治疗都需要父母/法定监护人同意。在同意过程中应审查副作用，风险和益处，以及未知长期风险的可能性。激素的同意过程应该包括关于生育的讨论。虽然正在探索各种选择以保存跨性别青少年未来的生育能力，但目前的现实是冷冻保存非常昂贵，在许多情况下对有卵巢者来说过于苛刻。对于早期暂停青春期过程，然后施用激素替代治疗的青少年，目前不太可能发育成熟的精子或卵子，尽管值得注意的是，青少年肿瘤学领域有一些活跃的体外发育生殖细胞的研究。未来的不育问题对于父母和家庭成员而言往往比青少年本人更为重要，特别是在讨论推进激素替代治疗的初期阶段。认为未来对后代的遗传贡献比避免产生不恰当的第二性征特征更重要的青少年可以选择停止GnRH类似物，并通过内源性青春期进展得以冷冻保存精子或收获卵子。</p> <h3 id="使用gnrh类似物抑制青春期的青少年的激素替代治疗"><a href="#使用gnrh类似物抑制青春期的青少年的激素替代治疗" class="header-anchor">#</a> 使用GnRH类似物抑制青春期的青少年的激素替代治疗</h3> <p>对于那些使用GnRH类似物进行青春期抑制的年轻人来说，医疗提供者有机会用外源激素创造更自然的青春期。因为不需要使用外源性激素来抑制性激素的内源性分泌，所以可以使用递增剂量的睾酮（对于跨性别男性）或雌二醇（对于跨性别女性）。</p> <h3 id="跨性别男性青少年-使用gnrh类似物时的激素治疗"><a href="#跨性别男性青少年-使用gnrh类似物时的激素治疗" class="header-anchor">#</a> 跨性别男性青少年——使用GnRH类似物时的激素治疗</h3> <p>对于那些在出生时指派性别为女性而处于跨性别男性光谱的青少年，睾酮被用于发展男性的第二性征。睾酮可以通过注射给药，或通过凝胶，复合乳膏或贴片局部给药。大多数青少年由于各种原因不热衷于使用凝胶或贴片，原因包括日常使用的必要性，近距离接触其他人的潜在吸收，以及使用贴剂时局部皮肤刺激的高发生率。尽管睾酮注射剂在历史上通过肌肉注射，但许多实践已经转向痛苦较少且同样有效的皮下给药机制。[16]一些患者注意到皮下给药导致激素激增，因为血清睾酮水平可能迅速上升。皮下给药必须每周一次，因为睾酮水平在一周内显著下降，而肌注睾酮持续时间更长，可以每周或每隔一周给药。</p> <h4 id="使用gnrh类似物时的皮下注射睾酮剂量"><a href="#使用gnrh类似物时的皮下注射睾酮剂量" class="header-anchor">#</a> 使用GnRH类似物时的皮下注射睾酮剂量</h4> <p>给药时间表可以从每周12.5mg 皮下注射开始，持续8-12周，每周增加至25mg 皮下注射。三个月后检查水平，并相应地以12.5mg间隔调整。</p> <p>实践者可能决定模仿与Tanner阶段相对应的总睾酮水平，并以6个月的间隔增加。大多数患者在每周皮下注射50-75mg睾酮时达到正常男性范围的总睾酮和良好的临床结果。提供或开出1mL注射器以达到这样的小剂量是有帮助的。供应者还应开出用于吸取药物的18号1英寸针头，以及用于皮下注射的25号5/8英寸针头。青少年可以学会自行注射到侧腹或大腿的皮下空间，每周换侧。常见的副作用是注射区域中的硬结，不过在注射后大量按摩该区域可以最小化这一状况。</p> <h4 id="使用gnrh类似物时的肌肉注射睾酮剂量"><a href="#使用gnrh类似物时的肌肉注射睾酮剂量" class="header-anchor">#</a> 使用GnRH类似物时的肌肉注射睾酮剂量</h4> <p>每周或每两周肌肉注射一次睾酮，时间表相似；每周25mg 肌注，持续8周，然后每周增加至50mg 肌注。如果每两周给药一次，应剂量加倍，但患者在周期第二周结束时经历疲劳，烦躁和整体缺乏能量的情况并不少见；每周注射有助于减少这些问题。在激素水平监测的指导下，以25mg的增量调整剂量。大多数患者每周最终剂量为50-100mg肌注，或每两周100-200mg。从业者应提供或开出1毫升注射器，18克1英寸针头用于吸取药物，21/22/23/25克1英寸针头（最常用23或25号）用于肌内注射。可以教导青少年自行注入大腿，每次换侧。</p> <p>睾酮注射剂通常是油悬浊液，商业上用棉籽油，但经常混合芝麻油作为较便宜的形式。临床医生应该意识到一些年轻人可能对这些油中的任何一种都有过敏反应，并且通常换用另一种油可以成功地缓解这个问题。</p> <h4 id="使用gnrh类似物时的局部使用睾酮剂量"><a href="#使用gnrh类似物时的局部使用睾酮剂量" class="header-anchor">#</a> 使用GnRH类似物时的局部使用睾酮剂量</h4> <p>偶尔会有年轻人偏好局部睾酮给药，而不是睾酮注射剂。睾酮可作为贴片，凝胶或乳剂使用。睾酮贴剂和凝胶可商购，乳剂可由专业药房配制。</p> <p>睾酮贴剂的药量为2mg和4mg，睾酮凝胶的浓度为1％和1.62％。在男性青春期的诱导中，没有关于睾酮贴片或睾酮凝胶的共识给药方案，只有性腺功能减退的顺性别男孩通过局部给药睾酮诱导男性青春期的病例被引用[17]。睾酮贴片只有两种药量因此难以进行药量滴定，但睾酮泵使药量滴定更为可行。[18]</p> <h4 id="监测"><a href="#监测" class="header-anchor">#</a> 监测</h4> <p>本指南的其他部分概述了对睾酮使用安全性的监测，内分泌学会也发布了睾酮给药的指南。[11]应根据临床反应和睾酮水平进行剂量调整。根据患者的年龄，提供者可能希望在剂量提高时以与Tanner阶段相对应的睾酮水平为目标。</p> <h3 id="跨性别女性青少年-使用gnrh类似物时的激素治疗"><a href="#跨性别女性青少年-使用gnrh类似物时的激素治疗" class="header-anchor">#</a> 跨性别女性青少年——使用GnRH类似物时的激素治疗</h3> <p>对于那些在出生时指派性别为男性而处于跨性别女性光谱的青少年，17β雌二醇用于诱导女性化的第二性征：乳房发育，髋部和胸部脂肪分布，以及面部特征软化。雌二醇也有助于抑制睾酮的产生，尽管对于使用GnRH类似物的青少年不必要。单独的雌激素通常不足以完全抑制睾酮的产生，并且应该使用第二种药剂——GnRH类似物或抗雄激素如螺内酯（见下文）。如Rosenthal[12]最近的一篇综述所述，雌激素的药量增加可以通过以下方式实现：</p> <ul><li><ol><li>透皮：每周两次贴片（6.25μg [通过切割25-g贴片实现] 逐渐增加至400g的完全成人剂量）；</li> <li>口服/舌下含服：每日（0.25毫克，逐渐增加至6-8毫克/日的完全成人剂量）；</li> <li>肌注（17β-雌二醇的合成酯）：戊酸雌二醇（5-20mg至30-40mg/2周）或环戊丙酸雌二醇（2-10mg/周）。</li></ol></li></ul> <p>本指南的其他部分概述了对雌二醇使用安全性的监测，内分泌学会也发布了雌激素给药指南。[11]应根据临床反应和安全性进行剂量调整。</p> <h3 id="终止gnrh类似物使用的时机"><a href="#终止gnrh类似物使用的时机" class="header-anchor">#</a> 终止GnRH类似物使用的时机</h3> <p>关于GnRH类似物在青年开始激素替代治疗后应该持续的时间长度尚无共识。<em>荷兰模型</em>遵循如下方案：GnRH类似物和激素替代治疗同时使用，直到跨性别个体切除性腺。这种模式适用于荷兰，因为当地在18岁时更容易进行性腺切除术，并且性腺切除术和GnRH类似物都有医保支付。在美国，与表型性别转变相关的生殖器外科手术往往不在保险范围内，从而为其获取造成重要问题。</p> <p>另外，对于所有跨性别者来说，性腺切除术并不一定是理想的，特别是如果需要未来保留生育能力。GnRH类似物与青春期后期甚至成年早期的激素替代治疗一起延续可能是有益的。继续抑制下丘脑 - 垂体 - 性腺轴将允许使用较低剂量的雌二醇，并且可能不需要抗雄激素。</p> <h3 id="不使用gnrh类似物抑制青春期的青少年的激素替代治疗"><a href="#不使用gnrh类似物抑制青春期的青少年的激素替代治疗" class="header-anchor">#</a> 不使用GnRH类似物抑制青春期的青少年的激素替代治疗</h3> <p>许多跨性别青少年获得服务时已经远远超出了青春期的早期阶段，且许多人无法获得保险所涵盖的GnRH类似物。由于GnRH类似物的成本对于大多数家庭而言过高，因此激素替代治疗（与激素拮抗剂等其他药物联合使用）可用于抑制内源性激素的产生及使身体男性化或女性化。</p> <p>青少年时期的激素剂量会根据年龄，健康状况以及年轻人特有的其他因素而有所不同。为了单独使用睾酮来实现闭经，可能会发生男性化，这可能是也可能不是被期望的。在这些情况下，其他抑制月经的方法的可能发挥作用，例如连续服用复合或仅含孕激素的口服避孕药，注射醋酸去甲羟孕酮，使用含左炔诺孕酮的宫内节育器或依托孕烯棒植入物。</p> <h3 id="跨性别男性青少年-未使用gnrh类似物时的激素治疗"><a href="#跨性别男性青少年-未使用gnrh类似物时的激素治疗" class="header-anchor">#</a> 跨性别男性青少年——未使用GnRH类似物时的激素治疗</h3> <p>类似于使用GnRH类似物的跨性别男性患者，睾酮用于诱导男性化特征，包括身体和面部毛发生长，增加的肌肉质量，声音变低和身体脂肪再分布。对于那些不使用GnRH类似物抑制下丘脑 - 垂体 - 性腺轴的年轻人，可以通过注射（皮下或肌肉内）或局部（通过凝胶，复合乳膏或贴片）摄入睾酮。</p> <h4 id="皮下给药"><a href="#皮下给药" class="header-anchor">#</a> 皮下给药</h4> <p>给药时间表可以每周25mg皮下注射开始，持续8-12周，每周增加至50mg皮下注射。三个月后检查激素水平，并相应地以25mg为间隔调整。</p> <p>实践者可能决定模仿与Tanner阶段相对应的总睾酮水平，并以3-6个月的间隔增加。大多数患者将经历正常男性范围的总睾酮和良好的临床反应，每周皮下注射50-75mg。提供或开出1mL注射器以达到这些小剂量是有帮助的。供应商还应开出用于吸取药物的18号1英寸针头，以及用于注射的25号5/8英寸针头。青年人可以学会自行注射到侧腹或大腿的皮下空间，每周换侧。常见的副作用是在注射区域中的硬结，不过如果在注射后该区域被大量按摩可以最小化这一状况。</p> <h4 id="肌内给药"><a href="#肌内给药" class="header-anchor">#</a> 肌内给药</h4> <p>如果偏好肌内给药，一些专家建议将上述剂量加倍。肌肉注射剂量可以每隔一周或两周进行一次，其药量增加时间表相似；每周25mg肌肉注射，或每两周50mg肌肉注射，持续8-12周，然后每周增加至50mg或每两周增加100mg 肌肉注射。检查激素水平，并相应地以25mg的增量调整。大多数患者每周最终剂量为50-100mg肌肉注射，或每两周100-200mg。患者在周期的第二周结束时经历疲劳，易怒和整体缺乏能量的情况并不少见。</p> <p>一些患者喜欢在调整剂量的情况下以其他间隔（例如每10天）给药。从业者应提供或开出1毫升注射器，18克1英寸针头用于吸取药物，21/22/23/25克1英寸针头用于肌内注射。可以教导青少年自行注入大腿，每次换侧。</p> <p>值得注意的是，对于已经过了内源性青春期的年龄较大的年轻人来说，缓慢提高药量的价值尚不明确，如果男性化需要数年才能实现，可能会造成不必要的痛苦。</p> <p>无论使用何种技术，注射用睾酮环丙酸酯使用油悬浊液，商业上用棉籽油。临床医生应该意识到一些年轻人可能对这些油中的任何一种都有过敏反应，并且通常换用另一种油可以成功地缓解这个问题。对于那些对棉籽油过敏的年轻人，庚酸睾酮在商业上使用芝麻油悬浊液。此外，一些配药房提供睾酮环丙酸酯芝麻油悬浊液作为更廉价的选择。</p> <h3 id="跨性别女性青少年-未使用gnrh类似物时的激素治疗"><a href="#跨性别女性青少年-未使用gnrh类似物时的激素治疗" class="header-anchor">#</a> 跨性别女性青少年——未使用GnRH类似物时的激素治疗</h3> <p>17β雌二醇用于诱导女性化的第二性征：乳房发育，髋部和胸部脂肪分布，以及面部特征的软化。雌二醇也有助于抑制睾酮的产生，但通常与抗雄激素如螺内酯一起给药。雌二醇可通过口服，注射，或贴片和复合乳膏局部给药。</p> <p>雌激素给药的方法根据年轻人的年龄而变化。雌二醇的缓慢增加可能对乳房发育有益，尽管对于患者而言缓慢通常难以忍受。对于年轻患者，较小的起始剂量可能更为可取。如Rosenthal[12]最近的一篇综述所述，雌激素的药量增加可以通过以下方式实现：</p> <ol><li>透皮：每周两次贴片（6.25μg [通过切割25-g贴片实现] 逐渐增加至400g的完全成人剂量）；</li> <li>口服/舌下含服：每日（0.25毫克，逐渐增加至6-8毫克/日的完全成人剂量）；</li> <li>肌注（17β-雌二醇的合成酯）：戊酸雌二醇（5-20mg至30-40mg/2周）或环戊丙酸雌二醇（2-10mg/周）。</li></ol> <p>由于没有伴随使用GnRH类似物，因此需要的初始给药剂量可能高于上述方案。剂量的初始剂量和增加过程应针对每个年轻人量身定制。例如，经历过内源性男性青春期并在16或17岁时进入护理的年轻人可遵循以下给药方案：</p> <p>口服17β-雌二醇：以2mg/天开始，持续4-8周，并根据临床反应增加1mg增量。</p> <p>肌注（17β-雌二醇的合成酯）：戊酸雌二醇10-15mg 肌注 每14天，持续8-12周，然后根据临床和监测结果根据需要增加5mg。</p> <p>值得注意的是，对于已经过了内源性青春期的年龄较大的年轻人来说，非常缓慢地提高药量的价值尚不明确，如果女性化需要数年才能实现，可能会造成不必要的痛苦。</p> <p>逐渐增加螺内酯（以减少副作用，包括血压不稳定或头晕）的效用尚不清楚，但由于利尿作用，以25mg（分为每日两次）开始逐渐增加至最终剂量200（分为每日两次）可能是有用的。</p> <p>跨性别女性个体中孕酮的使用在提供者之间没有达成共识。若使用黄体酮，选择生物同一性的微粉化黄体酮可能是明智之举，因为一些专家担心合成孕酮的副作用，如潜在的抑郁症加重或体重增加。关于孕激素的作用和剂量的详细讨论包括在成人指南中。</p> <h3 id="跨性别青少年的手术干预"><a href="#跨性别青少年的手术干预" class="header-anchor">#</a> 跨性别青少年的手术干预</h3> <p>经历过内源性青春期的跨性别男性青年通常会出现明显的胸部不安，并且可能会采用不适当的束胸方法。使用胶带，绷带和保鲜膜粘合都可以导致严重的医疗并发症。即使是合身的胸部粘合剂也很热，不舒适并且使体育锻炼困难。男性胸部重建是许多跨性别个体的表型性别转变的医学必需部分。虽然越来越多的保险公司承担了男性胸部重建的费用，但手术通常存在专断的障碍，要求年轻人需要在接受此手术之前至少年满18岁。提供者应参与申诉程序，以便患者可以接受胸部手术。目前没有可用的数据报告男性化胸部重建对未成年人的积极影响，尽管目前正在进行一项研究。</p> <p>尽管青少年护理方面取得了进展，包括在青春期使用青春期阻滞剂和激素，但许多跨性别青少年（特别是跨性别女性青少年）经常会出现生殖器不安，导致严重的焦虑和抑郁，并且许多年轻人报告对生活质量造成损害。在那些生殖器与其性别认同不匹配的青年中，发展社会关系技能和经验的能力受到负面影响。高中是一个年轻人开始探索亲密关系，以及体验他们自己和彼此身体的时候。对于跨性别青少年来说，与潜在伴侣分享私密空间的想法往往是绝对可怕的，因为如果他们的身体无意中暴露，他们的跨性别状态可以在瞬间被披露。对于许多跨性别女性来说，这种披露导致了愤怒的伴侣对她们身体上的攻击，而且往往造成死亡。对于许多年轻人来说，社交场合和约会被放弃，在这个发展阶段学习必要的社交技能的机会也会丧失。内分泌学会指南和世界跨性别健康专业协会（WPATH）护理标准7.0版都建议将跨性别男性和女性青少年的生殖器手术推迟至18岁。随着年轻人在越来越早的年龄进行性别过渡，为了解决上述问题，生殖器外科手术在未成年人中根据具体情况被更频繁地进行。</p> <p><em>编者按：对跨性别青年的性别肯定护理是一个年轻且快速发展的领域。在缺乏可靠证据的情况下，提供者通常必须依赖于该领域创新者和思想领袖的专家意见；本青少年指南中表达了许多这些专家意见。该青少年方案的四位主要作者代表了多年的临床护理和研究专业经验，包括学术和社区实践环境，以及青少年医学，儿科内分泌学，家庭医学和高级实践护理学科。</em></p> <h3 id="参考文献-37"><a href="#参考文献-37" class="header-anchor">#</a> 参考文献</h3> <ol><li>de Vries AL, McGuire JK, Steensma TD, Wagenaar EC, Doreleijers TA, Cohen-Kettenis PT. Young adult psychological outcome after puberty suppression and gender reassignment. <em>Pediatrics.</em> 2014;134(4):696-704.</li> <li>Sun SS, Schubert CM, Chumlea WC, et al. National estimates of the timing of sexual maturation and racial differences among U.S. children. <em>Pediatrics.</em> 2002;110(5):911-919.</li> <li>Reisner SL, Vetters R, Leclerc M, et al. Mental health of transgender youth in care at an adolescent urban community health center: a matched retrospective cohort study. <em>J Adolesc Health.</em> 2015;56(3):274-279.</li> <li>Hidalgo M.A ED, Tishelman A.C., Clark L.F, Garofalo R, Rosenthal S.M, Spack N.P, Olson J. The Gender Affirmative Model: What We Know and What We Aim to Learn. <em>Human Development</em> 2013;56(5):285-290.</li> <li>Olson KR, Durwood L, DeMeules M, McLaughlin KA. Mental Health of Transgender Children Who Are Supported in Their Identities. <em>Pediatrics.</em> 2016;137(3):1-8.</li> <li>WPATH. WPATH Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People Version 7 In: Fall H, ed. SOC version 72011. Accessed February 14, 2012.</li> <li>Biro FM, Galvez MP, Greenspan LC, et al. Pubertal assessment method and baseline characteristics in a mixed longitudinal study of girls. <em>Pediatrics.</em> 2010;126(3):e583-590.</li> <li>Delemarre-van de Waal HA, Cohen-Kettenis PT. Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects. <em>European Journal of Endocrinology.</em> 2006;155(suppl 1):S131-S137.</li> <li>Mul D, Hughes IA. The use of GnRH agonists in precocious puberty. <em>European journal of endocrinology / European Federation of Endocrine Societies.</em> 2008;159 Suppl 1:S3-8.</li> <li>de Vries AL, Steensma TD, Doreleijers TA, Cohen-Kettenis PT. Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. <em>The journal of sexual medicine.</em> 2011;8(8):2276-2283.</li> <li>Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. <em>The Journal of clinical endocrinology and metabolism.</em> 2009;94(9):3132-3154.</li> <li>Rosenthal SM. Approach to the patient: transgender youth: endocrine considerations.<em>The Journal of clinical endocrinology and metabolism.</em> 2014;99(12):4379-4389.</li> <li>Neely EK, Silverman LA, Geffner ME, Danoff TM, Gould E, Thornton PS. Random unstimulated pediatric luteinizing hormone levels are not reliable in the assessment of pubertal suppression during histrelin implant therapy. <em>Int J Pediatr Endocrinol.</em> 2013;2013(1):20.</li> <li>Ruble DN, Taylor LJ, Cyphers L, Greulich FK, Lurye LE, Shrout PE. The role of gender constancy in early gender development. <em>Child Dev.</em> 2007;78(4):1121-1136.</li> <li>Kantartzis KL, Sucato GS. Menstrual suppression in the adolescent. <em>J Pediatr Adolesc Gynecol.</em> 2013;26(3):132-137.</li> <li>Olson J, Schrager SM, Clark LF, Dunlap SL, Belzer M. Subcutaneous Testosterone: An Effective Delivery Mechanism for Masculinizing Young Transgender Men. LGBT Health. 2014;1(3):165-167.</li> <li>Contreras MF, Raisingani M, Franklin BH, Prasad K, Shah B. Induction and Continuation of Puberty in Adolescent Boys with Transdermal Testosterone Gel [Internet]. FRI-175 presented at: Endocrine Society’s 97th Annual Meeting and Expo; 2015 Mar 6 [cited 2016 May 23]; San Diego, CA. Available from: http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2015.PE.12.FRI-175</li> <li>Drobac S, Rubin K, Rogol AD, Rosenfield RL. A workshop on pubertal hormone replacement options in the United States. J Pediatr Endocrinol Metab JPEM. 2006 Jan;19(1):55–64.</li></ol></div> <footer class="page-edit"><!----> <!----></footer> <!----> </main></div><div class="global-ui"><!----></div></div>
    <script src="/assets/js/app.00bfe73e.js" defer=""></script><script src="/assets/js/2.85a7ba3d.js" defer=""></script><script src="/assets/js/15.1830f165.js" defer=""></script>
  

</body></html>
